
<html lang="en"     class="pb-page"  data-request-id="b9389a3a-81e5-4c82-962c-c01adce9c6d7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2017.60.issue-21;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b00510;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8)" /></meta><meta name="dc.Creator" content="Yong  Ma" /></meta><meta name="dc.Creator" content="Yue  Fu" /></meta><meta name="dc.Creator" content="S. Cyrus  Khojasteh" /></meta><meta name="dc.Creator" content="Deepak  Dalvie" /></meta><meta name="dc.Creator" content="Donglu  Zhang" /></meta><meta name="dc.Description" content="Glucuronidation is in general considered as a terminal metabolic step that leads to direct elimination of drugs and generally abolishes their biological activity. However, there is growing evidence..." /></meta><meta name="Description" content="Glucuronidation is in general considered as a terminal metabolic step that leads to direct elimination of drugs and generally abolishes their biological activity. However, there is growing evidence..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 27, 2017" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00510" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00510" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00510" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00510" /></link>
        
    
    

<title>Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00510" /></meta><meta property="og:title" content="Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0001.jpeg" /></meta><meta property="og:description" content="Glucuronidation is in general considered as a terminal metabolic step that leads to direct elimination of drugs and generally abolishes their biological activity. However, there is growing evidence to suggest that glucuronides can be ligands of human CYP2C8, making CYP2C8 distinct from the other CYP isoforms. Several classes of glucuronide conjugates, which include acyl glucuronides, ether glucuronides, N-glucuronides, and carbamoyl glucuronides, have been shown to be substrates or time-dependent inhibitors of CYP2C8. Although the structures of CYP2C8-glucuronide complexes have not been determined, the structural features of CYP2C8 active site support its binding to anionic and bulky ligands like glucuronides. As interaction perpetrators with CYP2C8, glucuronides of gemfibrozil and clopidogrel showed marked clinical drug–drug interactions (e.g., with cerivastatin and repaglinide), which are more than expected from the parent drug. This review summarizes glucuronides as CYP2C8 ligands and the active-site structural features of CYP2C8 that allow potential binding to glucuronides." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00510"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00510">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00510&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00510&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00510&amp;href=/doi/10.1021/acs.jmedchem.7b00510" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 8691-8705</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00329" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.7b01497" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8)</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Ma">Yong Ma</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-5901-5440" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yue++Fu">Yue Fu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=S.+Cyrus++Khojasteh">S. Cyrus Khojasteh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deepak++Dalvie">Deepak Dalvie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Donglu++Zhang">Donglu Zhang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-8677-9737" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Drug Metabolism & Pharmacokinetics and <sup>‡</sup>Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">Celgene Corporation, 10300 Campus Point Drive, San Diego California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 650-291-0058. E-mail: <a href="/cdn-cgi/l/email-protection#5b21333a353c753f34353c372e1b3c3e353e75383436"><span class="__cf_email__" data-cfemail="9ee4f6fff0f9b0faf1f0f9f2ebdef9fbf0fbb0fdf1f3">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00510&amp;href=/doi/10.1021%2Facs.jmedchem.7b00510" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 8691–8705</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 27, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 April 2017</li><li><span class="item_label"><b>Published</b> online</span>27 June 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 November 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00510" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00510</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8691%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYong%2BMa%252C%2BYue%2BFu%252C%2BS.%2BCyrus%2BKhojasteh%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D21%26contentID%3Dacs.jmedchem.7b00510%26title%3DGlucuronides%2Bas%2BPotential%2BAnionic%2BSubstrates%2Bof%2BHuman%2BCytochrome%2BP450%2B2C8%2B%2528CYP2C8%2529%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8705%26publicationDate%3DNovember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00510"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1351</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00510" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Yue&quot;,&quot;last_name&quot;:&quot;Fu&quot;},{&quot;first_name&quot;:&quot;S.&quot;,&quot;last_name&quot;:&quot;Cyrus Khojasteh&quot;},{&quot;first_name&quot;:&quot;Deepak&quot;,&quot;last_name&quot;:&quot;Dalvie&quot;},{&quot;first_name&quot;:&quot;Donglu&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;8691-8705&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00510&quot;},&quot;abstract&quot;:&quot;Glucuronidation is in general considered as a terminal metabolic step that leads to direct elimination of drugs and generally abolishes their biological activity. However, there is growing evidence to suggest that glucuronides can be ligands of human CYP2C8, making CYP2C8 distinct from the other CYP isoforms. Several classes of glucuronide conjugates, which include acyl glucuronides, ether glucuronides, N-glucuronides, and carbamoyl glucuronides, have been shown to be substrates or time-dependent inhibitors of CYP2C8. Although the structures of CYP2C8-glucuronide complexes have not been determined, the structural features of CYP2C8 active site support its binding to anionic and bulky ligands like glucuronides. As interaction perpetrators with CYP2C8, glucuronides of gemfibrozil and clopidogrel showed marked clinical drug–drug interactions (e.g., with cerivastatin and repaglinide), which are more than expected from the parent drug. This review summarizes glucuronides as CYP2C8 ligands and the active-site struc&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00510&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00510" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00510&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00510" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00510&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00510" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00510&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00510&amp;href=/doi/10.1021/acs.jmedchem.7b00510" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00510" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00510" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00510%26sid%3Dliteratum%253Aachs%26pmid%3D28653847%26genre%3Darticle%26aulast%3DMa%26date%3D2017%26atitle%3DGlucuronides%2Bas%2BPotential%2BAnionic%2BSubstrates%2Bof%2BHuman%2BCytochrome%2BP450%2B2C8%2B%2528CYP2C8%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D21%26spage%3D8691%26epage%3D8705%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=291091" title="Oxidation">Oxidation</a>,</li><li><a href="/action/doSearch?ConceptID=291645" title="Acyls">Acyls</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/jmcmar.2017.60.issue-21/20171109/jmcmar.2017.60.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Glucuronidation is in general considered as a terminal metabolic step that leads to direct elimination of drugs and generally abolishes their biological activity. However, there is growing evidence to suggest that glucuronides can be ligands of human CYP2C8, making CYP2C8 distinct from the other CYP isoforms. Several classes of glucuronide conjugates, which include acyl glucuronides, ether glucuronides, <i>N</i>-glucuronides, and carbamoyl glucuronides, have been shown to be substrates or time-dependent inhibitors of CYP2C8. Although the structures of CYP2C8-glucuronide complexes have not been determined, the structural features of CYP2C8 active site support its binding to anionic and bulky ligands like glucuronides. As interaction perpetrators with CYP2C8, glucuronides of gemfibrozil and clopidogrel showed marked clinical drug–drug interactions (e.g., with cerivastatin and repaglinide), which are more than expected from the parent drug. This review summarizes glucuronides as CYP2C8 ligands and the active-site structural features of CYP2C8 that allow potential binding to glucuronides.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08768" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08768" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Glucuronidation is an important metabolism pathway for many drugs and endogenous substances.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Liver, gastrointestinal tracts, and kidney are the major organs where glucuronidation occurs. Mechanistically, the glucuronosyl group is enzymatically transferred from the cofactor uridine 5′-diphosphoglucuronic acid (UDPGA) to the substrates with the nucleophilic function groups of –OH, –NH<sub>2</sub>, –SH, –COOH, or others, which are catalyzed by the enzyme family of uridine 5′-diphosphoglucuronosyltransferases (UGTs).<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2-4)</a> Compared to parent molecules, the glucuronides have remarkably increased molecular weights (+176 Da) and altered physicochemical properties (e.g., decreased log <i>P</i> and increased hydrogen-bond donors/acceptors) with enhanced water solubility. The glucuronide conjugates of drugs are usually excreted from the cells by drug efflux transporters since the anionic nature of glucuronic acid does not easily allow the passive diffusion of glucuronides across cellular membrane.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> These conjugates have also been known to be metabolically unstable and are prone to hydrolytic cleavage by β-glucuronidase in liver or by intestinal microflora, and in some cases this results in enterohepatic recycling.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a></div><div class="NLM_p">Cytochrome P450 enzymes (CYPs) are an important family of heme-containing proteins involved in the metabolism of xenobiotics and endogenous substances using nicotinamide adenine dinucleotide phosphate (NADPH) as the cofactor.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Fifty-seven CYP isoforms have been identified in human, which are divided into different families of 1A, 2A, 2B, 2C, 2D, 2E, 2J, 3A, 4F, 11A, and 11B and subfamilies such as 2C8 and 2C9 based on the homology of their primary amino acid sequences.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Most of the human CYPs are encoded by polymorphic genes and the allelic variants. CYPs have broad substrate selectivity as most clinical drugs are metabolized by CYP enzymes. It is common that one CYP can catalyze multiple types of reactions such as hydroxylation, dealkylation, and heteroatom oxidation and multiple enzymes can participate in metabolism of the same drug. Among all of the human CYPs, the CYP2Cs are an important subfamily that includes 2C8, 2C9, 2C18, and 2C19 with over 80% sequence homology.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> CYP2C9 and 2C19 are usually considered to be among the most important enzymes in drug metabolism, and this is even more highlighted due to their polymorphic properties.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> However, since late 1990s, the significant contribution of CYP2C8 in drug metabolism has been recognized. The important drugs that are metabolized by CYP2C8 include rosiglitazone, cerivastatin, amodiaquine, and paclitaxel.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12-15)</a> Various CYP2C8 alleles have been reported in pharmacogenomics studies, and the importance of CYP2C8-mediated drug metabolism in certain subgroups of patients has been established.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Several excellent reviews have comprehensively summarized the contributions of CYP2C8 to drug metabolism.<a onclick="showRef(event, 'ref11 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref11 ref17 ref18 ref19">(11, 17-19)</a></div><div class="NLM_p last">Compared with other CYP isoforms, CYP2C8 possesses a distinctive active site, which determines its substrate selectivity and unique catalytic function. One of the uncommon features of CYP2C8 is that it can metabolize certain chemicals that contain an anionic moiety in steroids, arachidonic acid, retinoids, and some drugs.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Oxidation of conjugative metabolites can be a main clearance pathway for certain drugs. Interestingly, several glucuronide conjugates have been shown to interact with CYP2C8. When these conjugates turn to be a ligand (substrate or inhibitor) of CYP2C8, a specific drug–drug interaction (DDI) may occur. For instance, gemfibrozil glucuronide has been identified as a potent time-dependent CYP2C8 inhibitor and its clinical interactions have been observed with other drugs that are CYP2C8 substrates.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> A better understanding of the glucuronide structure binding to CYP2C8 may help understand and predict such DDIs. In this review, the studies on the structure and substrate selectivity of CYP2C8 are summarized to provide a perspective on the binding of anionic ligands in the CYP2C8 binding site and on associated examples.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Glucuronide Conjugates as Substrates of CYP2C8</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27731" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27731" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A number of glucuronides have so far been identified as CYP2C8 ligands. Interestingly, CYP2C8 is not in general involved in the oxidative metabolism of their parent compounds for most of these glucuronides. However, CYP2C8 instead of other CYP isoforms can metabolize these glucuronides, yielding oxidative conjugates that are excreted in the urine or feces or detected in circulation. Some glucuronides can modulate CYP2C8 activity by inhibition in a time- and metabolism-dependent manner and thus induce DDIs. In this section, the example glucucronides as CYP2C8 substrates were summarized.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Acyl Glucuronides</h3><div class="NLM_p">Acyl glucuronide conjugates of several structurally diverse drugs have been shown to interact with CYP2C8. Oxidation of diclofenac glucuronide by CYP2C8 is perhaps the first example demonstrating that a glucuronide conjugate could be further oxidized.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) widely used for the treatment of acute muscle aches and several inflammatory diseases.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In humans, diclofenac is primarily oxidized via CYP2C9 to 4′-hydroxydiclofenac, which accounts for 30% of the dose in vivo as a major metabolic pathway.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> Diclofenac also undergoes UGT2B7-catalyzed glucuronidation to the corresponding acyl glucuronide, but only 10–20% of the dose is excreted as the acyl glucuronide in human urine, suggesting that glucuronidation is a minor pathway in humans (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> However, in vitro studies with NADPH and UDPGA-supplemented human liver microsomes (HLM) by Kumar et al. demonstrate that glucuronidation of diclofenac is a more efficient pathway (at least 3-fold) than 4′-hydroxydiclofenac formation with CL<sub>int</sub> estimates of the glucuronidation and oxidation pathways being 639 versus 215 (μL/min)/mg protein, respectively.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Further investigation into the metabolism by the authors revealed that diclofenac acyl glucuronide can readily undergo oxidation in HLM supplemented with NADPH-regenerating system, yielding significant amounts of 4′-hydroxydiclofenac and 4′-hydroxydiclofenac acyl glucuronide. Absence of hydroxylated glucuronide in control microsomal incubations lacking NADPH-regenerating system confirmed that the glucuronide conjugate directly undergoes oxidative metabolism. Additional experiments with monoclonal antibodies against individual CYP isozymes or recombinant CYP isozymes indicated that this oxidative reaction is primarily catalyzed by CYP2C8. These findings led the authors to conclude that excretion of 4′-hydroxydiclofenac as the major urinary metabolite following diclofenac administration to humans is probably a consequence of direct oxidation of the parent drug as well as the secondary oxidation of diclofenac acyl glucuronide. They further speculated that the first step in the metabolism of diclofenac is perhaps conversion to the acyl glucuronide in the liver followed by its CYP2C8-catalyzed oxidation to 4′-hydroxydiclofenac glucuronide, and subsequent glucuronide hydrolysis yields 4′-hydroxydiclofenac.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Metabolic pathways of diclofenac involving UGT2B7 and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Licofelone represents another example in the NSAID class of drugs where the acyl glucuronide undergoes further CYP2C8-catalyzed oxidation to hydroxylated metabolites. Licofelone was developed as a dual inhibitor of both cyclooxygenase isoforms 1 and 2 as well as 5-lipooxygenase with better gastrointestinal tolerability than traditional NSAIDs.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> Preliminary metabolic profiling in healthy male volunteers demonstrated that the acyl glucuronide (M1) and hydroxylated metabolite (M2) of licofelone are primary circulating metabolites with exposure of M1 and M2 accounting for 2% and 20% of that of the parent drug, respectively, following oral administration of licofelone to humans (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In vitro metabolism studies in HLM revealed that licofelone was rapidly converted to M1 in UDPGA-supplemented liver microsomal incubations.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In contrast, high metabolic stability of licofelone was observed in NADPH fortified liver microsomal incubations and M2 was detected at a very low concentration. Interestingly, subsequent studies with HLM containing both cofactors, UDPGA and NADPH, yielded M3, which is a glucuronide conjugate of M2, suggesting that both cofactors are required for oxidation of licofelone and that M3 is probably produced from M1 rather than the conventional pathway of oxidation followed by glucuronidation. Metabolite M2 is subsequently produced via hydrolysis of M3 in vivo. In vitro studies of M1 with NADPH-fortified liver microsomes also yielded M3 and further confirmed the involvement of UGTs and CYPs in the formation of M2 via oxidation of M1. Reaction phenotyping studies revealed that while several UGTs (UGT1A3, 1A7, 1A9, and 2B7) are involved in the formation of M1, formation of M3 is catalyzed specifically by CYP2C8 and can be inhibited by montelukast, a selective inhibitor of CYP2C8.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Metabolic pathways of licofelone involving UGT(s) and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Early work with naproxen acyl glucuronide has also provided some evidence that this metabolite undergoes CYP2C8-mediated aromatic hydroxylation similar to that observed for diclofenac and licofelone.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> However, no additional further reaction phenotyping has been done to assess its substrate properties.</div><div class="NLM_p">Our recent studies with the NSAID ibuprofen also suggest that the glucuronide conjugate of ibuprofen, a drug that is widely used for treating pain, fever, and inflammation, is also a substrate for CYP2C8.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In humans, the major metabolic pathway for ibuprofen is oxidation by CYPs. Several oxidative metabolites, including carboxy-ibuprofen, 2-hydroxy-ibuprofen, 3-hydroxy-ibuprofen, and 1-hydroxy-ibuprofen, have been detected in the urine of humans administered with ibuprofen (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). Also, approximately 10–15% of ibuprofen dose is also converted to its corresponding glucuronide conjugate.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> A previous study had shown that ibuprofen acyl glucuronide does not inhibit the activity of CYP2C8 in vitro.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> However, our investigation suggests that the ibuprofen glucuronide is oxidized to several oxidative metabolites when incubated with recombinant CYP2C8 in the presence of NADPH (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). Liquid chromatography–mass spectrometry analysis of the incubation mixture revealed at least 12 peaks that showed addition of oxygen to ibuprofen glucuronide (M1–12), some of which could be acyl migration products of hydroxylated glucuronide metabolites. These oxidative conjugate peaks suggested that hydroxylation of the acyl glucuronide can occur at different positions in the structure of ibuprofen acyl glucuronide (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). CYP2C8 is specifically involved in hydroxylation of this glucuronide since no oxidative products were observed when the acyl glucuronide was incubated with other CYP isoforms including CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, 3A4, or 3A5 (data not shown).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Metabolic pathways of ibuprofen in vivo and (B) in vitro oxidation of ibuprofen acyl-β-<span class="smallcaps smallerCapital">d</span>-glucuronide by CYP2C8 detected in LC–high resolution mass spectrometry analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Oxidative metabolism of acyl glucuronide conjugates has also been observed for several compounds belonging to the “glitazar class” of peroxisome proliferator-activated receptors (PPAR) agonists which are used in treating type-2 diabetes and dyslipidemia. Sipoglitazar, a triple agonist of PPAR-γ/α/δ, was discontinued from development due to lack of efficacy and safety concerns.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Metabolism studies in rats, monkeys and humans have shown that oxidative dealkylation and glucuronidation are the primary routes of drug clearance for sipoglitazar (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Deethylated sipoglitazar (M1) is detected as the major circulating metabolite following oral administration of sipoglitazar to human subjects. Although M1 appears to be a typical CYP-catalyzed product, investigation into its formation using HLM and human hepatocytes suggests that glucuronidation of sipoglitazar is a prerequisite for the dealkylation step.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Phenotyping studies have revealed that sipoglitazar is converted to sipoglitazar-β-1-<i>O</i>-acyl glucuronide (SG1) by UGT2B15 and the formation of deethylated SG1 is exclusively catalyzed by CYP2C8. Interestingly, sipoglitazar-α-2-<i>O</i>-acyl glucuronide (SG2), which is the acyl migration product of SG1 detected in the bile of rats, is not prone to CYP2C8-catalyzed oxidation. These findings led the authors to speculate that formation of M1 involves the dealkylation of the glucuronide SG1 to deethylated SG1, followed by hydrolysis of the glucuronide intermediate.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Metabolic pathways of sipoglitazar involving UGT2B15 and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Studies with two other novel PPAR activators, muraglitazar and peliglitazar, also suggest that their corresponding acyl glucuronide conjugates undergo CYP-mediated oxidation. After oral administration to humans, both [<sup>14</sup>C]muraglitazar and [<sup>14</sup>C]peliglitazar undergo extensive conjugation, and the major portion of each radioactive dose is excreted as acyl glucuronide metabolites in human bile.<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38-40)</a> Oxidative metabolism is also prominent in humans for both muraglitazar and peliglitazar. In vitro incubations in NADPH-supplemented HLM catalyze hydroxylation or demethylation of their acyl glucuronides, suggesting CYP-mediated metabolism of the glucuronide conjugates. Although one can speculate that this oxidative conversion of the acyl glucuronide is CYP2C8-mediated, no detailed phenotyping studies have been conducted to suggest the role of CYP2C8 in their metabolism.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p">2-[[5,7-Dipropyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy]-2-methylpropanoic acid (MRL-C) is another PPAR agonist with potent activation effect on PPARα but weak effect on PPARγ.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Kochansky and co-workers have presented evidence suggesting that the acyl glucuronide of MRL-C also undergoes CYP-mediated oxidative metabolism in monkeys and humans (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The parent MRL-C is a substrate of UGTs, and the acyl glucuronide is the primary metabolite in hepatocytes of rats, dogs, monkeys, and humans. The acyl glucuronide is further metabolized to several oxidative metabolites especially in the monkey, which has been confirmed by incubating [<sup>14</sup>C]MRL-C acyl glucuronide with NADPH-supplemented liver microsomes. Further investigation and phenotyping studies with human CYP enzymes have indicated that oxidative metabolism of the glucuronide conjugate is catalyzed by CYP2C8. Preincubation with anti-CYP2C8/9 antibodies also results in 92% inhibition of oxidative metabolism of the glucuronide in HLM.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Metabolic pathways of MRL-C involving UGT(s) and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Ether Glucuronides</h3><div class="NLM_p">Formation of 2-hydroxyestradiol-17β-glucuronide from estradiol 17β-glucuronide is perhaps the first and so far the only confirmed example that exemplifies the CYP2C8-catalyzed oxidative conversion of ether glucuronide conjugates. Estradiol is a primary female steroidal estrogen sex hormone and is essential for development and maintenance of female reproductive tissues. Estradiol is primarily metabolized via two pathways: CYP3A4/3A5-mediated oxidation leading to formation of 2-hydroxyestradiol and UGT-catalyzed glucuronidation resulting in either estradiol-17β-glucuronide or estradiol-3-glucuronide (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Delaforge and co-workers demonstrated that estradiol-17β-glucuronide is converted to the corresponding 2-hydroxyestradiol-17β-glucuronide metabolite when the glucuronide conjugate is incubated with NADPH-fortified HLM.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Furthermore, incubation of estradiol 17β-glucuronide with NADPH-fortified recombinant CYP2C8 also yielded the corresponding 2-hydroxyestradiol glucuronide metabolite, suggesting that the oxidation of the glucuronide was specifically catalyzed by CYP2C8. Experiments using male and female HLM have suggested that the conversion is more active in female than in male HLM. Michaelis–Menten kinetics for formation of the 2-hydroxy metabolite from the glucuronide conjugate in yeast-expressed CYP2C8 yielded a <i>K</i><sub>M</sub> of 88 μM and a <i>V</i><sub>max</sub> of 1.86 (nmol/min)/nmol CYP (<i>V</i><sub>max</sub>/<i>K</i><sub>M</sub> = 2.1 (μL/min)/nmol CYP). In addition, the oxidation is region-selective since estradiol-3-glucuronide is not metabolized in NADPH-fortified incubations with liver microsomes or expressed CYPs. Docking exercise in the crystal structure of CYP2C8 indicates that the active site of the enzyme is large enough to accommodate the glucuronide conjugate. The most energetically favored position of the glucuronide in the docking exercise is consistent with the observation that oxidation occurs at the carbon-2 in the steroidal ring of the substrate. Testosterone-17β-glucuronide is also a substrate of CYPs in NADPH-fortified HLM. However, the site of metabolism and the isoform responsible for this transformation have not been identified.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Metabolic pathways of estradiol involving UGT2B7 and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> <i>N</i>-Glucuronides as Substrates of CYP2C8</h3><div class="NLM_p">Transformation of desloratadine-<i>N</i>-glucuronide to 3-hydroxydesloratadine-<i>N</i>-glucuronide by CYP2C8 exemplifies the interaction of <i>N</i>-glucuronide conjugates with this enzyme (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Desloratadine, a second generation nonsedating long-lasting antihistamine, is widely used in the treatment of seasonal allergic rhinitis and chronic idiopathic urticarcia and nasal congestion.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> In humans, desloratadine is extensively metabolized to an active metabolite 3-hydroxydesloratadine, which is subsequently converted to 3-hydroxydesloratadine-<i>O</i>-glucuronide. Approximately 13% of the dose is eliminated in the urine as 3-hydroxydesloratadine-<i>O</i>-glucuronide, while 3-hydroxydesloratadine is the major fecal metabolite accounting for 17% of the dose.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Metabolic pathways of desloratadine involving UGTs and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The enzymology surrounding the formation of 3-hydroxydesloratadine has remained a mystery until recently. Kazmi and co-workers have established that N-glucuronidation of desloratadine is an obligatory step in formation of 3-hydroxydesloratadine although it is still unknown which nitrogen (the piperidine nitrogen or the pyridine nitrogen) is conjugated.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Investigation using subcellular fractions or sonicated/saponin-treated cryopreserved hepatocytes suggested that 3-hydroxydesloratadine was not detected when NADPH or UDPGA alone was added to the incubation and both NADPH and UDPGA were required for its formation. 3-Hydroxydesloratadine and its corresponding <i>O</i>-glucuronide were only detected in intact cryopreserved human hepatocytes, and its formation was inhibited by gemfibrozil glucuronide, a potent mechanism-based inactivator of CYP2C8.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Other inhibitors of CYP2C8 such as montelukast and clopidogrel glucuronide also caused significant inhibition of 3-hydroxydesloratadine formation, and the inhibitors of other CYP isoforms were ineffective. Furthermore, evaluation of desloratadine, amodiaquine, and paclitaxel metabolism in a panel of individual cryopreserved human hepatocytes demonstrated that 3-hydroxydesloratadine formation correlated well with the CYP2C8 marker activity (<i>r</i><sup>2</sup> of 0.7–0.9).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The UGT isoform implicated in the N-glucuronidation of desloratadine has also been identified as UGT2B10.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Overall, these studies suggested that CYP2C8 plays an essential role in 3-hydroxydesloratadine formation and the biotransformation of desloratadine to 3-hydroxydesloratadine is a multiple-step process, which includes glucuronidation by UGT2B10, oxidation by CYP2C8, and then hydrolysis of the <i>N</i>-glucuronide.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Glucuronide Conjugates as Mechanism-Based Inactivators of CYP2C8</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07475" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07475" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">By definition, a mechanism-based inhibitor is a compound that inactivates the enzyme which metabolizes it. The product formed is a highly reactive species that ultimately results in formation of covalent complex with the enzyme that produces it and thus renders it inactive.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The process leading to inactivation is generally irreversible and the catalytic activity cannot be restored unless the enzyme is regenerated. Among the glucuronide substrates of CYP2C8, some can also act as inactivators of this enzyme.</div><div class="NLM_p">Gemfibrozil is perhaps the most important and first example where inactivation of a CYP enzyme involves conjugation.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Gemfibrozil is an amphipathic carboxylic acid drug used to treat hyperlipidemia and hypertriglyceridemia in patients.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> In humans, gemfibrozil is primarily metabolized via the oxidation and glucuronidation (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). While the principal oxidative metabolite is the benzoic acid derivative, glucuronidation of the drug (and its metabolites) is a primary metabolic pathway. After an oral dose of 450 mg to humans, 32% of the dose is excreted as a glucuronide conjugate of gemfibrozil in urine by 24 h, while benzoic acid derivative and its conjugate account for approximately 20% of the dose. The enzyme responsible for conjugating gemfibrozil has been identified as UGT2B7.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Metabolic pathways of gemfibrozil involving UGT2B7 and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite the weak reversible inhibition of CYP2C8 by gemfibrozil in in vitro studies using HLM (IC<sub>50</sub> ≈ 95 μM),<a onclick="showRef(event, 'ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53">(51-53)</a> several clinical interactions between gemfibrozil and CYP2C8 substrates such as cerivastatin, repaglinide, rosiglitazone, and pioglitazone have been reported.<a onclick="showRef(event, 'ref54 ref55 ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref56 ref57">(54-57)</a> For instance, combined use of gemfibrozil and cerivastatin, a cholesterol lowering agent, substantially increased the risk of fatal rhabdomyolysis, which is a severe adverse effect of cerivastatin in patients.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58, 59)</a> Likewise, sustained and significant increase in the repaglinide plasma exposure has been observed in subjects that were administered 600 mg dose of gemfibrozil and 0.25 mg of repaglinide.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> In another study, after a single dose of 30 mg of gemfibrozil, approximately 50% CYP2C8 activity in humans was inhibited and the area under the concentration–time curve (AUC) of repaglinide was increased by 1.8-fold.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> The rapid inactivation of CYP2C8 in vivo occurred within 1 h after gemfibrozil administration, and the full recovery of CYP2C8 activity could take as long as 96 h after gemfibrozil discontinuation.<a onclick="showRef(event, 'ref17 ref62'); return false;" href="javascript:void(0);" class="ref ref17 ref62">(17, 62)</a> This inconsistency between the in vitro and in vivo studies has been resolved by demonstrating that the glucuronide conjugate of gemfibrozil is a more potent inhibitor of CYP2C8 than gemfibrozil itself.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> It has also been demonstrated that the glucuronide conjugate inhibits the human organic anion transporting polypeptide 2 (OATP2) mediated uptake of cerivastatin.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Although the inhibition of human OATP2 can slow down the hepatocyte uptake of cerivastatin and thus contribute to the AUC increase in plasma, the inhibition of the CYP2C8-mediated metabolism of cerivastatin by the gemfibrozil glucuronide is considered as the main mechanism for the clinically relevant DDI because of the possible high concentrations of unbound gemfibrozil glucuronide inside the hepatocytes.</div><div class="NLM_p">Subsequent studies by Oglivie et al. showed that gemfibrozil glucuronide is not only a reversible inhibitor but also a metabolism-dependent inhibitor of CYP2C8.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Preincubation of the metabolite with HLM for 30 min in the presence of NADPH caused the IC<sub>50</sub> to shift from 24 to 1.8 μM for inhibition of CYP2C8 activity. Detailed mechanistic studies with gemfibrozil glucuronide have shown that the metabolite inhibits CYP2C8 with a <i>K</i><sub>I</sub> (inhibitor concentration that supports half the maximal rate of enzyme inactivation) of 20–52 μM and a <i>k</i><sub>inact</sub> (maximal rate of inactivation) of 0.21 min<sup>–1</sup>. The metabolism-based inactivation is not observed in control experiments that lack NADPH, indicating that NADPH is required for inhibition and the possibility of inactivation via the covalent binding of the acyl glucuronide moiety is ruled out. Additional mass spectrometry studies with inactivated CYP2C8 enzyme by Baer and co-workers suggest that inactivation is due to a direct covalent bond between one benzylic carbon in the 2′,5′-dimethylphenoxy group with the heme prosthetic group of the CYP.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> This is consistent with the computational docking experiments in which the most energetically efficient binding mode is where the glucuronosyl moiety is located distal to the heme and interacts with Ser100, Ser103, Gln214, and Asn217 of the apoprotein.<a onclick="showRef(event, 'ref34 ref64'); return false;" href="javascript:void(0);" class="ref ref34 ref64">(34, 64)</a> While the exact site of adduction in the heme was not confirmed experimentally, modeling studies proposed the involvement of the γ-meso position of the porphyrin ring in the adduction. Overall, these results suggest that the inactivation mechanism involves formation of a benzylic radical intermediate from gemfibrozil glucuronide and its adduction to the heme of CYP2C8. Consistently, a structure–activity relationship (SAR) study showed that replacement of the aromatic methyl groups in gemfibrozil with trifluoromethyl groups abolishes mechanism-based inactivation of CYP2C8.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The same SAR study on inactivation also suggested that the interaction between gemfibrozil glucuronide and CYP2C8 is very unique since the acyl glucuronides of several other structurally diverse drugs evaluated in this study are not associated with mechanism-based inactivation of CYP2C8.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p">Like gemfibrozil, severe clinical DDIs have been observed when clopidogrel is administered with CYP2C8 substrates. Clopidogrel belongs to tetrahydrothienopyridines class of antiplatelet agents and is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease and to prevent heart attack and stroke.<a onclick="showRef(event, 'ref65 ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref65 ref66 ref67">(65-67)</a> It is a prodrug that requires metabolic activation by multiple CYPs into “active” reactive metabolites for the antithrombotic activity.<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68, 69)</a> However, in humans, only 15% of total clopidogrel is oxidized to the active thiol metabolite via 2-oxoclopidogrel and the primary route of clopidogrel metabolism (approximately 70% or greater) is hydrolysis by human carboxylesterases, resulting in an inactive carboxylic acid metabolite (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Approximately 25% of the carboxylic acid metabolite is circulating as its corresponding acyl glucuronide conjugate before it is eliminated.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70, 71)</a> The analysis based on a case-control study of rhabdomyolysis revealed that the coadministration of clopidogrel with cerivastatin can significantly increase the risk of rhabdomyolysis in patients.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Another study indicated that in healthy volunteers receiving clopidogrel for 3 consecutive days (300 mg on day 1, followed by 75 mg daily), the systemic exposure of repaglinide was increased 5.1-fold on day 1 and 3.9-fold on day 3.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> These DDIs could be explained by further investigations that demonstrated that clopidogrel acyl glucuronide is a potent mechanism-based inactivator of CYP2C8.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Detailed experiments indicate that clopidogrel acyl glucuronide inactivates CYP2C8 with a <i>K</i><sub>I</sub> of 9.90 μM and a <i>k</i><sub>inact</sub> of 0.047 min<sup>–1</sup>.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Montelukast, a competitive inhibitor of CYP2C8, reduces CYP2C8 inactivation by clopidogrel acyl glucuronide and thus confirms that the inactivating species is formed enzymatically in the active site of CYP2C8.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Like gemfibrozil, the adduction was covalent in nature since dialysis of preincubated HLM-inhibitor mixtures did not reduce the inhibitory effects of the glucuronide. Docking exercises indicated that like gemfibrozil acyl glucuronide, clopidogrel acyl glucuronide is most likely orientated with the thiophene moiety in close proximity to the heme and the hydrophilic glucuronide group between Ser103, Leu208, and Ile213 in the active site cavity of CYP2C8.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> This orientation was consistent with an inactivation mechanism wherein the reactive electrophiles from the thiophene group add to the heme and cause the dysfunction of the enzyme.<a onclick="showRef(event, 'ref71 ref73'); return false;" href="javascript:void(0);" class="ref ref71 ref73">(71, 73)</a> In addition, clopidogrel and its acyl glucuronide show an inhibitory effect on OATP1B1-mediated uptake of cerivastatin in vitro, suggesting that the inhibition of OATP(s) may also contribute to the DDI between clopidogrel and cerivastatin.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Metabolic pathways of clopidogrel involving hydrolysis, glucuronidation, and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Deleobuvir represents a recent example where its glucuronide conjugate is a potent time-dependent inhibitor of CYP2C8.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Deleobuvir is an inhibitor of hepatitis C virus NS5B RNA polymerase.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> The pharmacokinetics, mass balance, and metabolism studies with [<sup>14</sup>C]deleobuvir in healthy subjects at 800 mg dose have revealed two major circulating metabolites: an acyl glucuronide (M1) and a reduced metabolite (M2), representing 20% and 15% of the total drug related material, respectively (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Metabolic pathways of deleobuvir involving glucuronidation, reduction, and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In vitro DDI assessment of deleobuvir and its two metabolites suggests that M1 is a reversible CYP2C8 inhibitor with a <i>K</i><sub>I</sub> of 0.022 μM. Although deleobuvir and M2 also inhibit CYP2C8 activity, the <i>K</i><sub>I</sub> values are 6- to 12-fold higher than that of M1.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In addition, M1 also exhibits a more potent time-dependent inhibition of CYP2C8 than deleobuvir and M2. The corresponding <i>K</i><sub>I</sub> and <i>k</i><sub>inact</sub> values for M1 were 0.0521 μM and 0.0521 min<sup>–1</sup>, respectively, suggesting an inactivation potency of 1 μM<sup>–1</sup> min<sup>–1</sup>. Interestingly, M1 is also an inactivator of CYP1A2; however, the inhibitory potency is much lower than that observed for CYP2C8 (<i>K</i><sub>I</sub> of 54.6 μM and <i>k</i><sub>inact</sub> of 0.044 min<sup>–1</sup>). While the influence of inhibition was not evaluated clinically for CYP2C8, a DDI projection suggests that deleobuvir may cause a moderate-to-high increase in AUC for the two CYP2C8 substrates, repaglinide and cerivastatin.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><div class="NLM_p">Inactivation of CYP2C8 by Lu-A (LuAA34893, full structure not disclosed)<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> represents a noteworthy example wherein a carbamoyl glucuronide functions as an irreversible mechanism-based inhibitor of CYP2C8. Lu-A, a drug candidate under development by Lundbeck A/S to treat major depressive and bipolar disorder, is a secondary amine that forms a carbamoyl glucuronide (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). Carbamoyl glucuronides are generally formed when primary or secondary amines react with carbon dioxide to form carbamic acids that subsequently undergo glucuronidation to form a corresponding glucuronide conjugate. Although little is known about the mechanism and the UGT isoforms that catalyze this reaction, a similar biotransformation pathway has been reported for several amino acids and drugs.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> From a DDI perspective, the parent compound Lu-A causes direct inhibition of all CYP enzymes evaluated and is a potent reversible inhibitor of CYP2C19. The carbamoyl glucuronide of Lu-A is only a weak reversible inhibitor of CYP2C8 (IC<sub>50</sub> = 71 μM). However, a 30 min preincubation of the carbamoyl glucuronide with NADPH-supplemented HLM largely enhances its inhibition of CYP2C8 activity (IC<sub>50</sub> = 8.5 μM), indicating a time-dependent inhibition with a <i>K</i><sub>I</sub> of 48 μM and a <i>k</i><sub>inact</sub> of 0.038 min<sup>–1</sup> (<i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> = 0.79 min<sup>–1</sup> mM<sup>–1</sup>). Overall, LuAA34893 serves as another example, along with gemfibrozil, clopidogrel, and deleobuvir, of a compound that is converted by glucuronidation to a conjugated metabolite that functions as an irreversible metabolism-dependent inhibitor of CYP2C8.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Metabolic pathways of Lu-A involving the reaction with CO<sub>2</sub>, glucuronidation (R<sub>1</sub> and R<sub>2</sub> represent proprietary substructures), and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Structure of Human CYP2C8</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Structural Models of Human CYP2C8</h3><div class="NLM_p">The crystal structure of rabbit CYP2C5 is the first experimentally determined mammalian CYP structure, and it offers a template to build homology models of other mammalian CYPs.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> By combination of in silico computation and statistical analysis, the homology models were established by Williams et al. to explain why the substrate specificity differs among the major human CYP2C isoforms (2C8, 2C9, 2C18, and 2C19).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The key residues in the active site conferring substrate selectivity were computationally identified in each CYP2C homology model. The selectivity analysis showed that the shape of substrate binding sites and hydrophobic interactions between substrates and binding site residues may be the primary determinants of the substrate selectivity. Interestingly, the authors pointed out that among the four isoforms, CYP2C8 is unique because its selective region contains several distinct residues, which renders its active site to adopt a different shape and be less hydrophobic than that of the other CYP2C isoforms. Ser114, Phe205, and Ile476 are considered to be the major contributors to the substrate specificity of CYP2C8. This study indicates that CYP2C8 may be more prone to take hydrophilic substrates compared with other CYP2C isoforms.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p last">Besides the homology models, ligand-based approaches have also been employed to gain a better understanding of substrate specificity of CYP2C8. By superimposition of the structures of various CYP2C8 substrates, a pharmacophore was built to show their common characteristics by Melet et al.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> The result indicated that in the structures of these substrates an acidic or polar functional group can usually be found at one end of a hydrophobic chain, while the oxidation usually occurs at the other end. This pharmacophore model shed light on the conformation and orientation of the substrate with a negatively charged or polar function group in the active site of CYP2C8. The binding of glucuronides into the active site of CYP2C8 may share a similar conformation because they are negatively charged at a physiological pH.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Ligand-Free Crystal Structures of CYP2C8</h3><div class="NLM_p">The first X-ray crystal structure of human CYP2C8 without a ligand in the active site was reported by Schoch et al. in 2004 (2.7 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PQ2">1PQ2</a>) (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>A).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> To obtain CYP2C8 crystal, the N-terminal of CYP2C8 was engineered by a method that was previously applied in the structure determination of rabbit CYP2C5.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> The CYP2C8 protein crystallized as a symmetric dimer in this structure. The active site of CYP2C8 comprises several secondary structures and the loops between them, including mainly β sheet 1, loop–helix B′-loop, helix F to G (excluding helix G′), helix I, the loop between helix K and β sheets 1–3, and β sheet 4 (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>B). The active site cavity in human CYP2C8 is almost twice as large as that of rabbit CYP2C5. The change of cavity volume is due to different conformation of the polypeptide backbones, as well as the various side-chain size and/or polarity of amino acid residues in the active sites. Most prominently, the relatively smaller side chains of Ser114 and Ile476 in CYP2C8 do not block the space between heme and helix F′ and thus create a much larger cavity than that in CYP2C5 where the corresponding Phe114 and Phe473 show steric hindrance. In addition, there are 23 extra residues in the secondary structures and loops surrounding the active site cavity of CYP2C8, compared to that of CYP2C5. These additional amino acids are involved in formation of the CYP2C8 active site and may potentially interact with substrates. Paclitaxel, a probe commonly used to study CYP2C8 activity in vitro, is a relatively large substrate (molecular weight of 853.9 Da) that can still fit into the active site cavity of CYP2C8.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Although glucuronides are larger than their parents, it is still possible for them to fit into the active site cavity of CYP2C8. Besides the large cavity volume, the properties of amino acid residues in the active cavity may also contribute to the substrate selectivity of CYP2C8. Among the 48 amino acid residues comprising the active site of CYP2C8, 16 residues (N72, N99, S100, S103, T107, S114, N202, N204, N209, N217, N218, N236, T240, T301, T364, and T386) are noncharged and hydrophilic, which may increase the binding affinity of relatively polar substrates including glucuronides.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> More importantly, three positive-charged arginine residues (R97, R200, and R241) in the active site may help anchor the binding of negative-charged glucuronide via an electrostatic interaction. The features of CYP2C8 active site cavity imply that glucuronides can be CYP2C8 ligands.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of human microsomal CYP2C8. (A) CYP2C8 dimer in the asymmetric manner. Two palmitic acid molecules (shown in sphere) are positioned at the dimer interface. (B) Side view of CYP2C8 monomer. Secondary structures are labeled sequentially from the N terminus to the C terminus.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Crystal Structures of CYP2C8 with Ligand</h3><div class="NLM_p">Four CYP2C8 crystal structures of enzyme complex with montelukast, troglitazone, felodipine, or 9-cis-retinoic acid have been solved (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>).<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> These four ligands differ from one another in molecular weight, shape, flexibility, and charge at a physiological pH, and their chemical structures are shown in <a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>. The investigation into the binding of various substrates into the active site cavity of CYP2C8 reveals the mechanism by which CYP2C8 enzymes are involved in the metabolism of a broad panel of drugs, especially the large and anionic molecules.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Active site of CYP2C8 complex with ligands. (A) The interactions between montelukast and the residues in the ligand-binding site of CYP2C8. Heme and montelukast (labeled as MTK) are shown as sphere and stick. Portion of CYP2C8 protein harboring ligand-binding site residues was rendered as transparent cartoon. Residues making close contact to montelukast (less than 4 Å) are labeled with their side chains shown as stick. Potential hydrogen bonding interactions between residues in CYP2C8 and montelukast are depicted using dashed lines. For the following panels, the atom and structure color codes and depiction are the same as described in panel A. (B) Interactions between troglitazone and the residues in the ligand-binding site of CYP2C8. Due to the smaller size of troglitzone, only the upper-half space (away from heme) of the ligand-binding site of CYP2C8 was occupied. (C) Interactions between felodipine and the residues in the ligand-binding site of CYP2C8. (D) Interactions between retinoic acids and the residues in the ligand-binding site of CYP2C8. The proximal molecule of retinoic acid to the heme is labeled as REA1, and the distal molecule is labeled as REA2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of montelukast, troglitazone, felodipine, and 9-cis-retinoic acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Montelukast is the largest substrate among the four CYP2C8 ligands, and the molecular structure comprises three branches connected to a tertiary carbon atom in the center. The branch terminating with a dimethylphenylcarbinol resides deeply in the active site cavity, approaching the heme iron (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>A). The other two branches reside distally from the bottom of the cavity, and each of them occupies one of the two subcavities divided by helix B′–C loop. The longest branch with a planar conformation, which is also the most hydrophobic one, complements the subcavity with an opening on the C-terminal side of helix B′. The hydrophilic branch terminating with a carboxyl group occupies the other subcavity, and the carboxyl group is anchored by hydrogen bonds donated by Ser100 and Ser103 at N-terminal of helix B′ (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>A). Troglitazone is a ligand smaller and more linear in shape than montelukast. It is also anionic at physiological pH because of the weakly acidic thiazolidinedione group. This linear and flexible ligand exhibits a bent conformation in the active site cavity of CYP2C8, occupying only the upper part of the active site (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>B). The position of troglitazone is far from the heme, with an unoccupied volume as large as 500 Å<sup>3</sup> between them. Compared with troglitazone, felodipine has a slightly lower molecular weight (384.3 Da). The nonlinear shape and nonionic nature make it distinct from the two substrates described above. Interestingly, in contrast to troglitazone, felodipine occupies the lower part of active site cavity, residing close to the heme (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>C). The remaining volume of the cavity is filled with several water molecules. No hydrogen bonds are formed between felodipine and the water molecules or the protein residues. The contact between felodipine and CYP2C8 is dominated by hydrophobic interactions. Retinoic acid is the smallest among the four ligands, and two molecules of retinoic acid are found in the active site cavity of CYP2C8 in the crystal structure (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>D). The two molecules are aligned vertically, occupying the upper and lower part of the cavity, respectively. The trimethylcyclohexenyl moiety of the lower molecule is oriented close to the heme iron, and the carboxyl group at the other end of the linear molecule forms hydrogen bonds with Gly98 in helix B–B′ loop and Ser100 in helix B′. The upper retinoic acid molecule stacks on the first one and resides distally from the heme. Its trimethylcyclohexenyl moiety contacts the isoprenoid chain of the lower molecule, while its own isoprenoid chain inclines upward and the terminal carboxyl group forms hydrogen bonds with Asn204 in helix F and Arg241 in helix G (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>, D).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Glucuronides as Ligands of CYP2C8</h3><div class="NLM_p">Although several glucuronides have already been identified as CYP2C8 inhibitors or substrates, no crystal structures have been obtained for CYP2C8 bound with a glucuronide as its ligand. Thus, it is still unknown how the glucuronides complement the active site cavity of CYP2C8. The possible conformational changes of CYP2C8 upon the binding of glucuronides are also unknown. However, on the basis of the currently available CYP2C8-ligand complex structures, some predictions can be made regarding the binding of large and anionic substrates with CYP2C8. For the glucuronides to become CYP2C8 substrates, the sites of oxidation should be positioned close enough to the heme iron at bottom of the active site. Glucuronidation generates more bulky conjugates that can be accommodated by the large active site cavity of CYP2C8, although the upper limit for molecular weight of CYP2C8 ligands is not yet known. The conjugation of a flat but nonplanar glucuronosyl moiety can more or less change the conformation and flexibility of the structures and result in new properties that are not observed before conjugation. More importantly, introduction of glucuronosyl moiety into the structure may alter the charge of the structures at a physiological pH. The negative charges may largely increase the binding affinity due to enhanced hydrophilic interactions (e.g., hydrogen bond or charge-stabilized hydrogen bond) between the ligand and CYP2C8 residues. This can help explain the observations that certain compounds are not CYP2C8 substrates or inhibitors until they undergo glucuronidation.</div><div class="NLM_p last">In general, glucuronides tend to be less pharmacologically efficacious than the parents, perhaps due to the possible interruption in binding to the targets by the glucuronosyl group.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> However, there are also exceptions. For example, the binding affinity between morphine and δ-opioid receptor is largely increased after 6-glucuronidation.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> The changes in structural conformation brought by glucuronidation can unexpectedly alter the binding affinity between ligand and protein. Glucuronides as a CYP2C8 substrate could have a binding mechanism similar to that in the alteration of pharmacological effects by glucuronidation.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Summary and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63637" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63637" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although the DDI interactions by metabolites are usually less easy to detect than those occurring from parent drugs, the risk of such unfavorable DDIs should not be ignored, especially when glucuronidation is the predominant metabolism pathway or the glucuronides have high binding affinities with or inactivate the metabolism enzymes. Glucuronidation could be a potential liability as gemfibrozil and clopidogrel themselves do not inhibit CYP2C8 but are classified as strong CYP2C8 inhibitors because of their glucuronide metabolites by U.S. Food and Drug Administration. Moreover, oxidation of a glucuronide can generate “mysterious” metabolites that complicate metabolite identification as observed for desloratadine. After consecutive oxidation, glucuronidation, and hydrolysis of glucuronides, some oxidation metabolites can become difficult to be traced in source because they cannot be generated by incubating parent compounds with single CYP isoforms in the presence of the cofactor NADPH.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a></div><div class="NLM_p">The metabolic scheme of oxidation of glucuronides and other conjugate metabolites challenges the traditional classification system of metabolites as oxidative metabolites are normally classified as phase I metabolites and conjugates as phase II metabolites. Both oxidation and conjugation can be the primary metabolic pathway of a drug.</div><div class="NLM_p last">Several glucuronides have been identified as substrates or mechanism-based inhibitors of human CYP2C8, and the list is still growing. However, no systemic studies have yet been conducted to investigate the inherent properties of glucuronides as a unique category of CYP2C8 ligands. It is still largely unknown how the glucuronides exactly fit into the active site of CYP2C8 and why glucuronidation converts certain drugs to CYP2C8 ligands. This review summarized examples of drugs that are glucuronidated to become CYP2C8 ligands, and structural characteristics of human CYP2C8 related to the binding of anionic and bulky ligands. We hope this review will prompt general interest to identify future glucuronides or any other conjugation metabolites that may undergo oxidation leading to drug clearance and potential DDIs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00510" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74574" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74574" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donglu Zhang</span> - <span class="hlFld-Affiliation affiliation">†Drug Metabolism
& Pharmacokinetics and ‡Early Discovery Biochemistry, Genentech, South
San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Celgene
Corporation, 10300 Campus
Point Drive, San Diego California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8677-9737" title="Orcid link">http://orcid.org/0000-0001-8677-9737</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f48e9c959a93da909b9a939881b493919a91da979b99"><span class="__cf_email__" data-cfemail="c6bcaea7a8a1e8a2a9a8a1aab386a1a3a8a3e8a5a9ab">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Ma</span> - <span class="hlFld-Affiliation affiliation">†Drug Metabolism
& Pharmacokinetics and ‡Early Discovery Biochemistry, Genentech, South
San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Celgene
Corporation, 10300 Campus
Point Drive, San Diego California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5901-5440" title="Orcid link">http://orcid.org/0000-0001-5901-5440</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yue Fu</span> - <span class="hlFld-Affiliation affiliation">†Drug Metabolism
& Pharmacokinetics and ‡Early Discovery Biochemistry, Genentech, South
San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Celgene
Corporation, 10300 Campus
Point Drive, San Diego California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">S. Cyrus Khojasteh</span> - <span class="hlFld-Affiliation affiliation">†Drug Metabolism
& Pharmacokinetics and ‡Early Discovery Biochemistry, Genentech, South
San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Celgene
Corporation, 10300 Campus
Point Drive, San Diego California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepak Dalvie</span> - <span class="hlFld-Affiliation affiliation">Celgene
Corporation, 10300 Campus
Point Drive, San Diego California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Yong Ma</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=BIO-d7e948-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yong Ma</b> received his Ph.D. in Pharmaceutical Sciences from College of Pharmacy, University of Houston under the direction of Dr. Ming Hu. From 2015, he is employed by PPD and works as a research scientist in the Department of Drug Metabolism and Pharmacokinetics at Genentech (South San Francisco, CA). His research interest is focused on (1) the absorption, distribution, metabolism, and excretion (ADME) properties of small molecule drugs and (2) the catabolism of antibody–drug conjugates (ADCs).</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Yue Fu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=BIO-d7e953-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yue Fu</b> is a senior scientific researcher at Genentech. He is a structural biologist using X-ray crystallography to study protein structures and protein–ligand interactions. He received his Bachelor degree in Biosciences from University of Science and Technology of China and his Ph.D. in Molecular and Cellular Biochemistry from Indiana University Bloomington under the direction of Dr. David Giedroc. He then completed a 2-year postdoctoral training with Dr. Wayne Fairbrother at Genentech.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="17" class="article__inlineFigure"><h2 class="fig-label">S. Cyrus Khojasteh</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=BIO-d7e958-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>S. Cyrus Khojasteh</b> leads the Biotransformation Group at Genentech (South San Francisco) and was at Pfizer (Groton, CT) prior to 2000. His research focuses on the mechanisms of biotransformation in drug discovery and development with a particular interest in metabolism mediated by cytochrome P450 and non-cytochrome P450 enzymes. Cyrus received his B.S. from the University of California at Berkeley and his Ph.D. in Medicinal Chemistry from the University of Washington under the direction of Dr. Sidney D. Nelson.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Deepak Dalvie</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=BIO-d7e963-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Deepak Dalvie</b> is a Sr. Director in Drug Metabolism and Pharmacokinetics at Celgene. He received his B.Sc. in Chemistry and M.Sc. in the Technology of Pharmaceutical and Fine Chemicals at the University of Bombay, India, and his Ph.D. in Medicinal Chemistry at SUNY Buffalo, NY. After a postdoctoral fellowship in the areas of chemistry and metabolism under the supervision of firstly Professor Richard Sundberg at the University of Virginia and then Professor Neal Castagnoli at Virginia Tech, he joined Pfizer as a research scientist in 1992. His research interests include the biotransformation and bioactivation of xenobiotics and understanding the molecular mechanisms of drug metabolism and metabolic activation.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Donglu Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=BIO-d7e968-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Donglu Zhang</b> received a Ph.D. in Organic Chemistry from University of Utah and had postdoctoral trainings at University of Utah and U.S. Food and Drug Administration. He worked at Bristol-Myers Squibb at Princeton, NJ, and ARIAD Pharmaceuticals at Cambridge, MA, and joined Genentech at South San Francisco, CA, in 2014. His research interests include studying drug metabolites and drug metabolism enzymes in drug design and development of both small molecule drugs and antibody–drug conjugates (ADC). The mass defect filter (MDF) methodologies he and his colleague invented have been widely used for metabolite identification.</p></figure></div><div class="ack" id="ACK-d7e939-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78633" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78633" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. A. David Rodrigues from Pfizer and Drs. Shuguang Ma and Marcel Hop from Genentech for helpful discussion.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i19" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i19"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i20" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i20"> Abbreviations Used</h2><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the concentration–time curve</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interaction</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">NSAID</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drug</p></td></tr><tr><td class="NLM_term">OATP</td><td class="NLM_def"><p class="first last">organic anion-transporting polypeptide</p></td></tr><tr><td class="NLM_term">PPAR</td><td class="NLM_def"><p class="first last">peroxisome proliferator-activated receptors</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">UDPGA</td><td class="NLM_def"><p class="first last">uridine 5′-diphosphoglucuronic acid</p></td></tr><tr><td class="NLM_term">UGT</td><td class="NLM_def"><p class="first last">5′-diphosphoglucuronosyltransferase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26513" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26513" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 85 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">de Wildt, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearns, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeder, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Anker, J. N.</span><span> </span><span class="NLM_article-title">Glucuronidation in Humans</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span><span class="refDoi"> DOI: 10.2165/00003088-199936060-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2165%2F00003088-199936060-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10427468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaK1MXkvFeju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1999&pages=439-452&author=S.+N.+de+Wildtauthor=G.+L.+Kearnsauthor=J.+S.+Leederauthor=J.+N.+van+den+Anker&title=Glucuronidation+in+Humans&doi=10.2165%2F00003088-199936060-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Glucuronidation in humans: pharmacogenetic and developmental aspects</span></div><div class="casAuthors">De Wildt, Saskia N.; Kearns, Gregory L.; Leeder, J. Steven; Van den Anker, John N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">439-452</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 103 refs.  During human development impressive changes in drug disposition occur.  An important determinant of drug clearance is metab., something that is not only detd. by ontogenic regulation but also by genetic processes which add to the variability of drug metab. during different stages of childhood.  Therefore, an understanding of the developmental regulation of different metabolic pathways, together with information on the genetic determinants of drug metab., will increase the knowledge of inter- and intraindividual variability in drug disposition during childhood.  Conjugation has historically received less attention than cytochrome P 450 metab.  An important group of conjugation reactions are catalyzed by the UDP (UDP)-glucuronosyltransferases (UGTs); to date at least 10 different UGT isoforms have been identified.  The UGTs are not only involved in the metab. of many drugs [e.g. morphine, paracetamol (acetaminophen)] but also capable of the biotransformation of important endogenous substrates (e.g. bilirubin, ethinylestradiol) and several xenobiotics.  Isoform specificity for these substrates has, however, not been fully characterized.  Serious adverse events assocd. with chloramphenicol toxicity in the neonate have highlighted the importance of developmental changes in UGT activity. However, isoform-specific differences preclude the generalization of a simple developmental pattern for UGT activity.  UGT2B7 is the only UGT isoform for which ontogeny has been characterized both in vitro and in vivo, using morphine as the probe drug.  However, no general developmental pattern for the individual UGT isoforms which might be of value for the clinician is currently available.  Genetic polymorphisms have been identified for the UGT family.  Not only for the UGT1A gene, which reduces bilirubin glucuronidation, leading to genetic hyperbilirubinemia (the Crigler-Najjar and Gilbert's syndromes), but also for 3 other UGT isoforms.  However, the impact of these genetic differences on drug metab. remains to be established because of overlapping isoform specificity of the drugs studied, as well as a lack of specific probe substrates to test the activity of individual UGT isoforms in relation to these gene mutations.  Clearly, an information gap exists regarding the developmental and genetic aspects of UGT regulation and its potential impact on therapy.  More research is needed on the pharmacogenetics and ontogeny of the UGTs for effective translation of scientific information into clin. applicable knowledge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYL6-MjX3cLVg90H21EOLACvtfcHk0lgWn7oCK771WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvFeju7Y%253D&md5=b96b4918d8ab736ebac239cb17a13f9f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2165%2F00003088-199936060-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199936060-00005%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWildt%26aufirst%3DS.%2BN.%26aulast%3DKearns%26aufirst%3DG.%2BL.%26aulast%3DLeeder%26aufirst%3DJ.%2BS.%26aulast%3Dvan%2Bden%2BAnker%26aufirst%3DJ.%2BN.%26atitle%3DGlucuronidation%2520in%2520Humans%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1999%26volume%3D36%26spage%3D439%26epage%3D452%26doi%3D10.2165%2F00003088-199936060-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Tukey, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strassburg, C. P.</span><span> </span><span class="NLM_article-title">Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">616</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.40.1.581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1146%2Fannurev.pharmtox.40.1.581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10836148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjs1yht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2000&pages=581-616&author=R.+H.+Tukeyauthor=C.+P.+Strassburg&title=Human+UDP-Glucuronosyltransferases%3A+Metabolism%2C+Expression%2C+and+Disease&doi=10.1146%2Fannurev.pharmtox.40.1.581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Human UDP-glucuronosyltransferases. Metabolism, expression, and disease</span></div><div class="casAuthors">Tukey, Robert H.; Strassburg, Christian P.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">581-616, 2 plates</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review is given with 163 refs.  In vertebrates, the glucuronidation of small lipophilic agents is catalyzed by the endoplasmic reticulum UDP-glucuronosyltransferases (UGTs).  This metabolic pathway leads to the formation of water-sol. metabolites originating from normal dietary processes, cellular catabolism, or exposure to drugs and xenobiotics.  This classic detoxification process, which led to the discovery nearly 50 yr ago of the cosubstrate UDP-glucuronic acid, is now known to be carried out by 15 human UGTs.  Characterization of the individual gene products using cDNA expression expts. has led to the identification of over 350 individual compds. that serve as substrates for this superfamily of proteins.  This data, coupled with the introduction of sophisticated RNA detection techniques designed to elucidate patterns of gene expression of the UGT superfamily in human liver and extrahepatic tissues of the gastrointestinal tract, has aided in understanding the contribution of glucuronidation toward epithelial first-pass metab.  In addn., characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochem. basis of the clin. symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms assocd. with Crigler-Najjar's and Gilbert's syndrome.  The role of the UGTs in metab. and different disease states in humans is the topic of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKZgb1RfxRL7Vg90H21EOLACvtfcHk0licqjGMcfr8Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjs1yht7k%253D&md5=416a716f086fc387c95a97624b543f87</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.40.1.581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.40.1.581%26sid%3Dliteratum%253Aachs%26aulast%3DTukey%26aufirst%3DR.%2BH.%26aulast%3DStrassburg%26aufirst%3DC.%2BP.%26atitle%3DHuman%2520UDP-Glucuronosyltransferases%253A%2520Metabolism%252C%2520Expression%252C%2520and%2520Disease%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2000%26volume%3D40%26spage%3D581%26epage%3D616%26doi%3D10.1146%2Fannurev.pharmtox.40.1.581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Argikar, U. A.</span><span> </span><span class="NLM_article-title">Unusual Glucuronides</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1239</span><span class="NLM_x">–</span> <span class="NLM_lpage">1251</span><span class="refDoi"> DOI: 10.1124/dmd.112.045096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.112.045096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1239-1251&author=U.+A.+Argikar&title=Unusual+Glucuronides&doi=10.1124%2Fdmd.112.045096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.045096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.045096%26sid%3Dliteratum%253Aachs%26aulast%3DArgikar%26aufirst%3DU.%2BA.%26atitle%3DUnusual%2520Glucuronides%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1239%26epage%3D1251%26doi%3D10.1124%2Fdmd.112.045096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Kaivosaari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koskinen, M.</span><span> </span><span class="NLM_article-title">N-Glucuronidation Of Drugs And Other Xenobiotics By Human And Animal UDP-Glucuronosyltransferases</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">652</span><span class="NLM_x">–</span> <span class="NLM_lpage">669</span><span class="refDoi"> DOI: 10.3109/00498254.2011.563327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.3109%2F00498254.2011.563327" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=652-669&author=S.+Kaivosaariauthor=M.+Finelauthor=M.+Koskinen&title=N-Glucuronidation+Of+Drugs+And+Other+Xenobiotics+By+Human+And+Animal+UDP-Glucuronosyltransferases&doi=10.3109%2F00498254.2011.563327"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3109%2F00498254.2011.563327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2011.563327%26sid%3Dliteratum%253Aachs%26aulast%3DKaivosaari%26aufirst%3DS.%26aulast%3DFinel%26aufirst%3DM.%26aulast%3DKoskinen%26aufirst%3DM.%26atitle%3DN-Glucuronidation%2520Of%2520Drugs%2520And%2520Other%2520Xenobiotics%2520By%2520Human%2520And%2520Animal%2520UDP-Glucuronosyltransferases%26jtitle%3DXenobiotica%26date%3D2011%26volume%3D41%26spage%3D652%26epage%3D669%26doi%3D10.3109%2F00498254.2011.563327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Keppler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jedlitschky, G.</span><span> </span><span class="NLM_article-title">Transport Of Glutathione Conjugates And Glucuronides By The Multidrug Resistance Proteins MRP1 And MRP2</span> <span class="citation_source-journal">Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">378</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">791</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=1997&pages=787-791&author=D.+Kepplerauthor=I.+Leierauthor=G.+Jedlitschky&title=Transport+Of+Glutathione+Conjugates+And+Glucuronides+By+The+Multidrug+Resistance+Proteins+MRP1+And+MRP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DLeier%26aufirst%3DI.%26aulast%3DJedlitschky%26aufirst%3DG.%26atitle%3DTransport%2520Of%2520Glutathione%2520Conjugates%2520And%2520Glucuronides%2520By%2520The%2520Multidrug%2520Resistance%2520Proteins%2520MRP1%2520And%2520MRP2%26jtitle%3DBiol.%2520Chem.%26date%3D1997%26volume%3D378%26spage%3D787%26epage%3D791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Zamek-Gliszczynski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmaster, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nezasa, K.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallman, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brouwer, K. L. R.</span><span> </span><span class="NLM_article-title">Integration Of Hepatic Drug Transporters And Phase II Metabolizing Enzymes: Mechanisms Of Hepatic Excretion Of Sulfate, Glucuronide, And Glutathione Metabolites</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">447</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span><span class="refDoi"> DOI: 10.1016/j.ejps.2005.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2Fj.ejps.2005.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=16472997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Cht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=447-486&author=M.+J.+Zamek-Gliszczynskiauthor=K.+A.+Hoffmasterauthor=K.-i.+Nezasaauthor=M.+N.+Tallmanauthor=K.+L.+R.+Brouwer&title=Integration+Of+Hepatic+Drug+Transporters+And+Phase+II+Metabolizing+Enzymes%3A+Mechanisms+Of+Hepatic+Excretion+Of+Sulfate%2C+Glucuronide%2C+And+Glutathione+Metabolites&doi=10.1016%2Fj.ejps.2005.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites</span></div><div class="casAuthors">Zamek-Gliszczynski, Maciej J.; Hoffmaster, Keith A.; Nezasa, Ken-ichi; Tallman, Melanie N.; Brouwer, Kim L. R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">447-486</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The liver is the primary site of drug metab. in the body.  Typically, metabolic conversion of a drug results in inactivation, detoxification, and enhanced likelihood for excretion in urine or feces.  Sulfation, glucuronidation, and glutathione conjugation represent the three most prevalent classes of phase II metab., which may occur directly on the parent compds. that contain appropriate structural motifs, or, as is usually the case, on functional groups added or exposed by phase I oxidn.  These 3 conjugation reactions increase the mol. wt. and water soly. of the compd., in addn. to adding a neg. charge to the mol.  As a result of these changes in the physicochem. properties, phase II conjugates tend to have very poor membrane permeability, and necessitate carrier-mediated transport for biliary or hepatic basolateral excretion into sinusoidal blood for eventual excretion into urine.  This review summarizes sulfation, glucuronidation, and glutathione conjugation reactions, as well as recent progress in elucidating the hepatic transport mechanisms responsible for the excretion of these conjugates from the liver.  The discussion focuses on alterations of metab. and transport by chem. modulators, and disease states, as well as pharmacodynamic and toxicol. implications of hepatic metab. and/or transport modulation for certain active phase II conjugates.  A brief discussion of issues that must be considered in the design and interpretation of phase II metabolite transport studies follows.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGfVj8nU-TvLVg90H21EOLACvtfcHk0licqjGMcfr8Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Cht74%253D&md5=79b0cbce0c9a8c99167aca2b6e924955</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2005.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2005.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26aulast%3DHoffmaster%26aufirst%3DK.%2BA.%26aulast%3DNezasa%26aufirst%3DK.-i.%26aulast%3DTallman%26aufirst%3DM.%2BN.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%2BR.%26atitle%3DIntegration%2520Of%2520Hepatic%2520Drug%2520Transporters%2520And%2520Phase%2520II%2520Metabolizing%2520Enzymes%253A%2520Mechanisms%2520Of%2520Hepatic%2520Excretion%2520Of%2520Sulfate%252C%2520Glucuronide%252C%2520And%2520Glutathione%2520Metabolites%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D447%26epage%3D486%26doi%3D10.1016%2Fj.ejps.2005.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Zenser, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakshmi, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, B. B.</span><span> </span><span class="NLM_article-title">Human and Escherichia coli β-Glucuronidase Hydrolysis of Glucuronide Conjugates of Benzidine and 4-Aminobiphenyl, and Their Hydroxy Metabolites</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1064</span><span class="NLM_x">–</span> <span class="NLM_lpage">1067</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1064-1067&author=T.+V.+Zenserauthor=V.+M.+Lakshmiauthor=B.+B.+Davis&title=Human+and+Escherichia+coli+%CE%B2-Glucuronidase+Hydrolysis+of+Glucuronide+Conjugates+of+Benzidine+and+4-Aminobiphenyl%2C+and+Their+Hydroxy+Metabolites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZenser%26aufirst%3DT.%2BV.%26aulast%3DLakshmi%26aufirst%3DV.%2BM.%26aulast%3DDavis%26aufirst%3DB.%2BB.%26atitle%3DHuman%2520and%2520Escherichia%2520coli%2520%25CE%25B2-Glucuronidase%2520Hydrolysis%2520of%2520Glucuronide%2520Conjugates%2520of%2520Benzidine%2520and%25204-Aminobiphenyl%252C%2520and%2520Their%2520Hydroxy%2520Metabolites%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1064%26epage%3D1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Brunelle, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbeeck, R. K.</span><span> </span><span class="NLM_article-title">Conjugation-Deconjugation Cycling Of Diflunisal Via B-Glucuronidase Catalyzed Hydrolysis Of Its Acyl Glucuronide In The Rat</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2013</span><span class="NLM_x">–</span> <span class="NLM_lpage">2021</span><span class="refDoi"> DOI: 10.1016/S0024-3205(97)00166-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS0024-3205%2897%2900166-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1997&pages=2013-2021&author=F.+M.+Brunelleauthor=R.+K.+Verbeeck&title=Conjugation-Deconjugation+Cycling+Of+Diflunisal+Via+B-Glucuronidase+Catalyzed+Hydrolysis+Of+Its+Acyl+Glucuronide+In+The+Rat&doi=10.1016%2FS0024-3205%2897%2900166-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2897%2900166-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252897%252900166-5%26sid%3Dliteratum%253Aachs%26aulast%3DBrunelle%26aufirst%3DF.%2BM.%26aulast%3DVerbeeck%26aufirst%3DR.%2BK.%26atitle%3DConjugation-Deconjugation%2520Cycling%2520Of%2520Diflunisal%2520Via%2520B-Glucuronidase%2520Catalyzed%2520Hydrolysis%2520Of%2520Its%2520Acyl%2520Glucuronide%2520In%2520The%2520Rat%26jtitle%3DLife%2520Sci.%26date%3D1997%26volume%3D60%26spage%3D2013%26epage%3D2021%26doi%3D10.1016%2FS0024-3205%2897%2900166-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Danielson, P. B.</span><span> </span><span class="NLM_article-title">The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">597</span><span class="refDoi"> DOI: 10.2174/1389200023337054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2174%2F1389200023337054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=12369887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD38XoslKiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=561-597&author=P.+B.+Danielson&title=The+Cytochrome+P450+Superfamily%3A+Biochemistry%2C+Evolution+and+Drug+Metabolism+in+Humans&doi=10.2174%2F1389200023337054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The cytochrome P 450 superfamily: Biochemistry, evolution and drug metabolism in humans</span></div><div class="casAuthors">Danielson, P. B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">561-597</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 349 refs.  Cytochrome P 450s comprise a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their CO-bound species at 450 nm.  Having been found in every class of organism, including Archaea, the P 450 superfamily is believed to have originated from an ancestral gene that existed >3 × 109 yr ago.  Repeated gene duplications have subsequently given rise to one of the largest of multigene families.  These enzymes are notable both for the diversity of reactions that they catalyze and the range of chem. dissimilar substrates upon which they act.  Cytochrome P 450s support the oxidative, peroxidative, and reductive metab. of such endogenous and xenobiotic substrates as environmental pollutants, agrochems., plant allelochems., steroids, prostaglandins, and fatty acids.  In humans, cytochrome P 450s are best known for their central role in phase I drug metab. where they are of crit. importance to 2 of the most significant problems in clin. pharmacol.: drug interactions and interindividual variability in drug metab.  Recent advances in the understanding of cytochrome P 450-mediated drug metab. have been accelerated as a result of an increasing emphasis on functional genomic approaches to P 450 research.  Whereas human cytochrome P 450 databases have swelled with a flood of new human sequence variants, the functional characterization of the corresponding gene products has not kept pace.  In response, researchers have begun to apply the tools of proteomics as well as homol.-based and ab initio modeling to salient questions of cytochrome P 450 structure/function.  This review examines the latest advances in the understanding of human cytochrome P 450s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqurWL0xT89zrVg90H21EOLACvtfcHk0lhTUN_9_VeqLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XoslKiu7s%253D&md5=213ff54b516026f85862c08b179ba3bd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F1389200023337054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200023337054%26sid%3Dliteratum%253Aachs%26aulast%3DDanielson%26aufirst%3DP.%2BB.%26atitle%3DThe%2520Cytochrome%2520P450%2520Superfamily%253A%2520Biochemistry%252C%2520Evolution%2520and%2520Drug%2520Metabolism%2520in%2520Humans%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2002%26volume%3D3%26spage%3D561%26epage%3D597%26doi%3D10.2174%2F1389200023337054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Ridderström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamora, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fjellström, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, T. B.</span><span> </span><span class="NLM_article-title">Analysis of Selective Regions in the Active Sites of Human Cytochromes P450, 2C8, 2C9, 2C18, and 2C19 Homology Models Using GRID/CPCA</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4072</span><span class="NLM_x">–</span> <span class="NLM_lpage">4081</span><span class="refDoi"> DOI: 10.1021/jm0109107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0109107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4072-4081&author=M.+Ridderstr%C3%B6mauthor=I.+Zamoraauthor=O.+Fjellstr%C3%B6mauthor=T.+B.+Andersson&title=Analysis+of+Selective+Regions+in+the+Active+Sites+of+Human+Cytochromes+P450%2C+2C8%2C+2C9%2C+2C18%2C+and+2C19+Homology+Models+Using+GRID%2FCPCA&doi=10.1021%2Fjm0109107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm0109107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0109107%26sid%3Dliteratum%253Aachs%26aulast%3DRidderstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DZamora%26aufirst%3DI.%26aulast%3DFjellstr%25C3%25B6m%26aufirst%3DO.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DAnalysis%2520of%2520Selective%2520Regions%2520in%2520the%2520Active%2520Sites%2520of%2520Human%2520Cytochromes%2520P450%252C%25202C8%252C%25202C9%252C%25202C18%252C%2520and%25202C19%2520Homology%2520Models%2520Using%2520GRID%252FCPCA%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4072%26epage%3D4081%26doi%3D10.1021%2Fjm0109107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Lai, X.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.-F.</span><span> </span><span class="NLM_article-title">Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1009</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span><span class="refDoi"> DOI: 10.2174/138920009790711832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2174%2F138920009790711832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=20214592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFGjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1009-1047&author=X.-S.+Laiauthor=L.-P.+Yangauthor=X.-T.+Liauthor=J.-P.+Liuauthor=Z.-W.+Zhouauthor=S.-F.+Zhou&title=Human+CYP2C8%3A+Structure%2C+Substrate+Specificity%2C+Inhibitor+Selectivity%2C+Inducers+and+Polymorphisms&doi=10.2174%2F138920009790711832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms</span></div><div class="casAuthors">Lai, Xin-Sheng; Yang, Li-Ping; Li, Xiao-Tian; Liu, Jun-Ping; Zhou, Zhi-Wei; Zhou, Shu-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1009-1047</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Human CYP2C8 is a key member of the CYP2C family and metabolizes more than 60 clin. drugs.  A no. of active site residues in CYP2C8 have been identified based on homol. modeling and site-directed mutagenesis studies.  In the structure of CYP2C8, the large active site cavity exhibits a trifurcated topol. that approximates a T or Y shape, which is consistent with the finding that CYP2C8 can efficiently oxidize relatively large substrates such as paclitaxel and cerivastatin.  The active site cavity of CYP2C8 contains at least 48 amino acid residues and many of them are important for substrate binding.  The structures of CYP2C8 in complex with distinct ligands have revealed that the enzyme can bind divergent substrates and inhibitors without extensive conformational changes.  CYP2C8 is a major catalyst in the metab. of paclitaxel, amodiaquine, troglitazone, amiodarone, verapamil and ibuprofen, with a secondary role in the biotransformation of cerivastatin and fluvastatin.  CYP2C8 also metabolizes endogenous compds. such as retinoids and arachidonic acid.  Many drugs are inhibitors of CYP2C8 and inhibition of this enzyme may result in clin. drug interactions.  The pregnane X receptor, constitutive androstane receptor, and glucocorticoid receptor are likely to involve the regulation of CYP2C8.  A no. of genetic mutations in the CYP2C8 gene have been identified in humans and some of them have functional impact on the clearance of drugs.  Further studies are needed to delineate the role of CYP2C8 in drug development and clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk08nPzZToRbVg90H21EOLACvtfcHk0liOUjfxQvsFRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFGjtbY%253D&md5=a0788a14c7bfaa3cc8db1fb512587648</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F138920009790711832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920009790711832%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DX.-S.%26aulast%3DYang%26aufirst%3DL.-P.%26aulast%3DLi%26aufirst%3DX.-T.%26aulast%3DLiu%26aufirst%3DJ.-P.%26aulast%3DZhou%26aufirst%3DZ.-W.%26aulast%3DZhou%26aufirst%3DS.-F.%26atitle%3DHuman%2520CYP2C8%253A%2520Structure%252C%2520Substrate%2520Specificity%252C%2520Inhibitor%2520Selectivity%252C%2520Inducers%2520and%2520Polymorphisms%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2009%26volume%3D10%26spage%3D1009%26epage%3D1047%26doi%3D10.2174%2F138920009790711832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kirchheiner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomalik-Scharte, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hering, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshyenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jetter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stehle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsahuridu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meineke, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockmöller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuhr, U.</span><span> </span><span class="NLM_article-title">Pharmacokinetics And Pharmacodynamics Of Rosiglitazone In Relation To CYP2C8 Genotype</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span><span class="refDoi"> DOI: 10.1016/j.clpt.2006.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2Fj.clpt.2006.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=17178266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtleisb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=657-667&author=J.+Kirchheinerauthor=S.+Thomasauthor=S.+Bauerauthor=D.+Tomalik-Scharteauthor=U.+Heringauthor=O.+Doroshyenkoauthor=A.+Jetterauthor=S.+Stehleauthor=M.+Tsahuriduauthor=I.+Meinekeauthor=J.+Brockm%C3%B6llerauthor=U.+Fuhr&title=Pharmacokinetics+And+Pharmacodynamics+Of+Rosiglitazone+In+Relation+To+CYP2C8+Genotype&doi=10.1016%2Fj.clpt.2006.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype</span></div><div class="casAuthors">Kirchheiner, Julia; Thomas, Soju; Bauer, Steffen; Tomalik-Scharte, Dorota; Hering, Ursula; Doroshyenko, Oxana; Jetter, Alexander; Stehle, Simone; Tsahuridu, Martina; Meineke, Ingolf; Brockmoeller, Juergen; Fuhr, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">657-667</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Rosiglitazone is metabolically inactivated predominantly via the cytochrome P 450 (CYP) enzyme CYP2C8.  The functional impact of the CYP2C8*3 allele coding for the Arg139Lys and Lys399Arg amino acid substitutions is controversial.  The purpose of this was to clarify the role of this polymorphism with regard to the pharmacokinetics and clin. effects of rosiglitazone.  From a large sample of healthy volunteers, 14 carriers of the CYP2C8*1/*1 allele, 13 carriers of the *1/*3 allele, and 4 carriers the *3/*3 allele were selected for a clin. study.  Rosiglitazone (8 mg) single-dose and multiple-dose pharmacokinetics and its effects on glucose level and body wt. were monitored.  Plasma and urine concns. of rosiglitazone and desmethylrosiglitazone were measured, and kinetics was analyzed by noncompartmental and population-kinetic compartmental methods.  Mean total clearance values were 0.033 L/h-1/kg-1 (95% confidence interval [CI], 0.030-0.037 L/h-1/kg-1), 0.038 L/h-1/kg-1 (95% CI, 0.033-0.044 L/h-1/kg-1), and 0.046 L/h-1/kg-1 (95% CI, 0.033-0.058 L/h-1/kg-1) in carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, resp., on day 1 (P = .02, ANOVA [F test]).  Rosiglitazone kinetics could be adequately described by a 1-compartmental model with first-order absorption.  Besides CYP2C8 genotype, body wt. was a significant covariate (P < .001, log-likelihood ratio test).  Elimination half-lives were 4.3, 3.5, and 2.9 h in CYP2C8*1/*1, *1/*3, and *3/*3 carriers, resp.  Clearance of desmethylrosiglitazone was also higher in CYP2C8*3 allele carriers, with mean values of 1.96 L/h (95% CI, 1.42-2.69 L/h), 2.22 L/h (95% CI, 1.61-3.04 L/h), and 2.47 L/h (95% CI, 1.80-3.39 L/h), resp. (P = .03).  The plasma glucose area under the concn. curve was significantly lower after 14 days of taking rosiglitazone compared with day 1 (P = .01, paired t test), but no relationship of the glucose-lowering effect of rosiglitazone with CYP2C8 genotype was obsd.  This study showed that the CYP2C8*3 allele confers higher in vivo metabolic capacity than the wild-type CYP2C8*1 allele but the pharmacokinetic differences resulting from CYP2C8*3 were quant. moderate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohGEb91I4sObVg90H21EOLACvtfcHk0liOUjfxQvsFRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtleisb7J&md5=9286decbf161a5ce7feaf2c52c43bc15</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2006.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2006.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DKirchheiner%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DTomalik-Scharte%26aufirst%3DD.%26aulast%3DHering%26aufirst%3DU.%26aulast%3DDoroshyenko%26aufirst%3DO.%26aulast%3DJetter%26aufirst%3DA.%26aulast%3DStehle%26aufirst%3DS.%26aulast%3DTsahuridu%26aufirst%3DM.%26aulast%3DMeineke%26aufirst%3DI.%26aulast%3DBrockm%25C3%25B6ller%26aufirst%3DJ.%26aulast%3DFuhr%26aufirst%3DU.%26atitle%3DPharmacokinetics%2520And%2520Pharmacodynamics%2520Of%2520Rosiglitazone%2520In%2520Relation%2520To%2520CYP2C8%2520Genotype%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2006%26volume%3D80%26spage%3D657%26epage%3D667%26doi%3D10.1016%2Fj.clpt.2006.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kaspera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naraharisetti, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamraz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahele, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheesman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwok, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciante, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckbert, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Psaty, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totah, R. A.</span><span> </span><span class="NLM_article-title">Cerivastatin In Vitro Metabolism By CYP2C8 Variants Found In Patients Experiencing Rhabdomyolysis</span> <span class="citation_source-journal">Pharmacogenet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">619</span><span class="NLM_x">–</span> <span class="NLM_lpage">629</span><span class="refDoi"> DOI: 10.1097/FPC.0b013e32833ecace</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1097%2FFPC.0b013e32833ecace" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=20739906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKlsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=619-629&author=R.+Kasperaauthor=S.+B.+Naraharisettiauthor=B.+Tamrazauthor=T.+Saheleauthor=M.+J.+Cheesmanauthor=P.-Y.+Kwokauthor=K.+Marcianteauthor=S.+R.+Heckbertauthor=B.+M.+Psatyauthor=R.+A.+Totah&title=Cerivastatin+In+Vitro+Metabolism+By+CYP2C8+Variants+Found+In+Patients+Experiencing+Rhabdomyolysis&doi=10.1097%2FFPC.0b013e32833ecace"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis</span></div><div class="casAuthors">Kaspera, Ruediger; Naraharisetti, Suresh B.; Tamraz, Bani; Sahele, Tariku; Cheesman, Matthew J.; Kwok, Pui-Yan; Marciante, Kristin; Heckbert, Susan R.; Psaty, Bruce M.; Totah, Rheem A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">619-629</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Cerivastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor withdrawn from the market because of serious adverse effects, is metabolized primarily by CYP2C8.  The occurrence of assocd. myotoxicity and rhabdomyolysis were attributed to altered cerivastatin pharmacokinetics on account of gemfibrozil-inhibition or genetic variations in CYP2C8 and drug transporters involved in cerivastatin clearance.  However, the effect of CYP2C8 genetic variation on cerivastatin metab. has not been fully elucidated.  In this study, patients (n=126) with confirmed cases of rhabdomyolysis after cerivastatin administration had their CYP2C8 gene resequenced and the metab. of cerivastatin by the discovered CYP2C8 variants was assessed in proteins expressed in Escherichia coli.  In this unique patient population, 12 novel single nucleotide polymorphisms were discovered of which six were exclusively found in patients not using gemfibrozil.  Three rare exonic variants resulted in amino acid substitutions and a frame shift deletion (V472fsL494 generating a defective mostly heme-free CYP2C8 protein).  A particular promoter located deletion (-635_-634delTA) was tightly linked to CYP2C8*3.  Heterologously expressed CYP2C8.3 and CYP2C8.4 displayed an increase in cerivastatin metabolic clearance of up to six-fold compared with the wild-type enzyme.  Similarly, an independent sample of microsomes from human livers carrying the CYP2C8*3 and CYP2C8*4 alleles exhibited a 2-fold to 14-fold increase in normalized cerivastatin intrinsic clearance, compared with microsomes from livers carrying only the wild type allele.  Gain or loss of catalytic function found in the CYP2C8 gene could certainly alter cerivastatin pharmacokinetics and may influence, at least in part, susceptibility to the development of myotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoabUTTU4RlQrVg90H21EOLACvtfcHk0liWGQg5yGr6fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKlsL3I&md5=60c06d1669981a75b539bbff52021b0d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e32833ecace&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e32833ecace%26sid%3Dliteratum%253Aachs%26aulast%3DKaspera%26aufirst%3DR.%26aulast%3DNaraharisetti%26aufirst%3DS.%2BB.%26aulast%3DTamraz%26aufirst%3DB.%26aulast%3DSahele%26aufirst%3DT.%26aulast%3DCheesman%26aufirst%3DM.%2BJ.%26aulast%3DKwok%26aufirst%3DP.-Y.%26aulast%3DMarciante%26aufirst%3DK.%26aulast%3DHeckbert%26aufirst%3DS.%2BR.%26aulast%3DPsaty%26aufirst%3DB.%2BM.%26aulast%3DTotah%26aufirst%3DR.%2BA.%26atitle%3DCerivastatin%2520In%2520Vitro%2520Metabolism%2520By%2520CYP2C8%2520Variants%2520Found%2520In%2520Patients%2520Experiencing%2520Rhabdomyolysis%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2010%26volume%3D20%26spage%3D619%26epage%3D629%26doi%3D10.1097%2FFPC.0b013e32833ecace" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Li, X.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Björkman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridderström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masimirembwa, C. M.</span><span> </span><span class="NLM_article-title">Amodiaquine Clearance and Its Metabolism toN-Desethylamodiaquine Is Mediated by CYP2C8: A New High Affinity and Turnover Enzyme-Specific Probe Substrate</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">300</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span><span class="refDoi"> DOI: 10.1124/jpet.300.2.399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fjpet.300.2.399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=11805197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1ynsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2002&pages=399-407&author=X.-Q.+Liauthor=A.+Bj%C3%B6rkmanauthor=T.+B.+Anderssonauthor=M.+Ridderstr%C3%B6mauthor=C.+M.+Masimirembwa&title=Amodiaquine+Clearance+and+Its+Metabolism+toN-Desethylamodiaquine+Is+Mediated+by+CYP2C8%3A+A+New+High+Affinity+and+Turnover+Enzyme-Specific+Probe+Substrate&doi=10.1124%2Fjpet.300.2.399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate</span></div><div class="casAuthors">Li, Xue-Qing; Bjorkman, Anders; Andersson, Tommy B.; Ridderstrom, Marianne; Masimirembwa, Collen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">300</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">399-407</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Amodiaquine (AQ) metab. to N-desethylamodiaquine (DEAQ) is the principal route of disposition in humans.  Using human liver microsomes and 2 sets of recombinant human cytochrome P 450 isoforms (from lymphoblastoids and yeast) the authors performed studies to identify the CYP isoform(s) involved in the metab. of AQ.  CYP2C8 was the main hepatic isoform that cleared AQ and catalyzed the formation of DEAQ.  The extrahepatic P450s, 1A1 and 1B1, also cleared AQ and catalyzed the formation of an unknown metabolite M2.  The Km and Vmax values for AQ N-desethylation were 1.2 μM and 2.6 pmol/min/pmol of CYP2C8 for recombinant CYP2C8, and 2.4 μM and 1462 pmol/min/mg of protein for human liver microsomes (HLMs), resp.  Relative contribution of CYP2C8 in the formation of DEAQ was estd. at 100% using the relative activity factor method.  Correlation analyses between AQ metab. and the activities of 8 hepatic P450s were made on 10 different HLM samples.  Both the formation of DEAQ and the clearance of AQ showed excellent correlations (r2 = 0.98 and 0.95) with 6α-hydroxylation of paclitaxel, a marker substrate for CYP2C8.  The inhibition of DEAQ formation by quercetin was competitive with Ki values of 1.96 for CYP2C8 and 1.56 μM for HLMs.  Docking of AQ into the active site homol. models of the CYP2C isoforms showed favorable interactions with CYP2C8, which supported the likelihood of an N-desethylation reaction.  These data show that CYP2C8 is the main hepatic isoform responsible for the metab. of AQ.  The specificity, high affinity, and high turnover make AQ desethylation an excellent marker reaction for CYP2C8 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6UmpNdA6McrVg90H21EOLACvtfcHk0liWGQg5yGr6fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1ynsw%253D%253D&md5=b4cc92f1cf92e34e9daa26b0ef825875</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.300.2.399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.300.2.399%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.-Q.%26aulast%3DBj%25C3%25B6rkman%26aufirst%3DA.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26aulast%3DRidderstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DMasimirembwa%26aufirst%3DC.%2BM.%26atitle%3DAmodiaquine%2520Clearance%2520and%2520Its%2520Metabolism%2520toN-Desethylamodiaquine%2520Is%2520Mediated%2520by%2520CYP2C8%253A%2520A%2520New%2520High%2520Affinity%2520and%2520Turnover%2520Enzyme-Specific%2520Probe%2520Substrate%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D300%26spage%3D399%26epage%3D407%26doi%3D10.1124%2Fjpet.300.2.399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Bahadur, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leathart, J. B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steimel-Crespi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houdt, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohets, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, A. K.</span><span> </span><span class="NLM_article-title">CYP2C8 Polymorphisms In Caucasians And Their Relationship With Paclitaxel 6α-Hydroxylase Activity In Human Liver Microsomes</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1579</span><span class="NLM_x">–</span> <span class="NLM_lpage">1589</span><span class="refDoi"> DOI: 10.1016/S0006-2952(02)01354-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS0006-2952%2802%2901354-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2002&pages=1579-1589&author=N.+Bahadurauthor=J.+B.+S.+Leathartauthor=E.+Mutchauthor=D.+Steimel-Crespiauthor=S.+A.+Dunnauthor=R.+Gilissenauthor=J.+V.+Houdtauthor=J.+Hendrickxauthor=G.+Mannensauthor=H.+Bohetsauthor=F.+M.+Williamsauthor=M.+Armstrongauthor=C.+L.+Crespiauthor=A.+K.+Daly&title=CYP2C8+Polymorphisms+In+Caucasians+And+Their+Relationship+With+Paclitaxel+6%CE%B1-Hydroxylase+Activity+In+Human+Liver+Microsomes&doi=10.1016%2FS0006-2952%2802%2901354-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2802%2901354-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252802%252901354-0%26sid%3Dliteratum%253Aachs%26aulast%3DBahadur%26aufirst%3DN.%26aulast%3DLeathart%26aufirst%3DJ.%2BB.%2BS.%26aulast%3DMutch%26aufirst%3DE.%26aulast%3DSteimel-Crespi%26aufirst%3DD.%26aulast%3DDunn%26aufirst%3DS.%2BA.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DHoudt%26aufirst%3DJ.%2BV.%26aulast%3DHendrickx%26aufirst%3DJ.%26aulast%3DMannens%26aufirst%3DG.%26aulast%3DBohets%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DF.%2BM.%26aulast%3DArmstrong%26aufirst%3DM.%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26atitle%3DCYP2C8%2520Polymorphisms%2520In%2520Caucasians%2520And%2520Their%2520Relationship%2520With%2520Paclitaxel%25206%25CE%25B1-Hydroxylase%2520Activity%2520In%2520Human%2520Liver%2520Microsomes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2002%26volume%3D64%26spage%3D1579%26epage%3D1589%26doi%3D10.1016%2FS0006-2952%2802%2901354-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Daily, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aquilante, C. L.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2C8 Pharmacogenetics: A Review Of Clinical Studies</span> <span class="citation_source-journal">Pharmacogenomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1489</span><span class="NLM_x">–</span> <span class="NLM_lpage">1510</span><span class="refDoi"> DOI: 10.2217/pgs.09.82</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2217%2Fpgs.09.82" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1489-1510&author=E.+B.+Dailyauthor=C.+L.+Aquilante&title=Cytochrome+P450+2C8+Pharmacogenetics%3A+A+Review+Of+Clinical+Studies&doi=10.2217%2Fpgs.09.82"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2217%2Fpgs.09.82&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fpgs.09.82%26sid%3Dliteratum%253Aachs%26aulast%3DDaily%26aufirst%3DE.%2BB.%26aulast%3DAquilante%26aufirst%3DC.%2BL.%26atitle%3DCytochrome%2520P450%25202C8%2520Pharmacogenetics%253A%2520A%2520Review%2520Of%2520Clinical%2520Studies%26jtitle%3DPharmacogenomics%26date%3D2009%26volume%3D10%26spage%3D1489%26epage%3D1510%26doi%3D10.2217%2Fpgs.09.82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honkalammi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurkinen, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tornio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2359</span><span class="NLM_x">–</span> <span class="NLM_lpage">2366</span><span class="refDoi"> DOI: 10.1124/dmd.109.029728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.109.029728" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=2359-2366&author=J.+T.+Backmanauthor=J.+Honkalammiauthor=M.+Neuvonenauthor=K.+J.+Kurkinenauthor=A.+Tornioauthor=M.+Niemiauthor=P.+J.+Neuvonen&title=CYP2C8+Activity+Recovers+within+96+Hours+after+Gemfibrozil+Dosing%3A+Estimation+of+CYP2C8+Half-Life+Using+Repaglinide+as+an+in+Vivo+Probe&doi=10.1124%2Fdmd.109.029728"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.029728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.029728%26sid%3Dliteratum%253Aachs%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DHonkalammi%26aufirst%3DJ.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DKurkinen%26aufirst%3DK.%2BJ.%26aulast%3DTornio%26aufirst%3DA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DCYP2C8%2520Activity%2520Recovers%2520within%252096%2520Hours%2520after%2520Gemfibrozil%2520Dosing%253A%2520Estimation%2520of%2520CYP2C8%2520Half-Life%2520Using%2520Repaglinide%2520as%2520an%2520in%2520Vivo%2520Probe%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D2359%26epage%3D2366%26doi%3D10.1124%2Fdmd.109.029728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Totah, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettie, A. E.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1016/j.clpt.2004.12.267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2Fj.clpt.2004.12.267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=15900280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFCrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=341-352&author=R.+A.+Totahauthor=A.+E.+Rettie&title=Cytochrome+P450+2C8%3A+Substrates%2C+Inhibitors%2C+Pharmacogenetics%2C+and+Clinical+Relevance&doi=10.1016%2Fj.clpt.2004.12.267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P 450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance</span></div><div class="casAuthors">Totah, Rheem A.; Rettie, Allan E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-352</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 (CYP) 2C9 has been a relatively neglected member of the human CYP2C family.  Over the period of 2000-2003, PubMed searches with the key word CYP2C8 returned only 10-15% of the citations obtained for all of the CYP2C enzymes combined.  However, in the past year a crystal structure for CYP2C8 has been described, new inhibitors and probe substrates for the enzyme have been in development, the 1st case study was published linking CYP2C8 genetic polymorphisms to a disease state, and there has been an increasing awareness of the role that CYP2C8 plays in the disposition of therapeutic agents, esp. from the pharmacogenetic and drug-drug interaction perspectives.  This report discusses baseline characteristics of the enzyme and summarizes recent developments in these areas and their clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXLgu0RrkE6LVg90H21EOLACvtfcHk0liT83oN8BFfPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFCrt70%253D&md5=a8b79c67e57ba839dc59a43609bb9ffb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.12.267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.12.267%26sid%3Dliteratum%253Aachs%26aulast%3DTotah%26aufirst%3DR.%2BA.%26aulast%3DRettie%26aufirst%3DA.%2BE.%26atitle%3DCytochrome%2520P450%25202C8%253A%2520Substrates%252C%2520Inhibitors%252C%2520Pharmacogenetics%252C%2520and%2520Clinical%2520Relevance%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D341%26epage%3D352%26doi%3D10.1016%2Fj.clpt.2004.12.267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Lv, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2C8 And Drug Metabolism</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2241</span><span class="NLM_x">–</span> <span class="NLM_lpage">2253</span><span class="refDoi"> DOI: 10.2174/15680266113136660157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2174%2F15680266113136660157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=24047136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CgurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=2241-2253&author=X.+Lvauthor=F.+Zhongauthor=X.+Tan&title=Cytochrome+P450+2C8+And+Drug+Metabolism&doi=10.2174%2F15680266113136660157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 2C8 and Drug Metabolism</span></div><div class="casAuthors">Lv, Xiaoping; Zhong, Fangfang; Tan, Xiangshi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2241-2253</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  CYP 2C8, which carries out the oxidative metab. of at least 5% of clin. drugs, has attracted increasing attention in recent years.  New drugs (substances), inducers and inhibitors of CYP 2C8 have been developed and the drug metab. has been investigated to understand the clin. role of CYP2C8.  The cases of CYP2C8 genetic polymorphisms linked to diseases have increased and have been investigated.  Herein, important progress in these areas has been reviewed with an emphasis on drug metab.  Polymorphisms, diseases related to CYP2C8, some important drugs (substances) and inhibitors are reviewed and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4H6PuJRAo1LVg90H21EOLACvtfcHk0liT83oN8BFfPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CgurbK&md5=584b1251bfb7d98d19216444c41e99cd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F15680266113136660157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266113136660157%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DTan%26aufirst%3DX.%26atitle%3DCytochrome%2520P450%25202C8%2520And%2520Drug%2520Metabolism%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D2241%26epage%3D2253%26doi%3D10.2174%2F15680266113136660157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Ogilvie, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gipson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holsapple, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">Glucuronidation Converts Gemfibrozil To A Potent, Metabolism-Dependent Inhibitor Of Cyp2c8: Implications For Drug-Drug Interactions</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span><span class="refDoi"> DOI: 10.1124/dmd.105.007633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.105.007633" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=191-197&author=B.+W.+Ogilvieauthor=D.+Zhangauthor=W.+Liauthor=A.+D.+Rodriguesauthor=A.+E.+Gipsonauthor=J.+Holsappleauthor=P.+Torenauthor=A.+Parkinson&title=Glucuronidation+Converts+Gemfibrozil+To+A+Potent%2C+Metabolism-Dependent+Inhibitor+Of+Cyp2c8%3A+Implications+For+Drug-Drug+Interactions&doi=10.1124%2Fdmd.105.007633"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.007633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.007633%26sid%3Dliteratum%253Aachs%26aulast%3DOgilvie%26aufirst%3DB.%2BW.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DGipson%26aufirst%3DA.%2BE.%26aulast%3DHolsapple%26aufirst%3DJ.%26aulast%3DToren%26aufirst%3DP.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DGlucuronidation%2520Converts%2520Gemfibrozil%2520To%2520A%2520Potent%252C%2520Metabolism-Dependent%2520Inhibitor%2520Of%2520Cyp2c8%253A%2520Implications%2520For%2520Drug-Drug%2520Interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D191%26epage%3D197%26doi%3D10.1124%2Fdmd.105.007633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Kyrklund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivistö, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laitila, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Plasma Concentrations Of Active Lovastatin Acid Are Markedly Increased By Gemfibrozil But Not By Bezafibrate</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">345</span><span class="refDoi"> DOI: 10.1067/mcp.2001.115542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1067%2Fmcp.2001.115542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=11372002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlyhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2001&pages=340-345&author=C.+Kyrklundauthor=J.+T.+Backmanauthor=K.+T.+Kivist%C3%B6author=M.+Neuvonenauthor=J.+Laitilaauthor=P.+J.+Neuvonen&title=Plasma+Concentrations+Of+Active+Lovastatin+Acid+Are+Markedly+Increased+By+Gemfibrozil+But+Not+By+Bezafibrate&doi=10.1067%2Fmcp.2001.115542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate</span></div><div class="casAuthors">Kyrklund, Carl; Backman, Janne T.; Kivisto, Kari T.; Neuvonen, Mikko; Laitila, Jouko; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Concomitant use of fibrates with statins has been assocd. with an increased risk of myopathy, but the underlying mechanism of this adverse reaction remains unclear.  Our aim was to study the effects of bezafibrate and gemfibrozil on the pharmacokinetics of lovastatin.  This was a randomized, double-blind, 3-phase crossover study.  Eleven healthy volunteers took 400 mg/day bezafibrate, 1200 mg/day gemfibrozil, or placebo for 3 days.  On day 3, each subject ingested a single 40 mg dose of lovastatin.  Plasma concns. of lovastatin, lovastatin acid, gemfibrozil, and bezafibrate were measured up to 24 h.  Gemfibrozil markedly increased the plasma concns. of lovastatin acid, without affecting those of the parent lovastatin compared with placebo.  During the gemfibrozil phase, the mean area under the plasma concn.-time curve from 0 to 24 h [AUC(0-24)] of lovastatin acid was 280% (range, 131% to 1184%; P <.001) and the peak plasma concn. (Cmax) was 280% (range, 123% to 1042%; P <.05) of the corresponding value during the placebo phase.  Bezafibrate had no statistically significant effect on the AUC(0-24) or Cmax of lovastatin or lovastatin acid compared with placebo.  Gemfibrozil markedly increases plasma concns. of lovastatin acid, but bezafibrate does not.  The increased risk of myopathy obsd. during concomitant treatment with statins and fibrates may be partially of a pharmacokinetic origin.  The risk of developing myopathy during concomitant therapy with lovastatin and a fibrate may be smaller with bezafibrate than with gemfibrozil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlz_ewmutjLLVg90H21EOLACvtfcHk0lhbRIAt8dQhGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlyhsL8%253D&md5=884322ec09d4798fe2800689fa5e1c94</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2001.115542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2001.115542%26sid%3Dliteratum%253Aachs%26aulast%3DKyrklund%26aufirst%3DC.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DKivist%25C3%25B6%26aufirst%3DK.%2BT.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DLaitila%26aufirst%3DJ.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DPlasma%2520Concentrations%2520Of%2520Active%2520Lovastatin%2520Acid%2520Are%2520Markedly%2520Increased%2520By%2520Gemfibrozil%2520But%2520Not%2520By%2520Bezafibrate%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D69%26spage%3D340%26epage%3D345%26doi%3D10.1067%2Fmcp.2001.115542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, S.-H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Extrapolation of Diclofenac Clearance from in Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">969</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span><span class="refDoi"> DOI: 10.1124/jpet.102.038992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fjpet.102.038992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=12438516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD38Xptlamt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=969-978&author=S.+Kumarauthor=K.+Samuelauthor=R.+Subramanianauthor=M.+P.+Braunauthor=R.+A.+Stearnsauthor=S.-H.+L.+Chiuauthor=D.+C.+Evansauthor=T.+A.+Baillie&title=Extrapolation+of+Diclofenac+Clearance+from+in+Vitro+Microsomal+Metabolism+Data%3A+Role+of+Acyl+Glucuronidation+and+Sequential+Oxidative+Metabolism+of+the+Acyl+Glucuronide&doi=10.1124%2Fjpet.102.038992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide</span></div><div class="casAuthors">Kumar, Sanjeev; Samuel, Koppara; Subramanian, Ramaswamy; Braun, Matthew P.; Stearns, Ralph A.; Chiu, Shuet-Hing Lee; Evans, David C.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">969-978</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Diclofenac is eliminated predominantly (∼50%) as its 4'-hydroxylated metabolite in humans, whereas the acyl glucuronide (AG) pathway appears more important in rats (∼50%) and dogs (>80-90%).  However, previous studies of diclofenac oxidative metab. in human liver microsomes (HLMs) have yielded pronounced underprediction of human in vivo clearance.  We detd. the relative quant. importance of 4'-hydroxy and AG pathways of diclofenac metab. in rat, dog, and human liver microsomes.  Microsomal intrinsic clearance values (CLint = Vmax/Km) were detd. and used to extrapolate the in vivo blood clearance of diclofenac in these species.  Clearance of diclofenac was accurately predicted from microsomal data only when both the AG and the 4'-hydroxy pathways were considered.  However, the fact that the AG pathway in HLMs accounted for ∼75% of the estd. hepatic CLint of diclofenac is apparently inconsistent with the 4'-hydroxydiclofenac excretion data in humans.  Interestingly, upon incubation with HLMs, significant oxidative metab. of diclofenac AG, directly to 4'-hydroxy diclofenac AG, was obsd.  The estd. hepatic CLint of this pathway suggested that a significant fraction of the intrahepatically formed diclofenac AG may be converted to its 4'-hydroxy deriv. in vivo.  Further expts. indicated that this novel oxidative reaction was catalyzed by CYP2C8, as opposed to CYP2C9-catalyzed 4'-hydroxylation of diclofenac.  These findings may have general implications in the use of total (free + conjugated) oxidative metabolite excretion for detg. primary routes of drug clearance and may question the utility of diclofenac as a probe for phenotyping human CYP2C9 activity in vivo via measurement of its pharmacokinetics and total 4'-hydroxydiclofenac urinary excretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgA3RsS4GJ5LVg90H21EOLACvtfcHk0lhbRIAt8dQhGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xptlamt7Y%253D&md5=0e3fbd3cec4fb7eb62df4cb162b64609</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.038992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.038992%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSamuel%26aufirst%3DK.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DBraun%26aufirst%3DM.%2BP.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DChiu%26aufirst%3DS.-H.%2BL.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DExtrapolation%2520of%2520Diclofenac%2520Clearance%2520from%2520in%2520Vitro%2520Microsomal%2520Metabolism%2520Data%253A%2520Role%2520of%2520Acyl%2520Glucuronidation%2520and%2520Sequential%2520Oxidative%2520Metabolism%2520of%2520the%2520Acyl%2520Glucuronide%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D969%26epage%3D978%26doi%3D10.1124%2Fjpet.102.038992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Small, R. E.</span><span> </span><span class="NLM_article-title">Diclofenac Sodium</span> <span class="citation_source-journal">Clin. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">558</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=2670397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaL1MXlt1KgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1989&pages=545-558&author=R.+E.+Small&title=Diclofenac+Sodium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Diclofenac sodium</span></div><div class="casAuthors">Small, Ralph E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacy</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">545-58</span>CODEN:
                <span class="NLM_cas:coden">CPHADV</span>;
        ISSN:<span class="NLM_cas:issn">0278-2677</span>.
    </div><div class="casAbstract">A review with 124 refs. on the pharmacol., pharmacokinetics, clin. efficacy, adverse effects and recommended dosages of diclofenac sodium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmB5gieDLxoLVg90H21EOLACvtfcHk0lhW_C-_lXuoBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlt1KgsLw%253D&md5=b0c81c304e47ccf97311299c0abdf62d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmall%26aufirst%3DR.%2BE.%26atitle%3DDiclofenac%2520Sodium%26jtitle%3DClin.%2520Pharm.%26date%3D1989%26volume%3D8%26spage%3D545%26epage%3D558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Bort, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macé, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boobis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Lechón, M. a.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeifer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castell, J.</span><span> </span><span class="NLM_article-title">Hepatic Metabolism Of Diclofenac: Role Of Human CYP In The Minor Oxidative Pathways</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span><span class="refDoi"> DOI: 10.1016/S0006-2952(99)00167-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS0006-2952%2899%2900167-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10449188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaK1MXltVyjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1999&pages=787-796&author=R.+Bortauthor=K.+Mac%C3%A9author=A.+Boobisauthor=M.+a.-J.+G%C3%B3mez-Lech%C3%B3nauthor=A.+Pfeiferauthor=J.+Castell&title=Hepatic+Metabolism+Of+Diclofenac%3A+Role+Of+Human+CYP+In+The+Minor+Oxidative+Pathways&doi=10.1016%2FS0006-2952%2899%2900167-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways</span></div><div class="casAuthors">Bort, Roque; Mace, Katherine; Boobis, Alan; Gomez-Lechon, Maria-Jose; Pfeifer, Andrea; Castell, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">787-796</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The aim of this study was to re-examine the human hepatic metab. of diclofenac, with special focus on the generation of minor hydroxylated metabolites implicated in the idiosyncratic hepatotoxicity of the drug.  Different exptl. approaches were used: human hepatocytes, human microsomes, and engineered cells expressing single human CYP (cytochromes P 450).  Human hepatocytes formed 3'-hydroxy-, 4'-hydroxy-, 5-hydroxy-4',5-dihydroxy-, and N,5-dihydroxydiclofenac, as well as several lactams.  Formation of 4'- and 5-hydroxydiclofenac by human liver microsomes followed a Michaelis-Menten kinetics (Km 9±1 μM; Vmax 432±15 pmol/min/mg and Km 43±5 μM; and Vmax 15.4±0.6 pmol/min/mg, resp.).  Secondary metabolites were detected after incubation of 5-hydroxydiclofenac with human liver microsomes, yielding 4',5-dihydroxydiclofenac (Km 15±1 μM; Vmax 96±3 pmol/min/mg) and small amts. of N,5-dihydroxydiclofenac (non-Michaelis-Menten kinetics).  Based on microsome studies and the incubations with human hepatocytes and engineered cells, we estd. that in vivo CYP2C9 would be exclusively responsible for the 4' hydroxylation of diclofenac (>99.5%) as well as 5-hydroxydiclofenac (>97%).  CYP2C9 was exclusively responsible for the formation of 3'-hydroxydiclofenac.  Multiple regression anal. evidenced that the rate of prodn. of 5-hydroxydiclofenac in human microsomes followed the algorithm: 0.040 × S-mephenytoin 4'-hydroxylation + 0.083 × tolbutamide methylhydroxylation, (multiple correlation coeff. = 0.969).  However, the incubation of diclofenac with cell lines expressing different human CYP suggested that 7 isoforms could be involved.  Comparison of data obtained with CYP-expressing cells and human hepatocytes suggests that CYP2C8 > CYP2C19 ≃ CYP2C18 >> CYP2B6 are the isoforms implicated in the 5-hydroxylation of diclofenac in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKYjl48rn-ELVg90H21EOLACvtfcHk0lhW_C-_lXuoBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVyjt7o%253D&md5=66ebc46f6555d8fad144404dad5a8fb6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2899%2900167-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252899%252900167-7%26sid%3Dliteratum%253Aachs%26aulast%3DBort%26aufirst%3DR.%26aulast%3DMac%25C3%25A9%26aufirst%3DK.%26aulast%3DBoobis%26aufirst%3DA.%26aulast%3DG%25C3%25B3mez-Lech%25C3%25B3n%26aufirst%3DM.%2Ba.-J.%26aulast%3DPfeifer%26aufirst%3DA.%26aulast%3DCastell%26aufirst%3DJ.%26atitle%3DHepatic%2520Metabolism%2520Of%2520Diclofenac%253A%2520Role%2520Of%2520Human%2520CYP%2520In%2520The%2520Minor%2520Oxidative%2520Pathways%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1999%26volume%3D58%26spage%3D787%26epage%3D796%26doi%3D10.1016%2FS0006-2952%2899%2900167-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Stierlin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faigle, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kriemler, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alt, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, T.</span><span> </span><span class="NLM_article-title">Biotransformation Of Diclofenac Sodium (Voltaren®) In Animals And In Man</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">610</span><span class="refDoi"> DOI: 10.3109/00498257909042327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.3109%2F00498257909042327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=119352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaL3cXhsFOntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1979&pages=601-610&author=H.+Stierlinauthor=J.+W.+Faigleauthor=A.+Sallmannauthor=W.+Kungauthor=W.+J.+Richterauthor=H.+P.+Kriemlerauthor=K.+O.+Altauthor=T.+Winkler&title=Biotransformation+Of+Diclofenac+Sodium+%28Voltaren%C2%AE%29+In+Animals+And+In+Man&doi=10.3109%2F00498257909042327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Biotransformation of diclofenac sodium (Voltaren) in animals and in man.  I.  Isolation and identification of principal metabolites</span></div><div class="casAuthors">Stierlin, H.; Faigle, J. W.; Sallmann, A.; Kueng, W.; Richter, W. J.; Kriemler, H. P.; Alt, K. O.; Winkler, T.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">601-10</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    </div><div class="casAbstract">The antiinflammatory agent, diclofenac Na (Voltaren)(I)  [15307-79-6], was extensively metabolized after oral, i.v., or i.m. dosing by rat, dog, baboon, and man, and the main metabolites were isolated from urine of all species and from bile of rat and dog and identified.  Metab. involved direct conjugation of unchanged I, or oxidn. of the arom. rings usually followed by conjugation.  Oxidn. sites were either position 3' or 4' of the dichlorophenyl ring or position 5 of the Ph ring attached to the acetic acid moiety.  In the urine of rat, baboon, and man, conjugates of the hydroxylated metabolites predominate, but in dog urine the taurine conjugate of unchanged I was the major metabolite.  In bile of rat and dog, the ester glucuronide of unchanged I was the main metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsQa-zjp1qPbVg90H21EOLACvtfcHk0lhW_C-_lXuoBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhsFOntbw%253D&md5=f256da7d10e4fc3359217520713edbe9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3109%2F00498257909042327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498257909042327%26sid%3Dliteratum%253Aachs%26aulast%3DStierlin%26aufirst%3DH.%26aulast%3DFaigle%26aufirst%3DJ.%2BW.%26aulast%3DSallmann%26aufirst%3DA.%26aulast%3DKung%26aufirst%3DW.%26aulast%3DRichter%26aufirst%3DW.%2BJ.%26aulast%3DKriemler%26aufirst%3DH.%2BP.%26aulast%3DAlt%26aufirst%3DK.%2BO.%26aulast%3DWinkler%26aufirst%3DT.%26atitle%3DBiotransformation%2520Of%2520Diclofenac%2520Sodium%2520%2528Voltaren%25C2%25AE%2529%2520In%2520Animals%2520And%2520In%2520Man%26jtitle%3DXenobiotica%26date%3D1979%26volume%3D9%26spage%3D601%26epage%3D610%26doi%3D10.3109%2F00498257909042327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">King, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tephly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, M.</span><span> </span><span class="NLM_article-title">Characterization of Rat and Human UDP-Glucuronosyltransferases Responsible for the in Vitro Glucuronidation of Diclofenac</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span><span class="refDoi"> DOI: 10.1093/toxsci/61.1.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1093%2Ftoxsci%2F61.1.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=11294973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtV2rs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=49-53&author=C.+Kingauthor=W.+Tangauthor=J.+Nguiauthor=T.+Tephlyauthor=M.+Braun&title=Characterization+of+Rat+and+Human+UDP-Glucuronosyltransferases+Responsible+for+the+in+Vitro+Glucuronidation+of+Diclofenac&doi=10.1093%2Ftoxsci%2F61.1.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac</span></div><div class="casAuthors">King, C.; Tang, W.; Ngui, J.; Tephly, T.; Braun, M.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-53</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">In the current study, the identification of the rat and human UDP-glucuronosyltransferase (UGT) isoforms responsible for the glucuronidation of diclofenac was detd.  Recombinant human UGT1A9 catalyzed the glucuronidation of diclofenac at a moderate rate of 166-pmol/min/mg protein, while UGT1A6 and 2B15 catalyzed the glucuronidation of diclofenac at low rates (<20-pmol/min/mg protein).  Conversely, human UGT2B7 displayed a high rate of diclofenac glucuronide formation (>500 pmol/min/mg protein).  Recombinant rat UGT2B1 catalyzed the glucuronidation of diclofenac at a rate of 250-pmol/min/mg protein.  Rat UGT2B1 and human UGT2B7 displayed a similar, low apparent Km value of <15 μM for both UGT isoforms and high Vmax values 0.3 and 2.8 nmol/min/mg, resp.  Using diclofenac as a substrate, enzyme kinetics in rat and human liver microsomes showed that the enzyme(s) involved in diclofenac glucuronidation had a low apparent Km value of <20 μM and a high Vmax value of 0.9 and 4.3 nmol/min/mg protein, resp.  Morphine is a known substrate for rat UGT2B1 and human UGT2B7 and both total morphine glucuronidation (3-O- and 6-O-glucuronides) and diclofenac glucuronidation reactions showed a strong correlation with one another in human liver microsome samples.  In addn., diclofenac inhibited the glucuronidation of morphine in human liver microsomes.  These data suggested that rat UGT2B1 and human UGT2B7 were the major UGT isoforms involved in the glucuronidation of diclofenac.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-AFb4daZw07Vg90H21EOLACvtfcHk0lhxPr7BvP6XhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtV2rs74%253D&md5=84358ad742d33f27ac424d0fe5625191</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2F61.1.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252F61.1.49%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DNgui%26aufirst%3DJ.%26aulast%3DTephly%26aufirst%3DT.%26aulast%3DBraun%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520Rat%2520and%2520Human%2520UDP-Glucuronosyltransferases%2520Responsible%2520for%2520the%2520in%2520Vitro%2520Glucuronidation%2520of%2520Diclofenac%26jtitle%3DToxicol.%2520Sci.%26date%3D2001%26volume%3D61%26spage%3D49%26epage%3D53%26doi%3D10.1093%2Ftoxsci%2F61.1.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Davies, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. E.</span><span> </span><span class="NLM_article-title">Clinical Pharmacokinetics of Diclofenac</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span><span class="refDoi"> DOI: 10.2165/00003088-199733030-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2165%2F00003088-199733030-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=9314611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVeltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1997&pages=184-213&author=N.+M.+Daviesauthor=K.+E.+Anderson&title=Clinical+Pharmacokinetics+of+Diclofenac&doi=10.2165%2F00003088-199733030-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls</span></div><div class="casAuthors">Davies, Neal M.; Anderson, Keith E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-213</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review with 203 refs.  Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class.  When given orally the absorption of diclofenac is rapid and complete.  Diclofenac binds extensively to plasma albumin.  The area under the plasma concn.-time curve (AUC) of diclofenac is proportional to the dose for oral doses between 25 to 150 mg.  Substantial concns. of drug are attained in synovial fluid, which is the proposed site of action for NSAIDs.  Concn.-effect relationships have been established for total bound, unbound and synovial fluid diclofenac concns.  Diclofenac is eliminated following biotransformation to glucoroconjugated and sulfate metabolites which are excreted in urine, very little drug is eliminated unchanged.  The excretion of conjugates may be related to renal function.  Conjugate accumulation occurs in end-stage renal disease; however, no accumulation is apparent upon comparison of young and elderly individuals.  Dosage adjustments for the elderly, children or for patients with various disease states (such as hepatic disease or rheumatoid arthritis) may not be required.  Significant drug interactions have been demonstrated for aspirin (acetylsalicylic acid), lithium, digoxin, methotrexate, cyclosporin, cholestyramine and colestipol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkTAhShlnbwLVg90H21EOLACvtfcHk0lhxPr7BvP6XhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVeltr4%253D&md5=198d8e4035a4a79966ae081e9ac75a9c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2165%2F00003088-199733030-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199733030-00003%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DN.%2BM.%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26atitle%3DClinical%2520Pharmacokinetics%2520of%2520Diclofenac%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1997%26volume%3D33%26spage%3D184%26epage%3D213%26doi%3D10.2165%2F00003088-199733030-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Kulkarni, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pal Singh, V.</span><span> </span><span class="NLM_article-title">Licofelone-A Novel Analgesic and Anti-Inflammatory Agent</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.2174/156802607779941305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2174%2F156802607779941305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=17305568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Wjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=251-263&author=S.+K.+Kulkarniauthor=V.+Pal+Singh&title=Licofelone-A+Novel+Analgesic+and+Anti-Inflammatory+Agent&doi=10.2174%2F156802607779941305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Licofelone-A novel analgesic and anti-inflammatory agent</span></div><div class="casAuthors">Kulkarni, S. K.; Singh, Vijay Pal</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-263</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Dual inhibitors that block both cyclooxygenase (COX) and lipoxygenase (LOX) metabolic pathways of arachidonic acid are expected to possess clin. advantages over the selective inhibitors of COX enzyme.  One of the most promising compds. belonging to this category is licofelone ([2,2 -dimethyl-6-(4-chlorophenyl-7-phenyl)-2,3-dihydro-1H-pyrazoline-5-yl] acetic acid).  Originally discovered by Merckle GmbH and developed by EuroAllaince, licofelone (IC50 COX = 0.21 μM, IC50 5-LOX = 0.18μM) possesses significant analgesic, anti-inflammatory, and antiasthmatic effects at doses that cause no gastrointestinal (GI) side effects.  The pharmacodynamic profile of licofelone has been assessed and compared with widely used NSAIDs in different animal models.  The ED50 value of licofelone is reported to be 11.22-27.07 mg/kg, po and 39.5-55-8 mg/kg, po against carrageenan-induced paw edema and Randal Selitto hyperalgesic assay in rats, resp.  Licofelone showed analgesic effect (ED50 = 31.33 mg/kg) against acetic acid-induced writhing in mice.  Licofelone has long duration of action and more effective than indomethacin and zileuton with ED50 values of 2.92 mg/kg, po and 36.77 mg/kg, po, in the mech. hyperalgesia and cold allodynia testing, resp., against rat model of incisional pain.  Licofelone significantly ameliorated indomethacin-induced gastric ulceration, neutrophil adhesion in mesentery, and lipid peroxides in rat gastric mucosa.  Also, licofelone reversed the altered vascular permeability, morphol. changes, and prevented NSAIDs-related increase in leukotriene levels in gastric mucosa.  The preclin. studies have shown that licofelone not only has convincing pharmacodynamic effect but also it is well tolerated.  It is currently under clin. evaluation in osteoarthritis (OA), the most common form of arthritis.  The present review describes pharmacol. and clin. development of licofelone as a dual inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq60C70bAEHxbVg90H21EOLACvtfcHk0lhxPr7BvP6XhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Wjsb8%253D&md5=dba46be57a155d0995a3ff79cc9b3c47</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F156802607779941305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607779941305%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DS.%2BK.%26aulast%3DPal%2BSingh%26aufirst%3DV.%26atitle%3DLicofelone-A%2520Novel%2520Analgesic%2520and%2520Anti-Inflammatory%2520Agent%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D251%26epage%3D263%26doi%3D10.2174%2F156802607779941305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Bias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klesser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">The Gastrointestinal Tolerability of the LOX//COX Inhibitor, Licofelone, is Similar to Placebo and Superior to Naproxen Therapy in Healthy Volunteers: Results From a Randomized, Controlled Trial</span> <span class="citation_source-journal">Am. J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">618</span><span class="refDoi"> DOI: 10.1111/j.1572-0241.2004.04133.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1111%2Fj.1572-0241.2004.04133.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=15089890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFGgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2004&pages=611-618&author=P.+Biasauthor=A.+Buchnerauthor=B.+Klesserauthor=S.+Laufer&title=The+Gastrointestinal+Tolerability+of+the+LOX%2F%2FCOX+Inhibitor%2C+Licofelone%2C+is+Similar+to+Placebo+and+Superior+to+Naproxen+Therapy+in+Healthy+Volunteers%3A+Results+From+a+Randomized%2C+Controlled+Trial&doi=10.1111%2Fj.1572-0241.2004.04133.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial</span></div><div class="casAuthors">Bias, Peter; Buchner, Anton; Klesser, Bernard; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">611-618</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">OBJECTIVE: Concerns exist over the safety of conventional nonsteroidal antiinflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors.  In exptl. models, licofelone, a competitive inhibitor of 5-lipoxygenase (5-LOX) and COX-1/-2, has been shown to have good gastrointestinal and general tolerability and analgesic and anti inflammatory properties.  The aim of the present endoscopy trial was to investigate the gastroduodenal tolerability of licofelone compared to placebo and naproxen in healthy volunteers.  METHODS: In this randomized, parallel-group trial, healthy volunteers received licofelone 200 mg b.i.d. (n = 30), licofelone 400 mg b.i.d. (n = 30), naproxen 500 mg b.i.d. (n = 30), or placebo (n = 31).  Tolerability was assessed by gastro/duodenoscopy following 4 wk of treatment.  Lab. parameters and the incidence of ulcers and adverse events were recorded.  RESULTS: Ulcers were obsd. in 20% of the naproxen-treated volunteers, compared with 0% of those receiving licofelone 200 mg, licofelone 400 mg, and placebo (p = 0.024).  Posttreatment mean gastric Lanza scores were similar for volunteers who received placebo or either dose of licofelone, while Lanza scores were significantly worse following naproxen therapy (p < 0.00001).  The gastric mucosa was normal in 93%, 89%, and 90% of volunteers who received licofelone 200 mg, licofelone 400 mg, or placebo, resp., compared with 37% of volunteers receiving naproxen.  The incidence of adverse events did not differ significantly between licofelone 200 mg or naproxen therapy.  No clin. relevant changes in lab. parameters were obsd. with licofelone or naproxen therapy.  CONCLUSIONS: The results from this trial indicate that licofelone has a potential gastrointestinal safety advantage over conventional NSAID therapy, as licofelone was assocd. with significantly superior gastric tolerability and a lower incidence of ulcers compared with naproxen in healthy volunteers.  Further trials will be required to investigate the safety and efficacy of licofelone in the treatment of diseases such as osteoarthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4_sMdLBAfl7Vg90H21EOLACvtfcHk0lj4jI85hiZ69w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFGgsrs%253D&md5=ab304b86eb0d5f6ab8bfa251ee0f6ae3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1572-0241.2004.04133.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1572-0241.2004.04133.x%26sid%3Dliteratum%253Aachs%26aulast%3DBias%26aufirst%3DP.%26aulast%3DBuchner%26aufirst%3DA.%26aulast%3DKlesser%26aufirst%3DB.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DThe%2520Gastrointestinal%2520Tolerability%2520of%2520the%2520LOX%252F%252FCOX%2520Inhibitor%252C%2520Licofelone%252C%2520is%2520Similar%2520to%2520Placebo%2520and%2520Superior%2520to%2520Naproxen%2520Therapy%2520in%2520Healthy%2520Volunteers%253A%2520Results%2520From%2520a%2520Randomized%252C%2520Controlled%2520Trial%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2004%26volume%3D99%26spage%3D611%26epage%3D618%26doi%3D10.1111%2Fj.1572-0241.2004.04133.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Albrecht, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussler, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and −2 and 5-Lipoxygenase</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">894</span><span class="NLM_x">–</span> <span class="NLM_lpage">903</span><span class="refDoi"> DOI: 10.1124/dmd.108.020347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.108.020347" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=894-903&author=W.+Albrechtauthor=A.+Ungerauthor=A.+K.+Nusslerauthor=S.+Laufer&title=In+Vitro+Metabolism+of+2-%5B6-%284-Chlorophenyl%29-2%2C2-dimethyl-7-phenyl-2%2C3-dihydro-1H-pyrrolizin-5-yl%5D+Acetic+Acid+%28Licofelone%2C+ML3000%29%2C+an+Inhibitor+of+Cyclooxygenase-1+and+%E2%88%922+and+5-Lipoxygenase&doi=10.1124%2Fdmd.108.020347"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020347%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DNussler%26aufirst%3DA.%2BK.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DIn%2520Vitro%2520Metabolism%2520of%25202-%255B6-%25284-Chlorophenyl%2529-2%252C2-dimethyl-7-phenyl-2%252C3-dihydro-1H-pyrrolizin-5-yl%255D%2520Acetic%2520Acid%2520%2528Licofelone%252C%2520ML3000%2529%252C%2520an%2520Inhibitor%2520of%2520Cyclooxygenase-1%2520and%2520%25E2%2588%25922%2520and%25205-Lipoxygenase%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D894%26epage%3D903%26doi%3D10.1124%2Fdmd.108.020347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Delaforge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pruvost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">André, F.</span><span> </span><span class="NLM_article-title">Cytochrome P450-Mediated Oxidation Of Glucuronide Derivatives: Example Of Estradiol-17β-Glucuronide Oxidation To 2-Hydroxy-Estradiol-17β-Glucuronide By Cyp 2c8</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1124/dmd.104.002097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.104.002097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=466-473&author=M.+Delaforgeauthor=A.+Pruvostauthor=L.+Perrinauthor=F.+Andr%C3%A9&title=Cytochrome+P450-Mediated+Oxidation+Of+Glucuronide+Derivatives%3A+Example+Of+Estradiol-17%CE%B2-Glucuronide+Oxidation+To+2-Hydroxy-Estradiol-17%CE%B2-Glucuronide+By+Cyp+2c8&doi=10.1124%2Fdmd.104.002097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.104.002097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.104.002097%26sid%3Dliteratum%253Aachs%26aulast%3DDelaforge%26aufirst%3DM.%26aulast%3DPruvost%26aufirst%3DA.%26aulast%3DPerrin%26aufirst%3DL.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26atitle%3DCytochrome%2520P450-Mediated%2520Oxidation%2520Of%2520Glucuronide%2520Derivatives%253A%2520Example%2520Of%2520Estradiol-17%25CE%25B2-Glucuronide%2520Oxidation%2520To%25202-Hydroxy-Estradiol-17%25CE%25B2-Glucuronide%2520By%2520Cyp%25202c8%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D466%26epage%3D473%26doi%3D10.1124%2Fdmd.104.002097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Rainsford, K. D.</span><span> </span><span class="NLM_article-title">Ibuprofen: Pharmacology, Efficacy And Safety</span> <span class="citation_source-journal">Inflammopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span><span class="refDoi"> DOI: 10.1007/s10787-009-0016-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1007%2Fs10787-009-0016-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=19949916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2mtrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=275-342&author=K.+D.+Rainsford&title=Ibuprofen%3A+Pharmacology%2C+Efficacy+And+Safety&doi=10.1007%2Fs10787-009-0016-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ibuprofen: pharmacology, efficacy and safety</span></div><div class="casAuthors">Rainsford, K. D.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">275-342</span>CODEN:
                <span class="NLM_cas:coden">IAOAES</span>;
        ISSN:<span class="NLM_cas:issn">0925-4692</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">Objectives: This review attempts to bring together information from a large no. of recent studies on the clin. uses, safety and pharmacol. properties of ibuprofen.  Ibuprofen is widely used in many countries for the relief of symptoms of pain, inflammation and fever.  The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.  Summary of outcomes: At low doses (800-1,200 mg day-1) which in many countries are approved for non-prescription (over-the-counter) sale ibuprofen has a good safety profile comparable with paracetamol.  Its analgesic activity is linked to its anti-inflammatory effects and is related to redn. in the ex vivo prodn. in blood of cyclo-oxygenase (COX)-1 and COX-2 derived prostanoids.  Higher prescription doses (circa 1,800-2,400 mg day-1) are employed long-term for the treatment of rheumatic and other more severe musculo-skeletal conditions.  Recent evidence from large-scale clin. trials with the newer coxibs, where ibuprofen was as a comparator, have confirmed earlier studies which have shown that ibuprofen has comparable therapeutic benefits with coxibs and other NSAIDs.  For long-term usage (6+ months) there are greater nos. of drop-outs due to reduced effectiveness of therapy, a feature which is common with NSAIDs.  Spontaneous reports of adverse events and adverse drug reactions (ADRs) in clin. trails from long-term coxib comparator studies, as well as in epidemiol. studies, shows that ibuprofen has relatively low risks for gastro-intestinal (GI), hepato-renal and other, rarer, ADRs compared with other NSAIDs and coxibs.  A slightly higher risk of cardiovascular (CV) events has been reported in some, but not all studies, but the risks are in general lower than with some coxibs and diclofenac.  The possibility that ibuprofen may interfere with the anti-platelet effects of aspirin, though arguably of low grade or significance, has given rise to caution on its use in patients that are at risk for CV conditions that take aspirin for preventing these conditions.  Paediatric use of ibuprofen is reviewed and the main results are that the drug is relatively safe and effective as a treatment of acute pain and fever.  It is probably more effective than paracetamol as an antipyretic.  Conclusions: This assessment of the safety and benefits of ibuprofen can be summarized thus: (1) Ibuprofen at OTC doses has low possibilities of serious GI events, and little prospect of developing renal and assocd. CV events.  Ibuprofen OTC does not represent a risk for developing liver injury esp. the irreversible liver damage obsd. with paracetamol and the occasional liver reactions from aspirin.  (2) The pharmacokinetic properties of ibuprofen, esp. the short plasma half-life of elimination, lack of development of pathol. related metabolites (e.g. covalent modification of liver proteins by the quinine-imine metabolite of paracetamol or irreversible acetylation of biomols. by aspirin) are support for the view that these pharmacokinetic and notably metabolic effects of ibuprofen favor its low toxic potential.  (3) The multiple actions of ibuprofen in controlling inflammation combine with moderate inhibition of COX-1 and COX-2 and low residence time of the drug in the body may account for the low GI, CV and renal risks from ibuprofen, esp. at OTC doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHjA0RUBqP_7Vg90H21EOLACvtfcHk0lj4jI85hiZ69w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2mtrvP&md5=940d686cf8ce694c9ef273c2a170a556</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs10787-009-0016-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10787-009-0016-x%26sid%3Dliteratum%253Aachs%26aulast%3DRainsford%26aufirst%3DK.%2BD.%26atitle%3DIbuprofen%253A%2520Pharmacology%252C%2520Efficacy%2520And%2520Safety%26jtitle%3DInflammopharmacology%26date%3D2009%26volume%3D17%26spage%3D275%26epage%3D342%26doi%3D10.1007%2Fs10787-009-0016-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Mazaleuskaya, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theken, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorn, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FitzGerald, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T. E.</span><span> </span><span class="NLM_article-title">Pharmocology Summary: Ibuprofen Pathways</span> <span class="citation_source-journal">Pharmacogenet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1097/FPC.0000000000000113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1097%2FFPC.0000000000000113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=25502615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKqsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=96-106&author=L.+L.+Mazaleuskayaauthor=K.+N.+Thekenauthor=L.+Gongauthor=C.+F.+Thornauthor=G.+A.+FitzGeraldauthor=R.+B.+Altmanauthor=T.+E.+Klein&title=Pharmocology+Summary%3A+Ibuprofen+Pathways&doi=10.1097%2FFPC.0000000000000113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">PharmGKB summary: ibuprofen pathways</span></div><div class="casAuthors">Mazaleuskaya, Liudmila L.; Theken, Katherine N.; Gong, Li; Thorn, Caroline F.; FitzGerald, Garret A.; Altman, Russ B.; Klein, Teri E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">96-106</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5JB2Ls4azxbVg90H21EOLACvtfcHk0lj7zUwpkYLf5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKqsb7M&md5=d665cba994d93024b38703726e24ca62</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1097%2FFPC.0000000000000113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0000000000000113%26sid%3Dliteratum%253Aachs%26aulast%3DMazaleuskaya%26aufirst%3DL.%2BL.%26aulast%3DTheken%26aufirst%3DK.%2BN.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DThorn%26aufirst%3DC.%2BF.%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26aulast%3DKlein%26aufirst%3DT.%2BE.%26atitle%3DPharmocology%2520Summary%253A%2520Ibuprofen%2520Pathways%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2015%26volume%3D25%26spage%3D96%26epage%3D106%26doi%3D10.1097%2FFPC.0000000000000113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Jenkins, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span> </span><span class="NLM_article-title">Studies to Further Investigate the Inhibition of Human Liver Microsomal CYP2C8 by the Acyl-β-Glucuronide of Gemfibrozil</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2421</span><span class="NLM_x">–</span> <span class="NLM_lpage">2430</span><span class="refDoi"> DOI: 10.1124/dmd.111.041947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.111.041947" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2421-2430&author=S.+M.+Jenkinsauthor=T.+Zvyagaauthor=S.+R.+Johnsonauthor=J.+Hurleyauthor=A.+Wagnerauthor=R.+Burrellauthor=W.+Turleyauthor=J.+E.+Leetauthor=T.+Philipauthor=A.+D.+Rodrigues&title=Studies+to+Further+Investigate+the+Inhibition+of+Human+Liver+Microsomal+CYP2C8+by+the+Acyl-%CE%B2-Glucuronide+of+Gemfibrozil&doi=10.1124%2Fdmd.111.041947"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.041947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.041947%26sid%3Dliteratum%253Aachs%26aulast%3DJenkins%26aufirst%3DS.%2BM.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DHurley%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DBurrell%26aufirst%3DR.%26aulast%3DTurley%26aufirst%3DW.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DPhilip%26aufirst%3DT.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26atitle%3DStudies%2520to%2520Further%2520Investigate%2520the%2520Inhibition%2520of%2520Human%2520Liver%2520Microsomal%2520CYP2C8%2520by%2520the%2520Acyl-%25CE%25B2-Glucuronide%2520of%2520Gemfibrozil%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2421%26epage%3D2430%26doi%3D10.1124%2Fdmd.111.041947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Colca, J. R.</span><span> </span><span class="NLM_article-title">Discontinued Drugs In 2006: Renal, Endocrine And Metabolic Drugs</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1517</span><span class="NLM_x">–</span> <span class="NLM_lpage">1523</span><span class="refDoi"> DOI: 10.1517/13543784.16.10.1517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1517%2F13543784.16.10.1517" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=1517-1523&author=J.+R.+Colca&title=Discontinued+Drugs+In+2006%3A+Renal%2C+Endocrine+And+Metabolic+Drugs&doi=10.1517%2F13543784.16.10.1517"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.10.1517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.10.1517%26sid%3Dliteratum%253Aachs%26aulast%3DColca%26aufirst%3DJ.%2BR.%26atitle%3DDiscontinued%2520Drugs%2520In%25202006%253A%2520Renal%252C%2520Endocrine%2520And%2520Metabolic%2520Drugs%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D1517%26epage%3D1523%26doi%3D10.1517%2F13543784.16.10.1517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Nishihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeshiba, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyota, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahi, S.</span><span> </span><span class="NLM_article-title">Metabolic Fate of Sipoglitazar a Novel Oral PPAR Agonist with Activities for PPAR-γ, -α and -δ, in Rats and Monkeys and Comparison with Humans In Vitro</span> <span class="citation_source-journal">Drug Metab. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.2133/dmpk.DMPK-11-RG-061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2133%2Fdmpk.DMPK-11-RG-061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=22123126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1yisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=223-231&author=M.+Nishiharaauthor=M.+Sudoauthor=H.+Kamiguchiauthor=N.+Kawaguchiauthor=Y.+Maeshibaauthor=Y.+Kiyotaauthor=J.+Takahashiauthor=Y.+Tagawaauthor=T.+Kondoauthor=S.+Asahi&title=Metabolic+Fate+of+Sipoglitazar+a+Novel+Oral+PPAR+Agonist+with+Activities+for+PPAR-%CE%B3%2C+-%CE%B1+and+-%CE%B4%2C+in+Rats+and+Monkeys+and+Comparison+with+Humans+In+Vitro&doi=10.2133%2Fdmpk.DMPK-11-RG-061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro</span></div><div class="casAuthors">Nishihara, Mitsuhiro; Sudo, Miyako; Kamiguchi, Hidenori; Kawaguchi, Naohiro; Maeshiba, Yoshihiro; Kiyota, Yutaka; Takahashi, Junzo; Tagawa, Yoshihiko; Kondo, Takahiro; Asahi, Satoru</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-231</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">Sipoglitazar is a novel anti-diabetic agent with triple agonistic activities on the human peroxisome proliferator-activated receptors, hPPAR-γ, -α, and -δ.  The bioavailability for sipoglitazar was 95.0% and 72.6% in rats and monkeys resp. and sipoglitazar is hardly subject to first pass metab. in either species.  Following oral administration of [14C]sipoglitazar to rats, sipoglitazar and its metabolites were distributed to the rat tissues with relatively high concns. in the liver and also to the target tissue, the adipose tissue.  The major component was sipoglitazar in the plasma of rats and monkeys.  In rats, sipoglitazar was mainly excreted into the feces via biliary excretion as sipoglitazar-G, while the major component was M-I-G in the urine and M-I in the feces of monkeys.  In hepatocytes, the metab. was not extensively advanced in rats and the main metabolites were M-I and sipoglitazar-G in humans, similar to the metabolic profile in monkeys.  There was no metabolite specific for humans in vitro.  In conclusion, the formation of M-I, M-I-G and sipoglitazar-G is considered to be crucial and sipoglitazar is presumed to be cleared primarily by oxidn. and glucuronidation in humans, when examd. in vivo and in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc21Xaw_X1QLVg90H21EOLACvtfcHk0liNyedA4Bwx8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1yisLk%253D&md5=cbb9ad3c8bb47d59e09745df03fdec81</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.DMPK-11-RG-061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.DMPK-11-RG-061%26sid%3Dliteratum%253Aachs%26aulast%3DNishihara%26aufirst%3DM.%26aulast%3DSudo%26aufirst%3DM.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DKawaguchi%26aufirst%3DN.%26aulast%3DMaeshiba%26aufirst%3DY.%26aulast%3DKiyota%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DJ.%26aulast%3DTagawa%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DAsahi%26aufirst%3DS.%26atitle%3DMetabolic%2520Fate%2520of%2520Sipoglitazar%2520a%2520Novel%2520Oral%2520PPAR%2520Agonist%2520with%2520Activities%2520for%2520PPAR-%25CE%25B3%252C%2520-%25CE%25B1%2520and%2520-%25CE%25B4%252C%2520in%2520Rats%2520and%2520Monkeys%2520and%2520Comparison%2520with%2520Humans%2520In%2520Vitro%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2012%26volume%3D27%26spage%3D223%26epage%3D231%26doi%3D10.2133%2Fdmpk.DMPK-11-RG-061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Nishihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyota, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahi, S.</span><span> </span><span class="NLM_article-title">An Unusual Metabolic Pathway of Sipoglitazar, a Novel Antidiabetic Agent: Cytochrome P450-Catalyzed Oxidation of Sipoglitazar Acyl Glucuronide</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span><span class="refDoi"> DOI: 10.1124/dmd.111.040105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.111.040105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=249-258&author=M.+Nishiharaauthor=M.+Sudoauthor=N.+Kawaguchiauthor=J.+Takahashiauthor=Y.+Kiyotaauthor=T.+Kondoauthor=S.+Asahi&title=An+Unusual+Metabolic+Pathway+of+Sipoglitazar%2C+a+Novel+Antidiabetic+Agent%3A+Cytochrome+P450-Catalyzed+Oxidation+of+Sipoglitazar+Acyl+Glucuronide&doi=10.1124%2Fdmd.111.040105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040105%26sid%3Dliteratum%253Aachs%26aulast%3DNishihara%26aufirst%3DM.%26aulast%3DSudo%26aufirst%3DM.%26aulast%3DKawaguchi%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DJ.%26aulast%3DKiyota%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DAsahi%26aufirst%3DS.%26atitle%3DAn%2520Unusual%2520Metabolic%2520Pathway%2520of%2520Sipoglitazar%252C%2520a%2520Novel%2520Antidiabetic%2520Agent%253A%2520Cytochrome%2520P450-Catalyzed%2520Oxidation%2520of%2520Sipoglitazar%2520Acyl%2520Glucuronide%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D249%26epage%3D258%26doi%3D10.1124%2Fdmd.111.040105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munsick, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonacorsi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span> </span><span class="NLM_article-title">Metabolism and Disposition of 14C-Labeled Peliglitazar in Humans</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span><span class="refDoi"> DOI: 10.1124/dmd.110.035089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.110.035089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=228-238&author=L.+Wangauthor=C.+Munsickauthor=S.+Chenauthor=S.+Bonacorsiauthor=P.+T.+Chengauthor=W.+G.+Humphreysauthor=D.+Zhang&title=Metabolism+and+Disposition+of+14C-Labeled+Peliglitazar+in+Humans&doi=10.1124%2Fdmd.110.035089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035089%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMunsick%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBonacorsi%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DP.%2BT.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DMetabolism%2520and%2520Disposition%2520of%252014C-Labeled%2520Peliglitazar%2520in%2520Humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D228%26epage%3D238%26doi%3D10.1124%2Fdmd.110.035089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaminathan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosqueda-Garcia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aurang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everett, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span> </span><span class="NLM_article-title">Glucuronidation As A Major Metabolic Clearance Pathway Of <sup>14</sup>C-Labeled Muraglitazar In Humans: Metabolic Profiles In Subjects With Or Without Bile Collection</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1124/dmd.105.007617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.105.007617" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=427-439&author=L.+Wangauthor=D.+Zhangauthor=A.+Swaminathanauthor=Y.+Xueauthor=P.+T.+Chengauthor=S.+Wuauthor=R.+Mosqueda-Garciaauthor=C.+Aurangauthor=D.+W.+Everettauthor=W.+G.+Humphreys&title=Glucuronidation+As+A+Major+Metabolic+Clearance+Pathway+Of+14C-Labeled+Muraglitazar+In+Humans%3A+Metabolic+Profiles+In+Subjects+With+Or+Without+Bile+Collection&doi=10.1124%2Fdmd.105.007617"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.007617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.007617%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DSwaminathan%26aufirst%3DA.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DP.%2BT.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DMosqueda-Garcia%26aufirst%3DR.%26aulast%3DAurang%26aufirst%3DC.%26aulast%3DEverett%26aufirst%3DD.%2BW.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DGlucuronidation%2520As%2520A%2520Major%2520Metabolic%2520Clearance%2520Pathway%2520Of%252014C-Labeled%2520Muraglitazar%2520In%2520Humans%253A%2520Metabolic%2520Profiles%2520In%2520Subjects%2520With%2520Or%2520Without%2520Bile%2520Collection%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D427%26epage%3D439%26doi%3D10.1124%2Fdmd.105.007617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obermeier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span> </span><span class="NLM_article-title">Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span><span class="refDoi"> DOI: 10.1124/dmd.110.035048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.110.035048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=123-131&author=D.+Zhangauthor=N.+Raghavanauthor=L.+Wangauthor=Y.+Xueauthor=M.+Obermeierauthor=S.+Chenauthor=S.+Taoauthor=H.+Zhangauthor=P.+T.+Chengauthor=W.+Liauthor=R.+Ramanathanauthor=Z.+Yangauthor=W.+G.+Humphreys&title=Plasma+Stability-Dependent+Circulation+of+Acyl+Glucuronide+Metabolites+in+Humans%3A+How+Circulating+Metabolite+Profiles+of+Muraglitazar+and+Peliglitazar+Can+Lead+to+Misleading+Risk+Assessment&doi=10.1124%2Fdmd.110.035048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035048%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DRaghavan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DTao%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DRamanathan%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DPlasma%2520Stability-Dependent%2520Circulation%2520of%2520Acyl%2520Glucuronide%2520Metabolites%2520in%2520Humans%253A%2520How%2520Circulating%2520Metabolite%2520Profiles%2520of%2520Muraglitazar%2520and%2520Peliglitazar%2520Can%2520Lead%2520to%2520Misleading%2520Risk%2520Assessment%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D123%26epage%3D131%26doi%3D10.1124%2Fdmd.110.035048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Liu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNaul, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebber, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. B.</span><span> </span><span class="NLM_article-title">Discovery of a Novel Series of Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes and Dyslipidemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2262</span><span class="NLM_x">–</span> <span class="NLM_lpage">2265</span><span class="refDoi"> DOI: 10.1021/jm048993p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm048993p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2262-2265&author=K.+Liuauthor=L.+Xuauthor=J.+P.+Bergerauthor=K.+L.+MacNaulauthor=G.+Zhouauthor=T.+W.+Doebberauthor=M.+J.+Forrestauthor=D.+E.+Mollerauthor=A.+B.+Jones&title=Discovery+of+a+Novel+Series+of+Peroxisome+Proliferator-Activated+Receptor+%CE%B1%2F%CE%B3+Dual+Agonists+for+the+Treatment+of+Type+2+Diabetes+and+Dyslipidemia&doi=10.1021%2Fjm048993p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm048993p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm048993p%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DBerger%26aufirst%3DJ.%2BP.%26aulast%3DMacNaul%26aufirst%3DK.%2BL.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DDoebber%26aufirst%3DT.%2BW.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26aulast%3DMoller%26aufirst%3DD.%2BE.%26aulast%3DJones%26aufirst%3DA.%2BB.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Series%2520of%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520%25CE%25B1%252F%25CE%25B3%2520Dual%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%2520and%2520Dyslipidemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2262%26epage%3D2265%26doi%3D10.1021%2Fjm048993p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Kochansky, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cato, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. R.</span><span> </span><span class="NLM_article-title">Species Differences In The Elimination Of A Peroxisome Proliferator-Activated Receptor Agonist Highlighted By Oxidative Metabolism Of Its Acyl Glucuronide</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1894</span><span class="NLM_x">–</span> <span class="NLM_lpage">1904</span><span class="refDoi"> DOI: 10.1124/dmd.105.004010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.105.004010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=1894-1904&author=C.+J.+Kochanskyauthor=Y.-Q.+Xiaauthor=S.+Wangauthor=B.+Catoauthor=M.+Creightonauthor=S.+H.+Vincentauthor=R.+B.+Franklinauthor=J.+R.+Reed&title=Species+Differences+In+The+Elimination+Of+A+Peroxisome+Proliferator-Activated+Receptor+Agonist+Highlighted+By+Oxidative+Metabolism+Of+Its+Acyl+Glucuronide&doi=10.1124%2Fdmd.105.004010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.004010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.004010%26sid%3Dliteratum%253Aachs%26aulast%3DKochansky%26aufirst%3DC.%2BJ.%26aulast%3DXia%26aufirst%3DY.-Q.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCato%26aufirst%3DB.%26aulast%3DCreighton%26aufirst%3DM.%26aulast%3DVincent%26aufirst%3DS.%2BH.%26aulast%3DFranklin%26aufirst%3DR.%2BB.%26aulast%3DReed%26aufirst%3DJ.%2BR.%26atitle%3DSpecies%2520Differences%2520In%2520The%2520Elimination%2520Of%2520A%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520Agonist%2520Highlighted%2520By%2520Oxidative%2520Metabolism%2520Of%2520Its%2520Acyl%2520Glucuronide%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D1894%26epage%3D1904%26doi%3D10.1124%2Fdmd.105.004010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Kreutner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozzi, S.</span><span> </span><span class="NLM_article-title">Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1 Receptor Antagonist</span> <span class="citation_source-journal">Arzneim. Forsch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1055/s-0031-1300213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1055%2Fs-0031-1300213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10800633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtFSlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2000&pages=345-352&author=W.+Kreutnerauthor=J.+A.+Heyauthor=J.+Anthesauthor=A.+Barnettauthor=S.+Youngauthor=S.+Tozzi&title=Preclinical+Pharmacology+of+Desloratadine%2C+a+Selective+and+Nonsedating+Histamine+H1+Receptor+Antagonist&doi=10.1055%2Fs-0031-1300213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist: receptor selectivity, antihistaminic activity, and antiallergenic effects</span></div><div class="casAuthors">Kreutner, William; Hey, John A.; Anthes, John; Barnett, Allen; Young, Simon; Tozzi, Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">345-352</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    
            (<span class="NLM_cas:orgname">Editio Cantor Verlag</span>)
        </div><div class="casAbstract">Desloratadine (descarboethoxyloratadine, CAS 100643-71-8) is an active metabolite of loratadine (CAS 79794-75-5) that exhibits qual. similar pharmacodynamic activity with a relative oral potency in animals 2.5-4 times greater than loratadine.  Its antihistaminic effect lasts 24 h.  Desloratadine was shown to be a selective H1 antagonist with more potent antihistaminic activity in vitro than either loratadine or terfenadine (CAS 50679-08-8), as indicated by its displacement of 3H-mepyramine from H1 receptors in rat brain, guinea pig brain, and guinea pig lung, and by its antagonism of histamine-induced contractions of guinea pig ileum.  Antihistaminic activity and antiallergic effects also were obsd. in vivo.  After oral administration, desloratadine was 2.5 to 4 times more potent than loratadine in protecting against histamine-induced lethality in the guinea pig and paw edema in the mouse; after topical administration, it was almost 10 times more potent in antagonizing histamine-induced increases in nasal microvascular permeability in the guinea pig.  Histamine-induced changes in pulmonary resistance and compliance were also prevented by oral administration of desloratadine and loratadine in the monkey.  An oral antiallergic effect was demonstrated by important redns. of acute bronchospasm in the allergic monkey and potent inhibition of allergic cough in the guinea pig.  These preclin. studies provide evidence that desloratadine is an antihistaminic agent with a greater potency than loratadine and, together with results from numerous published studies, suggest an antiallergic effect of desloratadine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6RLhnlxOAtrVg90H21EOLACvtfcHk0liM1KCu9oBb1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtFSlsro%253D&md5=e103cbb849ace7a9a17d7799155b467d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1055%2Fs-0031-1300213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0031-1300213%26sid%3Dliteratum%253Aachs%26aulast%3DKreutner%26aufirst%3DW.%26aulast%3DHey%26aufirst%3DJ.%2BA.%26aulast%3DAnthes%26aufirst%3DJ.%26aulast%3DBarnett%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DTozzi%26aufirst%3DS.%26atitle%3DPreclinical%2520Pharmacology%2520of%2520Desloratadine%252C%2520a%2520Selective%2520and%2520Nonsedating%2520Histamine%2520H1%2520Receptor%2520Antagonist%26jtitle%3DArzneim.%2520Forsch.%26date%3D2000%26volume%3D50%26spage%3D345%26epage%3D352%26doi%3D10.1055%2Fs-0031-1300213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Kreutner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, A.</span><span> </span><span class="NLM_article-title">Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1 Receptor Antagonist2nd Communication: Lack of central nervous system and cardiovascular effects</span> <span class="citation_source-journal">Arzneim. Forsch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span><span class="refDoi"> DOI: 10.1055/s-0031-1300228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1055%2Fs-0031-1300228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10858871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFOjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2000&pages=441-448&author=W.+Kreutnerauthor=J.+A.+Heyauthor=P.+Chiuauthor=A.+Barnett&title=Preclinical+Pharmacology+of+Desloratadine%2C+a+Selective+and+Nonsedating+Histamine+H1+Receptor+Antagonist2nd+Communication%3A+Lack+of+central+nervous+system+and+cardiovascular+effects&doi=10.1055%2Fs-0031-1300228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects</span></div><div class="casAuthors">Kreutner, William; Hey, John A.; Chiu, Peter; Barnett, Allen</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-448</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    
            (<span class="NLM_cas:orgname">Editio Cantor Verlag</span>)
        </div><div class="casAbstract">Desloratadine (descarboethoxyloratadine, CAS 100643-71-8) is a selective histamine H1 antagonist that exhibits qual. similar pharmacodynamic activity to its parent, loratadine (CAS 79794-7505), but is 2.5-4 times more potent orally.  In studies of central nervous system (CNS) effects that might lead to sedation, desloratadine had no behavioral, neurol. or autonomic effects in the conscious mouse and rat.  At large multiples of the antihistaminic dose in the mouse, it did not inhibit convulsions caused by electroconvulsive shock and inhibited acetic acid-induced writhing only at a dose approx. 1,000 times the antihistaminic dose in the mouse.  Desloratadine had no effects on blood pressure, heart rate or electrocardiog. parameters in the rat or guinea pig or on electrocardiog. parameters in the monkey.  Notably, there was no effect on the cor. Q-wave to T-wave (QTc) interval.  Desloratadine did not inhibit IKr channel human ether-a-go-go-related gene (HERG)-induced current in a study in which HERG was expressed in Xenopus oocytes.  In the rate, desloratadine did not cause effects in urine vol., electrolytes or creatinine, or inhibit gastric emptying or intestinal transit, or cause any harmful effects on gastric mucosa.  The results of these preclin. studies provide evidence that desloratadine is a safe antihistamine without CNS or cardiovascular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUmO5fgG2dz7Vg90H21EOLACvtfcHk0ljJ3fUhll30Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFOjtr4%253D&md5=78fedda7cca56828199db314d161c2d8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1055%2Fs-0031-1300228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0031-1300228%26sid%3Dliteratum%253Aachs%26aulast%3DKreutner%26aufirst%3DW.%26aulast%3DHey%26aufirst%3DJ.%2BA.%26aulast%3DChiu%26aufirst%3DP.%26aulast%3DBarnett%26aufirst%3DA.%26atitle%3DPreclinical%2520Pharmacology%2520of%2520Desloratadine%252C%2520a%2520Selective%2520and%2520Nonsedating%2520Histamine%2520H1%2520Receptor%2520Antagonist2nd%2520Communication%253A%2520Lack%2520of%2520central%2520nervous%2520system%2520and%2520cardiovascular%2520effects%26jtitle%3DArzneim.%2520Forsch.%26date%3D2000%26volume%3D50%26spage%3D441%26epage%3D448%26doi%3D10.1055%2Fs-0031-1300228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Ramanathan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyderman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulmatycki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdhury, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Statkevich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, J. E.</span><span> </span><span class="NLM_article-title">Disposition Of Loratadine In Healthy Volunteers</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span><span class="refDoi"> DOI: 10.1080/00498250701463317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1080%2F00498250701463317" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=753-769&author=R.+Ramanathanauthor=L.+Reydermanauthor=K.+Kulmatyckiauthor=A.+D.+Suauthor=N.+Alvarezauthor=S.+K.+Chowdhuryauthor=K.+B.+Altonauthor=M.+A.+Wirthauthor=R.+P.+Clementauthor=P.+Statkevichauthor=J.+E.+Patrick&title=Disposition+Of+Loratadine+In+Healthy+Volunteers&doi=10.1080%2F00498250701463317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1080%2F00498250701463317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250701463317%26sid%3Dliteratum%253Aachs%26aulast%3DRamanathan%26aufirst%3DR.%26aulast%3DReyderman%26aufirst%3DL.%26aulast%3DKulmatycki%26aufirst%3DK.%26aulast%3DSu%26aufirst%3DA.%2BD.%26aulast%3DAlvarez%26aufirst%3DN.%26aulast%3DChowdhury%26aufirst%3DS.%2BK.%26aulast%3DAlton%26aufirst%3DK.%2BB.%26aulast%3DWirth%26aufirst%3DM.%2BA.%26aulast%3DClement%26aufirst%3DR.%2BP.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DPatrick%26aufirst%3DJ.%2BE.%26atitle%3DDisposition%2520Of%2520Loratadine%2520In%2520Healthy%2520Volunteers%26jtitle%3DXenobiotica%26date%3D2007%26volume%3D37%26spage%3D753%26epage%3D769%26doi%3D10.1080%2F00498250701463317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Kazmi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbara, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yerino, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">A Long-Standing Mystery Solved: The Formation of 3-Hydroxydesloratadine Is Catalyzed by CYP2C8 But Prior Glucuronidation of Desloratadine by UDP-Glucuronosyltransferase 2B10 Is an Obligatory Requirement</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1124/dmd.114.062620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.114.062620" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=523-533&author=F.+Kazmiauthor=J.+E.+Barbaraauthor=P.+Yerinoauthor=A.+Parkinson&title=A+Long-Standing+Mystery+Solved%3A+The+Formation+of+3-Hydroxydesloratadine+Is+Catalyzed+by+CYP2C8+But+Prior+Glucuronidation+of+Desloratadine+by+UDP-Glucuronosyltransferase+2B10+Is+an+Obligatory+Requirement&doi=10.1124%2Fdmd.114.062620"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.062620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.062620%26sid%3Dliteratum%253Aachs%26aulast%3DKazmi%26aufirst%3DF.%26aulast%3DBarbara%26aufirst%3DJ.%2BE.%26aulast%3DYerino%26aufirst%3DP.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DA%2520Long-Standing%2520Mystery%2520Solved%253A%2520The%2520Formation%2520of%25203-Hydroxydesloratadine%2520Is%2520Catalyzed%2520by%2520CYP2C8%2520But%2520Prior%2520Glucuronidation%2520of%2520Desloratadine%2520by%2520UDP-Glucuronosyltransferase%25202B10%2520Is%2520an%2520Obligatory%2520Requirement%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D523%26epage%3D533%26doi%3D10.1124%2Fdmd.114.062620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Kazmi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yerino, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbara, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1294</span><span class="NLM_x">–</span> <span class="NLM_lpage">1302</span><span class="refDoi"> DOI: 10.1124/dmd.115.065011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.115.065011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1294-1302&author=F.+Kazmiauthor=P.+Yerinoauthor=J.+E.+Barbaraauthor=A.+Parkinson&title=Further+Characterization+of+the+Metabolism+of+Desloratadine+and+Its+Cytochrome+P450+and+UDP-glucuronosyltransferase+Inhibition+Potential%3A+Identification+of+Desloratadine+as+a+Relatively+Selective+UGT2B10+Inhibitor&doi=10.1124%2Fdmd.115.065011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.065011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.065011%26sid%3Dliteratum%253Aachs%26aulast%3DKazmi%26aufirst%3DF.%26aulast%3DYerino%26aufirst%3DP.%26aulast%3DBarbara%26aufirst%3DJ.%2BE.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DFurther%2520Characterization%2520of%2520the%2520Metabolism%2520of%2520Desloratadine%2520and%2520Its%2520Cytochrome%2520P450%2520and%2520UDP-glucuronosyltransferase%2520Inhibition%2520Potential%253A%2520Identification%2520of%2520Desloratadine%2520as%2520a%2520Relatively%2520Selective%2520UGT2B10%2520Inhibitor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D1294%26epage%3D1302%26doi%3D10.1124%2Fdmd.115.065011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Orr, S. T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripp, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span> </span><span class="NLM_article-title">Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4896</span><span class="NLM_x">–</span> <span class="NLM_lpage">4933</span><span class="refDoi"> DOI: 10.1021/jm300065h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300065h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4896-4933&author=S.+T.+M.+Orrauthor=S.+L.+Rippauthor=T.+E.+Ballardauthor=J.+L.+Hendersonauthor=D.+O.+Scottauthor=R.+S.+Obachauthor=H.+Sunauthor=A.+S.+Kalgutkar&title=Mechanism-Based+Inactivation+%28MBI%29+of+Cytochrome+P450+Enzymes%3A+Structure%E2%80%93Activity+Relationships+and+Discovery+Strategies+To+Mitigate+Drug%E2%80%93Drug+Interaction+Risks&doi=10.1021%2Fjm300065h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks</span></div><div class="casAuthors">Orr, Suvi T. M.; Ripp, Sharon L.; Ballard, T. Eric; Henderson, Jaclyn L.; Scott, Dennis O.; Obach, R. Scott; Sun, Hao; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4896-4933</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The importance of mitigating drug-drug interaction (DDI) risks, which arise from inhibition of major human cytochrome P 450 enzymes is a well-established component of the lead optimization process in drug discovery.  More recently, there has been much interest in clin. DDIs potentially arising via time- and concn.-dependent cytochrome P 450 inhibition, a phenomenon consistent with mechanism-based inactivation.  Inactivated P 450 is catalytically incompetent and must be replenished by newly synthesized protein.  Consequently, time-dependent inhibition of P450s presents a greater safety concern compared to reversible inhibition because of the increased propensity for pharmacokinetic interactions upon multiple dosing and the sustained duration of these interactions after discontinuation of the mechanism-based inactivator.  Mechanism-based or time-dependent P 450 inhibitors pose an addnl. risk of idiosyncratic drug toxicity since the mechanism of time-dependency often involves the formation of reactive metabolites, which can react with proteins other than the P 450 isoenzyme responsible for catalysis. in vitro time-dependent inhibition (TDI) of P 450 enzymes is now routinely assessed as part of lead optimization efforts in preclin. drug discovery.  However, identification of an in vitro TDI liability can raise several questions such as: What is the mechanism of TDI.  Does it involve the formation of reactive metabolites.  Is there a 1:1 correlation between P 450 TDI and RM formation (as measured from reactive metabolite trapping studies).  What is the likelihood that a P 450 time-dependent inhibitor will also cause toxicity.  What are the DDI risk mitigation options when dealing with P 450 inactivators in drug discovery - compd. progression or termination.  Several drugs exhibit in vitro TDI of P 450 enzymes, but only a fraction thereof causes clin. DDIs.  Hence, when do we initiate labor-intensive medicinal chem. efforts to design compds. devoid of P 450 TDI liability.  What are the best methods to precisely predict the likelihood of occurrence of clin. DDIs with drug candidates that inactivate P 450 enzymes.  What are (if any) the qualifying considerations for clin. progression of a P 450 time-dependent inactivator with projected clin. DDI risks.  In an effort to address these questions and hopefully provide answers to some of them, we embarked on the present venture wherein we highlight the current state-of-the-art knowledge in this field with a special emphasis on (a) available biochem. and mechanistic approaches in drug discovery to examine TDI of P 450 isoenzymes with new chem. entities, (b) structure-activity relationship studies with marketed drugs assocd. with DDIs via P 450 inactivation, (c) case studies of medicinal chem. tactics to abrogate P 450 inactivation liability, (d) strategies for progression of P 450 TDI-pos. drug candidates, and (e) the utility of in silico methodol., including the use of physiol.-based pharmacokinetic simulators, in drug discovery to predict the magnitude of clin. DDIs risks anticipated with new clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDO60qqRvpS7Vg90H21EOLACvtfcHk0lj6NrngCtod6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D&md5=aa4aa4f633b3b4f73b3d79917327b0de</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm300065h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300065h%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26aulast%3DBallard%26aufirst%3DT.%2BE.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DMechanism-Based%2520Inactivation%2520%2528MBI%2529%2520of%2520Cytochrome%2520P450%2520Enzymes%253A%2520Structure%25E2%2580%2593Activity%2520Relationships%2520and%2520Discovery%2520Strategies%2520To%2520Mitigate%2520Drug%25E2%2580%2593Drug%2520Interaction%2520Risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4896%26epage%3D4933%26doi%3D10.1021%2Fjm300065h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Todd, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, A.</span><span> </span><span class="NLM_article-title">Gemfibrozil</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.2165/00003495-198836030-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2165%2F00003495-198836030-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=3056692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaL1cXmtVChsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1988&pages=314-339&author=P.+A.+Toddauthor=A.+Ward&title=Gemfibrozil&doi=10.2165%2F00003495-198836030-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Gemfibrozil.  A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia</span></div><div class="casAuthors">Todd, Peter A.; Ward, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-39</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    </div><div class="casAbstract">A review with ∼140 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobDuwL7YkTf7Vg90H21EOLACvtfcHk0lj6NrngCtod6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmtVChsbk%253D&md5=efa6b048ad3e3c1badea9471cd11c2b7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2165%2F00003495-198836030-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-198836030-00004%26sid%3Dliteratum%253Aachs%26aulast%3DTodd%26aufirst%3DP.%2BA.%26aulast%3DWard%26aufirst%3DA.%26atitle%3DGemfibrozil%26jtitle%3DDrugs%26date%3D1988%26volume%3D36%26spage%3D314%26epage%3D339%26doi%3D10.2165%2F00003495-198836030-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Mano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamimura, H.</span><span> </span><span class="NLM_article-title">The UDP-Glucuronosyltransferase 2B7 Isozyme Is Responsible for Gemfibrozil Glucuronidation in the Human Liver</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2040</span><span class="NLM_x">–</span> <span class="NLM_lpage">2044</span><span class="refDoi"> DOI: 10.1124/dmd.107.017269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.107.017269" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=2040-2044&author=Y.+Manoauthor=T.+Usuiauthor=H.+Kamimura&title=The+UDP-Glucuronosyltransferase+2B7+Isozyme+Is+Responsible+for+Gemfibrozil+Glucuronidation+in+the+Human+Liver&doi=10.1124%2Fdmd.107.017269"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017269%26sid%3Dliteratum%253Aachs%26aulast%3DMano%26aufirst%3DY.%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DKamimura%26aufirst%3DH.%26atitle%3DThe%2520UDP-Glucuronosyltransferase%25202B7%2520Isozyme%2520Is%2520Responsible%2520for%2520Gemfibrozil%2520Glucuronidation%2520in%2520the%2520Human%2520Liver%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D2040%26epage%3D2044%26doi%3D10.1124%2Fdmd.107.017269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Wang, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1352</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span><span class="refDoi"> DOI: 10.1124/dmd.30.12.1352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.30.12.1352" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1352-1356&author=J.-S.+Wangauthor=M.+Neuvonenauthor=X.+Wenauthor=J.+T.+Backmanauthor=P.+J.+Neuvonen&title=Gemfibrozil+Inhibits+CYP2C8-Mediated+Cerivastatin+Metabolism+in+Human+Liver+Microsomes&doi=10.1124%2Fdmd.30.12.1352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.12.1352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.12.1352%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.-S.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520Inhibits%2520CYP2C8-Mediated%2520Cerivastatin%2520Metabolism%2520in%2520Human%2520Liver%2520Microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D1352%26epage%3D1356%26doi%3D10.1124%2Fdmd.30.12.1352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivistö, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil Is a Potent Inhibitor of Human Cytochrome P450 2C9</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=1359-1361&author=X.+Wenauthor=J.-S.+Wangauthor=J.+T.+Backmanauthor=K.+T.+Kivist%C3%B6author=P.+J.+Neuvonen&title=Gemfibrozil+Is+a+Potent+Inhibitor+of+Human+Cytochrome+P450+2C9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.-S.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DKivist%25C3%25B6%26aufirst%3DK.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Human%2520Cytochrome%2520P450%25202C9%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2001%26volume%3D29%26spage%3D1359%26epage%3D1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Fujino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsunenari, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, J.</span><span> </span><span class="NLM_article-title">Studies on the Interaction between Fibrates and Statins Using Human Hepatic Microsomes</span> <span class="citation_source-journal">Arzneim. Forsch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">707</span><span class="refDoi"> DOI: 10.1055/s-0031-1299815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1055%2Fs-0031-1299815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=14650362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFWntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2003&pages=701-707&author=H.+Fujinoauthor=S.+Shimadaauthor=I.+Yamadaauthor=M.+Hiranoauthor=Y.+Tsunenariauthor=J.+Kojima&title=Studies+on+the+Interaction+between+Fibrates+and+Statins+Using+Human+Hepatic+Microsomes&doi=10.1055%2Fs-0031-1299815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the interaction between fibrates and statins using human hepatic microsomes</span></div><div class="casAuthors">Fujino, Hideki; Shimada, Syunsuke; Yamada, Iwao; Hirano, Masaru; Tsunenari, Yoshihiko; Kojima, Junji</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">701-707</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    
            (<span class="NLM_cas:orgname">Editio Cantor Verlag</span>)
        </div><div class="casAbstract">To gain a better understanding of the mechanism of drug-drug interaction between fibrates and statins, several in vitro expts. were performed.  On coincubation with several fibrates, pitavastatin (CAS 147526-32-7) did not displace fibrates from their protein binding in human plasma.  The presence of gemfibrozil (CAS 25812-30-0) inhibited the metab. of statins (cerivastatin (CAS 145599-86-6) and atorvastatin (CAS 134523-00-5)) remarkably.  However, the increase of the unchanged form was fairly small for pitavastatin.  The metabolic profile of gemfibrozil was also investigated.  The cytochrome P (CYP) enzyme CYP2C9 plays a major role in the metab. of gemfibrozil.  Gemfibrozil showed a high affinity for CYP enzymes and a relatively high metab. velocity.  Moreover, several inhibitory effects of gemfibrozil on CYP-mediated metab. were detected - in contrast to other fibrates.  Although the mechanism of the drug-drug interaction was not completely clarified, it is suggested that the increase of plasma concn. caused by the coadministration of gemfibrozil and statins is at least partially due to the inhibition of the CYP-mediated metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNufjyfZRvz7Vg90H21EOLACvtfcHk0lj5EIK5bypkhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFWntb0%253D&md5=cb725daf696c593df3fe7c9f7bcc4256</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1055%2Fs-0031-1299815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0031-1299815%26sid%3Dliteratum%253Aachs%26aulast%3DFujino%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DS.%26aulast%3DYamada%26aufirst%3DI.%26aulast%3DHirano%26aufirst%3DM.%26aulast%3DTsunenari%26aufirst%3DY.%26aulast%3DKojima%26aufirst%3DJ.%26atitle%3DStudies%2520on%2520the%2520Interaction%2520between%2520Fibrates%2520and%2520Statins%2520Using%2520Human%2520Hepatic%2520Microsomes%26jtitle%3DArzneim.%2520Forsch.%26date%3D2003%26volume%3D53%26spage%3D701%26epage%3D707%26doi%3D10.1055%2Fs-0031-1299815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyrklund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil Greatly Increases Plasma Concentrations Of Cerivastatin</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span><span class="refDoi"> DOI: 10.1067/mcp.2002.128469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1067%2Fmcp.2002.128469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=12496749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1SjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2002&pages=685-691&author=J.+T.+Backmanauthor=C.+Kyrklundauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Gemfibrozil+Greatly+Increases+Plasma+Concentrations+Of+Cerivastatin&doi=10.1067%2Fmcp.2002.128469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Gemfibrozil greatly increases plasma concentrations of cerivastatin</span></div><div class="casAuthors">Backman, Janne T.; Kyrklund, Carl; Neuvonen, Mikko; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-691</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Concomitant use of gemfibrozil with statins, particularly with cerivastatin, increases the risk of rhabdomyolysis, but the mechanism of this potentially fatal drug interaction remains unclear.  Our aim was to study the effect of gemfibrozil on cerivastatin pharmacokinetics.  In a randomized, double-blind crossover study, 10 healthy volunteers took 600 mg gemfibrozil or placebo twice daily for 3 days.  On day 3, each subject ingested a single 0.3-mg dose of cerivastatin.  Plasma concns. of cerivastatin, its metabolites, and gemfibrozil were measured up to 24 h.  During gemfibrozil treatment, the area under the plasma concn.-time curve [AUC(0-∞)] of parent cerivastatin was on av. 559% (range, 138% to 995%; P =.0002) and the peak concn. in plasma was 307% (138% to 809%; P =.0019) of the corresponding values in the placebo phase.  Gemfibrozil increased the AUC(0-∞) of cerivastatin lactone, on av., to 440% (94% to 594%; P =.0024) and that of metabolite M-1 to 435% (216% to 802%; P =.0002) of the control (placebo) values, whereas the AUC(0-24) of metabolite M-23 was decreased to 22% (11% to 74%; P=.0017).  Gemfibrozil greatly increases plasma concns. of cerivastatin, cerivastatin lactone, and metabolite M-1, whereas the level of metabolite M-23 is markedly reduced by gemfibrozil.  Gemfibrozil therefore inhibits the formation of M-23, which is thought to be dependent on CYP2C8.  The increased exposure to cerivastatin in the presence of gemfibrozil may explain the high incidence of myopathy obsd. with this combination, although the role of pharmacodynamic interactions between these 2 agents cannot be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyOpdQOdq0kLVg90H21EOLACvtfcHk0lhClmLrp_kf5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1SjsQ%253D%253D&md5=2dce3480b6cea92874faf468c81b834c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2002.128469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2002.128469%26sid%3Dliteratum%253Aachs%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DKyrklund%26aufirst%3DC.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520Greatly%2520Increases%2520Plasma%2520Concentrations%2520Of%2520Cerivastatin%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D72%26spage%3D685%26epage%3D691%26doi%3D10.1067%2Fmcp.2002.128469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Jaakkola, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics of Pioglitazone</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">404</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span><span class="refDoi"> DOI: 10.1016/j.clpt.2004.12.266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2Fj.clpt.2004.12.266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=15900286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFCrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=404-414&author=T.+Jaakkolaauthor=J.+T.+Backmanauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Effects+of+Gemfibrozil%2C+Itraconazole%2C+and+Their+Combination+on+the+Pharmacokinetics+of+Pioglitazone&doi=10.1016%2Fj.clpt.2004.12.266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone</span></div><div class="casAuthors">Jaakkola, Tiina; Backman, Janne T.; Neuvonen, Mikko; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-414</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background and objective: The thiazolidinedione antidiabetic drug pioglitazone is metabolized mainly by cytochrome P 450 (CYP) 2C8 and CYP3A4 in vitro.  Our objective was to study the effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone to det. the role of these enzymes in the fate of pioglitazone in humans.  Methods: In a randomized, double-blind, 4-phase crossover study, 12 healthy volunteers took either 600 mg gemfibrozil or 100 mg itraconazole (first dose, 200 mg), both gemfibrozil and itraconazole, or placebo twice daily for 4 days.  On day 3, they received a single dose of 15 mg pioglitazone.  Plasma drug concns. and the cumulative excretion of pioglitazone and its metabolites into urine were measured for up to 48 h.  Results: Gemfibrozil alone raised the mean total area under the plasma concn.-time curve from time 0 to infinity [AUC(0-∞)] of pioglitazone 3.2-fold (range, 2.3-fold to 6.5-fold; P <.001) and prolonged its elimination half-life (t1/2) from 8.3 to 22.7 h (P <.001) but had no significant effect on its peak concn. (Cmax) compared with placebo (control).  Gemfibrozil increased the 48-h excretion of pioglitazone into urine by 2.5-fold (P <.001) and reduced the ratios of the active metabolites M-III and M-IV to pioglitazone in plasma and urine.  Gemfibrozil decreased the area under the plasma concn.-time curve from time 0 to 48 h [AUC(0-48)] of the metabolites M-III and M-IV by 42% (P <.05) and 45% (P <.001), resp., but their total AUC(0-∞) values were reduced by less or not at all.  Itraconazole had no significant effect on the pharmacokinetics of pioglitazone and did not alter the effect of gemfibrozil on pioglitazone pharmacokinetics.  The mean area under the concn. vs. time curve to 49 h [AUC(0-49)] of itraconazole was 46% lower (P <.001) during the gemfibrozil-itraconazole phase than during the itraconazole phase.  Conclusions: Gemfibrozil elevates the plasma concns. of pioglitazone, probably by inhibition of its CYP2C8-mediated metab.  CYP2C8 appears to be of major importance and CYP3A4 of minor importance in pioglitazone metab. in vivo in humans.  Concomitant use of gemfibrozil with pioglitazone may increase the effects and risk of dose-related adverse effects of pioglitazone.  However, studies in diabetic patients are needed to det. the clin. significance of the gemfibrozil-pioglitazone interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjiP-NzZlXnrVg90H21EOLACvtfcHk0lhClmLrp_kf5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFCrtLg%253D&md5=44f68ebede1b1bf43cd353ac13007899</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.12.266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.12.266%26sid%3Dliteratum%253Aachs%26aulast%3DJaakkola%26aufirst%3DT.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DEffects%2520of%2520Gemfibrozil%252C%2520Itraconazole%252C%2520and%2520Their%2520Combination%2520on%2520the%2520Pharmacokinetics%2520of%2520Pioglitazone%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D404%26epage%3D414%26doi%3D10.1016%2Fj.clpt.2004.12.266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granfors, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laitila, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil Considerably Increases The Plasma Concentrations Of Rosiglitazone</span> <span class="citation_source-journal">Diabetologia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1319</span><span class="NLM_x">–</span> <span class="NLM_lpage">1323</span><span class="refDoi"> DOI: 10.1007/s00125-003-1181-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1007%2Fs00125-003-1181-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1319-1323&author=M.+Niemiauthor=J.+T.+Backmanauthor=M.+Granforsauthor=J.+Laitilaauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Gemfibrozil+Considerably+Increases+The+Plasma+Concentrations+Of+Rosiglitazone&doi=10.1007%2Fs00125-003-1181-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs00125-003-1181-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-003-1181-x%26sid%3Dliteratum%253Aachs%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DGranfors%26aufirst%3DM.%26aulast%3DLaitila%26aufirst%3DJ.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520Considerably%2520Increases%2520The%2520Plasma%2520Concentrations%2520Of%2520Rosiglitazone%26jtitle%3DDiabetologia%26date%3D2003%26volume%3D46%26spage%3D1319%26epage%3D1323%26doi%3D10.1007%2Fs00125-003-1181-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Effects Of Gemfibrozil, Itraconazole, And Their Combination On The Pharmacokinetics And Pharmacodynamics Of Repaglinide: Potentially Hazardous Interaction Between Gemfibrozil And Repaglinide</span> <span class="citation_source-journal">Diabetologia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span><span class="refDoi"> DOI: 10.1007/s00125-003-1034-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1007%2Fs00125-003-1034-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=347-351&author=M.+Niemiauthor=J.+T.+Backmanauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Effects+Of+Gemfibrozil%2C+Itraconazole%2C+And+Their+Combination+On+The+Pharmacokinetics+And+Pharmacodynamics+Of+Repaglinide%3A+Potentially+Hazardous+Interaction+Between+Gemfibrozil+And+Repaglinide&doi=10.1007%2Fs00125-003-1034-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs00125-003-1034-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-003-1034-7%26sid%3Dliteratum%253Aachs%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DEffects%2520Of%2520Gemfibrozil%252C%2520Itraconazole%252C%2520And%2520Their%2520Combination%2520On%2520The%2520Pharmacokinetics%2520And%2520Pharmacodynamics%2520Of%2520Repaglinide%253A%2520Potentially%2520Hazardous%2520Interaction%2520Between%2520Gemfibrozil%2520And%2520Repaglinide%26jtitle%3DDiabetologia%26date%3D2003%26volume%3D46%26spage%3D347%26epage%3D351%26doi%3D10.1007%2Fs00125-003-1034-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Farmer, J. A.</span><span> </span><span class="NLM_article-title">Learning from the cerivastatin experience</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1383</span><span class="NLM_x">–</span> <span class="NLM_lpage">1385</span><span class="refDoi"> DOI: 10.1016/S0140-6736(01)06489-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS0140-6736%2801%2906489-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2001&pages=1383-1385&author=J.+A.+Farmer&title=Learning+from+the+cerivastatin+experience&doi=10.1016%2FS0140-6736%2801%2906489-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2801%2906489-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252801%252906489-3%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DJ.%2BA.%26atitle%3DLearning%2520from%2520the%2520cerivastatin%2520experience%26jtitle%3DLancet%26date%3D2001%26volume%3D358%26spage%3D1383%26epage%3D1385%26doi%3D10.1016%2FS0140-6736%2801%2906489-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Pogson, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindred, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carper, B. G.</span><span> </span><span class="NLM_article-title">Rhabdomyolysis And Renal Failure Associated With Cerivastatin-Gemfibrozil Combination Therapy</span> <span class="citation_source-journal">Am. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">1146</span><span class="refDoi"> DOI: 10.1016/S0002-9149(99)00034-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS0002-9149%2899%2900034-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1999&pages=1146&author=G.+W.+Pogsonauthor=L.+H.+Kindredauthor=B.+G.+Carper&title=Rhabdomyolysis+And+Renal+Failure+Associated+With+Cerivastatin-Gemfibrozil+Combination+Therapy&doi=10.1016%2FS0002-9149%2899%2900034-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0002-9149%2899%2900034-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9149%252899%252900034-X%26sid%3Dliteratum%253Aachs%26aulast%3DPogson%26aufirst%3DG.%2BW.%26aulast%3DKindred%26aufirst%3DL.%2BH.%26aulast%3DCarper%26aufirst%3DB.%2BG.%26atitle%3DRhabdomyolysis%2520And%2520Renal%2520Failure%2520Associated%2520With%2520Cerivastatin-Gemfibrozil%2520Combination%2520Therapy%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1999%26volume%3D83%26spage%3D1146%26doi%3D10.1016%2FS0002-9149%2899%2900034-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Tornio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laitila, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalliokoski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span><span class="refDoi"> DOI: 10.1038/clpt.2008.34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1038%2Fclpt.2008.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=18388877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVShtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2008&pages=403-411&author=A.+Tornioauthor=M.+Niemiauthor=M.+Neuvonenauthor=J.+Laitilaauthor=A.+Kalliokoskiauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=The+Effect+of+Gemfibrozil+on+Repaglinide+Pharmacokinetics+Persists+for+at+Least+12+h+After+the+Dose%3A+Evidence+for+Mechanism-based+Inhibition+of+CYP2C8+In+Vivo&doi=10.1038%2Fclpt.2008.34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo</span></div><div class="casAuthors">Tornio, A.; Niemi, M.; Neuvonen, M.; Laitila, J.; Kalliokoski, A.; Neuvonen, P. J.; Backman, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-411</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Repaglinide is metabolized by cytochrome P 450 (CYP) 2C8 and 3A4.  Gemfibrozil has the effect of increasing the area under the concn.-time curve (AUC) of repaglinide eightfold.  We studied the effect of dosing interval on the extent of the gemfibrozil-repaglinide interaction.  In a randomized five-phase crossover study, 10 healthy volunteers ingested 0.25 mg repaglinide, with or without gemfibrozil pretreatment.  Plasma repaglinide, gemfibrozil, their metabolites, and blood glucose were measured.  When the last dose of 600 mg gemfibrozil was ingested simultaneously with repaglinide, or 3, 6, or 12 h before, it increased the AUC0-∞ of repaglinide 7.0-, 6.5-, 6.2- and 5.0-fold, resp. (P < 0.001).  The peak repaglinide concn. increased approx. twofold (P < 0.001), and the half-life was prolonged from 1.2 h to 2-3 h (P < 0.001) during all the gemfibrozil phases.  The drug interaction effects persisted at least 12 h after gemfibrozil was administered, although plasma gemfibrozil and gemfibrozil 1-O-β-glucuronide concns. were only 5 and 10% of their peak values, resp.  The long-lasting interaction is likely caused by mechanism-based inhibition of CYP2C8 by gemfibrozil glucuronide.  Clin. Pharmacol. & Therapeutics (2008); 84, 3, 403-411 doi:10.1038/clpt.2008.34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrcii5pN3YQLVg90H21EOLACvtfcHk0lgmFfGpSR9Gaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVShtr7K&md5=bb45f6f89c9f504af39116de52b5b825</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2008.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2008.34%26sid%3Dliteratum%253Aachs%26aulast%3DTornio%26aufirst%3DA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DLaitila%26aufirst%3DJ.%26aulast%3DKalliokoski%26aufirst%3DA.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520Effect%2520of%2520Gemfibrozil%2520on%2520Repaglinide%2520Pharmacokinetics%2520Persists%2520for%2520at%2520Least%252012%2520h%2520After%2520the%2520Dose%253A%2520Evidence%2520for%2520Mechanism-based%2520Inhibition%2520of%2520CYP2C8%2520In%2520Vivo%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2008%26volume%3D84%26spage%3D403%26epage%3D411%26doi%3D10.1038%2Fclpt.2008.34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Honkalammi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1977</span><span class="NLM_x">–</span> <span class="NLM_lpage">1986</span><span class="refDoi"> DOI: 10.1124/dmd.111.040931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.111.040931" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1977-1986&author=J.+Honkalammiauthor=M.+Niemiauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=Dose-Dependent+Interaction+between+Gemfibrozil+and+Repaglinide+in+Humans%3A+Strong+Inhibition+of+CYP2C8+with+Subtherapeutic+Gemfibrozil+Doses&doi=10.1124%2Fdmd.111.040931"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040931%26sid%3Dliteratum%253Aachs%26aulast%3DHonkalammi%26aufirst%3DJ.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DDose-Dependent%2520Interaction%2520between%2520Gemfibrozil%2520and%2520Repaglinide%2520in%2520Humans%253A%2520Strong%2520Inhibition%2520of%2520CYP2C8%2520with%2520Subtherapeutic%2520Gemfibrozil%2520Doses%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1977%26epage%3D1986%26doi%3D10.1124%2Fdmd.111.040931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Honkalammi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span><span class="refDoi"> DOI: 10.1038/clpt.2010.358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1038%2Fclpt.2010.358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=21368757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1Cls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=579-586&author=J.+Honkalammiauthor=M.+Niemiauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=Mechanism-Based+Inactivation+of+CYP2C8+by+Gemfibrozil+Occurs+Rapidly+in+Humans&doi=10.1038%2Fclpt.2010.358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans</span></div><div class="casAuthors">Honkalammi, J.; Niemi, M.; Neuvonen, P. J.; Backman, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-586</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To study the time to onset of mechanism-based inactivation of cytochrome P 450 (CYP) 2C8 by gemfibrozil in vivo, we conducted a randomized five-phase crossover study in 10 healthy volunteers.  In one phase the volunteers ingested 0.25 mg of repaglinide alone (control), and in the other phases they received 600 mg of gemfibrozil 0-6 h prior to the repaglinide dose.  When gemfibrozil was taken 0, 1, 3, or 6 h before repaglinide, the geometric mean ratio relative to control (90% confidence interval (CI)) of repaglinide area under the plasma concn.-time curve (AUC0-∞) was 5.0-fold (4.3-5.7-fold), 6.3-fold (5.4-7.5-fold), 6.6-fold (5.6-7.7-fold), and 5.4-fold (4.8-6.1-fold), resp. (P < 0.001 vs. control).  The geometric mean ratio relative to control (90% CI) of the max. plasma concn. (Cmax) of the CYP2C8-mediated metabolite M4 was 1.0-fold (0.8-1.3-fold), 0.10-fold (0.06-0.17-fold, P < 0.001), 0.06-fold (0.04-0.10-fold, P < 0.001), and 0.09-fold (0.05-0.14-fold, P < 0.001), resp.  The strong inactivation of CYP2C8, evident as soon as 1 h after gemfibrozil dosing, has implications in clin. practice and in studies with gemfibrozil as a CYP2C8 model inhibitor.  Clin. Pharmacol. & Therapeutics (2011) 89 4, 579-586. doi:10.1038/clpt.2010.358.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0t7uqdCQkRLVg90H21EOLACvtfcHk0lgmFfGpSR9Gaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1Cls70%253D&md5=6aaf0c8576c45142bb428bad130cae77</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.358%26sid%3Dliteratum%253Aachs%26aulast%3DHonkalammi%26aufirst%3DJ.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DMechanism-Based%2520Inactivation%2520of%2520CYP2C8%2520by%2520Gemfibrozil%2520Occurs%2520Rapidly%2520in%2520Humans%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D579%26epage%3D586%26doi%3D10.1038%2Fclpt.2010.358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Shitara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span> </span><span class="NLM_article-title">Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span><span class="refDoi"> DOI: 10.1124/jpet.104.068536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fjpet.104.068536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=15194707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosVKrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=228-236&author=Y.+Shitaraauthor=M.+Hiranoauthor=H.+Satoauthor=Y.+Sugiyama&title=Gemfibrozil+and+Its+Glucuronide+Inhibit+the+Organic+Anion+Transporting+Polypeptide+2+%28OATP2%2FOATP1B1%3ASLC21A6%29-Mediated+Hepatic+Uptake+and+CYP2C8-Mediated+Metabolism+of+Cerivastatin%3A+Analysis+of+the+Mechanism+of+the+Clinically+Relevant+Drug-Drug+Interaction+between+Cerivastatin+and+Gemfibrozil&doi=10.1124%2Fjpet.104.068536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil</span></div><div class="casAuthors">Shitara, Yoshihisa; Hirano, Masaru; Sato, Hitoshi; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-236</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A serious pharmacokinetic interaction between cerivastatin (CER) and gemfibrozil (GEM) has been reported.  In the present study, we examd. the inhibitory effects of GEM and its metabolites, M3 and gemfibrozil 1-O-β-glucuronide (GEM-1-O-glu), on the uptake of CER by human org. anion transporting polypeptide 2 (OATP2)-expressing cells and its metab. in cytochrome P 450 expression systems.  Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC50 values of 72 and 24 μM, resp.  They also inhibited the CYP2C8-mediated metab. of CER with IC50 values of 28 and 4 μM, resp., whereas M3 had no effects.  GEM and GEM-1-O-glu minimally inhibited the CYP3A4-mediated metab. of CER.  The IC50 values of GEM and GEM-1-O-glu for the uptake and the metab. of CER obtained in the present study were lower than their total, and not unbound, plasma concns.  However, considering the possibly concd. high unbound concns. of GEM-1-O-glu in the liver and its relatively larger plasma unbound fraction compared with GEM itself, the glucuronide inhibition of the CYP2C8-mediated metab. of CER appears to be the main mechanism for the clin. relevant drug-drug interaction.  Previously reported clin. drug interaction studies showing that coadministration of GEM with pravastatin or pitavastatin, both of which are known to be cleared from the plasma by the uptake transporters in the liver, only minimally (less than 2-fold) increased the area under the plasma concn.-time curve of these statins, also supported our present conclusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplgMf8fP3WyrVg90H21EOLACvtfcHk0lgXl6Acqljxag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosVKrt7g%253D&md5=47713127a0aa0747c2e9520811193a22</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.068536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.068536%26sid%3Dliteratum%253Aachs%26aulast%3DShitara%26aufirst%3DY.%26aulast%3DHirano%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DGemfibrozil%2520and%2520Its%2520Glucuronide%2520Inhibit%2520the%2520Organic%2520Anion%2520Transporting%2520Polypeptide%25202%2520%2528OATP2%252FOATP1B1%253ASLC21A6%2529-Mediated%2520Hepatic%2520Uptake%2520and%2520CYP2C8-Mediated%2520Metabolism%2520of%2520Cerivastatin%253A%2520Analysis%2520of%2520the%2520Mechanism%2520of%2520the%2520Clinically%2520Relevant%2520Drug-Drug%2520Interaction%2520between%2520Cerivastatin%2520and%2520Gemfibrozil%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D228%26epage%3D236%26doi%3D10.1124%2Fjpet.104.068536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Baer, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLisle, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Benzylic Oxidation of Gemfibrozil-1-O-β-Glucuronide by P450 2C8 Leads to Heme Alkylation and Irreversible Inhibition</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">–</span> <span class="NLM_lpage">1309</span><span class="refDoi"> DOI: 10.1021/tx900105n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx900105n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=1298-1309&author=B.+R.+Baerauthor=R.+K.+DeLisleauthor=A.+Allen&title=Benzylic+Oxidation+of+Gemfibrozil-1-O-%CE%B2-Glucuronide+by+P450+2C8+Leads+to+Heme+Alkylation+and+Irreversible+Inhibition&doi=10.1021%2Ftx900105n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Ftx900105n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900105n%26sid%3Dliteratum%253Aachs%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DDeLisle%26aufirst%3DR.%2BK.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DBenzylic%2520Oxidation%2520of%2520Gemfibrozil-1-O-%25CE%25B2-Glucuronide%2520by%2520P450%25202C8%2520Leads%2520to%2520Heme%2520Alkylation%2520and%2520Irreversible%2520Inhibition%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D1298%26epage%3D1309%26doi%3D10.1021%2Ftx900105n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Hollopeter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantzen, H.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramakrishnan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julius, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, P. B.</span><span> </span><span class="NLM_article-title">Identification Of The Platelet ADP Receptor Targeted By Antithrombotic Drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">409</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span><span class="refDoi"> DOI: 10.1038/35051599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1038%2F35051599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=11196645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2001&pages=202-207&author=G.+Hollopeterauthor=H.-M.+Jantzenauthor=D.+Vincentauthor=G.+Liauthor=L.+Englandauthor=V.+Ramakrishnanauthor=R.-B.+Yangauthor=P.+Nurdenauthor=A.+Nurdenauthor=D.+Juliusauthor=P.+B.+Conley&title=Identification+Of+The+Platelet+ADP+Receptor+Targeted+By+Antithrombotic+Drugs&doi=10.1038%2F35051599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the platelet ADP receptor targeted by antithrombotic drugs</span></div><div class="casAuthors">Hollopeter, Gunther; Jantzen, Hans-Michiel; Vincent, Diana; Li, Georgia; England, Laura; Ramakrishnan, Vanitha; Yang, Ruey-Bing; Nurden, Paquita; Nurden, Alan; Julius, David; Conley, Pamela B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">6817</span>),
    <span class="NLM_cas:pages">202-207</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Platelets have a crucial role in the maintenance of normal hemostasis, and perturbations of this system can lead to pathol. thrombus formation and vascular occlusion, resulting in stroke; myocardial infarction and unstable angina.  ADP released from damaged vessels and red blood cells induces platelet aggregation through activation of the integrin GPIIb-IIIa and subsequent binding of fibrinogen.  ADP is also secreted from platelets on activation, providing pos. feedback that potentiates the actions of many platelet activators.  ADP mediates platelet aggregation through its action on two G-protein-coupled receptor subtypes.  The P2Y1 receptor couples to Gq and. mobilizes intracellular calcium ions to mediate platelet shape change and aggregation.  The second ADP receptor required for aggregation (variously called P2YADP, P2YAC, P2Ycyc or P2TAC) is coupled to the inhibition of adenylyl cyclase through Gi.  The mol. identity of the Gi-linked receptor is still elusive, even though it is the target of efficacious antithrombotic agents, such as ticlopidine and clopidogrel and AR-C66096. Here the authors describe the cloning of this receptor, designated P2Y12, and provide evidence that a patient with a bleeding disorder has a defect in this gene.  Cloning of the P2Y12 receptor should facilitate the development- of better antiplatelet agents to treat cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNuDi2tNS7bVg90H21EOLACvtfcHk0lgXl6Acqljxag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D&md5=fe30017f0d3bd9aacb4ad3bd6189c5d9</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2F35051599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35051599%26sid%3Dliteratum%253Aachs%26aulast%3DHollopeter%26aufirst%3DG.%26aulast%3DJantzen%26aufirst%3DH.-M.%26aulast%3DVincent%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DEngland%26aufirst%3DL.%26aulast%3DRamakrishnan%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DR.-B.%26aulast%3DNurden%26aufirst%3DP.%26aulast%3DNurden%26aufirst%3DA.%26aulast%3DJulius%26aufirst%3DD.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DIdentification%2520Of%2520The%2520Platelet%2520ADP%2520Receptor%2520Targeted%2520By%2520Antithrombotic%2520Drugs%26jtitle%3DNature%26date%3D2001%26volume%3D409%26spage%3D202%26epage%3D207%26doi%3D10.1038%2F35051599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Foster, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prosser, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agans, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monsma, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiekowski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbondanzo, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayne, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lira, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chintala, M. S.</span><span> </span><span class="NLM_article-title">Molecular Identification And Characterization Of The Platelet ADP Receptor Targeted By Thienopyridine Antithrombotic Drugs</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">–</span> <span class="NLM_lpage">1598</span><span class="refDoi"> DOI: 10.1172/JCI12242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1172%2FJCI12242" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2001&pages=1591-1598&author=C.+J.+Fosterauthor=D.+M.+Prosserauthor=J.+M.+Agansauthor=Y.+Zhaiauthor=M.+D.+Smithauthor=J.+E.+Lachowiczauthor=F.+L.+Zhangauthor=E.+Gustafsonauthor=F.+J.+Monsmaauthor=M.+T.+Wiekowskiauthor=S.+J.+Abbondanzoauthor=D.+N.+Cookauthor=M.+L.+Bayneauthor=S.+A.+Liraauthor=M.+S.+Chintala&title=Molecular+Identification+And+Characterization+Of+The+Platelet+ADP+Receptor+Targeted+By+Thienopyridine+Antithrombotic+Drugs&doi=10.1172%2FJCI12242"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1172%2FJCI12242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI12242%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DC.%2BJ.%26aulast%3DProsser%26aufirst%3DD.%2BM.%26aulast%3DAgans%26aufirst%3DJ.%2BM.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DF.%2BL.%26aulast%3DGustafson%26aufirst%3DE.%26aulast%3DMonsma%26aufirst%3DF.%2BJ.%26aulast%3DWiekowski%26aufirst%3DM.%2BT.%26aulast%3DAbbondanzo%26aufirst%3DS.%2BJ.%26aulast%3DCook%26aufirst%3DD.%2BN.%26aulast%3DBayne%26aufirst%3DM.%2BL.%26aulast%3DLira%26aufirst%3DS.%2BA.%26aulast%3DChintala%26aufirst%3DM.%2BS.%26atitle%3DMolecular%2520Identification%2520And%2520Characterization%2520Of%2520The%2520Platelet%2520ADP%2520Receptor%2520Targeted%2520By%2520Thienopyridine%2520Antithrombotic%2520Drugs%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2001%26volume%3D107%26spage%3D1591%26epage%3D1598%26doi%3D10.1172%2FJCI12242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Sangkuhl, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, R. B.</span><span> </span><span class="NLM_article-title">Clopidogrel Pathway</span> <span class="citation_source-journal">Pharmacogenet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1097/FPC.0b013e3283385420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1097%2FFPC.0b013e3283385420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=20440227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=463-465&author=K.+Sangkuhlauthor=T.+E.+Kleinauthor=R.+B.+Altman&title=Clopidogrel+Pathway&doi=10.1097%2FFPC.0b013e3283385420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Clopidogrel pathway</span></div><div class="casAuthors">Sangkuhl, Katrin; Klein, Teri E.; Altman, Russ B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">463-465</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQIszvQeq0HLVg90H21EOLACvtfcHk0liWBSpW9t9b_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFGqs70%253D&md5=36ee29ecbf5fdb9b606e275c3a36ef27</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e3283385420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e3283385420%26sid%3Dliteratum%253Aachs%26aulast%3DSangkuhl%26aufirst%3DK.%26aulast%3DKlein%26aufirst%3DT.%2BE.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26atitle%3DClopidogrel%2520Pathway%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2010%26volume%3D20%26spage%3D463%26epage%3D465%26doi%3D10.1097%2FFPC.0b013e3283385420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Kazui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishizuka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span> </span><span class="NLM_article-title">Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">92</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1124/dmd.109.029132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.109.029132" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=92-99&author=M.+Kazuiauthor=Y.+Nishiyaauthor=T.+Ishizukaauthor=K.+Hagiharaauthor=N.+A.+Faridauthor=O.+Okazakiauthor=T.+Ikedaauthor=A.+Kurihara&title=Identification+of+the+Human+Cytochrome+P450+Enzymes+Involved+in+the+Two+Oxidative+Steps+in+the+Bioactivation+of+Clopidogrel+to+Its+Pharmacologically+Active+Metabolite&doi=10.1124%2Fdmd.109.029132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.029132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.029132%26sid%3Dliteratum%253Aachs%26aulast%3DKazui%26aufirst%3DM.%26aulast%3DNishiya%26aufirst%3DY.%26aulast%3DIshizuka%26aufirst%3DT.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DOkazaki%26aufirst%3DO.%26aulast%3DIkeda%26aufirst%3DT.%26aulast%3DKurihara%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520the%2520Human%2520Cytochrome%2520P450%2520Enzymes%2520Involved%2520in%2520the%2520Two%2520Oxidative%2520Steps%2520in%2520the%2520Bioactivation%2520of%2520Clopidogrel%2520to%2520Its%2520Pharmacologically%2520Active%2520Metabolite%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D92%26epage%3D99%26doi%3D10.1124%2Fdmd.109.029132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Dansette, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libraire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertho, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Metabolic Oxidative Cleavage of Thioesters: Evidence for the Formation of Sulfenic Acid Intermediates in the Bioactivation of the Antithrombotic Prodrugs Ticlopidine and Clopidogrel</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span><span class="refDoi"> DOI: 10.1021/tx8004828</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx8004828" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=369-373&author=P.+M.+Dansetteauthor=J.+Libraireauthor=G.+Berthoauthor=D.+Mansuy&title=Metabolic+Oxidative+Cleavage+of+Thioesters%3A+Evidence+for+the+Formation+of+Sulfenic+Acid+Intermediates+in+the+Bioactivation+of+the+Antithrombotic+Prodrugs+Ticlopidine+and+Clopidogrel&doi=10.1021%2Ftx8004828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Oxidative Cleavage of Thioesters: Evidence for the Formation of Sulfenic Acid Intermediates in the Bioactivation of the Antithrombotic Prodrugs Ticlopidine and Clopidogrel</span></div><div class="casAuthors">Dansette, Patrick M.; Libraire, Julie; Bertho, Gildas; Mansuy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">369-373</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metabolic cleavage of the CO-S bond of some thioesters RCOSR' with the formation of RCOOH requires a monooxygenase-dependent oxidative activation of this bond.  The nature of the S-contg. product(s) resulting from this cleavage remains unclear in most cases.  This communication provides the first evidence for the formation of sulfenic acid intermediates 4a and 4b during the oxidative cleavage of the CO-S bond of thiolactone metabolites 2a and 2b of antithrombotic prodrugs, ticlopidine and clopidogrel, by rat and human liver microsomes.  These intermediates have been trapped by dimedone, and the corresponding adducts 5a and 5b have been characterized by mass spectrometry (MS) and 1H and 13C NMR spectroscopy.  Their formation is monooxygenase-dependent and almost completely inhibited by microsomal cytochrome P 450 inhibitors.  Moreover, they were also formed upon incubation with microsomes contg. recombinant human P 450 3A4, 3A5, 2C8, 2C9, 2C19, 2D6, or 1A2.  In the presence of thiols such as mercaptoethanol, N-acetylcysteine, or glutathione, microsomal incubations of 2a led to mixed disulfides that have been characterized by MS and should result from reaction of 4a with these thiols.  At high thiol concns., one obsd. in HPLC-MS the formation of a product exhibiting the MS expected for the previously described thiol metabolite 3a, a redn. product of 4a that has been reported as the pharmacol. active metabolite of ticlopidine.  These data provide the first evidence for the formation of sulfenic acid reactive metabolites upon P 450-catalyzed oxidative cleavage of thioesters.  They also provide a first detailed mechanism for the previously described formation of pharmacol. active thiols such as 3a upon oxidative metab. of ticlopidine and clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT08wJDRg6g7Vg90H21EOLACvtfcHk0lg_PdSFPhf1Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D&md5=5b7783f3cfabd4dff3de96558bf9a63a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Ftx8004828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx8004828%26sid%3Dliteratum%253Aachs%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DLibraire%26aufirst%3DJ.%26aulast%3DBertho%26aufirst%3DG.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DMetabolic%2520Oxidative%2520Cleavage%2520of%2520Thioesters%253A%2520Evidence%2520for%2520the%2520Formation%2520of%2520Sulfenic%2520Acid%2520Intermediates%2520in%2520the%2520Bioactivation%2520of%2520the%2520Antithrombotic%2520Prodrugs%2520Ticlopidine%2520and%2520Clopidogrel%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D369%26epage%3D373%26doi%3D10.1021%2Ftx8004828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Silvestro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheorghe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iordachescu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuca, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudoroniu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizea Savu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarcomnicu, I.</span><span> </span><span class="NLM_article-title">Development And Validation Of An HPLC–MS/MS Method To Quantify Clopidogrel Acyl Glucuronide, Clopidogrel Acid Metabolite, And Clopidogrel In Plasma Samples Avoiding Analyte Back-Conversion</span> <span class="citation_source-journal">Anal. Bioanal. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">1023</span><span class="NLM_x">–</span> <span class="NLM_lpage">1034</span><span class="refDoi"> DOI: 10.1007/s00216-011-5147-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1007%2Fs00216-011-5147-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=21656175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntF2ntrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=2011&pages=1023-1034&author=L.+Silvestroauthor=M.+Gheorgheauthor=A.+Iordachescuauthor=V.+Ciucaauthor=A.+Tudoroniuauthor=S.+Rizea+Savuauthor=I.+Tarcomnicu&title=Development+And+Validation+Of+An+HPLC%E2%80%93MS%2FMS+Method+To+Quantify+Clopidogrel+Acyl+Glucuronide%2C+Clopidogrel+Acid+Metabolite%2C+And+Clopidogrel+In+Plasma+Samples+Avoiding+Analyte+Back-Conversion&doi=10.1007%2Fs00216-011-5147-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of an HPLC-MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion</span></div><div class="casAuthors">Silvestro, Luigi; Gheorghe, Mihaela; Iordachescu, Adriana; Ciuca, Valentin; Tudoroniu, Ariana; Rizea Savu, Simona; Tarcomnicu, Isabela</div><div class="citationInfo"><span class="NLM_cas:title">Analytical and Bioanalytical Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1023-1034</span>CODEN:
                <span class="NLM_cas:coden">ABCNBP</span>;
        ISSN:<span class="NLM_cas:issn">1618-2642</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A new sensitive and fast quant. anal. method for the simultaneous detn. of clopidogrel, its main metabolite clopidogrel carboxylic acid, and the newly described acyl glucuronide metabolite, in human plasma samples, is presented.  The anal. procedures (plasma storage, handling, and ext. storage in the autosampler) were optimized to avoid back-conversion; a known drawback in measurements of clopidogrel.  Clopidogrel acyl glucuronide was confirmed as a major source of back-conversion to the parent drug in the presence of methanol, and thorough stability expts. were carried out to find the most appropriate conditions for an accurate anal. of clopidogrel and the two metabolites.  The method was validated by assessing selectivity, sensitivity, linearity, accuracy, and precision for all three analytes, in accordance to Food and Drug Administration guidelines.  Spiked quality controls in plasma as well as incurred samples were used to verify back-conversion in the selected conditions, with results meeting European Medicines Agency acceptance criteria (concns. within 80-120% of the first reading).  The method was then applied to a pharmacokinetic study, and for the first time, a pharmacokinetic curve of clopidogrel acyl glucuronide in human plasma is presented.  The concns. ranged up to 1048.684 ng/mL, with a mean of 470.268 ng/mL, while clopidogrel had a mean Cmax of 1.348 ng/mL; these orders of magnitude show how much the back-conversion of this metabolite may influence clopidogrel quantification if it is not properly controlled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi2UiVPQVdY7Vg90H21EOLACvtfcHk0lg_PdSFPhf1Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntF2ntrw%253D&md5=639623f564eefaa208c95f984335dad7</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs00216-011-5147-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00216-011-5147-4%26sid%3Dliteratum%253Aachs%26aulast%3DSilvestro%26aufirst%3DL.%26aulast%3DGheorghe%26aufirst%3DM.%26aulast%3DIordachescu%26aufirst%3DA.%26aulast%3DCiuca%26aufirst%3DV.%26aulast%3DTudoroniu%26aufirst%3DA.%26aulast%3DRizea%2BSavu%26aufirst%3DS.%26aulast%3DTarcomnicu%26aufirst%3DI.%26atitle%3DDevelopment%2520And%2520Validation%2520Of%2520An%2520HPLC%25E2%2580%2593MS%252FMS%2520Method%2520To%2520Quantify%2520Clopidogrel%2520Acyl%2520Glucuronide%252C%2520Clopidogrel%2520Acid%2520Metabolite%252C%2520And%2520Clopidogrel%2520In%2520Plasma%2520Samples%2520Avoiding%2520Analyte%2520Back-Conversion%26jtitle%3DAnal.%2520Bioanal.%2520Chem.%26date%3D2011%26volume%3D401%26spage%3D1023%26epage%3D1034%26doi%3D10.1007%2Fs00216-011-5147-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Tornio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filppula, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kailari, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyrönen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapaninen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">–</span> <span class="NLM_lpage">507</span><span class="refDoi"> DOI: 10.1038/clpt.2014.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1038%2Fclpt.2014.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=24971633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWksr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2014&pages=498-507&author=A.+Tornioauthor=A.+M.+Filppulaauthor=O.+Kailariauthor=M.+Neuvonenauthor=T.+H.+Nyr%C3%B6nenauthor=T.+Tapaninenauthor=P.+J.+Neuvonenauthor=M.+Niemiauthor=J.+T.+Backman&title=Glucuronidation+Converts+Clopidogrel+to+a+Strong+Time-Dependent+Inhibitor+of+CYP2C8%3A+A+Phase+II+Metabolite+as+a+Perpetrator+of+Drug%E2%80%93Drug+Interactions&doi=10.1038%2Fclpt.2014.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions</span></div><div class="casAuthors">Tornio, A.; Filppula, A. M.; Kailari, O.; Neuvonen, M.; Nyronen, T. H.; Tapaninen, T.; Neuvonen, P. J.; Niemi, M.; Backman, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">498-507</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cerivastatin and repaglinide are substrates of cytochrome P 450 (CYP)2C8, CYP3A4, and org. anion-transporting polypeptide (OATP)1B1.  A recent study revealed an increased risk of rhabdomyolysis in patients using cerivastatin with clopidogrel, warranting further studies on clopidogrel interactions.  In healthy volunteers, repaglinide area under the concn.-time curve (AUC0-∞) was increased 5.1-fold by a 300-mg loading dose of clopidogrel and 3.9-fold by continued administration of 75 mg clopidogrel daily.  In vitro, we identified clopidogrel acyl-β-D-glucuronide as a potent time-dependent inhibitor of CYP2C8.  A physiol. based pharmacokinetic model indicated that inactivation of CYP2C8 by clopidogrel acyl-β-D-glucuronide leads to uninterrupted 60-85% inhibition of CYP2C8 during daily clopidogrel treatment.  Computational modeling resulted in docking of clopidogrel acyl-β-D-glucuronide at the CYP2C8 active site with its thiophene moiety close to heme.  The results indicate that clopidogrel is a strong CYP2C8 inhibitor via its acyl-β-D-glucuronide and imply that glucuronide metabolites should be considered potential inhibitors of CYP enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomkamVRNguLbVg90H21EOLACvtfcHk0liqkiU0i3Qlow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWksr3N&md5=9b034c0d2e4cfe17881ac79bbb87c613</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2014.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2014.141%26sid%3Dliteratum%253Aachs%26aulast%3DTornio%26aufirst%3DA.%26aulast%3DFilppula%26aufirst%3DA.%2BM.%26aulast%3DKailari%26aufirst%3DO.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNyr%25C3%25B6nen%26aufirst%3DT.%2BH.%26aulast%3DTapaninen%26aufirst%3DT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DGlucuronidation%2520Converts%2520Clopidogrel%2520to%2520a%2520Strong%2520Time-Dependent%2520Inhibitor%2520of%2520CYP2C8%253A%2520A%2520Phase%2520II%2520Metabolite%2520as%2520a%2520Perpetrator%2520of%2520Drug%25E2%2580%2593Drug%2520Interactions%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D96%26spage%3D498%26epage%3D507%26doi%3D10.1038%2Fclpt.2014.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Floyd, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciante, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckbert, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiggins, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamraz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwok, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totah, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Psaty, B. M.</span><span> </span><span class="NLM_article-title">A Screening Study of Drug–Drug Interactions in Cerivastatin Users: An Adverse Effect of Clopidogrel</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span><span class="refDoi"> DOI: 10.1038/clpt.2011.295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1038%2Fclpt.2011.295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=22419147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=896-904&author=J.+S.+Floydauthor=R.+Kasperaauthor=K.+D.+Marcianteauthor=N.+S.+Weissauthor=S.+R.+Heckbertauthor=T.+Lumleyauthor=K.+L.+Wigginsauthor=B.+Tamrazauthor=P.+Y.+Kwokauthor=R.+A.+Totahauthor=B.+M.+Psaty&title=A+Screening+Study+of+Drug%E2%80%93Drug+Interactions+in+Cerivastatin+Users%3A+An+Adverse+Effect+of+Clopidogrel&doi=10.1038%2Fclpt.2011.295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">A Screening Study of Drug-Drug Interactions in Cerivastatin Users: An Adverse Effect of Clopidogrel</span></div><div class="casAuthors">Floyd, J. S.; Kaspera, R.; Marciante, K. D.; Weiss, N. S.; Heckbert, S. R.; Lumley, T.; Wiggins, K. L.; Tamraz, B.; Kwok, P.-Y.; Totah, R. A.; Psaty, B. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">896-904</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">An anal. of a case-control study of rhabdomyolysis was conducted to screen for previously unrecognized cytochrome P 450 enzyme (CYP) 2C8 inhibitors that may cause other clin. important drug-drug interactions.  Medication use in cases of rhabdomyolysis using cerivastatin (n = 72) was compared with that in controls using atorvastatin (n = 287) for the period 1998-2001.  The use of clopidogrel was strongly assocd. with rhabdomyolysis (odds ratio (OR) 29.6; 95% confidence interval (CI), 6.1-143).  In a replication effort that used the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS), it was found that clopidogrel was used more commonly in patients with rhabdomyolysis receiving cerivastatin (17%) than in those receiving atorvastatin (0%, OR infinity; 95% CI = 5.2-infinity).  Several medications were tested in vitro for their potential to cause drug-drug interactions.  Clopidogrel, rosiglitazone, and montelukast were the most potent inhibitors of cerivastatin metab.  Clopidogrel and its metabolites also inhibited cerivastatin metab. in human hepatocytes.  These epidemiol. and in vitro findings suggest that clopidogrel may cause clin. important, dose-dependent drug-drug interactions with other medications metabolized by CYP2C8.  Clin. Pharmacol. & Therapeutics (2012); 91 5, 896-904. doi:10.1038/clpt.2011.295.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-xKBvrbsLErVg90H21EOLACvtfcHk0liqkiU0i3Qlow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWmt7s%253D&md5=184c1a95c592fac6027061058c715e08</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.295%26sid%3Dliteratum%253Aachs%26aulast%3DFloyd%26aufirst%3DJ.%2BS.%26aulast%3DKaspera%26aufirst%3DR.%26aulast%3DMarciante%26aufirst%3DK.%2BD.%26aulast%3DWeiss%26aufirst%3DN.%2BS.%26aulast%3DHeckbert%26aufirst%3DS.%2BR.%26aulast%3DLumley%26aufirst%3DT.%26aulast%3DWiggins%26aufirst%3DK.%2BL.%26aulast%3DTamraz%26aufirst%3DB.%26aulast%3DKwok%26aufirst%3DP.%2BY.%26aulast%3DTotah%26aufirst%3DR.%2BA.%26aulast%3DPsaty%26aufirst%3DB.%2BM.%26atitle%3DA%2520Screening%2520Study%2520of%2520Drug%25E2%2580%2593Drug%2520Interactions%2520in%2520Cerivastatin%2520Users%253A%2520An%2520Adverse%2520Effect%2520of%2520Clopidogrel%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D91%26spage%3D896%26epage%3D904%26doi%3D10.1038%2Fclpt.2011.295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amunugama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">Mechanism-Based Inactivation of Human Cytochrome P450 2B6 by Clopidogrel: Involvement of Both Covalent Modification of Cysteinyl Residue 475 and Loss of Heme</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">847</span><span class="refDoi"> DOI: 10.1124/mol.111.073783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fmol.111.073783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=839-847&author=H.+Zhangauthor=H.+Amunugamaauthor=S.+Neyauthor=N.+Cooperauthor=P.+F.+Hollenberg&title=Mechanism-Based+Inactivation+of+Human+Cytochrome+P450+2B6+by+Clopidogrel%3A+Involvement+of+Both+Covalent+Modification+of+Cysteinyl+Residue+475+and+Loss+of+Heme&doi=10.1124%2Fmol.111.073783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.073783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.073783%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DAmunugama%26aufirst%3DH.%26aulast%3DNey%26aufirst%3DS.%26aulast%3DCooper%26aufirst%3DN.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DMechanism-Based%2520Inactivation%2520of%2520Human%2520Cytochrome%2520P450%25202B6%2520by%2520Clopidogrel%253A%2520Involvement%2520of%2520Both%2520Covalent%2520Modification%2520of%2520Cysteinyl%2520Residue%2520475%2520and%2520Loss%2520of%2520Heme%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D839%26epage%3D847%26doi%3D10.1124%2Fmol.111.073783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Tamraz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukushima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totah, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciante, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckbert, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Psaty, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroetz, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwok, P.-Y.</span><span> </span><span class="NLM_article-title">OATP1B1-Related Drug–Drug And Drug–Gene Interactions As Potential Risk Factors For Cerivastatin-Induced Rhabdomyolysis</span> <span class="citation_source-journal">Pharmacogenet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span><span class="refDoi"> DOI: 10.1097/FPC.0b013e3283620c3b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1097%2FFPC.0b013e3283620c3b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=23652407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVeisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=355-364&author=B.+Tamrazauthor=H.+Fukushimaauthor=A.+R.+Wolfeauthor=R.+Kasperaauthor=R.+A.+Totahauthor=J.+S.+Floydauthor=B.+Maauthor=C.+Chuauthor=K.+D.+Marcianteauthor=S.+R.+Heckbertauthor=B.+M.+Psatyauthor=D.+L.+Kroetzauthor=P.-Y.+Kwok&title=OATP1B1-Related+Drug%E2%80%93Drug+And+Drug%E2%80%93Gene+Interactions+As+Potential+Risk+Factors+For+Cerivastatin-Induced+Rhabdomyolysis&doi=10.1097%2FFPC.0b013e3283620c3b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis</span></div><div class="casAuthors">Tamraz, Bani; Fukushima, Hisayo; Wolfe, Alan R.; Kaspera, Ruediger; Totah, Rheem A.; Floyd, James S.; Ma, Benjamin; Chu, Catherine; Marciante, Kristin D.; Heckbert, Susan R.; Psaty, Bruce M.; Kroetz, Deanna L.; Kwok, Pui-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">355-364</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: Genetic variation in drug metabolizing enzymes and membrane transporters as well as concomitant drug therapy can modulate the beneficial and the deleterious effects of drugs.  We investigated whether patients exhibiting rhabdomyolysis who were taking cerivastatin possess functional genetic variants in SLCO1B1 and whether they were on concomitant medications that inhibit OATP1B1, resulting in accumulation of cerivastatin.  Methods: This study had three components: (a) resequencing the SLCO1B1 gene in 122 patients who developed rhabdomyolysis while on cerivastatin; (b) functional evaluation of the identified SLCO1B1 nonsynonymous variants and haplotypes in in-vitro HEK293/FRT cells stably transfected with pcDNA5/FRT empty vector, SLCO1B1 ref., variants, and haplotypes; and (c) in-vitro screening of 15 drugs commonly used among the rhabdomyolysis cases for inhibition of OATP1B1-mediated uptake of cerivastatin in HEK293/FRT cells stably transfected with ref. SLCO1B1.  Results: The resequencing of the SLCO1B1 gene identified 54 variants.  In-vitro functional anal. of SLCO1B1 nonsynonymous variants and haplotypes showed that the V174A, R57Q, and P155T variants, a novel frameshift insertion, OATP1B1*14 and OATP1B1*15 haplotype were assocd. with a significant redn. (P<0.001) in cerivastatin uptake (32, 18, 72, 3.4, 2.1 and 5.7% of ref., resp.).  Furthermore, clopidogrel and seven other drugs were shown to inhibit OATP1B1-mediated uptake of cerivastatin.  Conclusion: Reduced function of OATP1B1 related to genetic variation and drug-drug interactions likely contributed to cerivastatin-induced rhabdomyolysis.  Although cerivastatin is no longer in clin. use, these findings may translate to related statins and other substrates of OATP1B1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow9hs2HfKb77Vg90H21EOLACvtfcHk0lgCsndXkXkMvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVeisLk%253D&md5=5b9001693de71ddd48bcd8e1d6b5dcad</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e3283620c3b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e3283620c3b%26sid%3Dliteratum%253Aachs%26aulast%3DTamraz%26aufirst%3DB.%26aulast%3DFukushima%26aufirst%3DH.%26aulast%3DWolfe%26aufirst%3DA.%2BR.%26aulast%3DKaspera%26aufirst%3DR.%26aulast%3DTotah%26aufirst%3DR.%2BA.%26aulast%3DFloyd%26aufirst%3DJ.%2BS.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DC.%26aulast%3DMarciante%26aufirst%3DK.%2BD.%26aulast%3DHeckbert%26aufirst%3DS.%2BR.%26aulast%3DPsaty%26aufirst%3DB.%2BM.%26aulast%3DKroetz%26aufirst%3DD.%2BL.%26aulast%3DKwok%26aufirst%3DP.-Y.%26atitle%3DOATP1B1-Related%2520Drug%25E2%2580%2593Drug%2520And%2520Drug%25E2%2580%2593Gene%2520Interactions%2520As%2520Potential%2520Risk%2520Factors%2520For%2520Cerivastatin-Induced%2520Rhabdomyolysis%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2013%26volume%3D23%26spage%3D355%26epage%3D364%26doi%3D10.1097%2FFPC.0b013e3283620c3b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Sane, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsden, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowland, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ting, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitcher-Johnstone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D. J.</span><span> </span><span class="NLM_article-title">Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">475</span><span class="refDoi"> DOI: 10.1124/dmd.115.066985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.115.066985" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=466-475&author=R.+S.+Saneauthor=D.+Ramsdenauthor=J.+P.+Saboauthor=C.+Cooperauthor=L.+Rowlandauthor=N.+Tingauthor=A.+Whitcher-Johnstoneauthor=D.+J.+Tweedie&title=Contribution+of+Major+Metabolites+toward+Complex+Drug-Drug+Interactions+of+Deleobuvir%3A+In+Vitro+Predictions+and+In+Vivo+Outcomes&doi=10.1124%2Fdmd.115.066985"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.066985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.066985%26sid%3Dliteratum%253Aachs%26aulast%3DSane%26aufirst%3DR.%2BS.%26aulast%3DRamsden%26aufirst%3DD.%26aulast%3DSabo%26aufirst%3DJ.%2BP.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DRowland%26aufirst%3DL.%26aulast%3DTing%26aufirst%3DN.%26aulast%3DWhitcher-Johnstone%26aufirst%3DA.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26atitle%3DContribution%2520of%2520Major%2520Metabolites%2520toward%2520Complex%2520Drug-Drug%2520Interactions%2520of%2520Deleobuvir%253A%2520In%2520Vitro%2520Predictions%2520and%2520In%2520Vivo%2520Outcomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D466%26epage%3D475%26doi%3D10.1124%2Fdmd.115.066985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Chen, L.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowland, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsden, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandarino, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sane, R. S.</span><span> </span><span class="NLM_article-title">Mass Balance, Metabolite Profile, and In Vitro-In Vivo Comparison of Clearance Pathways of Deleobuvir, a Hepatitis C Virus Polymerase Inhibitor</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1128/AAC.03861-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1128%2FAAC.03861-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=25-37&author=L.-Z.+Chenauthor=J.+P.+Saboauthor=E.+Philipauthor=L.+Rowlandauthor=Y.+Maoauthor=B.+Latliauthor=D.+Ramsdenauthor=D.+A.+Mandarinoauthor=R.+S.+Sane&title=Mass+Balance%2C+Metabolite+Profile%2C+and+In+Vitro-In+Vivo+Comparison+of+Clearance+Pathways+of+Deleobuvir%2C+a+Hepatitis+C+Virus+Polymerase+Inhibitor&doi=10.1128%2FAAC.03861-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1128%2FAAC.03861-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03861-14%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.-Z.%26aulast%3DSabo%26aufirst%3DJ.%2BP.%26aulast%3DPhilip%26aufirst%3DE.%26aulast%3DRowland%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DLatli%26aufirst%3DB.%26aulast%3DRamsden%26aufirst%3DD.%26aulast%3DMandarino%26aufirst%3DD.%2BA.%26aulast%3DSane%26aufirst%3DR.%2BS.%26atitle%3DMass%2520Balance%252C%2520Metabolite%2520Profile%252C%2520and%2520In%2520Vitro-In%2520Vivo%2520Comparison%2520of%2520Clearance%2520Pathways%2520of%2520Deleobuvir%252C%2520a%2520Hepatitis%2520C%2520Virus%2520Polymerase%2520Inhibitor%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D25%26epage%3D37%26doi%3D10.1128%2FAAC.03861-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Kazmi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hvenegaard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendahl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gipson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">Identification Of A Novel Carbamoyl Glucuronide As A Metabolism-Dependent Inhibitor Of CYP2C8</span> <span class="citation_source-journal">Drug Metab. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=143&author=F.+Kazmiauthor=B.+Smithauthor=M.+Hvenegaardauthor=L.+Bendahlauthor=A.+Gipsonauthor=D.+Buckleyauthor=B.+Ogilvieauthor=A.+Parkinson&title=Identification+Of+A+Novel+Carbamoyl+Glucuronide+As+A+Metabolism-Dependent+Inhibitor+Of+CYP2C8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKazmi%26aufirst%3DF.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DHvenegaard%26aufirst%3DM.%26aulast%3DBendahl%26aufirst%3DL.%26aulast%3DGipson%26aufirst%3DA.%26aulast%3DBuckley%26aufirst%3DD.%26aulast%3DOgilvie%26aufirst%3DB.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DIdentification%2520Of%2520A%2520Novel%2520Carbamoyl%2520Glucuronide%2520As%2520A%2520Metabolism-Dependent%2520Inhibitor%2520Of%2520CYP2C8%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2010%26volume%3D42%26spage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Schaefer, W. H.</span><span> </span><span class="NLM_article-title">Reaction of Primary and Secondary Amines to Form Carbamic Acid Glucuronides</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">881</span><span class="refDoi"> DOI: 10.2174/138920006779010629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2174%2F138920006779010629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=17168688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFymsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=873-881&author=W.+H.+Schaefer&title=Reaction+of+Primary+and+Secondary+Amines+to+Form+Carbamic+Acid+Glucuronides&doi=10.2174%2F138920006779010629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Reaction of primary and secondary amines to form carbamic acid glucuronides</span></div><div class="casAuthors">Schaefer, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">873-881</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Glucuronidation is an important mechanism used by mammalian systems to clear and eliminate both endogenous and foreign chems.  Many functional groups are susceptible to conjugation with glucuronic acid, including hydroxyls, phenols, carboxyls, activated carbons, thiols, amines, and selenium.  Primary and secondary amines can also react with carbon dioxide (CO2) via a reversible reaction to form a carbamic acid.  The carbamic acid is also a substrate for glucuronidation and results in a stable carbamate glucuronide metabolite.  The detection and characterization of these products has been facilitated greatly by the advent of soft ionization mass spectrometry techniques and high field NMR instrumentation.  The formation of carbamate glucuronide metabolites has been described for numerous pharmaceuticals and they have been identified in all of the species commonly used in drug metab. studies (rat, dog, mouse, rabbit, guinea pig, and human).  There has been no obvious species specificity for their formation and no preference for 1° or 2° amines.  Many biol. reactions have also been described in the literature that involve the reaction of CO2 with amino groups of biomols.  For example, CO2 generated from cellular respiration is expired in part through the reversible formation of a carbamate between CO2 and the α-amino groups of the α and β-chains of Hb.  Also, carbamic acid products of several amines, such as β-N-methylamino-L-alanine (BMAA), ethylenediamine, and L-cysteine have been implicated in toxicity.  Studies suggested that a significant portion of amino-compds. in biol. samples (that naturally contain CO2/bicarbonate) can be present as a carbamic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokytAdX5PD0LVg90H21EOLACvtfcHk0lhsHewBSrIw_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFymsr7N&md5=bd81203dafb1337b5f8d83f2820ebaae</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2174%2F138920006779010629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920006779010629%26sid%3Dliteratum%253Aachs%26aulast%3DSchaefer%26aufirst%3DW.%2BH.%26atitle%3DReaction%2520of%2520Primary%2520and%2520Secondary%2520Amines%2520to%2520Form%2520Carbamic%2520Acid%2520Glucuronides%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2006%26volume%3D7%26spage%3D873%26epage%3D881%26doi%3D10.2174%2F138920006779010629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Williams, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRee, D. E.</span><span> </span><span class="NLM_article-title">Mammalian Microsomal Cytochrome P450 Monooxygenase: Structural Adaptations for Membrane Binding and Functional Diversity</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span><span class="refDoi"> DOI: 10.1016/S1097-2765(00)80408-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS1097-2765%2800%2980408-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10678174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3cXpvFKnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2000&pages=121-131&author=P.+A.+Williamsauthor=J.+Cosmeauthor=V.+Sridharauthor=E.+F.+Johnsonauthor=D.+E.+McRee&title=Mammalian+Microsomal+Cytochrome+P450+Monooxygenase%3A+Structural+Adaptations+for+Membrane+Binding+and+Functional+Diversity&doi=10.1016%2FS1097-2765%2800%2980408-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity</span></div><div class="casAuthors">Williams, Pamela A.; Cosme, Jose; Sridhar, Vandana; Johnson, Eric F.; McRee, Duncan E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-131</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Microsomal cytochrome P 450s participate in xenobiotic detoxification, procarcinogen activation, and steroid hormone synthesis.  The first structure of a mammalian microsomal P 450 suggests that the assocn. of P 450s with the endoplasmic reticulum involves a hydrophobic surface of the protein formed by noncontiguous portions of the polypeptide chain.  This interaction places the entrance of the putative substrate access channel in or near the membrane and orients the face of the protein proximal to the heme cofactor perpendicular to the plane of the membrane for interaction with the cytochrome P 450 reductase.  This structure offers a template for modeling other mammalian P 450s and should aid drug discovery and the prediction of drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPvxT-fdyD1bVg90H21EOLACvtfcHk0lh4jwaaqW8qUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXpvFKnug%253D%253D&md5=6554880f1ae6291d7b03123bf68e533b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2980408-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252980408-6%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DP.%2BA.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DSridhar%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26atitle%3DMammalian%2520Microsomal%2520Cytochrome%2520P450%2520Monooxygenase%253A%2520Structural%2520Adaptations%2520for%2520Membrane%2520Binding%2520and%2520Functional%2520Diversity%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D5%26spage%3D121%26epage%3D131%26doi%3D10.1016%2FS1097-2765%2800%2980408-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Melet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marques-Soares, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoch, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macherey, A.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaouen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansette, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sari, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Analysis of Human Cytochrome P450 2C8 Substrate Specificity Using a Substrate Pharmacophore and Site-Directed Mutants</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">15379</span><span class="NLM_x">–</span> <span class="NLM_lpage">15392</span><span class="refDoi"> DOI: 10.1021/bi0489309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0489309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvVGgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=15379-15392&author=A.+Meletauthor=C.+Marques-Soaresauthor=G.+A.+Schochauthor=A.-C.+Machereyauthor=M.+Jaouenauthor=P.+M.+Dansetteauthor=M.-A.+Sariauthor=E.+F.+Johnsonauthor=D.+Mansuy&title=Analysis+of+Human+Cytochrome+P450+2C8+Substrate+Specificity+Using+a+Substrate+Pharmacophore+and+Site-Directed+Mutants&doi=10.1021%2Fbi0489309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Human Cytochrome P450 2C8 Substrate Specificity Using a Substrate Pharmacophore and Site-Directed Mutants</span></div><div class="casAuthors">Melet, Armelle; Marques-Soares, Cristina; Schoch, Guillaume A.; Macherey, Anne-Christine; Jaouen, Maryse; Dansette, Patrick M.; Sari, Marie-Agnes; Johnson, Eric F.; Mansuy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">15379-15392</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structural determinants of substrate specificity of human liver cytochrome P 450 2C8 (CYP2C8) were investigated using site-directed mutants chosen on the basis of a preliminary substrate pharmacophore and a three-dimensional (3D) model.  Anal. of the structural features common to CYP2C8 substrates exhibiting a micromolar Km led to a substrate pharmacophore in which the site of oxidn. by CYP2C8 is 12.9, 8.6, 4.4, and 3.9 Å from features that could establish ionic or hydrogen bonds, and hydrophobic interactions with protein amino acid residues.  Comparison of this pharmacophore with a 3D model of CYP2C8 constructed using the X-ray structure of CYP2C5 suggested potential CYP2C8 amino acid residues that could be involved in substrate recognition.  Twenty CYP2C8 site-directed mutants were constructed and expressed in yeast to compare their catalytic activities using five CYP2C8 substrates that exhibit different structures and sizes [paclitaxel, fluvastatin, retinoic acid, a sulfaphenazole deriv. (DMZ), and diclofenac].  Mutation of arginine 241 had marked effects on the hydroxylation of anionic substrates of CYP2C8 such as retinoic acid and fluvastatin.  Serine 100 appears to be involved in hydrogen bonding interactions with a polar site of the CYP2C8 substrate pharmacophore, as shown by the 3-4-fold increase in the Km of paclitaxel and DMZ hydroxylation after the S100A mutation.  Residues 114, 201, and 205 are predicted to be in close contact with substrates, and their mutations lead either to favorable hydrophobic interactions or to steric clashes with substrates.  For instance, the S114F mutant was unable to catalyze the 6α-hydroxylation of paclitaxel.  The S114F and F205A mutants were the best catalysts for retinoic acid and paclitaxel (or fluvastatin) hydroxylation, resp., with kcat/Km values 5 and 2.1 (or 2.4) times higher, resp., than those found for CYP2C8.  Preliminary expts. of docking of the substrate into the exptl. detd. X-ray structure of substrate-free CYP2C8, which became available quite recently [Schoch, G. A., et al. (2004) J. Biol. Chem. 279, 9497], were consistent with key roles for S100, S114, and F205 residues in substrate binding.  The results suggest that the effects of mutation of arginine 241 on anionic substrate hydroxylation could be indirect and result from alterations of the packing of helix G with helix B'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZZrn1vZeqlbVg90H21EOLACvtfcHk0lh4jwaaqW8qUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvVGgsr4%253D&md5=7bf3aa2049f582ed0f5ddf912fa848df</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fbi0489309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0489309%26sid%3Dliteratum%253Aachs%26aulast%3DMelet%26aufirst%3DA.%26aulast%3DMarques-Soares%26aufirst%3DC.%26aulast%3DSchoch%26aufirst%3DG.%2BA.%26aulast%3DMacherey%26aufirst%3DA.-C.%26aulast%3DJaouen%26aufirst%3DM.%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DSari%26aufirst%3DM.-A.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DAnalysis%2520of%2520Human%2520Cytochrome%2520P450%25202C8%2520Substrate%2520Specificity%2520Using%2520a%2520Substrate%2520Pharmacophore%2520and%2520Site-Directed%2520Mutants%26jtitle%3DBiochemistry%26date%3D2004%26volume%3D43%26spage%3D15379%26epage%3D15392%26doi%3D10.1021%2Fbi0489309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Schoch, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wester, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span> </span><span class="NLM_article-title">Structure Of Human Microsomal Cytochrome P450 2c8: Evidence For A Peripheral Fatty Acid Binding Site</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">9497</span><span class="NLM_x">–</span> <span class="NLM_lpage">9503</span><span class="refDoi"> DOI: 10.1074/jbc.M312516200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1074%2Fjbc.M312516200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=14676196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Omt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=9497-9503&author=G.+A.+Schochauthor=J.+K.+Yanoauthor=M.+R.+Westerauthor=K.+J.+Griffinauthor=C.+D.+Stoutauthor=E.+F.+Johnson&title=Structure+Of+Human+Microsomal+Cytochrome+P450+2c8%3A+Evidence+For+A+Peripheral+Fatty+Acid+Binding+Site&doi=10.1074%2Fjbc.M312516200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Human Microsomal Cytochrome P450 2C8: evidence for a peripheral fatty acid binding site</span></div><div class="casAuthors">Schoch, Guillaume A.; Yano, Jason K.; Wester, Michael R.; Griffin, Keith J.; Stout, C. David; Johnson, Eric F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">9497-9503</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A 2.7-Å mol. structure of human microsomal cytochrome P 450 2C8 (CYP2C8) was detd. by x-ray crystallog.  The membrane protein was modified for crystn. by replacement of the hydrophobic N-terminal transmembrane domain with a short hydrophilic sequence before residue 28.  The structure of the native sequence is complete from residue 28 to the beginning of a C-terminal histidine tag used for purifn.  CYP2C8 is one of the principal hepatic drug-metabolizing enzymes that oxidizes therapeutic drugs such as taxol and cerivastatin and endobiotics such as retinoic acid and arachidonic acid.  Consistent with the relatively large size of its preferred substrates, the active site vol. is twice that obsd. for the structure of CYP2C5.  The extended active site cavity is bounded by the β1 sheet and helix F' that have not previously been implicated in substrate recognition by mammalian P450s.  CYP2C8 crystd. as a sym. dimer formed by the interaction of helixes F, F', G', and G.  Two mols. of palmitic acid are bound in the dimer interface.  The dimer is obsd. in soln., and mass spectrometry confirmed the assocn. of palmitic acid with the enzyme.  This novel finding identifies a peripheral binding site in P450s that may contribute to drug-drug interactions in P 450 metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM_mLgb6K1XrVg90H21EOLACvtfcHk0lhHf53ZG8dZpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Omt78%253D&md5=433aca9f612b396ff3cc6f30291200a2</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M312516200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M312516200%26sid%3Dliteratum%253Aachs%26aulast%3DSchoch%26aufirst%3DG.%2BA.%26aulast%3DYano%26aufirst%3DJ.%2BK.%26aulast%3DWester%26aufirst%3DM.%2BR.%26aulast%3DGriffin%26aufirst%3DK.%2BJ.%26aulast%3DStout%26aufirst%3DC.%2BD.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26atitle%3DStructure%2520Of%2520Human%2520Microsomal%2520Cytochrome%2520P450%25202c8%253A%2520Evidence%2520For%2520A%2520Peripheral%2520Fatty%2520Acid%2520Binding%2520Site%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D9497%26epage%3D9503%26doi%3D10.1074%2Fjbc.M312516200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span> </span><span class="NLM_article-title">Characterization of the CYP2C8 Active Site by Homology Modeling</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">836</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span><span class="refDoi"> DOI: 10.1248/cpb.52.836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1248%2Fcpb.52.836" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=836-841&author=T.+Tanakaauthor=N.+Kamiguchiauthor=T.+Okudaauthor=Y.+Yamamoto&title=Characterization+of+the+CYP2C8+Active+Site+by+Homology+Modeling&doi=10.1248%2Fcpb.52.836"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1248%2Fcpb.52.836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.52.836%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKamiguchi%26aufirst%3DN.%26aulast%3DOkuda%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DCharacterization%2520of%2520the%2520CYP2C8%2520Active%2520Site%2520by%2520Homology%2520Modeling%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2004%26volume%3D52%26spage%3D836%26epage%3D841%26doi%3D10.1248%2Fcpb.52.836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Schoch, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansette, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span> </span><span class="NLM_article-title">Determinants Of Cytochrome P450 2c8 Substrate Binding: Structures Of Complexes With Montelukast, Troglitazone, Felodipine, And 9-Cis-Retinoic Acid</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">17227</span><span class="NLM_x">–</span> <span class="NLM_lpage">17237</span><span class="refDoi"> DOI: 10.1074/jbc.M802180200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1074%2Fjbc.M802180200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=18413310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFSntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=17227-17237&author=G.+A.+Schochauthor=J.+K.+Yanoauthor=S.+Sansenauthor=P.+M.+Dansetteauthor=C.+D.+Stoutauthor=E.+F.+Johnson&title=Determinants+Of+Cytochrome+P450+2c8+Substrate+Binding%3A+Structures+Of+Complexes+With+Montelukast%2C+Troglitazone%2C+Felodipine%2C+And+9-Cis-Retinoic+Acid&doi=10.1074%2Fjbc.M802180200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of Cytochrome P450 2C8 Substrate Binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid</span></div><div class="casAuthors">Schoch, Guillaume A.; Yano, Jason K.; Sansen, Stefaan; Dansette, Patrick M.; Stout, C. David; Johnson, Eric F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">17227-17237</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Although a crystal structure and a pharmacophore model are available for cytochrome P 450 2C8, the role of protein flexibility and specific ligand-protein interactions that govern substrate binding are poorly understood.  X-ray crystal structures of P 450 2C8 complexed with montelukast (2.8 Å), troglitazone (2.7 Å), felodipine (2.3 Å), and 9-cis-retinoic acid (2.6 Å) were detd. to examine ligand-protein interactions for these chem. diverse compds.  Montelukast is a relatively large anionic inhibitor that exhibits a tripartite structure and complements the size and shape of the active-site cavity.  The inhibitor troglitazone occupies the upper portion of the active-site cavity, leaving a substantial part of the cavity unoccupied.  The smaller neutral felodipine mol. is sequestered with its dichlorophenyl group positioned close to the heme iron, and water mols. fill the distal portion of the cavity.  The structure of the 9-cis-retinoic acid complex reveals that two substrate mols. bind simultaneously in the active site of P 450 2C8.  A second mol. of 9-cis-retinoic acid is located above the proximal mol. and can restrain the position of the latter for more efficient oxygenation.  Soln. binding studies do not discriminate between cooperative and noncooperative models for multiple substrate binding.  The complexes with structurally distinct ligands further demonstrate the conformational adaptability of active site-constituting residues, esp. Arg-241, that can reorient in the active-site cavity to stabilize a neg. charged functional group and define two spatially distinct binding sites for anionic moieties of substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKJYX0FJXu6rVg90H21EOLACvtfcHk0lhHf53ZG8dZpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFSntLo%253D&md5=6c4d8f308239f45f3779e5e3015bcdc2</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M802180200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M802180200%26sid%3Dliteratum%253Aachs%26aulast%3DSchoch%26aufirst%3DG.%2BA.%26aulast%3DYano%26aufirst%3DJ.%2BK.%26aulast%3DSansen%26aufirst%3DS.%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DStout%26aufirst%3DC.%2BD.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26atitle%3DDeterminants%2520Of%2520Cytochrome%2520P450%25202c8%2520Substrate%2520Binding%253A%2520Structures%2520Of%2520Complexes%2520With%2520Montelukast%252C%2520Troglitazone%252C%2520Felodipine%252C%2520And%25209-Cis-Retinoic%2520Acid%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D17227%26epage%3D17237%26doi%3D10.1074%2Fjbc.M802180200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Mulder, G. J.</span><span> </span><span class="NLM_article-title">Glucuronidation and its Role in Regulation of Biological Activity of Drugs</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span><span class="refDoi"> DOI: 10.1146/annurev.pa.32.040192.000325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1146%2Fannurev.pa.32.040192.000325" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1992&pages=25-49&author=G.+J.+Mulder&title=Glucuronidation+and+its+Role+in+Regulation+of+Biological+Activity+of+Drugs&doi=10.1146%2Fannurev.pa.32.040192.000325"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pa.32.040192.000325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pa.32.040192.000325%26sid%3Dliteratum%253Aachs%26aulast%3DMulder%26aufirst%3DG.%2BJ.%26atitle%3DGlucuronidation%2520and%2520its%2520Role%2520in%2520Regulation%2520of%2520Biological%2520Activity%2520of%2520Drugs%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1992%26volume%3D32%26spage%3D25%26epage%3D49%26doi%3D10.1146%2Fannurev.pa.32.040192.000325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Mignat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wille, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegler, A.</span><span> </span><span class="NLM_article-title">Affinity Profiles Of Morphine, Codeine, Dihydrocodeine And Their Glucuronides At Opioid Receptor Subtypes</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">799</span><span class="refDoi"> DOI: 10.1016/0024-3205(95)00010-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2F0024-3205%2895%2900010-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1995&pages=793-799&author=C.+Mignatauthor=U.+Willeauthor=A.+Ziegler&title=Affinity+Profiles+Of+Morphine%2C+Codeine%2C+Dihydrocodeine+And+Their+Glucuronides+At+Opioid+Receptor+Subtypes&doi=10.1016%2F0024-3205%2895%2900010-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2895%2900010-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252895%252900010-4%26sid%3Dliteratum%253Aachs%26aulast%3DMignat%26aufirst%3DC.%26aulast%3DWille%26aufirst%3DU.%26aulast%3DZiegler%26aufirst%3DA.%26atitle%3DAffinity%2520Profiles%2520Of%2520Morphine%252C%2520Codeine%252C%2520Dihydrocodeine%2520And%2520Their%2520Glucuronides%2520At%2520Opioid%2520Receptor%2520Subtypes%26jtitle%3DLife%2520Sci.%26date%3D1995%26volume%3D56%26spage%3D793%26epage%3D799%26doi%3D10.1016%2F0024-3205%2895%2900010-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deepak K.  Dalvie</span>, <span class="hlFld-ContribAuthor ">Bernard  Testa</span>. </span><span class="cited-content_cbyCitation_article-title">Principles of Drug Metabolism. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-139. <a href="https://doi.org/10.1002/0471266949.bmc033.pub3" title="DOI URL">https://doi.org/10.1002/0471266949.bmc033.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc033.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc033.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DPrinciples%252Bof%252BDrug%252BMetabolism%26aulast%3DDalvie%26aufirst%3DDeepak%2BK.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D139%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikhilesh V.  Dhuria</span>, <span class="hlFld-ContribAuthor ">Bianka  Haro</span>, <span class="hlFld-ContribAuthor ">Amit  Kapadia</span>, <span class="hlFld-ContribAuthor ">Khadjia A.  Lobo</span>, <span class="hlFld-ContribAuthor ">Bernice  Matusow</span>, <span class="hlFld-ContribAuthor ">Mary A.  Schleiff</span>, <span class="hlFld-ContribAuthor ">Christina  Tantoy</span>, <span class="hlFld-ContribAuthor ">Jasleen K.  Sodhi</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in predicting CYP-independent metabolism. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism Reviews</span><span> <strong>2021,</strong> <em>53 </em>
                                    (2)
                                     , 188-206. <a href="https://doi.org/10.1080/03602532.2021.1923728" title="DOI URL">https://doi.org/10.1080/03602532.2021.1923728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/03602532.2021.1923728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F03602532.2021.1923728%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520Reviews%26atitle%3DRecent%252Bdevelopments%252Bin%252Bpredicting%252BCYP-independent%252Bmetabolism%26aulast%3DDhuria%26aufirst%3DNikhilesh%2BV.%26date%3D2021%26date%3D2021%26volume%3D53%26issue%3D2%26spage%3D188%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmad  Sattari</span>, <span class="hlFld-ContribAuthor ">Ali  Ramazani</span>, <span class="hlFld-ContribAuthor ">Hamideh  Aghahosseini</span>. </span><span class="cited-content_cbyCitation_article-title">Repositioning therapeutics for COVID-19: virtual screening of the potent synthetic and natural compounds as SARS-CoV-2 3CLpro inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Iranian Chemical Society</span><span> <strong>2021,</strong> <em>24 </em><a href="https://doi.org/10.1007/s13738-021-02235-7" title="DOI URL">https://doi.org/10.1007/s13738-021-02235-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13738-021-02235-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13738-021-02235-7%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Iranian%2520Chemical%2520Society%26atitle%3DRepositioning%252Btherapeutics%252Bfor%252BCOVID-19%25253A%252Bvirtual%252Bscreening%252Bof%252Bthe%252Bpotent%252Bsynthetic%252Band%252Bnatural%252Bcompounds%252Bas%252BSARS-CoV-2%252B3CLpro%252Binhibitors%26aulast%3DSattari%26aufirst%3DAhmad%26date%3D2021%26date%3D2021%26volume%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teresa  Mulder</span>, <span class="hlFld-ContribAuthor ">Sudheer  Bobba</span>, <span class="hlFld-ContribAuthor ">Kevin  Johnson</span>, <span class="hlFld-ContribAuthor ">Jessica M.  Grandner</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Chenghong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jingwei  Cai</span>, <span class="hlFld-ContribAuthor ">Edna F.  Choo</span>, <span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>, <span class="hlFld-ContribAuthor ">Donglu  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Bioactivation of
              α
              ,
              β
              -Unsaturated Carboxylic Acids Through Acyl Glucuronidation. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2020,</strong> <em>48 </em>
                                    (9)
                                     , 819-829. <a href="https://doi.org/10.1124/dmd.120.000096" title="DOI URL">https://doi.org/10.1124/dmd.120.000096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.120.000096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.120.000096%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DBioactivation%252Bof%252B%2525CE%2525B1%252B%25252C%252B%2525CE%2525B2%252B-Unsaturated%252BCarboxylic%252BAcids%252BThrough%252BAcyl%252BGlucuronidation%26aulast%3DMulder%26aufirst%3DTeresa%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D9%26spage%3D819%26epage%3D829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changjiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Meiling  He</span>, <span class="hlFld-ContribAuthor ">Lihua  Ni</span>, <span class="hlFld-ContribAuthor ">Ke  He</span>, <span class="hlFld-ContribAuthor ">Ke  Su</span>, <span class="hlFld-ContribAuthor ">Yinzhi  Deng</span>, <span class="hlFld-ContribAuthor ">Yuanhong  Li</span>, <span class="hlFld-ContribAuthor ">Hao  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Arachidonic Acid Metabolism in Myocardial Ischemia–Reperfusion Injury. </span><span class="cited-content_cbyCitation_journal-name">Cell Biochemistry and Biophysics</span><span> <strong>2020,</strong> <em>78 </em>
                                    (3)
                                     , 255-265. <a href="https://doi.org/10.1007/s12013-020-00928-z" title="DOI URL">https://doi.org/10.1007/s12013-020-00928-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12013-020-00928-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12013-020-00928-z%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Biochemistry%2520and%2520Biophysics%26atitle%3DThe%252BRole%252Bof%252BArachidonic%252BAcid%252BMetabolism%252Bin%252BMyocardial%252BIschemia%2525E2%252580%252593Reperfusion%252BInjury%26aulast%3DZhang%26aufirst%3DChangjiang%26date%3D2020%26date%3D2020%26volume%3D78%26issue%3D3%26spage%3D255%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liam  Evans</span>, <span class="hlFld-ContribAuthor ">Richard  Phipps</span>, <span class="hlFld-ContribAuthor ">Julia  Shanu-Wilson</span>, <span class="hlFld-ContribAuthor ">Jonathan  Steele</span>, <span class="hlFld-ContribAuthor ">Stephen  Wrigley</span>. </span><span class="cited-content_cbyCitation_article-title">Methods for metabolite generation and characterization by NMR. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 119-150. <a href="https://doi.org/10.1016/B978-0-12-820018-6.00004-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-820018-6.00004-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820018-6.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820018-6.00004-1%26sid%3Dliteratum%253Aachs%26atitle%3DMethods%252Bfor%252Bmetabolite%252Bgeneration%252Band%252Bcharacterization%252Bby%252BNMR%26aulast%3DEvans%26aufirst%3DLiam%26date%3D2020%26spage%3D119%26epage%3D150%26pub%3DElsevier%26atitle%3DIdentification%252Band%252BQuantification%252Bof%252BDrugs%25252C%252BMetabolites%25252C%252BDrug%252BMetabolizing%252BEnzymes%25252C%252Band%252BTransporters%26date%3D2020%26volume%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Andrew  Rowland</span>. </span><span class="cited-content_cbyCitation_article-title">From Endogenous Compounds as Biomarkers to Plasma‐Derived Nanovesicles as Liquid Biopsy; Has the Golden Age of Translational Pharmacokinetics‐Absorption, Distribution, Metabolism, Excretion‐Drug–Drug Interaction Science Finally Arrived?. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology & Therapeutics</span><span> <strong>2019,</strong> <em>105 </em>
                                    (6)
                                     , 1407-1420. <a href="https://doi.org/10.1002/cpt.1328" title="DOI URL">https://doi.org/10.1002/cpt.1328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpt.1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpt.1328%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DFrom%252BEndogenous%252BCompounds%252Bas%252BBiomarkers%252Bto%252BPlasma%2525E2%252580%252590Derived%252BNanovesicles%252Bas%252BLiquid%252BBiopsy%25253B%252BHas%252Bthe%252BGolden%252BAge%252Bof%252BTranslational%252BPharmacokinetics%2525E2%252580%252590Absorption%25252C%252BDistribution%25252C%252BMetabolism%25252C%252BExcretion%2525E2%252580%252590Drug%2525E2%252580%252593Drug%252BInteraction%252BScience%252BFinally%252BArrived%25253F%26aulast%3DRodrigues%26aufirst%3DDavid%26date%3D2019%26date%3D2019%26volume%3D105%26issue%3D6%26spage%3D1407%26epage%3D1420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tashinga E.  Bapiro</span>, <span class="hlFld-ContribAuthor ">Andy  Sykes</span>, <span class="hlFld-ContribAuthor ">Scott  Martin</span>, <span class="hlFld-ContribAuthor ">Michael  Davies</span>, <span class="hlFld-ContribAuthor ">James W. T.  Yates</span>, <span class="hlFld-ContribAuthor ">Matthias  Hoch</span>, <span class="hlFld-ContribAuthor ">Helen E.  Rollison</span>, <span class="hlFld-ContribAuthor ">Barry  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Complete Substrate Inhibition of Cytochrome P450 2C8 by AZD9496, an Oral Selective Estrogen Receptor Degrader. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2018,</strong> <em>46 </em>
                                    (9)
                                     , 1268-1276. <a href="https://doi.org/10.1124/dmd.118.081539" title="DOI URL">https://doi.org/10.1124/dmd.118.081539</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.118.081539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.118.081539%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DComplete%252BSubstrate%252BInhibition%252Bof%252BCytochrome%252BP450%252B2C8%252Bby%252BAZD9496%25252C%252Ban%252BOral%252BSelective%252BEstrogen%252BReceptor%252BDegrader%26aulast%3DBapiro%26aufirst%3DTashinga%2BE.%26date%3D2018%26date%3D2018%26volume%3D46%26issue%3D9%26spage%3D1268%26epage%3D1276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tian  Yue</span>, <span class="hlFld-ContribAuthor ">Ke-Bo  Xie</span>, <span class="hlFld-ContribAuthor ">Zhen  Tan</span>, <span class="hlFld-ContribAuthor ">Ri-Dao  Chen</span>, <span class="hlFld-ContribAuthor ">Da-Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Ji-Mei  Liu</span>, <span class="hlFld-ContribAuthor ">Jun-Gui  Dai</span>. </span><span class="cited-content_cbyCitation_article-title">Enzymatic synthesis of glucuronidated metabolites of two neurological active agents using plant glucuronosyltransferases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Asian Natural Products Research</span><span> <strong>2018,</strong> <em>20 </em>
                                    (7)
                                     , 605-614. <a href="https://doi.org/10.1080/10286020.2018.1490276" title="DOI URL">https://doi.org/10.1080/10286020.2018.1490276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10286020.2018.1490276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10286020.2018.1490276%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Asian%2520Natural%2520Products%2520Research%26atitle%3DEnzymatic%252Bsynthesis%252Bof%252Bglucuronidated%252Bmetabolites%252Bof%252Btwo%252Bneurological%252Bactive%252Bagents%252Busing%252Bplant%252Bglucuronosyltransferases%26aulast%3DYue%26aufirst%3DTian%26date%3D2018%26date%3D2018%26volume%3D20%26issue%3D7%26spage%3D605%26epage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caroline A.  Lee</span>, <span class="hlFld-ContribAuthor ">Chun  Yang</span>, <span class="hlFld-ContribAuthor ">Vishal  Shah</span>, <span class="hlFld-ContribAuthor ">Zancong  Shen</span>, <span class="hlFld-ContribAuthor ">David M.  Wilson</span>, <span class="hlFld-ContribAuthor ">Traci M.  Ostertag</span>, <span class="hlFld-ContribAuthor ">Jean-Luc  Girardet</span>, <span class="hlFld-ContribAuthor ">Jesse  Hall</span>, <span class="hlFld-ContribAuthor ">Michael  Gillen</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2018,</strong> <em>46 </em>
                                    (5)
                                     , 532-541. <a href="https://doi.org/10.1124/dmd.117.078220" title="DOI URL">https://doi.org/10.1124/dmd.117.078220</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.117.078220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.117.078220%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DMetabolism%252Band%252BDisposition%252Bof%252BVerinurad%25252C%252Ba%252BUric%252BAcid%252BReabsorption%252BInhibitor%25252C%252Bin%252BHumans%26aulast%3DLee%26aufirst%3DCaroline%2BA.%26date%3D2018%26date%3D2018%26volume%3D46%26issue%3D5%26spage%3D532%26epage%3D541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin-Zi  Ji</span>, <span class="hlFld-ContribAuthor ">Bei-Bei  Huang</span>, <span class="hlFld-ContribAuthor ">Tong-Tong  Gu</span>, <span class="hlFld-ContribAuthor ">Ting  Tai</span>, <span class="hlFld-ContribAuthor ">Huan  Zhou</span>, <span class="hlFld-ContribAuthor ">Yu-Meng  Jia</span>, <span class="hlFld-ContribAuthor ">Qiong-Yu  Mi</span>, <span class="hlFld-ContribAuthor ">Meng-Ran  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong-Guang  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Human UGT2B7 is the major isoform responsible for the glucuronidation of clopidogrel carboxylate. </span><span class="cited-content_cbyCitation_journal-name">Biopharmaceutics & Drug Disposition</span><span> <strong>2018,</strong> <em>39 </em>
                                    (2)
                                     , 88-98. <a href="https://doi.org/10.1002/bdd.2117" title="DOI URL">https://doi.org/10.1002/bdd.2117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bdd.2117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbdd.2117%26sid%3Dliteratum%253Aachs%26jtitle%3DBiopharmaceutics%2520%2526%2520Drug%2520Disposition%26atitle%3DHuman%252BUGT2B7%252Bis%252Bthe%252Bmajor%252Bisoform%252Bresponsible%252Bfor%252Bthe%252Bglucuronidation%252Bof%252Bclopidogrel%252Bcarboxylate%26aulast%3DJi%26aufirst%3DJin-Zi%26date%3D2018%26date%3D2018%26volume%3D39%26issue%3D2%26spage%3D88%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Zhou</span>, <span class="hlFld-ContribAuthor ">Yong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">The importance of metabolite pharmacokinetics studies in drug development. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmacokinetics</span><span> <strong>2018,</strong> <em>3 </em>
                                    (1)
                                     , 5-9. <a href="https://doi.org/10.4155/ipk-2017-0020" title="DOI URL">https://doi.org/10.4155/ipk-2017-0020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/ipk-2017-0020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fipk-2017-0020%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmacokinetics%26atitle%3DThe%252Bimportance%252Bof%252Bmetabolite%252Bpharmacokinetics%252Bstudies%252Bin%252Bdrug%252Bdevelopment%26aulast%3DZhou%26aufirst%3DJian%26date%3D2018%26volume%3D3%26issue%3D1%26spage%3D5%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Metabolic pathways of diclofenac involving UGT2B7 and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Metabolic pathways of licofelone involving UGT(s) and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Metabolic pathways of ibuprofen in vivo and (B) in vitro oxidation of ibuprofen acyl-β-<span class="smallcaps smallerCapital">d</span>-glucuronide by CYP2C8 detected in LC–high resolution mass spectrometry analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Metabolic pathways of sipoglitazar involving UGT2B15 and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Metabolic pathways of MRL-C involving UGT(s) and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Metabolic pathways of estradiol involving UGT2B7 and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Metabolic pathways of desloratadine involving UGTs and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Metabolic pathways of gemfibrozil involving UGT2B7 and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Metabolic pathways of clopidogrel involving hydrolysis, glucuronidation, and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Metabolic pathways of deleobuvir involving glucuronidation, reduction, and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Metabolic pathways of Lu-A involving the reaction with CO<sub>2</sub>, glucuronidation (R<sub>1</sub> and R<sub>2</sub> represent proprietary substructures), and CYP2C8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of human microsomal CYP2C8. (A) CYP2C8 dimer in the asymmetric manner. Two palmitic acid molecules (shown in sphere) are positioned at the dimer interface. (B) Side view of CYP2C8 monomer. Secondary structures are labeled sequentially from the N terminus to the C terminus.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Active site of CYP2C8 complex with ligands. (A) The interactions between montelukast and the residues in the ligand-binding site of CYP2C8. Heme and montelukast (labeled as MTK) are shown as sphere and stick. Portion of CYP2C8 protein harboring ligand-binding site residues was rendered as transparent cartoon. Residues making close contact to montelukast (less than 4 Å) are labeled with their side chains shown as stick. Potential hydrogen bonding interactions between residues in CYP2C8 and montelukast are depicted using dashed lines. For the following panels, the atom and structure color codes and depiction are the same as described in panel A. (B) Interactions between troglitazone and the residues in the ligand-binding site of CYP2C8. Due to the smaller size of troglitzone, only the upper-half space (away from heme) of the ligand-binding site of CYP2C8 was occupied. (C) Interactions between felodipine and the residues in the ligand-binding site of CYP2C8. (D) Interactions between retinoic acids and the residues in the ligand-binding site of CYP2C8. The proximal molecule of retinoic acid to the heme is labeled as REA1, and the distal molecule is labeled as REA2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/medium/jm-2017-00510z_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of montelukast, troglitazone, felodipine, and 9-cis-retinoic acid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-21/acs.jmedchem.7b00510/20171103/images/large/jm-2017-00510z_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00510&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 85 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">de Wildt, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearns, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeder, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Anker, J. N.</span><span> </span><span class="NLM_article-title">Glucuronidation in Humans</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span><span class="refDoi"> DOI: 10.2165/00003088-199936060-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2165%2F00003088-199936060-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10427468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaK1MXkvFeju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1999&pages=439-452&author=S.+N.+de+Wildtauthor=G.+L.+Kearnsauthor=J.+S.+Leederauthor=J.+N.+van+den+Anker&title=Glucuronidation+in+Humans&doi=10.2165%2F00003088-199936060-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Glucuronidation in humans: pharmacogenetic and developmental aspects</span></div><div class="casAuthors">De Wildt, Saskia N.; Kearns, Gregory L.; Leeder, J. Steven; Van den Anker, John N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">439-452</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 103 refs.  During human development impressive changes in drug disposition occur.  An important determinant of drug clearance is metab., something that is not only detd. by ontogenic regulation but also by genetic processes which add to the variability of drug metab. during different stages of childhood.  Therefore, an understanding of the developmental regulation of different metabolic pathways, together with information on the genetic determinants of drug metab., will increase the knowledge of inter- and intraindividual variability in drug disposition during childhood.  Conjugation has historically received less attention than cytochrome P 450 metab.  An important group of conjugation reactions are catalyzed by the UDP (UDP)-glucuronosyltransferases (UGTs); to date at least 10 different UGT isoforms have been identified.  The UGTs are not only involved in the metab. of many drugs [e.g. morphine, paracetamol (acetaminophen)] but also capable of the biotransformation of important endogenous substrates (e.g. bilirubin, ethinylestradiol) and several xenobiotics.  Isoform specificity for these substrates has, however, not been fully characterized.  Serious adverse events assocd. with chloramphenicol toxicity in the neonate have highlighted the importance of developmental changes in UGT activity. However, isoform-specific differences preclude the generalization of a simple developmental pattern for UGT activity.  UGT2B7 is the only UGT isoform for which ontogeny has been characterized both in vitro and in vivo, using morphine as the probe drug.  However, no general developmental pattern for the individual UGT isoforms which might be of value for the clinician is currently available.  Genetic polymorphisms have been identified for the UGT family.  Not only for the UGT1A gene, which reduces bilirubin glucuronidation, leading to genetic hyperbilirubinemia (the Crigler-Najjar and Gilbert's syndromes), but also for 3 other UGT isoforms.  However, the impact of these genetic differences on drug metab. remains to be established because of overlapping isoform specificity of the drugs studied, as well as a lack of specific probe substrates to test the activity of individual UGT isoforms in relation to these gene mutations.  Clearly, an information gap exists regarding the developmental and genetic aspects of UGT regulation and its potential impact on therapy.  More research is needed on the pharmacogenetics and ontogeny of the UGTs for effective translation of scientific information into clin. applicable knowledge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYL6-MjX3cLVg90H21EOLACvtfcHk0lg3GVovG9MD-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvFeju7Y%253D&md5=b96b4918d8ab736ebac239cb17a13f9f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2165%2F00003088-199936060-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199936060-00005%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWildt%26aufirst%3DS.%2BN.%26aulast%3DKearns%26aufirst%3DG.%2BL.%26aulast%3DLeeder%26aufirst%3DJ.%2BS.%26aulast%3Dvan%2Bden%2BAnker%26aufirst%3DJ.%2BN.%26atitle%3DGlucuronidation%2520in%2520Humans%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1999%26volume%3D36%26spage%3D439%26epage%3D452%26doi%3D10.2165%2F00003088-199936060-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Tukey, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strassburg, C. P.</span><span> </span><span class="NLM_article-title">Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">616</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.40.1.581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1146%2Fannurev.pharmtox.40.1.581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10836148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjs1yht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2000&pages=581-616&author=R.+H.+Tukeyauthor=C.+P.+Strassburg&title=Human+UDP-Glucuronosyltransferases%3A+Metabolism%2C+Expression%2C+and+Disease&doi=10.1146%2Fannurev.pharmtox.40.1.581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Human UDP-glucuronosyltransferases. Metabolism, expression, and disease</span></div><div class="casAuthors">Tukey, Robert H.; Strassburg, Christian P.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">581-616, 2 plates</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review is given with 163 refs.  In vertebrates, the glucuronidation of small lipophilic agents is catalyzed by the endoplasmic reticulum UDP-glucuronosyltransferases (UGTs).  This metabolic pathway leads to the formation of water-sol. metabolites originating from normal dietary processes, cellular catabolism, or exposure to drugs and xenobiotics.  This classic detoxification process, which led to the discovery nearly 50 yr ago of the cosubstrate UDP-glucuronic acid, is now known to be carried out by 15 human UGTs.  Characterization of the individual gene products using cDNA expression expts. has led to the identification of over 350 individual compds. that serve as substrates for this superfamily of proteins.  This data, coupled with the introduction of sophisticated RNA detection techniques designed to elucidate patterns of gene expression of the UGT superfamily in human liver and extrahepatic tissues of the gastrointestinal tract, has aided in understanding the contribution of glucuronidation toward epithelial first-pass metab.  In addn., characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochem. basis of the clin. symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms assocd. with Crigler-Najjar's and Gilbert's syndrome.  The role of the UGTs in metab. and different disease states in humans is the topic of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKZgb1RfxRL7Vg90H21EOLACvtfcHk0liYXDEjREqsqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjs1yht7k%253D&md5=416a716f086fc387c95a97624b543f87</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.40.1.581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.40.1.581%26sid%3Dliteratum%253Aachs%26aulast%3DTukey%26aufirst%3DR.%2BH.%26aulast%3DStrassburg%26aufirst%3DC.%2BP.%26atitle%3DHuman%2520UDP-Glucuronosyltransferases%253A%2520Metabolism%252C%2520Expression%252C%2520and%2520Disease%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2000%26volume%3D40%26spage%3D581%26epage%3D616%26doi%3D10.1146%2Fannurev.pharmtox.40.1.581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Argikar, U. A.</span><span> </span><span class="NLM_article-title">Unusual Glucuronides</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1239</span><span class="NLM_x">–</span> <span class="NLM_lpage">1251</span><span class="refDoi"> DOI: 10.1124/dmd.112.045096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.112.045096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1239-1251&author=U.+A.+Argikar&title=Unusual+Glucuronides&doi=10.1124%2Fdmd.112.045096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.045096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.045096%26sid%3Dliteratum%253Aachs%26aulast%3DArgikar%26aufirst%3DU.%2BA.%26atitle%3DUnusual%2520Glucuronides%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1239%26epage%3D1251%26doi%3D10.1124%2Fdmd.112.045096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Kaivosaari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koskinen, M.</span><span> </span><span class="NLM_article-title">N-Glucuronidation Of Drugs And Other Xenobiotics By Human And Animal UDP-Glucuronosyltransferases</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">652</span><span class="NLM_x">–</span> <span class="NLM_lpage">669</span><span class="refDoi"> DOI: 10.3109/00498254.2011.563327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.3109%2F00498254.2011.563327" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=652-669&author=S.+Kaivosaariauthor=M.+Finelauthor=M.+Koskinen&title=N-Glucuronidation+Of+Drugs+And+Other+Xenobiotics+By+Human+And+Animal+UDP-Glucuronosyltransferases&doi=10.3109%2F00498254.2011.563327"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3109%2F00498254.2011.563327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2011.563327%26sid%3Dliteratum%253Aachs%26aulast%3DKaivosaari%26aufirst%3DS.%26aulast%3DFinel%26aufirst%3DM.%26aulast%3DKoskinen%26aufirst%3DM.%26atitle%3DN-Glucuronidation%2520Of%2520Drugs%2520And%2520Other%2520Xenobiotics%2520By%2520Human%2520And%2520Animal%2520UDP-Glucuronosyltransferases%26jtitle%3DXenobiotica%26date%3D2011%26volume%3D41%26spage%3D652%26epage%3D669%26doi%3D10.3109%2F00498254.2011.563327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Keppler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jedlitschky, G.</span><span> </span><span class="NLM_article-title">Transport Of Glutathione Conjugates And Glucuronides By The Multidrug Resistance Proteins MRP1 And MRP2</span> <span class="citation_source-journal">Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">378</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">791</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=1997&pages=787-791&author=D.+Kepplerauthor=I.+Leierauthor=G.+Jedlitschky&title=Transport+Of+Glutathione+Conjugates+And+Glucuronides+By+The+Multidrug+Resistance+Proteins+MRP1+And+MRP2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DLeier%26aufirst%3DI.%26aulast%3DJedlitschky%26aufirst%3DG.%26atitle%3DTransport%2520Of%2520Glutathione%2520Conjugates%2520And%2520Glucuronides%2520By%2520The%2520Multidrug%2520Resistance%2520Proteins%2520MRP1%2520And%2520MRP2%26jtitle%3DBiol.%2520Chem.%26date%3D1997%26volume%3D378%26spage%3D787%26epage%3D791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Zamek-Gliszczynski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmaster, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nezasa, K.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallman, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brouwer, K. L. R.</span><span> </span><span class="NLM_article-title">Integration Of Hepatic Drug Transporters And Phase II Metabolizing Enzymes: Mechanisms Of Hepatic Excretion Of Sulfate, Glucuronide, And Glutathione Metabolites</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">447</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span><span class="refDoi"> DOI: 10.1016/j.ejps.2005.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2Fj.ejps.2005.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=16472997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Cht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=447-486&author=M.+J.+Zamek-Gliszczynskiauthor=K.+A.+Hoffmasterauthor=K.-i.+Nezasaauthor=M.+N.+Tallmanauthor=K.+L.+R.+Brouwer&title=Integration+Of+Hepatic+Drug+Transporters+And+Phase+II+Metabolizing+Enzymes%3A+Mechanisms+Of+Hepatic+Excretion+Of+Sulfate%2C+Glucuronide%2C+And+Glutathione+Metabolites&doi=10.1016%2Fj.ejps.2005.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites</span></div><div class="casAuthors">Zamek-Gliszczynski, Maciej J.; Hoffmaster, Keith A.; Nezasa, Ken-ichi; Tallman, Melanie N.; Brouwer, Kim L. R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">447-486</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The liver is the primary site of drug metab. in the body.  Typically, metabolic conversion of a drug results in inactivation, detoxification, and enhanced likelihood for excretion in urine or feces.  Sulfation, glucuronidation, and glutathione conjugation represent the three most prevalent classes of phase II metab., which may occur directly on the parent compds. that contain appropriate structural motifs, or, as is usually the case, on functional groups added or exposed by phase I oxidn.  These 3 conjugation reactions increase the mol. wt. and water soly. of the compd., in addn. to adding a neg. charge to the mol.  As a result of these changes in the physicochem. properties, phase II conjugates tend to have very poor membrane permeability, and necessitate carrier-mediated transport for biliary or hepatic basolateral excretion into sinusoidal blood for eventual excretion into urine.  This review summarizes sulfation, glucuronidation, and glutathione conjugation reactions, as well as recent progress in elucidating the hepatic transport mechanisms responsible for the excretion of these conjugates from the liver.  The discussion focuses on alterations of metab. and transport by chem. modulators, and disease states, as well as pharmacodynamic and toxicol. implications of hepatic metab. and/or transport modulation for certain active phase II conjugates.  A brief discussion of issues that must be considered in the design and interpretation of phase II metabolite transport studies follows.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGfVj8nU-TvLVg90H21EOLACvtfcHk0lgHlMjXVSq9MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Cht74%253D&md5=79b0cbce0c9a8c99167aca2b6e924955</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2005.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2005.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26aulast%3DHoffmaster%26aufirst%3DK.%2BA.%26aulast%3DNezasa%26aufirst%3DK.-i.%26aulast%3DTallman%26aufirst%3DM.%2BN.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%2BR.%26atitle%3DIntegration%2520Of%2520Hepatic%2520Drug%2520Transporters%2520And%2520Phase%2520II%2520Metabolizing%2520Enzymes%253A%2520Mechanisms%2520Of%2520Hepatic%2520Excretion%2520Of%2520Sulfate%252C%2520Glucuronide%252C%2520And%2520Glutathione%2520Metabolites%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D447%26epage%3D486%26doi%3D10.1016%2Fj.ejps.2005.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Zenser, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakshmi, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, B. B.</span><span> </span><span class="NLM_article-title">Human and Escherichia coli β-Glucuronidase Hydrolysis of Glucuronide Conjugates of Benzidine and 4-Aminobiphenyl, and Their Hydroxy Metabolites</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1064</span><span class="NLM_x">–</span> <span class="NLM_lpage">1067</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1064-1067&author=T.+V.+Zenserauthor=V.+M.+Lakshmiauthor=B.+B.+Davis&title=Human+and+Escherichia+coli+%CE%B2-Glucuronidase+Hydrolysis+of+Glucuronide+Conjugates+of+Benzidine+and+4-Aminobiphenyl%2C+and+Their+Hydroxy+Metabolites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZenser%26aufirst%3DT.%2BV.%26aulast%3DLakshmi%26aufirst%3DV.%2BM.%26aulast%3DDavis%26aufirst%3DB.%2BB.%26atitle%3DHuman%2520and%2520Escherichia%2520coli%2520%25CE%25B2-Glucuronidase%2520Hydrolysis%2520of%2520Glucuronide%2520Conjugates%2520of%2520Benzidine%2520and%25204-Aminobiphenyl%252C%2520and%2520Their%2520Hydroxy%2520Metabolites%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1064%26epage%3D1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Brunelle, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbeeck, R. K.</span><span> </span><span class="NLM_article-title">Conjugation-Deconjugation Cycling Of Diflunisal Via B-Glucuronidase Catalyzed Hydrolysis Of Its Acyl Glucuronide In The Rat</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2013</span><span class="NLM_x">–</span> <span class="NLM_lpage">2021</span><span class="refDoi"> DOI: 10.1016/S0024-3205(97)00166-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS0024-3205%2897%2900166-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1997&pages=2013-2021&author=F.+M.+Brunelleauthor=R.+K.+Verbeeck&title=Conjugation-Deconjugation+Cycling+Of+Diflunisal+Via+B-Glucuronidase+Catalyzed+Hydrolysis+Of+Its+Acyl+Glucuronide+In+The+Rat&doi=10.1016%2FS0024-3205%2897%2900166-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2897%2900166-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252897%252900166-5%26sid%3Dliteratum%253Aachs%26aulast%3DBrunelle%26aufirst%3DF.%2BM.%26aulast%3DVerbeeck%26aufirst%3DR.%2BK.%26atitle%3DConjugation-Deconjugation%2520Cycling%2520Of%2520Diflunisal%2520Via%2520B-Glucuronidase%2520Catalyzed%2520Hydrolysis%2520Of%2520Its%2520Acyl%2520Glucuronide%2520In%2520The%2520Rat%26jtitle%3DLife%2520Sci.%26date%3D1997%26volume%3D60%26spage%3D2013%26epage%3D2021%26doi%3D10.1016%2FS0024-3205%2897%2900166-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Danielson, P. B.</span><span> </span><span class="NLM_article-title">The Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">597</span><span class="refDoi"> DOI: 10.2174/1389200023337054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2174%2F1389200023337054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=12369887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD38XoslKiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=561-597&author=P.+B.+Danielson&title=The+Cytochrome+P450+Superfamily%3A+Biochemistry%2C+Evolution+and+Drug+Metabolism+in+Humans&doi=10.2174%2F1389200023337054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The cytochrome P 450 superfamily: Biochemistry, evolution and drug metabolism in humans</span></div><div class="casAuthors">Danielson, P. B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">561-597</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 349 refs.  Cytochrome P 450s comprise a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their CO-bound species at 450 nm.  Having been found in every class of organism, including Archaea, the P 450 superfamily is believed to have originated from an ancestral gene that existed >3 × 109 yr ago.  Repeated gene duplications have subsequently given rise to one of the largest of multigene families.  These enzymes are notable both for the diversity of reactions that they catalyze and the range of chem. dissimilar substrates upon which they act.  Cytochrome P 450s support the oxidative, peroxidative, and reductive metab. of such endogenous and xenobiotic substrates as environmental pollutants, agrochems., plant allelochems., steroids, prostaglandins, and fatty acids.  In humans, cytochrome P 450s are best known for their central role in phase I drug metab. where they are of crit. importance to 2 of the most significant problems in clin. pharmacol.: drug interactions and interindividual variability in drug metab.  Recent advances in the understanding of cytochrome P 450-mediated drug metab. have been accelerated as a result of an increasing emphasis on functional genomic approaches to P 450 research.  Whereas human cytochrome P 450 databases have swelled with a flood of new human sequence variants, the functional characterization of the corresponding gene products has not kept pace.  In response, researchers have begun to apply the tools of proteomics as well as homol.-based and ab initio modeling to salient questions of cytochrome P 450 structure/function.  This review examines the latest advances in the understanding of human cytochrome P 450s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqurWL0xT89zrVg90H21EOLACvtfcHk0libXLM-YmnyDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XoslKiu7s%253D&md5=213ff54b516026f85862c08b179ba3bd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F1389200023337054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200023337054%26sid%3Dliteratum%253Aachs%26aulast%3DDanielson%26aufirst%3DP.%2BB.%26atitle%3DThe%2520Cytochrome%2520P450%2520Superfamily%253A%2520Biochemistry%252C%2520Evolution%2520and%2520Drug%2520Metabolism%2520in%2520Humans%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2002%26volume%3D3%26spage%3D561%26epage%3D597%26doi%3D10.2174%2F1389200023337054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Ridderström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamora, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fjellström, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, T. B.</span><span> </span><span class="NLM_article-title">Analysis of Selective Regions in the Active Sites of Human Cytochromes P450, 2C8, 2C9, 2C18, and 2C19 Homology Models Using GRID/CPCA</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4072</span><span class="NLM_x">–</span> <span class="NLM_lpage">4081</span><span class="refDoi"> DOI: 10.1021/jm0109107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0109107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4072-4081&author=M.+Ridderstr%C3%B6mauthor=I.+Zamoraauthor=O.+Fjellstr%C3%B6mauthor=T.+B.+Andersson&title=Analysis+of+Selective+Regions+in+the+Active+Sites+of+Human+Cytochromes+P450%2C+2C8%2C+2C9%2C+2C18%2C+and+2C19+Homology+Models+Using+GRID%2FCPCA&doi=10.1021%2Fjm0109107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm0109107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0109107%26sid%3Dliteratum%253Aachs%26aulast%3DRidderstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DZamora%26aufirst%3DI.%26aulast%3DFjellstr%25C3%25B6m%26aufirst%3DO.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DAnalysis%2520of%2520Selective%2520Regions%2520in%2520the%2520Active%2520Sites%2520of%2520Human%2520Cytochromes%2520P450%252C%25202C8%252C%25202C9%252C%25202C18%252C%2520and%25202C19%2520Homology%2520Models%2520Using%2520GRID%252FCPCA%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4072%26epage%3D4081%26doi%3D10.1021%2Fjm0109107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Lai, X.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.-F.</span><span> </span><span class="NLM_article-title">Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1009</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span><span class="refDoi"> DOI: 10.2174/138920009790711832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2174%2F138920009790711832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=20214592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFGjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1009-1047&author=X.-S.+Laiauthor=L.-P.+Yangauthor=X.-T.+Liauthor=J.-P.+Liuauthor=Z.-W.+Zhouauthor=S.-F.+Zhou&title=Human+CYP2C8%3A+Structure%2C+Substrate+Specificity%2C+Inhibitor+Selectivity%2C+Inducers+and+Polymorphisms&doi=10.2174%2F138920009790711832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms</span></div><div class="casAuthors">Lai, Xin-Sheng; Yang, Li-Ping; Li, Xiao-Tian; Liu, Jun-Ping; Zhou, Zhi-Wei; Zhou, Shu-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1009-1047</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Human CYP2C8 is a key member of the CYP2C family and metabolizes more than 60 clin. drugs.  A no. of active site residues in CYP2C8 have been identified based on homol. modeling and site-directed mutagenesis studies.  In the structure of CYP2C8, the large active site cavity exhibits a trifurcated topol. that approximates a T or Y shape, which is consistent with the finding that CYP2C8 can efficiently oxidize relatively large substrates such as paclitaxel and cerivastatin.  The active site cavity of CYP2C8 contains at least 48 amino acid residues and many of them are important for substrate binding.  The structures of CYP2C8 in complex with distinct ligands have revealed that the enzyme can bind divergent substrates and inhibitors without extensive conformational changes.  CYP2C8 is a major catalyst in the metab. of paclitaxel, amodiaquine, troglitazone, amiodarone, verapamil and ibuprofen, with a secondary role in the biotransformation of cerivastatin and fluvastatin.  CYP2C8 also metabolizes endogenous compds. such as retinoids and arachidonic acid.  Many drugs are inhibitors of CYP2C8 and inhibition of this enzyme may result in clin. drug interactions.  The pregnane X receptor, constitutive androstane receptor, and glucocorticoid receptor are likely to involve the regulation of CYP2C8.  A no. of genetic mutations in the CYP2C8 gene have been identified in humans and some of them have functional impact on the clearance of drugs.  Further studies are needed to delineate the role of CYP2C8 in drug development and clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk08nPzZToRbVg90H21EOLACvtfcHk0libXLM-YmnyDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFGjtbY%253D&md5=a0788a14c7bfaa3cc8db1fb512587648</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F138920009790711832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920009790711832%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DX.-S.%26aulast%3DYang%26aufirst%3DL.-P.%26aulast%3DLi%26aufirst%3DX.-T.%26aulast%3DLiu%26aufirst%3DJ.-P.%26aulast%3DZhou%26aufirst%3DZ.-W.%26aulast%3DZhou%26aufirst%3DS.-F.%26atitle%3DHuman%2520CYP2C8%253A%2520Structure%252C%2520Substrate%2520Specificity%252C%2520Inhibitor%2520Selectivity%252C%2520Inducers%2520and%2520Polymorphisms%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2009%26volume%3D10%26spage%3D1009%26epage%3D1047%26doi%3D10.2174%2F138920009790711832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kirchheiner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomalik-Scharte, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hering, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshyenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jetter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stehle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsahuridu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meineke, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockmöller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuhr, U.</span><span> </span><span class="NLM_article-title">Pharmacokinetics And Pharmacodynamics Of Rosiglitazone In Relation To CYP2C8 Genotype</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span><span class="refDoi"> DOI: 10.1016/j.clpt.2006.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2Fj.clpt.2006.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=17178266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtleisb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=657-667&author=J.+Kirchheinerauthor=S.+Thomasauthor=S.+Bauerauthor=D.+Tomalik-Scharteauthor=U.+Heringauthor=O.+Doroshyenkoauthor=A.+Jetterauthor=S.+Stehleauthor=M.+Tsahuriduauthor=I.+Meinekeauthor=J.+Brockm%C3%B6llerauthor=U.+Fuhr&title=Pharmacokinetics+And+Pharmacodynamics+Of+Rosiglitazone+In+Relation+To+CYP2C8+Genotype&doi=10.1016%2Fj.clpt.2006.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype</span></div><div class="casAuthors">Kirchheiner, Julia; Thomas, Soju; Bauer, Steffen; Tomalik-Scharte, Dorota; Hering, Ursula; Doroshyenko, Oxana; Jetter, Alexander; Stehle, Simone; Tsahuridu, Martina; Meineke, Ingolf; Brockmoeller, Juergen; Fuhr, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">657-667</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Rosiglitazone is metabolically inactivated predominantly via the cytochrome P 450 (CYP) enzyme CYP2C8.  The functional impact of the CYP2C8*3 allele coding for the Arg139Lys and Lys399Arg amino acid substitutions is controversial.  The purpose of this was to clarify the role of this polymorphism with regard to the pharmacokinetics and clin. effects of rosiglitazone.  From a large sample of healthy volunteers, 14 carriers of the CYP2C8*1/*1 allele, 13 carriers of the *1/*3 allele, and 4 carriers the *3/*3 allele were selected for a clin. study.  Rosiglitazone (8 mg) single-dose and multiple-dose pharmacokinetics and its effects on glucose level and body wt. were monitored.  Plasma and urine concns. of rosiglitazone and desmethylrosiglitazone were measured, and kinetics was analyzed by noncompartmental and population-kinetic compartmental methods.  Mean total clearance values were 0.033 L/h-1/kg-1 (95% confidence interval [CI], 0.030-0.037 L/h-1/kg-1), 0.038 L/h-1/kg-1 (95% CI, 0.033-0.044 L/h-1/kg-1), and 0.046 L/h-1/kg-1 (95% CI, 0.033-0.058 L/h-1/kg-1) in carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, resp., on day 1 (P = .02, ANOVA [F test]).  Rosiglitazone kinetics could be adequately described by a 1-compartmental model with first-order absorption.  Besides CYP2C8 genotype, body wt. was a significant covariate (P < .001, log-likelihood ratio test).  Elimination half-lives were 4.3, 3.5, and 2.9 h in CYP2C8*1/*1, *1/*3, and *3/*3 carriers, resp.  Clearance of desmethylrosiglitazone was also higher in CYP2C8*3 allele carriers, with mean values of 1.96 L/h (95% CI, 1.42-2.69 L/h), 2.22 L/h (95% CI, 1.61-3.04 L/h), and 2.47 L/h (95% CI, 1.80-3.39 L/h), resp. (P = .03).  The plasma glucose area under the concn. curve was significantly lower after 14 days of taking rosiglitazone compared with day 1 (P = .01, paired t test), but no relationship of the glucose-lowering effect of rosiglitazone with CYP2C8 genotype was obsd.  This study showed that the CYP2C8*3 allele confers higher in vivo metabolic capacity than the wild-type CYP2C8*1 allele but the pharmacokinetic differences resulting from CYP2C8*3 were quant. moderate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohGEb91I4sObVg90H21EOLACvtfcHk0lgS3gV3nwakRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtleisb7J&md5=9286decbf161a5ce7feaf2c52c43bc15</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2006.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2006.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DKirchheiner%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DTomalik-Scharte%26aufirst%3DD.%26aulast%3DHering%26aufirst%3DU.%26aulast%3DDoroshyenko%26aufirst%3DO.%26aulast%3DJetter%26aufirst%3DA.%26aulast%3DStehle%26aufirst%3DS.%26aulast%3DTsahuridu%26aufirst%3DM.%26aulast%3DMeineke%26aufirst%3DI.%26aulast%3DBrockm%25C3%25B6ller%26aufirst%3DJ.%26aulast%3DFuhr%26aufirst%3DU.%26atitle%3DPharmacokinetics%2520And%2520Pharmacodynamics%2520Of%2520Rosiglitazone%2520In%2520Relation%2520To%2520CYP2C8%2520Genotype%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2006%26volume%3D80%26spage%3D657%26epage%3D667%26doi%3D10.1016%2Fj.clpt.2006.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kaspera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naraharisetti, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamraz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahele, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheesman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwok, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciante, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckbert, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Psaty, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totah, R. A.</span><span> </span><span class="NLM_article-title">Cerivastatin In Vitro Metabolism By CYP2C8 Variants Found In Patients Experiencing Rhabdomyolysis</span> <span class="citation_source-journal">Pharmacogenet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">619</span><span class="NLM_x">–</span> <span class="NLM_lpage">629</span><span class="refDoi"> DOI: 10.1097/FPC.0b013e32833ecace</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1097%2FFPC.0b013e32833ecace" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=20739906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKlsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=619-629&author=R.+Kasperaauthor=S.+B.+Naraharisettiauthor=B.+Tamrazauthor=T.+Saheleauthor=M.+J.+Cheesmanauthor=P.-Y.+Kwokauthor=K.+Marcianteauthor=S.+R.+Heckbertauthor=B.+M.+Psatyauthor=R.+A.+Totah&title=Cerivastatin+In+Vitro+Metabolism+By+CYP2C8+Variants+Found+In+Patients+Experiencing+Rhabdomyolysis&doi=10.1097%2FFPC.0b013e32833ecace"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis</span></div><div class="casAuthors">Kaspera, Ruediger; Naraharisetti, Suresh B.; Tamraz, Bani; Sahele, Tariku; Cheesman, Matthew J.; Kwok, Pui-Yan; Marciante, Kristin; Heckbert, Susan R.; Psaty, Bruce M.; Totah, Rheem A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">619-629</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Cerivastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor withdrawn from the market because of serious adverse effects, is metabolized primarily by CYP2C8.  The occurrence of assocd. myotoxicity and rhabdomyolysis were attributed to altered cerivastatin pharmacokinetics on account of gemfibrozil-inhibition or genetic variations in CYP2C8 and drug transporters involved in cerivastatin clearance.  However, the effect of CYP2C8 genetic variation on cerivastatin metab. has not been fully elucidated.  In this study, patients (n=126) with confirmed cases of rhabdomyolysis after cerivastatin administration had their CYP2C8 gene resequenced and the metab. of cerivastatin by the discovered CYP2C8 variants was assessed in proteins expressed in Escherichia coli.  In this unique patient population, 12 novel single nucleotide polymorphisms were discovered of which six were exclusively found in patients not using gemfibrozil.  Three rare exonic variants resulted in amino acid substitutions and a frame shift deletion (V472fsL494 generating a defective mostly heme-free CYP2C8 protein).  A particular promoter located deletion (-635_-634delTA) was tightly linked to CYP2C8*3.  Heterologously expressed CYP2C8.3 and CYP2C8.4 displayed an increase in cerivastatin metabolic clearance of up to six-fold compared with the wild-type enzyme.  Similarly, an independent sample of microsomes from human livers carrying the CYP2C8*3 and CYP2C8*4 alleles exhibited a 2-fold to 14-fold increase in normalized cerivastatin intrinsic clearance, compared with microsomes from livers carrying only the wild type allele.  Gain or loss of catalytic function found in the CYP2C8 gene could certainly alter cerivastatin pharmacokinetics and may influence, at least in part, susceptibility to the development of myotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoabUTTU4RlQrVg90H21EOLACvtfcHk0lgS3gV3nwakRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKlsL3I&md5=60c06d1669981a75b539bbff52021b0d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e32833ecace&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e32833ecace%26sid%3Dliteratum%253Aachs%26aulast%3DKaspera%26aufirst%3DR.%26aulast%3DNaraharisetti%26aufirst%3DS.%2BB.%26aulast%3DTamraz%26aufirst%3DB.%26aulast%3DSahele%26aufirst%3DT.%26aulast%3DCheesman%26aufirst%3DM.%2BJ.%26aulast%3DKwok%26aufirst%3DP.-Y.%26aulast%3DMarciante%26aufirst%3DK.%26aulast%3DHeckbert%26aufirst%3DS.%2BR.%26aulast%3DPsaty%26aufirst%3DB.%2BM.%26aulast%3DTotah%26aufirst%3DR.%2BA.%26atitle%3DCerivastatin%2520In%2520Vitro%2520Metabolism%2520By%2520CYP2C8%2520Variants%2520Found%2520In%2520Patients%2520Experiencing%2520Rhabdomyolysis%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2010%26volume%3D20%26spage%3D619%26epage%3D629%26doi%3D10.1097%2FFPC.0b013e32833ecace" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Li, X.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Björkman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridderström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masimirembwa, C. M.</span><span> </span><span class="NLM_article-title">Amodiaquine Clearance and Its Metabolism toN-Desethylamodiaquine Is Mediated by CYP2C8: A New High Affinity and Turnover Enzyme-Specific Probe Substrate</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">300</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span><span class="refDoi"> DOI: 10.1124/jpet.300.2.399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fjpet.300.2.399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=11805197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1ynsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2002&pages=399-407&author=X.-Q.+Liauthor=A.+Bj%C3%B6rkmanauthor=T.+B.+Anderssonauthor=M.+Ridderstr%C3%B6mauthor=C.+M.+Masimirembwa&title=Amodiaquine+Clearance+and+Its+Metabolism+toN-Desethylamodiaquine+Is+Mediated+by+CYP2C8%3A+A+New+High+Affinity+and+Turnover+Enzyme-Specific+Probe+Substrate&doi=10.1124%2Fjpet.300.2.399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate</span></div><div class="casAuthors">Li, Xue-Qing; Bjorkman, Anders; Andersson, Tommy B.; Ridderstrom, Marianne; Masimirembwa, Collen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">300</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">399-407</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Amodiaquine (AQ) metab. to N-desethylamodiaquine (DEAQ) is the principal route of disposition in humans.  Using human liver microsomes and 2 sets of recombinant human cytochrome P 450 isoforms (from lymphoblastoids and yeast) the authors performed studies to identify the CYP isoform(s) involved in the metab. of AQ.  CYP2C8 was the main hepatic isoform that cleared AQ and catalyzed the formation of DEAQ.  The extrahepatic P450s, 1A1 and 1B1, also cleared AQ and catalyzed the formation of an unknown metabolite M2.  The Km and Vmax values for AQ N-desethylation were 1.2 μM and 2.6 pmol/min/pmol of CYP2C8 for recombinant CYP2C8, and 2.4 μM and 1462 pmol/min/mg of protein for human liver microsomes (HLMs), resp.  Relative contribution of CYP2C8 in the formation of DEAQ was estd. at 100% using the relative activity factor method.  Correlation analyses between AQ metab. and the activities of 8 hepatic P450s were made on 10 different HLM samples.  Both the formation of DEAQ and the clearance of AQ showed excellent correlations (r2 = 0.98 and 0.95) with 6α-hydroxylation of paclitaxel, a marker substrate for CYP2C8.  The inhibition of DEAQ formation by quercetin was competitive with Ki values of 1.96 for CYP2C8 and 1.56 μM for HLMs.  Docking of AQ into the active site homol. models of the CYP2C isoforms showed favorable interactions with CYP2C8, which supported the likelihood of an N-desethylation reaction.  These data show that CYP2C8 is the main hepatic isoform responsible for the metab. of AQ.  The specificity, high affinity, and high turnover make AQ desethylation an excellent marker reaction for CYP2C8 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6UmpNdA6McrVg90H21EOLACvtfcHk0lgS3gV3nwakRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1ynsw%253D%253D&md5=b4cc92f1cf92e34e9daa26b0ef825875</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.300.2.399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.300.2.399%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.-Q.%26aulast%3DBj%25C3%25B6rkman%26aufirst%3DA.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26aulast%3DRidderstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DMasimirembwa%26aufirst%3DC.%2BM.%26atitle%3DAmodiaquine%2520Clearance%2520and%2520Its%2520Metabolism%2520toN-Desethylamodiaquine%2520Is%2520Mediated%2520by%2520CYP2C8%253A%2520A%2520New%2520High%2520Affinity%2520and%2520Turnover%2520Enzyme-Specific%2520Probe%2520Substrate%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D300%26spage%3D399%26epage%3D407%26doi%3D10.1124%2Fjpet.300.2.399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Bahadur, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leathart, J. B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steimel-Crespi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houdt, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohets, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, A. K.</span><span> </span><span class="NLM_article-title">CYP2C8 Polymorphisms In Caucasians And Their Relationship With Paclitaxel 6α-Hydroxylase Activity In Human Liver Microsomes</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1579</span><span class="NLM_x">–</span> <span class="NLM_lpage">1589</span><span class="refDoi"> DOI: 10.1016/S0006-2952(02)01354-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS0006-2952%2802%2901354-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2002&pages=1579-1589&author=N.+Bahadurauthor=J.+B.+S.+Leathartauthor=E.+Mutchauthor=D.+Steimel-Crespiauthor=S.+A.+Dunnauthor=R.+Gilissenauthor=J.+V.+Houdtauthor=J.+Hendrickxauthor=G.+Mannensauthor=H.+Bohetsauthor=F.+M.+Williamsauthor=M.+Armstrongauthor=C.+L.+Crespiauthor=A.+K.+Daly&title=CYP2C8+Polymorphisms+In+Caucasians+And+Their+Relationship+With+Paclitaxel+6%CE%B1-Hydroxylase+Activity+In+Human+Liver+Microsomes&doi=10.1016%2FS0006-2952%2802%2901354-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2802%2901354-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252802%252901354-0%26sid%3Dliteratum%253Aachs%26aulast%3DBahadur%26aufirst%3DN.%26aulast%3DLeathart%26aufirst%3DJ.%2BB.%2BS.%26aulast%3DMutch%26aufirst%3DE.%26aulast%3DSteimel-Crespi%26aufirst%3DD.%26aulast%3DDunn%26aufirst%3DS.%2BA.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DHoudt%26aufirst%3DJ.%2BV.%26aulast%3DHendrickx%26aufirst%3DJ.%26aulast%3DMannens%26aufirst%3DG.%26aulast%3DBohets%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DF.%2BM.%26aulast%3DArmstrong%26aufirst%3DM.%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26aulast%3DDaly%26aufirst%3DA.%2BK.%26atitle%3DCYP2C8%2520Polymorphisms%2520In%2520Caucasians%2520And%2520Their%2520Relationship%2520With%2520Paclitaxel%25206%25CE%25B1-Hydroxylase%2520Activity%2520In%2520Human%2520Liver%2520Microsomes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2002%26volume%3D64%26spage%3D1579%26epage%3D1589%26doi%3D10.1016%2FS0006-2952%2802%2901354-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Daily, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aquilante, C. L.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2C8 Pharmacogenetics: A Review Of Clinical Studies</span> <span class="citation_source-journal">Pharmacogenomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1489</span><span class="NLM_x">–</span> <span class="NLM_lpage">1510</span><span class="refDoi"> DOI: 10.2217/pgs.09.82</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2217%2Fpgs.09.82" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1489-1510&author=E.+B.+Dailyauthor=C.+L.+Aquilante&title=Cytochrome+P450+2C8+Pharmacogenetics%3A+A+Review+Of+Clinical+Studies&doi=10.2217%2Fpgs.09.82"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2217%2Fpgs.09.82&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fpgs.09.82%26sid%3Dliteratum%253Aachs%26aulast%3DDaily%26aufirst%3DE.%2BB.%26aulast%3DAquilante%26aufirst%3DC.%2BL.%26atitle%3DCytochrome%2520P450%25202C8%2520Pharmacogenetics%253A%2520A%2520Review%2520Of%2520Clinical%2520Studies%26jtitle%3DPharmacogenomics%26date%3D2009%26volume%3D10%26spage%3D1489%26epage%3D1510%26doi%3D10.2217%2Fpgs.09.82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honkalammi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurkinen, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tornio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2359</span><span class="NLM_x">–</span> <span class="NLM_lpage">2366</span><span class="refDoi"> DOI: 10.1124/dmd.109.029728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.109.029728" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=2359-2366&author=J.+T.+Backmanauthor=J.+Honkalammiauthor=M.+Neuvonenauthor=K.+J.+Kurkinenauthor=A.+Tornioauthor=M.+Niemiauthor=P.+J.+Neuvonen&title=CYP2C8+Activity+Recovers+within+96+Hours+after+Gemfibrozil+Dosing%3A+Estimation+of+CYP2C8+Half-Life+Using+Repaglinide+as+an+in+Vivo+Probe&doi=10.1124%2Fdmd.109.029728"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.029728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.029728%26sid%3Dliteratum%253Aachs%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DHonkalammi%26aufirst%3DJ.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DKurkinen%26aufirst%3DK.%2BJ.%26aulast%3DTornio%26aufirst%3DA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DCYP2C8%2520Activity%2520Recovers%2520within%252096%2520Hours%2520after%2520Gemfibrozil%2520Dosing%253A%2520Estimation%2520of%2520CYP2C8%2520Half-Life%2520Using%2520Repaglinide%2520as%2520an%2520in%2520Vivo%2520Probe%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D2359%26epage%3D2366%26doi%3D10.1124%2Fdmd.109.029728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Totah, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettie, A. E.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1016/j.clpt.2004.12.267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2Fj.clpt.2004.12.267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=15900280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFCrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=341-352&author=R.+A.+Totahauthor=A.+E.+Rettie&title=Cytochrome+P450+2C8%3A+Substrates%2C+Inhibitors%2C+Pharmacogenetics%2C+and+Clinical+Relevance&doi=10.1016%2Fj.clpt.2004.12.267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P 450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance</span></div><div class="casAuthors">Totah, Rheem A.; Rettie, Allan E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-352</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 (CYP) 2C9 has been a relatively neglected member of the human CYP2C family.  Over the period of 2000-2003, PubMed searches with the key word CYP2C8 returned only 10-15% of the citations obtained for all of the CYP2C enzymes combined.  However, in the past year a crystal structure for CYP2C8 has been described, new inhibitors and probe substrates for the enzyme have been in development, the 1st case study was published linking CYP2C8 genetic polymorphisms to a disease state, and there has been an increasing awareness of the role that CYP2C8 plays in the disposition of therapeutic agents, esp. from the pharmacogenetic and drug-drug interaction perspectives.  This report discusses baseline characteristics of the enzyme and summarizes recent developments in these areas and their clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXLgu0RrkE6LVg90H21EOLACvtfcHk0ljHqXjrACIGJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFCrt70%253D&md5=a8b79c67e57ba839dc59a43609bb9ffb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.12.267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.12.267%26sid%3Dliteratum%253Aachs%26aulast%3DTotah%26aufirst%3DR.%2BA.%26aulast%3DRettie%26aufirst%3DA.%2BE.%26atitle%3DCytochrome%2520P450%25202C8%253A%2520Substrates%252C%2520Inhibitors%252C%2520Pharmacogenetics%252C%2520and%2520Clinical%2520Relevance%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D341%26epage%3D352%26doi%3D10.1016%2Fj.clpt.2004.12.267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Lv, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2C8 And Drug Metabolism</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2241</span><span class="NLM_x">–</span> <span class="NLM_lpage">2253</span><span class="refDoi"> DOI: 10.2174/15680266113136660157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2174%2F15680266113136660157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=24047136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CgurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=2241-2253&author=X.+Lvauthor=F.+Zhongauthor=X.+Tan&title=Cytochrome+P450+2C8+And+Drug+Metabolism&doi=10.2174%2F15680266113136660157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 2C8 and Drug Metabolism</span></div><div class="casAuthors">Lv, Xiaoping; Zhong, Fangfang; Tan, Xiangshi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2241-2253</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  CYP 2C8, which carries out the oxidative metab. of at least 5% of clin. drugs, has attracted increasing attention in recent years.  New drugs (substances), inducers and inhibitors of CYP 2C8 have been developed and the drug metab. has been investigated to understand the clin. role of CYP2C8.  The cases of CYP2C8 genetic polymorphisms linked to diseases have increased and have been investigated.  Herein, important progress in these areas has been reviewed with an emphasis on drug metab.  Polymorphisms, diseases related to CYP2C8, some important drugs (substances) and inhibitors are reviewed and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4H6PuJRAo1LVg90H21EOLACvtfcHk0ljHqXjrACIGJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CgurbK&md5=584b1251bfb7d98d19216444c41e99cd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F15680266113136660157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266113136660157%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DTan%26aufirst%3DX.%26atitle%3DCytochrome%2520P450%25202C8%2520And%2520Drug%2520Metabolism%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D2241%26epage%3D2253%26doi%3D10.2174%2F15680266113136660157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Ogilvie, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gipson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holsapple, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">Glucuronidation Converts Gemfibrozil To A Potent, Metabolism-Dependent Inhibitor Of Cyp2c8: Implications For Drug-Drug Interactions</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span><span class="refDoi"> DOI: 10.1124/dmd.105.007633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.105.007633" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=191-197&author=B.+W.+Ogilvieauthor=D.+Zhangauthor=W.+Liauthor=A.+D.+Rodriguesauthor=A.+E.+Gipsonauthor=J.+Holsappleauthor=P.+Torenauthor=A.+Parkinson&title=Glucuronidation+Converts+Gemfibrozil+To+A+Potent%2C+Metabolism-Dependent+Inhibitor+Of+Cyp2c8%3A+Implications+For+Drug-Drug+Interactions&doi=10.1124%2Fdmd.105.007633"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.007633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.007633%26sid%3Dliteratum%253Aachs%26aulast%3DOgilvie%26aufirst%3DB.%2BW.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DGipson%26aufirst%3DA.%2BE.%26aulast%3DHolsapple%26aufirst%3DJ.%26aulast%3DToren%26aufirst%3DP.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DGlucuronidation%2520Converts%2520Gemfibrozil%2520To%2520A%2520Potent%252C%2520Metabolism-Dependent%2520Inhibitor%2520Of%2520Cyp2c8%253A%2520Implications%2520For%2520Drug-Drug%2520Interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D191%26epage%3D197%26doi%3D10.1124%2Fdmd.105.007633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Kyrklund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivistö, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laitila, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Plasma Concentrations Of Active Lovastatin Acid Are Markedly Increased By Gemfibrozil But Not By Bezafibrate</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">345</span><span class="refDoi"> DOI: 10.1067/mcp.2001.115542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1067%2Fmcp.2001.115542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=11372002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlyhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2001&pages=340-345&author=C.+Kyrklundauthor=J.+T.+Backmanauthor=K.+T.+Kivist%C3%B6author=M.+Neuvonenauthor=J.+Laitilaauthor=P.+J.+Neuvonen&title=Plasma+Concentrations+Of+Active+Lovastatin+Acid+Are+Markedly+Increased+By+Gemfibrozil+But+Not+By+Bezafibrate&doi=10.1067%2Fmcp.2001.115542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate</span></div><div class="casAuthors">Kyrklund, Carl; Backman, Janne T.; Kivisto, Kari T.; Neuvonen, Mikko; Laitila, Jouko; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Concomitant use of fibrates with statins has been assocd. with an increased risk of myopathy, but the underlying mechanism of this adverse reaction remains unclear.  Our aim was to study the effects of bezafibrate and gemfibrozil on the pharmacokinetics of lovastatin.  This was a randomized, double-blind, 3-phase crossover study.  Eleven healthy volunteers took 400 mg/day bezafibrate, 1200 mg/day gemfibrozil, or placebo for 3 days.  On day 3, each subject ingested a single 40 mg dose of lovastatin.  Plasma concns. of lovastatin, lovastatin acid, gemfibrozil, and bezafibrate were measured up to 24 h.  Gemfibrozil markedly increased the plasma concns. of lovastatin acid, without affecting those of the parent lovastatin compared with placebo.  During the gemfibrozil phase, the mean area under the plasma concn.-time curve from 0 to 24 h [AUC(0-24)] of lovastatin acid was 280% (range, 131% to 1184%; P <.001) and the peak plasma concn. (Cmax) was 280% (range, 123% to 1042%; P <.05) of the corresponding value during the placebo phase.  Bezafibrate had no statistically significant effect on the AUC(0-24) or Cmax of lovastatin or lovastatin acid compared with placebo.  Gemfibrozil markedly increases plasma concns. of lovastatin acid, but bezafibrate does not.  The increased risk of myopathy obsd. during concomitant treatment with statins and fibrates may be partially of a pharmacokinetic origin.  The risk of developing myopathy during concomitant therapy with lovastatin and a fibrate may be smaller with bezafibrate than with gemfibrozil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlz_ewmutjLLVg90H21EOLACvtfcHk0lgNAZdVztfuFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlyhsL8%253D&md5=884322ec09d4798fe2800689fa5e1c94</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2001.115542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2001.115542%26sid%3Dliteratum%253Aachs%26aulast%3DKyrklund%26aufirst%3DC.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DKivist%25C3%25B6%26aufirst%3DK.%2BT.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DLaitila%26aufirst%3DJ.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DPlasma%2520Concentrations%2520Of%2520Active%2520Lovastatin%2520Acid%2520Are%2520Markedly%2520Increased%2520By%2520Gemfibrozil%2520But%2520Not%2520By%2520Bezafibrate%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D69%26spage%3D340%26epage%3D345%26doi%3D10.1067%2Fmcp.2001.115542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, S.-H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Extrapolation of Diclofenac Clearance from in Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">969</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span><span class="refDoi"> DOI: 10.1124/jpet.102.038992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fjpet.102.038992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=12438516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD38Xptlamt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=969-978&author=S.+Kumarauthor=K.+Samuelauthor=R.+Subramanianauthor=M.+P.+Braunauthor=R.+A.+Stearnsauthor=S.-H.+L.+Chiuauthor=D.+C.+Evansauthor=T.+A.+Baillie&title=Extrapolation+of+Diclofenac+Clearance+from+in+Vitro+Microsomal+Metabolism+Data%3A+Role+of+Acyl+Glucuronidation+and+Sequential+Oxidative+Metabolism+of+the+Acyl+Glucuronide&doi=10.1124%2Fjpet.102.038992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide</span></div><div class="casAuthors">Kumar, Sanjeev; Samuel, Koppara; Subramanian, Ramaswamy; Braun, Matthew P.; Stearns, Ralph A.; Chiu, Shuet-Hing Lee; Evans, David C.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">969-978</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Diclofenac is eliminated predominantly (∼50%) as its 4'-hydroxylated metabolite in humans, whereas the acyl glucuronide (AG) pathway appears more important in rats (∼50%) and dogs (>80-90%).  However, previous studies of diclofenac oxidative metab. in human liver microsomes (HLMs) have yielded pronounced underprediction of human in vivo clearance.  We detd. the relative quant. importance of 4'-hydroxy and AG pathways of diclofenac metab. in rat, dog, and human liver microsomes.  Microsomal intrinsic clearance values (CLint = Vmax/Km) were detd. and used to extrapolate the in vivo blood clearance of diclofenac in these species.  Clearance of diclofenac was accurately predicted from microsomal data only when both the AG and the 4'-hydroxy pathways were considered.  However, the fact that the AG pathway in HLMs accounted for ∼75% of the estd. hepatic CLint of diclofenac is apparently inconsistent with the 4'-hydroxydiclofenac excretion data in humans.  Interestingly, upon incubation with HLMs, significant oxidative metab. of diclofenac AG, directly to 4'-hydroxy diclofenac AG, was obsd.  The estd. hepatic CLint of this pathway suggested that a significant fraction of the intrahepatically formed diclofenac AG may be converted to its 4'-hydroxy deriv. in vivo.  Further expts. indicated that this novel oxidative reaction was catalyzed by CYP2C8, as opposed to CYP2C9-catalyzed 4'-hydroxylation of diclofenac.  These findings may have general implications in the use of total (free + conjugated) oxidative metabolite excretion for detg. primary routes of drug clearance and may question the utility of diclofenac as a probe for phenotyping human CYP2C9 activity in vivo via measurement of its pharmacokinetics and total 4'-hydroxydiclofenac urinary excretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgA3RsS4GJ5LVg90H21EOLACvtfcHk0lgNAZdVztfuFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xptlamt7Y%253D&md5=0e3fbd3cec4fb7eb62df4cb162b64609</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.038992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.038992%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSamuel%26aufirst%3DK.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DBraun%26aufirst%3DM.%2BP.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DChiu%26aufirst%3DS.-H.%2BL.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DExtrapolation%2520of%2520Diclofenac%2520Clearance%2520from%2520in%2520Vitro%2520Microsomal%2520Metabolism%2520Data%253A%2520Role%2520of%2520Acyl%2520Glucuronidation%2520and%2520Sequential%2520Oxidative%2520Metabolism%2520of%2520the%2520Acyl%2520Glucuronide%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D969%26epage%3D978%26doi%3D10.1124%2Fjpet.102.038992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Small, R. E.</span><span> </span><span class="NLM_article-title">Diclofenac Sodium</span> <span class="citation_source-journal">Clin. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">558</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=2670397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaL1MXlt1KgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1989&pages=545-558&author=R.+E.+Small&title=Diclofenac+Sodium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Diclofenac sodium</span></div><div class="casAuthors">Small, Ralph E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacy</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">545-58</span>CODEN:
                <span class="NLM_cas:coden">CPHADV</span>;
        ISSN:<span class="NLM_cas:issn">0278-2677</span>.
    </div><div class="casAbstract">A review with 124 refs. on the pharmacol., pharmacokinetics, clin. efficacy, adverse effects and recommended dosages of diclofenac sodium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmB5gieDLxoLVg90H21EOLACvtfcHk0lhvnRLGN6ZWBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlt1KgsLw%253D&md5=b0c81c304e47ccf97311299c0abdf62d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmall%26aufirst%3DR.%2BE.%26atitle%3DDiclofenac%2520Sodium%26jtitle%3DClin.%2520Pharm.%26date%3D1989%26volume%3D8%26spage%3D545%26epage%3D558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Bort, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macé, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boobis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Lechón, M. a.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeifer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castell, J.</span><span> </span><span class="NLM_article-title">Hepatic Metabolism Of Diclofenac: Role Of Human CYP In The Minor Oxidative Pathways</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span><span class="refDoi"> DOI: 10.1016/S0006-2952(99)00167-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS0006-2952%2899%2900167-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10449188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaK1MXltVyjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1999&pages=787-796&author=R.+Bortauthor=K.+Mac%C3%A9author=A.+Boobisauthor=M.+a.-J.+G%C3%B3mez-Lech%C3%B3nauthor=A.+Pfeiferauthor=J.+Castell&title=Hepatic+Metabolism+Of+Diclofenac%3A+Role+Of+Human+CYP+In+The+Minor+Oxidative+Pathways&doi=10.1016%2FS0006-2952%2899%2900167-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways</span></div><div class="casAuthors">Bort, Roque; Mace, Katherine; Boobis, Alan; Gomez-Lechon, Maria-Jose; Pfeifer, Andrea; Castell, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">787-796</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The aim of this study was to re-examine the human hepatic metab. of diclofenac, with special focus on the generation of minor hydroxylated metabolites implicated in the idiosyncratic hepatotoxicity of the drug.  Different exptl. approaches were used: human hepatocytes, human microsomes, and engineered cells expressing single human CYP (cytochromes P 450).  Human hepatocytes formed 3'-hydroxy-, 4'-hydroxy-, 5-hydroxy-4',5-dihydroxy-, and N,5-dihydroxydiclofenac, as well as several lactams.  Formation of 4'- and 5-hydroxydiclofenac by human liver microsomes followed a Michaelis-Menten kinetics (Km 9±1 μM; Vmax 432±15 pmol/min/mg and Km 43±5 μM; and Vmax 15.4±0.6 pmol/min/mg, resp.).  Secondary metabolites were detected after incubation of 5-hydroxydiclofenac with human liver microsomes, yielding 4',5-dihydroxydiclofenac (Km 15±1 μM; Vmax 96±3 pmol/min/mg) and small amts. of N,5-dihydroxydiclofenac (non-Michaelis-Menten kinetics).  Based on microsome studies and the incubations with human hepatocytes and engineered cells, we estd. that in vivo CYP2C9 would be exclusively responsible for the 4' hydroxylation of diclofenac (>99.5%) as well as 5-hydroxydiclofenac (>97%).  CYP2C9 was exclusively responsible for the formation of 3'-hydroxydiclofenac.  Multiple regression anal. evidenced that the rate of prodn. of 5-hydroxydiclofenac in human microsomes followed the algorithm: 0.040 × S-mephenytoin 4'-hydroxylation + 0.083 × tolbutamide methylhydroxylation, (multiple correlation coeff. = 0.969).  However, the incubation of diclofenac with cell lines expressing different human CYP suggested that 7 isoforms could be involved.  Comparison of data obtained with CYP-expressing cells and human hepatocytes suggests that CYP2C8 > CYP2C19 ≃ CYP2C18 >> CYP2B6 are the isoforms implicated in the 5-hydroxylation of diclofenac in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKYjl48rn-ELVg90H21EOLACvtfcHk0lhvnRLGN6ZWBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVyjt7o%253D&md5=66ebc46f6555d8fad144404dad5a8fb6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2899%2900167-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252899%252900167-7%26sid%3Dliteratum%253Aachs%26aulast%3DBort%26aufirst%3DR.%26aulast%3DMac%25C3%25A9%26aufirst%3DK.%26aulast%3DBoobis%26aufirst%3DA.%26aulast%3DG%25C3%25B3mez-Lech%25C3%25B3n%26aufirst%3DM.%2Ba.-J.%26aulast%3DPfeifer%26aufirst%3DA.%26aulast%3DCastell%26aufirst%3DJ.%26atitle%3DHepatic%2520Metabolism%2520Of%2520Diclofenac%253A%2520Role%2520Of%2520Human%2520CYP%2520In%2520The%2520Minor%2520Oxidative%2520Pathways%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1999%26volume%3D58%26spage%3D787%26epage%3D796%26doi%3D10.1016%2FS0006-2952%2899%2900167-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Stierlin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faigle, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kriemler, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alt, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, T.</span><span> </span><span class="NLM_article-title">Biotransformation Of Diclofenac Sodium (Voltaren®) In Animals And In Man</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">601</span><span class="NLM_x">–</span> <span class="NLM_lpage">610</span><span class="refDoi"> DOI: 10.3109/00498257909042327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.3109%2F00498257909042327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=119352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaL3cXhsFOntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1979&pages=601-610&author=H.+Stierlinauthor=J.+W.+Faigleauthor=A.+Sallmannauthor=W.+Kungauthor=W.+J.+Richterauthor=H.+P.+Kriemlerauthor=K.+O.+Altauthor=T.+Winkler&title=Biotransformation+Of+Diclofenac+Sodium+%28Voltaren%C2%AE%29+In+Animals+And+In+Man&doi=10.3109%2F00498257909042327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Biotransformation of diclofenac sodium (Voltaren) in animals and in man.  I.  Isolation and identification of principal metabolites</span></div><div class="casAuthors">Stierlin, H.; Faigle, J. W.; Sallmann, A.; Kueng, W.; Richter, W. J.; Kriemler, H. P.; Alt, K. O.; Winkler, T.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">601-10</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    </div><div class="casAbstract">The antiinflammatory agent, diclofenac Na (Voltaren)(I)  [15307-79-6], was extensively metabolized after oral, i.v., or i.m. dosing by rat, dog, baboon, and man, and the main metabolites were isolated from urine of all species and from bile of rat and dog and identified.  Metab. involved direct conjugation of unchanged I, or oxidn. of the arom. rings usually followed by conjugation.  Oxidn. sites were either position 3' or 4' of the dichlorophenyl ring or position 5 of the Ph ring attached to the acetic acid moiety.  In the urine of rat, baboon, and man, conjugates of the hydroxylated metabolites predominate, but in dog urine the taurine conjugate of unchanged I was the major metabolite.  In bile of rat and dog, the ester glucuronide of unchanged I was the main metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsQa-zjp1qPbVg90H21EOLACvtfcHk0lhvnRLGN6ZWBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhsFOntbw%253D&md5=f256da7d10e4fc3359217520713edbe9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3109%2F00498257909042327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498257909042327%26sid%3Dliteratum%253Aachs%26aulast%3DStierlin%26aufirst%3DH.%26aulast%3DFaigle%26aufirst%3DJ.%2BW.%26aulast%3DSallmann%26aufirst%3DA.%26aulast%3DKung%26aufirst%3DW.%26aulast%3DRichter%26aufirst%3DW.%2BJ.%26aulast%3DKriemler%26aufirst%3DH.%2BP.%26aulast%3DAlt%26aufirst%3DK.%2BO.%26aulast%3DWinkler%26aufirst%3DT.%26atitle%3DBiotransformation%2520Of%2520Diclofenac%2520Sodium%2520%2528Voltaren%25C2%25AE%2529%2520In%2520Animals%2520And%2520In%2520Man%26jtitle%3DXenobiotica%26date%3D1979%26volume%3D9%26spage%3D601%26epage%3D610%26doi%3D10.3109%2F00498257909042327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">King, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tephly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, M.</span><span> </span><span class="NLM_article-title">Characterization of Rat and Human UDP-Glucuronosyltransferases Responsible for the in Vitro Glucuronidation of Diclofenac</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span><span class="refDoi"> DOI: 10.1093/toxsci/61.1.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1093%2Ftoxsci%2F61.1.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=11294973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtV2rs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=49-53&author=C.+Kingauthor=W.+Tangauthor=J.+Nguiauthor=T.+Tephlyauthor=M.+Braun&title=Characterization+of+Rat+and+Human+UDP-Glucuronosyltransferases+Responsible+for+the+in+Vitro+Glucuronidation+of+Diclofenac&doi=10.1093%2Ftoxsci%2F61.1.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac</span></div><div class="casAuthors">King, C.; Tang, W.; Ngui, J.; Tephly, T.; Braun, M.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-53</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">In the current study, the identification of the rat and human UDP-glucuronosyltransferase (UGT) isoforms responsible for the glucuronidation of diclofenac was detd.  Recombinant human UGT1A9 catalyzed the glucuronidation of diclofenac at a moderate rate of 166-pmol/min/mg protein, while UGT1A6 and 2B15 catalyzed the glucuronidation of diclofenac at low rates (<20-pmol/min/mg protein).  Conversely, human UGT2B7 displayed a high rate of diclofenac glucuronide formation (>500 pmol/min/mg protein).  Recombinant rat UGT2B1 catalyzed the glucuronidation of diclofenac at a rate of 250-pmol/min/mg protein.  Rat UGT2B1 and human UGT2B7 displayed a similar, low apparent Km value of <15 μM for both UGT isoforms and high Vmax values 0.3 and 2.8 nmol/min/mg, resp.  Using diclofenac as a substrate, enzyme kinetics in rat and human liver microsomes showed that the enzyme(s) involved in diclofenac glucuronidation had a low apparent Km value of <20 μM and a high Vmax value of 0.9 and 4.3 nmol/min/mg protein, resp.  Morphine is a known substrate for rat UGT2B1 and human UGT2B7 and both total morphine glucuronidation (3-O- and 6-O-glucuronides) and diclofenac glucuronidation reactions showed a strong correlation with one another in human liver microsome samples.  In addn., diclofenac inhibited the glucuronidation of morphine in human liver microsomes.  These data suggested that rat UGT2B1 and human UGT2B7 were the major UGT isoforms involved in the glucuronidation of diclofenac.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-AFb4daZw07Vg90H21EOLACvtfcHk0lhvnRLGN6ZWBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtV2rs74%253D&md5=84358ad742d33f27ac424d0fe5625191</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2F61.1.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252F61.1.49%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DNgui%26aufirst%3DJ.%26aulast%3DTephly%26aufirst%3DT.%26aulast%3DBraun%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520Rat%2520and%2520Human%2520UDP-Glucuronosyltransferases%2520Responsible%2520for%2520the%2520in%2520Vitro%2520Glucuronidation%2520of%2520Diclofenac%26jtitle%3DToxicol.%2520Sci.%26date%3D2001%26volume%3D61%26spage%3D49%26epage%3D53%26doi%3D10.1093%2Ftoxsci%2F61.1.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Davies, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. E.</span><span> </span><span class="NLM_article-title">Clinical Pharmacokinetics of Diclofenac</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span><span class="refDoi"> DOI: 10.2165/00003088-199733030-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2165%2F00003088-199733030-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=9314611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVeltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1997&pages=184-213&author=N.+M.+Daviesauthor=K.+E.+Anderson&title=Clinical+Pharmacokinetics+of+Diclofenac&doi=10.2165%2F00003088-199733030-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls</span></div><div class="casAuthors">Davies, Neal M.; Anderson, Keith E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-213</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review with 203 refs.  Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class.  When given orally the absorption of diclofenac is rapid and complete.  Diclofenac binds extensively to plasma albumin.  The area under the plasma concn.-time curve (AUC) of diclofenac is proportional to the dose for oral doses between 25 to 150 mg.  Substantial concns. of drug are attained in synovial fluid, which is the proposed site of action for NSAIDs.  Concn.-effect relationships have been established for total bound, unbound and synovial fluid diclofenac concns.  Diclofenac is eliminated following biotransformation to glucoroconjugated and sulfate metabolites which are excreted in urine, very little drug is eliminated unchanged.  The excretion of conjugates may be related to renal function.  Conjugate accumulation occurs in end-stage renal disease; however, no accumulation is apparent upon comparison of young and elderly individuals.  Dosage adjustments for the elderly, children or for patients with various disease states (such as hepatic disease or rheumatoid arthritis) may not be required.  Significant drug interactions have been demonstrated for aspirin (acetylsalicylic acid), lithium, digoxin, methotrexate, cyclosporin, cholestyramine and colestipol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkTAhShlnbwLVg90H21EOLACvtfcHk0lgdzsdCeFbGiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVeltr4%253D&md5=198d8e4035a4a79966ae081e9ac75a9c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2165%2F00003088-199733030-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199733030-00003%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DN.%2BM.%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26atitle%3DClinical%2520Pharmacokinetics%2520of%2520Diclofenac%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1997%26volume%3D33%26spage%3D184%26epage%3D213%26doi%3D10.2165%2F00003088-199733030-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Kulkarni, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pal Singh, V.</span><span> </span><span class="NLM_article-title">Licofelone-A Novel Analgesic and Anti-Inflammatory Agent</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.2174/156802607779941305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2174%2F156802607779941305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=17305568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Wjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=251-263&author=S.+K.+Kulkarniauthor=V.+Pal+Singh&title=Licofelone-A+Novel+Analgesic+and+Anti-Inflammatory+Agent&doi=10.2174%2F156802607779941305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Licofelone-A novel analgesic and anti-inflammatory agent</span></div><div class="casAuthors">Kulkarni, S. K.; Singh, Vijay Pal</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-263</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Dual inhibitors that block both cyclooxygenase (COX) and lipoxygenase (LOX) metabolic pathways of arachidonic acid are expected to possess clin. advantages over the selective inhibitors of COX enzyme.  One of the most promising compds. belonging to this category is licofelone ([2,2 -dimethyl-6-(4-chlorophenyl-7-phenyl)-2,3-dihydro-1H-pyrazoline-5-yl] acetic acid).  Originally discovered by Merckle GmbH and developed by EuroAllaince, licofelone (IC50 COX = 0.21 μM, IC50 5-LOX = 0.18μM) possesses significant analgesic, anti-inflammatory, and antiasthmatic effects at doses that cause no gastrointestinal (GI) side effects.  The pharmacodynamic profile of licofelone has been assessed and compared with widely used NSAIDs in different animal models.  The ED50 value of licofelone is reported to be 11.22-27.07 mg/kg, po and 39.5-55-8 mg/kg, po against carrageenan-induced paw edema and Randal Selitto hyperalgesic assay in rats, resp.  Licofelone showed analgesic effect (ED50 = 31.33 mg/kg) against acetic acid-induced writhing in mice.  Licofelone has long duration of action and more effective than indomethacin and zileuton with ED50 values of 2.92 mg/kg, po and 36.77 mg/kg, po, in the mech. hyperalgesia and cold allodynia testing, resp., against rat model of incisional pain.  Licofelone significantly ameliorated indomethacin-induced gastric ulceration, neutrophil adhesion in mesentery, and lipid peroxides in rat gastric mucosa.  Also, licofelone reversed the altered vascular permeability, morphol. changes, and prevented NSAIDs-related increase in leukotriene levels in gastric mucosa.  The preclin. studies have shown that licofelone not only has convincing pharmacodynamic effect but also it is well tolerated.  It is currently under clin. evaluation in osteoarthritis (OA), the most common form of arthritis.  The present review describes pharmacol. and clin. development of licofelone as a dual inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq60C70bAEHxbVg90H21EOLACvtfcHk0lgdzsdCeFbGiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Wjsb8%253D&md5=dba46be57a155d0995a3ff79cc9b3c47</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F156802607779941305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607779941305%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DS.%2BK.%26aulast%3DPal%2BSingh%26aufirst%3DV.%26atitle%3DLicofelone-A%2520Novel%2520Analgesic%2520and%2520Anti-Inflammatory%2520Agent%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D251%26epage%3D263%26doi%3D10.2174%2F156802607779941305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Bias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klesser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">The Gastrointestinal Tolerability of the LOX//COX Inhibitor, Licofelone, is Similar to Placebo and Superior to Naproxen Therapy in Healthy Volunteers: Results From a Randomized, Controlled Trial</span> <span class="citation_source-journal">Am. J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">618</span><span class="refDoi"> DOI: 10.1111/j.1572-0241.2004.04133.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1111%2Fj.1572-0241.2004.04133.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=15089890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFGgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2004&pages=611-618&author=P.+Biasauthor=A.+Buchnerauthor=B.+Klesserauthor=S.+Laufer&title=The+Gastrointestinal+Tolerability+of+the+LOX%2F%2FCOX+Inhibitor%2C+Licofelone%2C+is+Similar+to+Placebo+and+Superior+to+Naproxen+Therapy+in+Healthy+Volunteers%3A+Results+From+a+Randomized%2C+Controlled+Trial&doi=10.1111%2Fj.1572-0241.2004.04133.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial</span></div><div class="casAuthors">Bias, Peter; Buchner, Anton; Klesser, Bernard; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">611-618</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">OBJECTIVE: Concerns exist over the safety of conventional nonsteroidal antiinflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors.  In exptl. models, licofelone, a competitive inhibitor of 5-lipoxygenase (5-LOX) and COX-1/-2, has been shown to have good gastrointestinal and general tolerability and analgesic and anti inflammatory properties.  The aim of the present endoscopy trial was to investigate the gastroduodenal tolerability of licofelone compared to placebo and naproxen in healthy volunteers.  METHODS: In this randomized, parallel-group trial, healthy volunteers received licofelone 200 mg b.i.d. (n = 30), licofelone 400 mg b.i.d. (n = 30), naproxen 500 mg b.i.d. (n = 30), or placebo (n = 31).  Tolerability was assessed by gastro/duodenoscopy following 4 wk of treatment.  Lab. parameters and the incidence of ulcers and adverse events were recorded.  RESULTS: Ulcers were obsd. in 20% of the naproxen-treated volunteers, compared with 0% of those receiving licofelone 200 mg, licofelone 400 mg, and placebo (p = 0.024).  Posttreatment mean gastric Lanza scores were similar for volunteers who received placebo or either dose of licofelone, while Lanza scores were significantly worse following naproxen therapy (p < 0.00001).  The gastric mucosa was normal in 93%, 89%, and 90% of volunteers who received licofelone 200 mg, licofelone 400 mg, or placebo, resp., compared with 37% of volunteers receiving naproxen.  The incidence of adverse events did not differ significantly between licofelone 200 mg or naproxen therapy.  No clin. relevant changes in lab. parameters were obsd. with licofelone or naproxen therapy.  CONCLUSIONS: The results from this trial indicate that licofelone has a potential gastrointestinal safety advantage over conventional NSAID therapy, as licofelone was assocd. with significantly superior gastric tolerability and a lower incidence of ulcers compared with naproxen in healthy volunteers.  Further trials will be required to investigate the safety and efficacy of licofelone in the treatment of diseases such as osteoarthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4_sMdLBAfl7Vg90H21EOLACvtfcHk0lgdzsdCeFbGiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFGgsrs%253D&md5=ab304b86eb0d5f6ab8bfa251ee0f6ae3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1572-0241.2004.04133.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1572-0241.2004.04133.x%26sid%3Dliteratum%253Aachs%26aulast%3DBias%26aufirst%3DP.%26aulast%3DBuchner%26aufirst%3DA.%26aulast%3DKlesser%26aufirst%3DB.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DThe%2520Gastrointestinal%2520Tolerability%2520of%2520the%2520LOX%252F%252FCOX%2520Inhibitor%252C%2520Licofelone%252C%2520is%2520Similar%2520to%2520Placebo%2520and%2520Superior%2520to%2520Naproxen%2520Therapy%2520in%2520Healthy%2520Volunteers%253A%2520Results%2520From%2520a%2520Randomized%252C%2520Controlled%2520Trial%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2004%26volume%3D99%26spage%3D611%26epage%3D618%26doi%3D10.1111%2Fj.1572-0241.2004.04133.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Albrecht, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussler, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and −2 and 5-Lipoxygenase</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">894</span><span class="NLM_x">–</span> <span class="NLM_lpage">903</span><span class="refDoi"> DOI: 10.1124/dmd.108.020347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.108.020347" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=894-903&author=W.+Albrechtauthor=A.+Ungerauthor=A.+K.+Nusslerauthor=S.+Laufer&title=In+Vitro+Metabolism+of+2-%5B6-%284-Chlorophenyl%29-2%2C2-dimethyl-7-phenyl-2%2C3-dihydro-1H-pyrrolizin-5-yl%5D+Acetic+Acid+%28Licofelone%2C+ML3000%29%2C+an+Inhibitor+of+Cyclooxygenase-1+and+%E2%88%922+and+5-Lipoxygenase&doi=10.1124%2Fdmd.108.020347"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020347%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DNussler%26aufirst%3DA.%2BK.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DIn%2520Vitro%2520Metabolism%2520of%25202-%255B6-%25284-Chlorophenyl%2529-2%252C2-dimethyl-7-phenyl-2%252C3-dihydro-1H-pyrrolizin-5-yl%255D%2520Acetic%2520Acid%2520%2528Licofelone%252C%2520ML3000%2529%252C%2520an%2520Inhibitor%2520of%2520Cyclooxygenase-1%2520and%2520%25E2%2588%25922%2520and%25205-Lipoxygenase%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D894%26epage%3D903%26doi%3D10.1124%2Fdmd.108.020347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Delaforge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pruvost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">André, F.</span><span> </span><span class="NLM_article-title">Cytochrome P450-Mediated Oxidation Of Glucuronide Derivatives: Example Of Estradiol-17β-Glucuronide Oxidation To 2-Hydroxy-Estradiol-17β-Glucuronide By Cyp 2c8</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1124/dmd.104.002097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.104.002097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=466-473&author=M.+Delaforgeauthor=A.+Pruvostauthor=L.+Perrinauthor=F.+Andr%C3%A9&title=Cytochrome+P450-Mediated+Oxidation+Of+Glucuronide+Derivatives%3A+Example+Of+Estradiol-17%CE%B2-Glucuronide+Oxidation+To+2-Hydroxy-Estradiol-17%CE%B2-Glucuronide+By+Cyp+2c8&doi=10.1124%2Fdmd.104.002097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.104.002097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.104.002097%26sid%3Dliteratum%253Aachs%26aulast%3DDelaforge%26aufirst%3DM.%26aulast%3DPruvost%26aufirst%3DA.%26aulast%3DPerrin%26aufirst%3DL.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26atitle%3DCytochrome%2520P450-Mediated%2520Oxidation%2520Of%2520Glucuronide%2520Derivatives%253A%2520Example%2520Of%2520Estradiol-17%25CE%25B2-Glucuronide%2520Oxidation%2520To%25202-Hydroxy-Estradiol-17%25CE%25B2-Glucuronide%2520By%2520Cyp%25202c8%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D466%26epage%3D473%26doi%3D10.1124%2Fdmd.104.002097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Rainsford, K. D.</span><span> </span><span class="NLM_article-title">Ibuprofen: Pharmacology, Efficacy And Safety</span> <span class="citation_source-journal">Inflammopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span><span class="refDoi"> DOI: 10.1007/s10787-009-0016-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1007%2Fs10787-009-0016-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=19949916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2mtrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=275-342&author=K.+D.+Rainsford&title=Ibuprofen%3A+Pharmacology%2C+Efficacy+And+Safety&doi=10.1007%2Fs10787-009-0016-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ibuprofen: pharmacology, efficacy and safety</span></div><div class="casAuthors">Rainsford, K. D.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">275-342</span>CODEN:
                <span class="NLM_cas:coden">IAOAES</span>;
        ISSN:<span class="NLM_cas:issn">0925-4692</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">Objectives: This review attempts to bring together information from a large no. of recent studies on the clin. uses, safety and pharmacol. properties of ibuprofen.  Ibuprofen is widely used in many countries for the relief of symptoms of pain, inflammation and fever.  The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug.  Summary of outcomes: At low doses (800-1,200 mg day-1) which in many countries are approved for non-prescription (over-the-counter) sale ibuprofen has a good safety profile comparable with paracetamol.  Its analgesic activity is linked to its anti-inflammatory effects and is related to redn. in the ex vivo prodn. in blood of cyclo-oxygenase (COX)-1 and COX-2 derived prostanoids.  Higher prescription doses (circa 1,800-2,400 mg day-1) are employed long-term for the treatment of rheumatic and other more severe musculo-skeletal conditions.  Recent evidence from large-scale clin. trials with the newer coxibs, where ibuprofen was as a comparator, have confirmed earlier studies which have shown that ibuprofen has comparable therapeutic benefits with coxibs and other NSAIDs.  For long-term usage (6+ months) there are greater nos. of drop-outs due to reduced effectiveness of therapy, a feature which is common with NSAIDs.  Spontaneous reports of adverse events and adverse drug reactions (ADRs) in clin. trails from long-term coxib comparator studies, as well as in epidemiol. studies, shows that ibuprofen has relatively low risks for gastro-intestinal (GI), hepato-renal and other, rarer, ADRs compared with other NSAIDs and coxibs.  A slightly higher risk of cardiovascular (CV) events has been reported in some, but not all studies, but the risks are in general lower than with some coxibs and diclofenac.  The possibility that ibuprofen may interfere with the anti-platelet effects of aspirin, though arguably of low grade or significance, has given rise to caution on its use in patients that are at risk for CV conditions that take aspirin for preventing these conditions.  Paediatric use of ibuprofen is reviewed and the main results are that the drug is relatively safe and effective as a treatment of acute pain and fever.  It is probably more effective than paracetamol as an antipyretic.  Conclusions: This assessment of the safety and benefits of ibuprofen can be summarized thus: (1) Ibuprofen at OTC doses has low possibilities of serious GI events, and little prospect of developing renal and assocd. CV events.  Ibuprofen OTC does not represent a risk for developing liver injury esp. the irreversible liver damage obsd. with paracetamol and the occasional liver reactions from aspirin.  (2) The pharmacokinetic properties of ibuprofen, esp. the short plasma half-life of elimination, lack of development of pathol. related metabolites (e.g. covalent modification of liver proteins by the quinine-imine metabolite of paracetamol or irreversible acetylation of biomols. by aspirin) are support for the view that these pharmacokinetic and notably metabolic effects of ibuprofen favor its low toxic potential.  (3) The multiple actions of ibuprofen in controlling inflammation combine with moderate inhibition of COX-1 and COX-2 and low residence time of the drug in the body may account for the low GI, CV and renal risks from ibuprofen, esp. at OTC doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHjA0RUBqP_7Vg90H21EOLACvtfcHk0liWkaVkvWLmKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2mtrvP&md5=940d686cf8ce694c9ef273c2a170a556</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs10787-009-0016-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10787-009-0016-x%26sid%3Dliteratum%253Aachs%26aulast%3DRainsford%26aufirst%3DK.%2BD.%26atitle%3DIbuprofen%253A%2520Pharmacology%252C%2520Efficacy%2520And%2520Safety%26jtitle%3DInflammopharmacology%26date%3D2009%26volume%3D17%26spage%3D275%26epage%3D342%26doi%3D10.1007%2Fs10787-009-0016-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Mazaleuskaya, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theken, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorn, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FitzGerald, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T. E.</span><span> </span><span class="NLM_article-title">Pharmocology Summary: Ibuprofen Pathways</span> <span class="citation_source-journal">Pharmacogenet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1097/FPC.0000000000000113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1097%2FFPC.0000000000000113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=25502615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKqsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=96-106&author=L.+L.+Mazaleuskayaauthor=K.+N.+Thekenauthor=L.+Gongauthor=C.+F.+Thornauthor=G.+A.+FitzGeraldauthor=R.+B.+Altmanauthor=T.+E.+Klein&title=Pharmocology+Summary%3A+Ibuprofen+Pathways&doi=10.1097%2FFPC.0000000000000113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">PharmGKB summary: ibuprofen pathways</span></div><div class="casAuthors">Mazaleuskaya, Liudmila L.; Theken, Katherine N.; Gong, Li; Thorn, Caroline F.; FitzGerald, Garret A.; Altman, Russ B.; Klein, Teri E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">96-106</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5JB2Ls4azxbVg90H21EOLACvtfcHk0liWkaVkvWLmKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKqsb7M&md5=d665cba994d93024b38703726e24ca62</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1097%2FFPC.0000000000000113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0000000000000113%26sid%3Dliteratum%253Aachs%26aulast%3DMazaleuskaya%26aufirst%3DL.%2BL.%26aulast%3DTheken%26aufirst%3DK.%2BN.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DThorn%26aufirst%3DC.%2BF.%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26aulast%3DKlein%26aufirst%3DT.%2BE.%26atitle%3DPharmocology%2520Summary%253A%2520Ibuprofen%2520Pathways%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2015%26volume%3D25%26spage%3D96%26epage%3D106%26doi%3D10.1097%2FFPC.0000000000000113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Jenkins, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span> </span><span class="NLM_article-title">Studies to Further Investigate the Inhibition of Human Liver Microsomal CYP2C8 by the Acyl-β-Glucuronide of Gemfibrozil</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2421</span><span class="NLM_x">–</span> <span class="NLM_lpage">2430</span><span class="refDoi"> DOI: 10.1124/dmd.111.041947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.111.041947" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2421-2430&author=S.+M.+Jenkinsauthor=T.+Zvyagaauthor=S.+R.+Johnsonauthor=J.+Hurleyauthor=A.+Wagnerauthor=R.+Burrellauthor=W.+Turleyauthor=J.+E.+Leetauthor=T.+Philipauthor=A.+D.+Rodrigues&title=Studies+to+Further+Investigate+the+Inhibition+of+Human+Liver+Microsomal+CYP2C8+by+the+Acyl-%CE%B2-Glucuronide+of+Gemfibrozil&doi=10.1124%2Fdmd.111.041947"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.041947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.041947%26sid%3Dliteratum%253Aachs%26aulast%3DJenkins%26aufirst%3DS.%2BM.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DHurley%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DBurrell%26aufirst%3DR.%26aulast%3DTurley%26aufirst%3DW.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DPhilip%26aufirst%3DT.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26atitle%3DStudies%2520to%2520Further%2520Investigate%2520the%2520Inhibition%2520of%2520Human%2520Liver%2520Microsomal%2520CYP2C8%2520by%2520the%2520Acyl-%25CE%25B2-Glucuronide%2520of%2520Gemfibrozil%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2421%26epage%3D2430%26doi%3D10.1124%2Fdmd.111.041947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Colca, J. R.</span><span> </span><span class="NLM_article-title">Discontinued Drugs In 2006: Renal, Endocrine And Metabolic Drugs</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1517</span><span class="NLM_x">–</span> <span class="NLM_lpage">1523</span><span class="refDoi"> DOI: 10.1517/13543784.16.10.1517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1517%2F13543784.16.10.1517" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=1517-1523&author=J.+R.+Colca&title=Discontinued+Drugs+In+2006%3A+Renal%2C+Endocrine+And+Metabolic+Drugs&doi=10.1517%2F13543784.16.10.1517"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.10.1517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.10.1517%26sid%3Dliteratum%253Aachs%26aulast%3DColca%26aufirst%3DJ.%2BR.%26atitle%3DDiscontinued%2520Drugs%2520In%25202006%253A%2520Renal%252C%2520Endocrine%2520And%2520Metabolic%2520Drugs%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D1517%26epage%3D1523%26doi%3D10.1517%2F13543784.16.10.1517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Nishihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeshiba, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyota, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahi, S.</span><span> </span><span class="NLM_article-title">Metabolic Fate of Sipoglitazar a Novel Oral PPAR Agonist with Activities for PPAR-γ, -α and -δ, in Rats and Monkeys and Comparison with Humans In Vitro</span> <span class="citation_source-journal">Drug Metab. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.2133/dmpk.DMPK-11-RG-061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2133%2Fdmpk.DMPK-11-RG-061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=22123126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1yisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=223-231&author=M.+Nishiharaauthor=M.+Sudoauthor=H.+Kamiguchiauthor=N.+Kawaguchiauthor=Y.+Maeshibaauthor=Y.+Kiyotaauthor=J.+Takahashiauthor=Y.+Tagawaauthor=T.+Kondoauthor=S.+Asahi&title=Metabolic+Fate+of+Sipoglitazar+a+Novel+Oral+PPAR+Agonist+with+Activities+for+PPAR-%CE%B3%2C+-%CE%B1+and+-%CE%B4%2C+in+Rats+and+Monkeys+and+Comparison+with+Humans+In+Vitro&doi=10.2133%2Fdmpk.DMPK-11-RG-061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro</span></div><div class="casAuthors">Nishihara, Mitsuhiro; Sudo, Miyako; Kamiguchi, Hidenori; Kawaguchi, Naohiro; Maeshiba, Yoshihiro; Kiyota, Yutaka; Takahashi, Junzo; Tagawa, Yoshihiko; Kondo, Takahiro; Asahi, Satoru</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-231</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">Sipoglitazar is a novel anti-diabetic agent with triple agonistic activities on the human peroxisome proliferator-activated receptors, hPPAR-γ, -α, and -δ.  The bioavailability for sipoglitazar was 95.0% and 72.6% in rats and monkeys resp. and sipoglitazar is hardly subject to first pass metab. in either species.  Following oral administration of [14C]sipoglitazar to rats, sipoglitazar and its metabolites were distributed to the rat tissues with relatively high concns. in the liver and also to the target tissue, the adipose tissue.  The major component was sipoglitazar in the plasma of rats and monkeys.  In rats, sipoglitazar was mainly excreted into the feces via biliary excretion as sipoglitazar-G, while the major component was M-I-G in the urine and M-I in the feces of monkeys.  In hepatocytes, the metab. was not extensively advanced in rats and the main metabolites were M-I and sipoglitazar-G in humans, similar to the metabolic profile in monkeys.  There was no metabolite specific for humans in vitro.  In conclusion, the formation of M-I, M-I-G and sipoglitazar-G is considered to be crucial and sipoglitazar is presumed to be cleared primarily by oxidn. and glucuronidation in humans, when examd. in vivo and in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc21Xaw_X1QLVg90H21EOLACvtfcHk0lhEtTRdhgDnPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1yisLk%253D&md5=cbb9ad3c8bb47d59e09745df03fdec81</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.DMPK-11-RG-061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.DMPK-11-RG-061%26sid%3Dliteratum%253Aachs%26aulast%3DNishihara%26aufirst%3DM.%26aulast%3DSudo%26aufirst%3DM.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DKawaguchi%26aufirst%3DN.%26aulast%3DMaeshiba%26aufirst%3DY.%26aulast%3DKiyota%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DJ.%26aulast%3DTagawa%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DAsahi%26aufirst%3DS.%26atitle%3DMetabolic%2520Fate%2520of%2520Sipoglitazar%2520a%2520Novel%2520Oral%2520PPAR%2520Agonist%2520with%2520Activities%2520for%2520PPAR-%25CE%25B3%252C%2520-%25CE%25B1%2520and%2520-%25CE%25B4%252C%2520in%2520Rats%2520and%2520Monkeys%2520and%2520Comparison%2520with%2520Humans%2520In%2520Vitro%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2012%26volume%3D27%26spage%3D223%26epage%3D231%26doi%3D10.2133%2Fdmpk.DMPK-11-RG-061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Nishihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyota, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahi, S.</span><span> </span><span class="NLM_article-title">An Unusual Metabolic Pathway of Sipoglitazar, a Novel Antidiabetic Agent: Cytochrome P450-Catalyzed Oxidation of Sipoglitazar Acyl Glucuronide</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span><span class="refDoi"> DOI: 10.1124/dmd.111.040105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.111.040105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=249-258&author=M.+Nishiharaauthor=M.+Sudoauthor=N.+Kawaguchiauthor=J.+Takahashiauthor=Y.+Kiyotaauthor=T.+Kondoauthor=S.+Asahi&title=An+Unusual+Metabolic+Pathway+of+Sipoglitazar%2C+a+Novel+Antidiabetic+Agent%3A+Cytochrome+P450-Catalyzed+Oxidation+of+Sipoglitazar+Acyl+Glucuronide&doi=10.1124%2Fdmd.111.040105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040105%26sid%3Dliteratum%253Aachs%26aulast%3DNishihara%26aufirst%3DM.%26aulast%3DSudo%26aufirst%3DM.%26aulast%3DKawaguchi%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DJ.%26aulast%3DKiyota%26aufirst%3DY.%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DAsahi%26aufirst%3DS.%26atitle%3DAn%2520Unusual%2520Metabolic%2520Pathway%2520of%2520Sipoglitazar%252C%2520a%2520Novel%2520Antidiabetic%2520Agent%253A%2520Cytochrome%2520P450-Catalyzed%2520Oxidation%2520of%2520Sipoglitazar%2520Acyl%2520Glucuronide%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D249%26epage%3D258%26doi%3D10.1124%2Fdmd.111.040105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munsick, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonacorsi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span> </span><span class="NLM_article-title">Metabolism and Disposition of 14C-Labeled Peliglitazar in Humans</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span><span class="refDoi"> DOI: 10.1124/dmd.110.035089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.110.035089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=228-238&author=L.+Wangauthor=C.+Munsickauthor=S.+Chenauthor=S.+Bonacorsiauthor=P.+T.+Chengauthor=W.+G.+Humphreysauthor=D.+Zhang&title=Metabolism+and+Disposition+of+14C-Labeled+Peliglitazar+in+Humans&doi=10.1124%2Fdmd.110.035089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035089%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMunsick%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBonacorsi%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DP.%2BT.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DMetabolism%2520and%2520Disposition%2520of%252014C-Labeled%2520Peliglitazar%2520in%2520Humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D228%26epage%3D238%26doi%3D10.1124%2Fdmd.110.035089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaminathan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosqueda-Garcia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aurang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everett, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span> </span><span class="NLM_article-title">Glucuronidation As A Major Metabolic Clearance Pathway Of <sup>14</sup>C-Labeled Muraglitazar In Humans: Metabolic Profiles In Subjects With Or Without Bile Collection</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1124/dmd.105.007617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.105.007617" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=427-439&author=L.+Wangauthor=D.+Zhangauthor=A.+Swaminathanauthor=Y.+Xueauthor=P.+T.+Chengauthor=S.+Wuauthor=R.+Mosqueda-Garciaauthor=C.+Aurangauthor=D.+W.+Everettauthor=W.+G.+Humphreys&title=Glucuronidation+As+A+Major+Metabolic+Clearance+Pathway+Of+14C-Labeled+Muraglitazar+In+Humans%3A+Metabolic+Profiles+In+Subjects+With+Or+Without+Bile+Collection&doi=10.1124%2Fdmd.105.007617"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.007617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.007617%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DSwaminathan%26aufirst%3DA.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DP.%2BT.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DMosqueda-Garcia%26aufirst%3DR.%26aulast%3DAurang%26aufirst%3DC.%26aulast%3DEverett%26aufirst%3DD.%2BW.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DGlucuronidation%2520As%2520A%2520Major%2520Metabolic%2520Clearance%2520Pathway%2520Of%252014C-Labeled%2520Muraglitazar%2520In%2520Humans%253A%2520Metabolic%2520Profiles%2520In%2520Subjects%2520With%2520Or%2520Without%2520Bile%2520Collection%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D427%26epage%3D439%26doi%3D10.1124%2Fdmd.105.007617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obermeier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span> </span><span class="NLM_article-title">Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span><span class="refDoi"> DOI: 10.1124/dmd.110.035048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.110.035048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=123-131&author=D.+Zhangauthor=N.+Raghavanauthor=L.+Wangauthor=Y.+Xueauthor=M.+Obermeierauthor=S.+Chenauthor=S.+Taoauthor=H.+Zhangauthor=P.+T.+Chengauthor=W.+Liauthor=R.+Ramanathanauthor=Z.+Yangauthor=W.+G.+Humphreys&title=Plasma+Stability-Dependent+Circulation+of+Acyl+Glucuronide+Metabolites+in+Humans%3A+How+Circulating+Metabolite+Profiles+of+Muraglitazar+and+Peliglitazar+Can+Lead+to+Misleading+Risk+Assessment&doi=10.1124%2Fdmd.110.035048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.035048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.035048%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DRaghavan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DTao%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DRamanathan%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DPlasma%2520Stability-Dependent%2520Circulation%2520of%2520Acyl%2520Glucuronide%2520Metabolites%2520in%2520Humans%253A%2520How%2520Circulating%2520Metabolite%2520Profiles%2520of%2520Muraglitazar%2520and%2520Peliglitazar%2520Can%2520Lead%2520to%2520Misleading%2520Risk%2520Assessment%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D123%26epage%3D131%26doi%3D10.1124%2Fdmd.110.035048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Liu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNaul, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebber, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. B.</span><span> </span><span class="NLM_article-title">Discovery of a Novel Series of Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes and Dyslipidemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2262</span><span class="NLM_x">–</span> <span class="NLM_lpage">2265</span><span class="refDoi"> DOI: 10.1021/jm048993p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm048993p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2262-2265&author=K.+Liuauthor=L.+Xuauthor=J.+P.+Bergerauthor=K.+L.+MacNaulauthor=G.+Zhouauthor=T.+W.+Doebberauthor=M.+J.+Forrestauthor=D.+E.+Mollerauthor=A.+B.+Jones&title=Discovery+of+a+Novel+Series+of+Peroxisome+Proliferator-Activated+Receptor+%CE%B1%2F%CE%B3+Dual+Agonists+for+the+Treatment+of+Type+2+Diabetes+and+Dyslipidemia&doi=10.1021%2Fjm048993p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm048993p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm048993p%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DBerger%26aufirst%3DJ.%2BP.%26aulast%3DMacNaul%26aufirst%3DK.%2BL.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DDoebber%26aufirst%3DT.%2BW.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26aulast%3DMoller%26aufirst%3DD.%2BE.%26aulast%3DJones%26aufirst%3DA.%2BB.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Series%2520of%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520%25CE%25B1%252F%25CE%25B3%2520Dual%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%2520and%2520Dyslipidemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2262%26epage%3D2265%26doi%3D10.1021%2Fjm048993p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Kochansky, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cato, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. R.</span><span> </span><span class="NLM_article-title">Species Differences In The Elimination Of A Peroxisome Proliferator-Activated Receptor Agonist Highlighted By Oxidative Metabolism Of Its Acyl Glucuronide</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1894</span><span class="NLM_x">–</span> <span class="NLM_lpage">1904</span><span class="refDoi"> DOI: 10.1124/dmd.105.004010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.105.004010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=1894-1904&author=C.+J.+Kochanskyauthor=Y.-Q.+Xiaauthor=S.+Wangauthor=B.+Catoauthor=M.+Creightonauthor=S.+H.+Vincentauthor=R.+B.+Franklinauthor=J.+R.+Reed&title=Species+Differences+In+The+Elimination+Of+A+Peroxisome+Proliferator-Activated+Receptor+Agonist+Highlighted+By+Oxidative+Metabolism+Of+Its+Acyl+Glucuronide&doi=10.1124%2Fdmd.105.004010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.004010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.004010%26sid%3Dliteratum%253Aachs%26aulast%3DKochansky%26aufirst%3DC.%2BJ.%26aulast%3DXia%26aufirst%3DY.-Q.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCato%26aufirst%3DB.%26aulast%3DCreighton%26aufirst%3DM.%26aulast%3DVincent%26aufirst%3DS.%2BH.%26aulast%3DFranklin%26aufirst%3DR.%2BB.%26aulast%3DReed%26aufirst%3DJ.%2BR.%26atitle%3DSpecies%2520Differences%2520In%2520The%2520Elimination%2520Of%2520A%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520Agonist%2520Highlighted%2520By%2520Oxidative%2520Metabolism%2520Of%2520Its%2520Acyl%2520Glucuronide%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D1894%26epage%3D1904%26doi%3D10.1124%2Fdmd.105.004010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Kreutner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozzi, S.</span><span> </span><span class="NLM_article-title">Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1 Receptor Antagonist</span> <span class="citation_source-journal">Arzneim. Forsch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1055/s-0031-1300213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1055%2Fs-0031-1300213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10800633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtFSlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2000&pages=345-352&author=W.+Kreutnerauthor=J.+A.+Heyauthor=J.+Anthesauthor=A.+Barnettauthor=S.+Youngauthor=S.+Tozzi&title=Preclinical+Pharmacology+of+Desloratadine%2C+a+Selective+and+Nonsedating+Histamine+H1+Receptor+Antagonist&doi=10.1055%2Fs-0031-1300213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist: receptor selectivity, antihistaminic activity, and antiallergenic effects</span></div><div class="casAuthors">Kreutner, William; Hey, John A.; Anthes, John; Barnett, Allen; Young, Simon; Tozzi, Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">345-352</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    
            (<span class="NLM_cas:orgname">Editio Cantor Verlag</span>)
        </div><div class="casAbstract">Desloratadine (descarboethoxyloratadine, CAS 100643-71-8) is an active metabolite of loratadine (CAS 79794-75-5) that exhibits qual. similar pharmacodynamic activity with a relative oral potency in animals 2.5-4 times greater than loratadine.  Its antihistaminic effect lasts 24 h.  Desloratadine was shown to be a selective H1 antagonist with more potent antihistaminic activity in vitro than either loratadine or terfenadine (CAS 50679-08-8), as indicated by its displacement of 3H-mepyramine from H1 receptors in rat brain, guinea pig brain, and guinea pig lung, and by its antagonism of histamine-induced contractions of guinea pig ileum.  Antihistaminic activity and antiallergic effects also were obsd. in vivo.  After oral administration, desloratadine was 2.5 to 4 times more potent than loratadine in protecting against histamine-induced lethality in the guinea pig and paw edema in the mouse; after topical administration, it was almost 10 times more potent in antagonizing histamine-induced increases in nasal microvascular permeability in the guinea pig.  Histamine-induced changes in pulmonary resistance and compliance were also prevented by oral administration of desloratadine and loratadine in the monkey.  An oral antiallergic effect was demonstrated by important redns. of acute bronchospasm in the allergic monkey and potent inhibition of allergic cough in the guinea pig.  These preclin. studies provide evidence that desloratadine is an antihistaminic agent with a greater potency than loratadine and, together with results from numerous published studies, suggest an antiallergic effect of desloratadine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6RLhnlxOAtrVg90H21EOLACvtfcHk0ljUQsvZlyNO5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtFSlsro%253D&md5=e103cbb849ace7a9a17d7799155b467d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1055%2Fs-0031-1300213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0031-1300213%26sid%3Dliteratum%253Aachs%26aulast%3DKreutner%26aufirst%3DW.%26aulast%3DHey%26aufirst%3DJ.%2BA.%26aulast%3DAnthes%26aufirst%3DJ.%26aulast%3DBarnett%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DTozzi%26aufirst%3DS.%26atitle%3DPreclinical%2520Pharmacology%2520of%2520Desloratadine%252C%2520a%2520Selective%2520and%2520Nonsedating%2520Histamine%2520H1%2520Receptor%2520Antagonist%26jtitle%3DArzneim.%2520Forsch.%26date%3D2000%26volume%3D50%26spage%3D345%26epage%3D352%26doi%3D10.1055%2Fs-0031-1300213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Kreutner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, A.</span><span> </span><span class="NLM_article-title">Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1 Receptor Antagonist2nd Communication: Lack of central nervous system and cardiovascular effects</span> <span class="citation_source-journal">Arzneim. Forsch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span><span class="refDoi"> DOI: 10.1055/s-0031-1300228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1055%2Fs-0031-1300228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10858871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFOjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2000&pages=441-448&author=W.+Kreutnerauthor=J.+A.+Heyauthor=P.+Chiuauthor=A.+Barnett&title=Preclinical+Pharmacology+of+Desloratadine%2C+a+Selective+and+Nonsedating+Histamine+H1+Receptor+Antagonist2nd+Communication%3A+Lack+of+central+nervous+system+and+cardiovascular+effects&doi=10.1055%2Fs-0031-1300228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects</span></div><div class="casAuthors">Kreutner, William; Hey, John A.; Chiu, Peter; Barnett, Allen</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-448</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    
            (<span class="NLM_cas:orgname">Editio Cantor Verlag</span>)
        </div><div class="casAbstract">Desloratadine (descarboethoxyloratadine, CAS 100643-71-8) is a selective histamine H1 antagonist that exhibits qual. similar pharmacodynamic activity to its parent, loratadine (CAS 79794-7505), but is 2.5-4 times more potent orally.  In studies of central nervous system (CNS) effects that might lead to sedation, desloratadine had no behavioral, neurol. or autonomic effects in the conscious mouse and rat.  At large multiples of the antihistaminic dose in the mouse, it did not inhibit convulsions caused by electroconvulsive shock and inhibited acetic acid-induced writhing only at a dose approx. 1,000 times the antihistaminic dose in the mouse.  Desloratadine had no effects on blood pressure, heart rate or electrocardiog. parameters in the rat or guinea pig or on electrocardiog. parameters in the monkey.  Notably, there was no effect on the cor. Q-wave to T-wave (QTc) interval.  Desloratadine did not inhibit IKr channel human ether-a-go-go-related gene (HERG)-induced current in a study in which HERG was expressed in Xenopus oocytes.  In the rate, desloratadine did not cause effects in urine vol., electrolytes or creatinine, or inhibit gastric emptying or intestinal transit, or cause any harmful effects on gastric mucosa.  The results of these preclin. studies provide evidence that desloratadine is a safe antihistamine without CNS or cardiovascular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUmO5fgG2dz7Vg90H21EOLACvtfcHk0ljUQsvZlyNO5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFOjtr4%253D&md5=78fedda7cca56828199db314d161c2d8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1055%2Fs-0031-1300228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0031-1300228%26sid%3Dliteratum%253Aachs%26aulast%3DKreutner%26aufirst%3DW.%26aulast%3DHey%26aufirst%3DJ.%2BA.%26aulast%3DChiu%26aufirst%3DP.%26aulast%3DBarnett%26aufirst%3DA.%26atitle%3DPreclinical%2520Pharmacology%2520of%2520Desloratadine%252C%2520a%2520Selective%2520and%2520Nonsedating%2520Histamine%2520H1%2520Receptor%2520Antagonist2nd%2520Communication%253A%2520Lack%2520of%2520central%2520nervous%2520system%2520and%2520cardiovascular%2520effects%26jtitle%3DArzneim.%2520Forsch.%26date%3D2000%26volume%3D50%26spage%3D441%26epage%3D448%26doi%3D10.1055%2Fs-0031-1300228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Ramanathan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyderman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulmatycki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdhury, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Statkevich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, J. E.</span><span> </span><span class="NLM_article-title">Disposition Of Loratadine In Healthy Volunteers</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span><span class="refDoi"> DOI: 10.1080/00498250701463317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1080%2F00498250701463317" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=753-769&author=R.+Ramanathanauthor=L.+Reydermanauthor=K.+Kulmatyckiauthor=A.+D.+Suauthor=N.+Alvarezauthor=S.+K.+Chowdhuryauthor=K.+B.+Altonauthor=M.+A.+Wirthauthor=R.+P.+Clementauthor=P.+Statkevichauthor=J.+E.+Patrick&title=Disposition+Of+Loratadine+In+Healthy+Volunteers&doi=10.1080%2F00498250701463317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1080%2F00498250701463317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250701463317%26sid%3Dliteratum%253Aachs%26aulast%3DRamanathan%26aufirst%3DR.%26aulast%3DReyderman%26aufirst%3DL.%26aulast%3DKulmatycki%26aufirst%3DK.%26aulast%3DSu%26aufirst%3DA.%2BD.%26aulast%3DAlvarez%26aufirst%3DN.%26aulast%3DChowdhury%26aufirst%3DS.%2BK.%26aulast%3DAlton%26aufirst%3DK.%2BB.%26aulast%3DWirth%26aufirst%3DM.%2BA.%26aulast%3DClement%26aufirst%3DR.%2BP.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DPatrick%26aufirst%3DJ.%2BE.%26atitle%3DDisposition%2520Of%2520Loratadine%2520In%2520Healthy%2520Volunteers%26jtitle%3DXenobiotica%26date%3D2007%26volume%3D37%26spage%3D753%26epage%3D769%26doi%3D10.1080%2F00498250701463317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Kazmi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbara, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yerino, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">A Long-Standing Mystery Solved: The Formation of 3-Hydroxydesloratadine Is Catalyzed by CYP2C8 But Prior Glucuronidation of Desloratadine by UDP-Glucuronosyltransferase 2B10 Is an Obligatory Requirement</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1124/dmd.114.062620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.114.062620" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=523-533&author=F.+Kazmiauthor=J.+E.+Barbaraauthor=P.+Yerinoauthor=A.+Parkinson&title=A+Long-Standing+Mystery+Solved%3A+The+Formation+of+3-Hydroxydesloratadine+Is+Catalyzed+by+CYP2C8+But+Prior+Glucuronidation+of+Desloratadine+by+UDP-Glucuronosyltransferase+2B10+Is+an+Obligatory+Requirement&doi=10.1124%2Fdmd.114.062620"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.062620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.062620%26sid%3Dliteratum%253Aachs%26aulast%3DKazmi%26aufirst%3DF.%26aulast%3DBarbara%26aufirst%3DJ.%2BE.%26aulast%3DYerino%26aufirst%3DP.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DA%2520Long-Standing%2520Mystery%2520Solved%253A%2520The%2520Formation%2520of%25203-Hydroxydesloratadine%2520Is%2520Catalyzed%2520by%2520CYP2C8%2520But%2520Prior%2520Glucuronidation%2520of%2520Desloratadine%2520by%2520UDP-Glucuronosyltransferase%25202B10%2520Is%2520an%2520Obligatory%2520Requirement%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D523%26epage%3D533%26doi%3D10.1124%2Fdmd.114.062620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Kazmi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yerino, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbara, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1294</span><span class="NLM_x">–</span> <span class="NLM_lpage">1302</span><span class="refDoi"> DOI: 10.1124/dmd.115.065011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.115.065011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1294-1302&author=F.+Kazmiauthor=P.+Yerinoauthor=J.+E.+Barbaraauthor=A.+Parkinson&title=Further+Characterization+of+the+Metabolism+of+Desloratadine+and+Its+Cytochrome+P450+and+UDP-glucuronosyltransferase+Inhibition+Potential%3A+Identification+of+Desloratadine+as+a+Relatively+Selective+UGT2B10+Inhibitor&doi=10.1124%2Fdmd.115.065011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.065011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.065011%26sid%3Dliteratum%253Aachs%26aulast%3DKazmi%26aufirst%3DF.%26aulast%3DYerino%26aufirst%3DP.%26aulast%3DBarbara%26aufirst%3DJ.%2BE.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DFurther%2520Characterization%2520of%2520the%2520Metabolism%2520of%2520Desloratadine%2520and%2520Its%2520Cytochrome%2520P450%2520and%2520UDP-glucuronosyltransferase%2520Inhibition%2520Potential%253A%2520Identification%2520of%2520Desloratadine%2520as%2520a%2520Relatively%2520Selective%2520UGT2B10%2520Inhibitor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D1294%26epage%3D1302%26doi%3D10.1124%2Fdmd.115.065011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Orr, S. T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripp, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span> </span><span class="NLM_article-title">Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4896</span><span class="NLM_x">–</span> <span class="NLM_lpage">4933</span><span class="refDoi"> DOI: 10.1021/jm300065h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300065h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4896-4933&author=S.+T.+M.+Orrauthor=S.+L.+Rippauthor=T.+E.+Ballardauthor=J.+L.+Hendersonauthor=D.+O.+Scottauthor=R.+S.+Obachauthor=H.+Sunauthor=A.+S.+Kalgutkar&title=Mechanism-Based+Inactivation+%28MBI%29+of+Cytochrome+P450+Enzymes%3A+Structure%E2%80%93Activity+Relationships+and+Discovery+Strategies+To+Mitigate+Drug%E2%80%93Drug+Interaction+Risks&doi=10.1021%2Fjm300065h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks</span></div><div class="casAuthors">Orr, Suvi T. M.; Ripp, Sharon L.; Ballard, T. Eric; Henderson, Jaclyn L.; Scott, Dennis O.; Obach, R. Scott; Sun, Hao; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4896-4933</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The importance of mitigating drug-drug interaction (DDI) risks, which arise from inhibition of major human cytochrome P 450 enzymes is a well-established component of the lead optimization process in drug discovery.  More recently, there has been much interest in clin. DDIs potentially arising via time- and concn.-dependent cytochrome P 450 inhibition, a phenomenon consistent with mechanism-based inactivation.  Inactivated P 450 is catalytically incompetent and must be replenished by newly synthesized protein.  Consequently, time-dependent inhibition of P450s presents a greater safety concern compared to reversible inhibition because of the increased propensity for pharmacokinetic interactions upon multiple dosing and the sustained duration of these interactions after discontinuation of the mechanism-based inactivator.  Mechanism-based or time-dependent P 450 inhibitors pose an addnl. risk of idiosyncratic drug toxicity since the mechanism of time-dependency often involves the formation of reactive metabolites, which can react with proteins other than the P 450 isoenzyme responsible for catalysis. in vitro time-dependent inhibition (TDI) of P 450 enzymes is now routinely assessed as part of lead optimization efforts in preclin. drug discovery.  However, identification of an in vitro TDI liability can raise several questions such as: What is the mechanism of TDI.  Does it involve the formation of reactive metabolites.  Is there a 1:1 correlation between P 450 TDI and RM formation (as measured from reactive metabolite trapping studies).  What is the likelihood that a P 450 time-dependent inhibitor will also cause toxicity.  What are the DDI risk mitigation options when dealing with P 450 inactivators in drug discovery - compd. progression or termination.  Several drugs exhibit in vitro TDI of P 450 enzymes, but only a fraction thereof causes clin. DDIs.  Hence, when do we initiate labor-intensive medicinal chem. efforts to design compds. devoid of P 450 TDI liability.  What are the best methods to precisely predict the likelihood of occurrence of clin. DDIs with drug candidates that inactivate P 450 enzymes.  What are (if any) the qualifying considerations for clin. progression of a P 450 time-dependent inactivator with projected clin. DDI risks.  In an effort to address these questions and hopefully provide answers to some of them, we embarked on the present venture wherein we highlight the current state-of-the-art knowledge in this field with a special emphasis on (a) available biochem. and mechanistic approaches in drug discovery to examine TDI of P 450 isoenzymes with new chem. entities, (b) structure-activity relationship studies with marketed drugs assocd. with DDIs via P 450 inactivation, (c) case studies of medicinal chem. tactics to abrogate P 450 inactivation liability, (d) strategies for progression of P 450 TDI-pos. drug candidates, and (e) the utility of in silico methodol., including the use of physiol.-based pharmacokinetic simulators, in drug discovery to predict the magnitude of clin. DDIs risks anticipated with new clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDO60qqRvpS7Vg90H21EOLACvtfcHk0lhC5IyRU9NpJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D&md5=aa4aa4f633b3b4f73b3d79917327b0de</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm300065h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300065h%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26aulast%3DBallard%26aufirst%3DT.%2BE.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DMechanism-Based%2520Inactivation%2520%2528MBI%2529%2520of%2520Cytochrome%2520P450%2520Enzymes%253A%2520Structure%25E2%2580%2593Activity%2520Relationships%2520and%2520Discovery%2520Strategies%2520To%2520Mitigate%2520Drug%25E2%2580%2593Drug%2520Interaction%2520Risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4896%26epage%3D4933%26doi%3D10.1021%2Fjm300065h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Todd, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, A.</span><span> </span><span class="NLM_article-title">Gemfibrozil</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.2165/00003495-198836030-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2165%2F00003495-198836030-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=3056692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADyaL1cXmtVChsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1988&pages=314-339&author=P.+A.+Toddauthor=A.+Ward&title=Gemfibrozil&doi=10.2165%2F00003495-198836030-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Gemfibrozil.  A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia</span></div><div class="casAuthors">Todd, Peter A.; Ward, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-39</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    </div><div class="casAbstract">A review with ∼140 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobDuwL7YkTf7Vg90H21EOLACvtfcHk0ljwUD7hjZLkJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmtVChsbk%253D&md5=efa6b048ad3e3c1badea9471cd11c2b7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2165%2F00003495-198836030-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-198836030-00004%26sid%3Dliteratum%253Aachs%26aulast%3DTodd%26aufirst%3DP.%2BA.%26aulast%3DWard%26aufirst%3DA.%26atitle%3DGemfibrozil%26jtitle%3DDrugs%26date%3D1988%26volume%3D36%26spage%3D314%26epage%3D339%26doi%3D10.2165%2F00003495-198836030-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Mano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamimura, H.</span><span> </span><span class="NLM_article-title">The UDP-Glucuronosyltransferase 2B7 Isozyme Is Responsible for Gemfibrozil Glucuronidation in the Human Liver</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2040</span><span class="NLM_x">–</span> <span class="NLM_lpage">2044</span><span class="refDoi"> DOI: 10.1124/dmd.107.017269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.107.017269" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=2040-2044&author=Y.+Manoauthor=T.+Usuiauthor=H.+Kamimura&title=The+UDP-Glucuronosyltransferase+2B7+Isozyme+Is+Responsible+for+Gemfibrozil+Glucuronidation+in+the+Human+Liver&doi=10.1124%2Fdmd.107.017269"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017269%26sid%3Dliteratum%253Aachs%26aulast%3DMano%26aufirst%3DY.%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DKamimura%26aufirst%3DH.%26atitle%3DThe%2520UDP-Glucuronosyltransferase%25202B7%2520Isozyme%2520Is%2520Responsible%2520for%2520Gemfibrozil%2520Glucuronidation%2520in%2520the%2520Human%2520Liver%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D2040%26epage%3D2044%26doi%3D10.1124%2Fdmd.107.017269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Wang, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1352</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span><span class="refDoi"> DOI: 10.1124/dmd.30.12.1352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.30.12.1352" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1352-1356&author=J.-S.+Wangauthor=M.+Neuvonenauthor=X.+Wenauthor=J.+T.+Backmanauthor=P.+J.+Neuvonen&title=Gemfibrozil+Inhibits+CYP2C8-Mediated+Cerivastatin+Metabolism+in+Human+Liver+Microsomes&doi=10.1124%2Fdmd.30.12.1352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.12.1352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.12.1352%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.-S.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520Inhibits%2520CYP2C8-Mediated%2520Cerivastatin%2520Metabolism%2520in%2520Human%2520Liver%2520Microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D1352%26epage%3D1356%26doi%3D10.1124%2Fdmd.30.12.1352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivistö, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil Is a Potent Inhibitor of Human Cytochrome P450 2C9</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=1359-1361&author=X.+Wenauthor=J.-S.+Wangauthor=J.+T.+Backmanauthor=K.+T.+Kivist%C3%B6author=P.+J.+Neuvonen&title=Gemfibrozil+Is+a+Potent+Inhibitor+of+Human+Cytochrome+P450+2C9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.-S.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DKivist%25C3%25B6%26aufirst%3DK.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Human%2520Cytochrome%2520P450%25202C9%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2001%26volume%3D29%26spage%3D1359%26epage%3D1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Fujino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsunenari, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, J.</span><span> </span><span class="NLM_article-title">Studies on the Interaction between Fibrates and Statins Using Human Hepatic Microsomes</span> <span class="citation_source-journal">Arzneim. Forsch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">707</span><span class="refDoi"> DOI: 10.1055/s-0031-1299815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1055%2Fs-0031-1299815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=14650362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFWntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2003&pages=701-707&author=H.+Fujinoauthor=S.+Shimadaauthor=I.+Yamadaauthor=M.+Hiranoauthor=Y.+Tsunenariauthor=J.+Kojima&title=Studies+on+the+Interaction+between+Fibrates+and+Statins+Using+Human+Hepatic+Microsomes&doi=10.1055%2Fs-0031-1299815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the interaction between fibrates and statins using human hepatic microsomes</span></div><div class="casAuthors">Fujino, Hideki; Shimada, Syunsuke; Yamada, Iwao; Hirano, Masaru; Tsunenari, Yoshihiko; Kojima, Junji</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">701-707</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    
            (<span class="NLM_cas:orgname">Editio Cantor Verlag</span>)
        </div><div class="casAbstract">To gain a better understanding of the mechanism of drug-drug interaction between fibrates and statins, several in vitro expts. were performed.  On coincubation with several fibrates, pitavastatin (CAS 147526-32-7) did not displace fibrates from their protein binding in human plasma.  The presence of gemfibrozil (CAS 25812-30-0) inhibited the metab. of statins (cerivastatin (CAS 145599-86-6) and atorvastatin (CAS 134523-00-5)) remarkably.  However, the increase of the unchanged form was fairly small for pitavastatin.  The metabolic profile of gemfibrozil was also investigated.  The cytochrome P (CYP) enzyme CYP2C9 plays a major role in the metab. of gemfibrozil.  Gemfibrozil showed a high affinity for CYP enzymes and a relatively high metab. velocity.  Moreover, several inhibitory effects of gemfibrozil on CYP-mediated metab. were detected - in contrast to other fibrates.  Although the mechanism of the drug-drug interaction was not completely clarified, it is suggested that the increase of plasma concn. caused by the coadministration of gemfibrozil and statins is at least partially due to the inhibition of the CYP-mediated metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNufjyfZRvz7Vg90H21EOLACvtfcHk0ljwUD7hjZLkJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFWntb0%253D&md5=cb725daf696c593df3fe7c9f7bcc4256</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1055%2Fs-0031-1299815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0031-1299815%26sid%3Dliteratum%253Aachs%26aulast%3DFujino%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DS.%26aulast%3DYamada%26aufirst%3DI.%26aulast%3DHirano%26aufirst%3DM.%26aulast%3DTsunenari%26aufirst%3DY.%26aulast%3DKojima%26aufirst%3DJ.%26atitle%3DStudies%2520on%2520the%2520Interaction%2520between%2520Fibrates%2520and%2520Statins%2520Using%2520Human%2520Hepatic%2520Microsomes%26jtitle%3DArzneim.%2520Forsch.%26date%3D2003%26volume%3D53%26spage%3D701%26epage%3D707%26doi%3D10.1055%2Fs-0031-1299815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyrklund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil Greatly Increases Plasma Concentrations Of Cerivastatin</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span><span class="refDoi"> DOI: 10.1067/mcp.2002.128469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1067%2Fmcp.2002.128469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=12496749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1SjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2002&pages=685-691&author=J.+T.+Backmanauthor=C.+Kyrklundauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Gemfibrozil+Greatly+Increases+Plasma+Concentrations+Of+Cerivastatin&doi=10.1067%2Fmcp.2002.128469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Gemfibrozil greatly increases plasma concentrations of cerivastatin</span></div><div class="casAuthors">Backman, Janne T.; Kyrklund, Carl; Neuvonen, Mikko; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-691</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Concomitant use of gemfibrozil with statins, particularly with cerivastatin, increases the risk of rhabdomyolysis, but the mechanism of this potentially fatal drug interaction remains unclear.  Our aim was to study the effect of gemfibrozil on cerivastatin pharmacokinetics.  In a randomized, double-blind crossover study, 10 healthy volunteers took 600 mg gemfibrozil or placebo twice daily for 3 days.  On day 3, each subject ingested a single 0.3-mg dose of cerivastatin.  Plasma concns. of cerivastatin, its metabolites, and gemfibrozil were measured up to 24 h.  During gemfibrozil treatment, the area under the plasma concn.-time curve [AUC(0-∞)] of parent cerivastatin was on av. 559% (range, 138% to 995%; P =.0002) and the peak concn. in plasma was 307% (138% to 809%; P =.0019) of the corresponding values in the placebo phase.  Gemfibrozil increased the AUC(0-∞) of cerivastatin lactone, on av., to 440% (94% to 594%; P =.0024) and that of metabolite M-1 to 435% (216% to 802%; P =.0002) of the control (placebo) values, whereas the AUC(0-24) of metabolite M-23 was decreased to 22% (11% to 74%; P=.0017).  Gemfibrozil greatly increases plasma concns. of cerivastatin, cerivastatin lactone, and metabolite M-1, whereas the level of metabolite M-23 is markedly reduced by gemfibrozil.  Gemfibrozil therefore inhibits the formation of M-23, which is thought to be dependent on CYP2C8.  The increased exposure to cerivastatin in the presence of gemfibrozil may explain the high incidence of myopathy obsd. with this combination, although the role of pharmacodynamic interactions between these 2 agents cannot be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyOpdQOdq0kLVg90H21EOLACvtfcHk0ljELHn-gn9HyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1SjsQ%253D%253D&md5=2dce3480b6cea92874faf468c81b834c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2002.128469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2002.128469%26sid%3Dliteratum%253Aachs%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DKyrklund%26aufirst%3DC.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520Greatly%2520Increases%2520Plasma%2520Concentrations%2520Of%2520Cerivastatin%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D72%26spage%3D685%26epage%3D691%26doi%3D10.1067%2Fmcp.2002.128469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Jaakkola, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics of Pioglitazone</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">404</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span><span class="refDoi"> DOI: 10.1016/j.clpt.2004.12.266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2Fj.clpt.2004.12.266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=15900286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFCrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=404-414&author=T.+Jaakkolaauthor=J.+T.+Backmanauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Effects+of+Gemfibrozil%2C+Itraconazole%2C+and+Their+Combination+on+the+Pharmacokinetics+of+Pioglitazone&doi=10.1016%2Fj.clpt.2004.12.266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone</span></div><div class="casAuthors">Jaakkola, Tiina; Backman, Janne T.; Neuvonen, Mikko; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">404-414</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background and objective: The thiazolidinedione antidiabetic drug pioglitazone is metabolized mainly by cytochrome P 450 (CYP) 2C8 and CYP3A4 in vitro.  Our objective was to study the effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone to det. the role of these enzymes in the fate of pioglitazone in humans.  Methods: In a randomized, double-blind, 4-phase crossover study, 12 healthy volunteers took either 600 mg gemfibrozil or 100 mg itraconazole (first dose, 200 mg), both gemfibrozil and itraconazole, or placebo twice daily for 4 days.  On day 3, they received a single dose of 15 mg pioglitazone.  Plasma drug concns. and the cumulative excretion of pioglitazone and its metabolites into urine were measured for up to 48 h.  Results: Gemfibrozil alone raised the mean total area under the plasma concn.-time curve from time 0 to infinity [AUC(0-∞)] of pioglitazone 3.2-fold (range, 2.3-fold to 6.5-fold; P <.001) and prolonged its elimination half-life (t1/2) from 8.3 to 22.7 h (P <.001) but had no significant effect on its peak concn. (Cmax) compared with placebo (control).  Gemfibrozil increased the 48-h excretion of pioglitazone into urine by 2.5-fold (P <.001) and reduced the ratios of the active metabolites M-III and M-IV to pioglitazone in plasma and urine.  Gemfibrozil decreased the area under the plasma concn.-time curve from time 0 to 48 h [AUC(0-48)] of the metabolites M-III and M-IV by 42% (P <.05) and 45% (P <.001), resp., but their total AUC(0-∞) values were reduced by less or not at all.  Itraconazole had no significant effect on the pharmacokinetics of pioglitazone and did not alter the effect of gemfibrozil on pioglitazone pharmacokinetics.  The mean area under the concn. vs. time curve to 49 h [AUC(0-49)] of itraconazole was 46% lower (P <.001) during the gemfibrozil-itraconazole phase than during the itraconazole phase.  Conclusions: Gemfibrozil elevates the plasma concns. of pioglitazone, probably by inhibition of its CYP2C8-mediated metab.  CYP2C8 appears to be of major importance and CYP3A4 of minor importance in pioglitazone metab. in vivo in humans.  Concomitant use of gemfibrozil with pioglitazone may increase the effects and risk of dose-related adverse effects of pioglitazone.  However, studies in diabetic patients are needed to det. the clin. significance of the gemfibrozil-pioglitazone interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjiP-NzZlXnrVg90H21EOLACvtfcHk0ljELHn-gn9HyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFCrtLg%253D&md5=44f68ebede1b1bf43cd353ac13007899</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.12.266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.12.266%26sid%3Dliteratum%253Aachs%26aulast%3DJaakkola%26aufirst%3DT.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DEffects%2520of%2520Gemfibrozil%252C%2520Itraconazole%252C%2520and%2520Their%2520Combination%2520on%2520the%2520Pharmacokinetics%2520of%2520Pioglitazone%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D404%26epage%3D414%26doi%3D10.1016%2Fj.clpt.2004.12.266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granfors, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laitila, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Gemfibrozil Considerably Increases The Plasma Concentrations Of Rosiglitazone</span> <span class="citation_source-journal">Diabetologia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1319</span><span class="NLM_x">–</span> <span class="NLM_lpage">1323</span><span class="refDoi"> DOI: 10.1007/s00125-003-1181-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1007%2Fs00125-003-1181-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1319-1323&author=M.+Niemiauthor=J.+T.+Backmanauthor=M.+Granforsauthor=J.+Laitilaauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Gemfibrozil+Considerably+Increases+The+Plasma+Concentrations+Of+Rosiglitazone&doi=10.1007%2Fs00125-003-1181-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs00125-003-1181-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-003-1181-x%26sid%3Dliteratum%253Aachs%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DGranfors%26aufirst%3DM.%26aulast%3DLaitila%26aufirst%3DJ.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DGemfibrozil%2520Considerably%2520Increases%2520The%2520Plasma%2520Concentrations%2520Of%2520Rosiglitazone%26jtitle%3DDiabetologia%26date%3D2003%26volume%3D46%26spage%3D1319%26epage%3D1323%26doi%3D10.1007%2Fs00125-003-1181-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span> </span><span class="NLM_article-title">Effects Of Gemfibrozil, Itraconazole, And Their Combination On The Pharmacokinetics And Pharmacodynamics Of Repaglinide: Potentially Hazardous Interaction Between Gemfibrozil And Repaglinide</span> <span class="citation_source-journal">Diabetologia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span><span class="refDoi"> DOI: 10.1007/s00125-003-1034-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1007%2Fs00125-003-1034-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=347-351&author=M.+Niemiauthor=J.+T.+Backmanauthor=M.+Neuvonenauthor=P.+J.+Neuvonen&title=Effects+Of+Gemfibrozil%2C+Itraconazole%2C+And+Their+Combination+On+The+Pharmacokinetics+And+Pharmacodynamics+Of+Repaglinide%3A+Potentially+Hazardous+Interaction+Between+Gemfibrozil+And+Repaglinide&doi=10.1007%2Fs00125-003-1034-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs00125-003-1034-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-003-1034-7%26sid%3Dliteratum%253Aachs%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DEffects%2520Of%2520Gemfibrozil%252C%2520Itraconazole%252C%2520And%2520Their%2520Combination%2520On%2520The%2520Pharmacokinetics%2520And%2520Pharmacodynamics%2520Of%2520Repaglinide%253A%2520Potentially%2520Hazardous%2520Interaction%2520Between%2520Gemfibrozil%2520And%2520Repaglinide%26jtitle%3DDiabetologia%26date%3D2003%26volume%3D46%26spage%3D347%26epage%3D351%26doi%3D10.1007%2Fs00125-003-1034-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Farmer, J. A.</span><span> </span><span class="NLM_article-title">Learning from the cerivastatin experience</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1383</span><span class="NLM_x">–</span> <span class="NLM_lpage">1385</span><span class="refDoi"> DOI: 10.1016/S0140-6736(01)06489-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS0140-6736%2801%2906489-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2001&pages=1383-1385&author=J.+A.+Farmer&title=Learning+from+the+cerivastatin+experience&doi=10.1016%2FS0140-6736%2801%2906489-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2801%2906489-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252801%252906489-3%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DJ.%2BA.%26atitle%3DLearning%2520from%2520the%2520cerivastatin%2520experience%26jtitle%3DLancet%26date%3D2001%26volume%3D358%26spage%3D1383%26epage%3D1385%26doi%3D10.1016%2FS0140-6736%2801%2906489-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Pogson, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindred, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carper, B. G.</span><span> </span><span class="NLM_article-title">Rhabdomyolysis And Renal Failure Associated With Cerivastatin-Gemfibrozil Combination Therapy</span> <span class="citation_source-journal">Am. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">1146</span><span class="refDoi"> DOI: 10.1016/S0002-9149(99)00034-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS0002-9149%2899%2900034-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1999&pages=1146&author=G.+W.+Pogsonauthor=L.+H.+Kindredauthor=B.+G.+Carper&title=Rhabdomyolysis+And+Renal+Failure+Associated+With+Cerivastatin-Gemfibrozil+Combination+Therapy&doi=10.1016%2FS0002-9149%2899%2900034-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0002-9149%2899%2900034-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9149%252899%252900034-X%26sid%3Dliteratum%253Aachs%26aulast%3DPogson%26aufirst%3DG.%2BW.%26aulast%3DKindred%26aufirst%3DL.%2BH.%26aulast%3DCarper%26aufirst%3DB.%2BG.%26atitle%3DRhabdomyolysis%2520And%2520Renal%2520Failure%2520Associated%2520With%2520Cerivastatin-Gemfibrozil%2520Combination%2520Therapy%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1999%26volume%3D83%26spage%3D1146%26doi%3D10.1016%2FS0002-9149%2899%2900034-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Tornio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laitila, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalliokoski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span><span class="refDoi"> DOI: 10.1038/clpt.2008.34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1038%2Fclpt.2008.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=18388877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVShtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2008&pages=403-411&author=A.+Tornioauthor=M.+Niemiauthor=M.+Neuvonenauthor=J.+Laitilaauthor=A.+Kalliokoskiauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=The+Effect+of+Gemfibrozil+on+Repaglinide+Pharmacokinetics+Persists+for+at+Least+12+h+After+the+Dose%3A+Evidence+for+Mechanism-based+Inhibition+of+CYP2C8+In+Vivo&doi=10.1038%2Fclpt.2008.34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo</span></div><div class="casAuthors">Tornio, A.; Niemi, M.; Neuvonen, M.; Laitila, J.; Kalliokoski, A.; Neuvonen, P. J.; Backman, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-411</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Repaglinide is metabolized by cytochrome P 450 (CYP) 2C8 and 3A4.  Gemfibrozil has the effect of increasing the area under the concn.-time curve (AUC) of repaglinide eightfold.  We studied the effect of dosing interval on the extent of the gemfibrozil-repaglinide interaction.  In a randomized five-phase crossover study, 10 healthy volunteers ingested 0.25 mg repaglinide, with or without gemfibrozil pretreatment.  Plasma repaglinide, gemfibrozil, their metabolites, and blood glucose were measured.  When the last dose of 600 mg gemfibrozil was ingested simultaneously with repaglinide, or 3, 6, or 12 h before, it increased the AUC0-∞ of repaglinide 7.0-, 6.5-, 6.2- and 5.0-fold, resp. (P < 0.001).  The peak repaglinide concn. increased approx. twofold (P < 0.001), and the half-life was prolonged from 1.2 h to 2-3 h (P < 0.001) during all the gemfibrozil phases.  The drug interaction effects persisted at least 12 h after gemfibrozil was administered, although plasma gemfibrozil and gemfibrozil 1-O-β-glucuronide concns. were only 5 and 10% of their peak values, resp.  The long-lasting interaction is likely caused by mechanism-based inhibition of CYP2C8 by gemfibrozil glucuronide.  Clin. Pharmacol. & Therapeutics (2008); 84, 3, 403-411 doi:10.1038/clpt.2008.34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrcii5pN3YQLVg90H21EOLACvtfcHk0lhwVi-2PVJzlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVShtr7K&md5=bb45f6f89c9f504af39116de52b5b825</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2008.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2008.34%26sid%3Dliteratum%253Aachs%26aulast%3DTornio%26aufirst%3DA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DLaitila%26aufirst%3DJ.%26aulast%3DKalliokoski%26aufirst%3DA.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520Effect%2520of%2520Gemfibrozil%2520on%2520Repaglinide%2520Pharmacokinetics%2520Persists%2520for%2520at%2520Least%252012%2520h%2520After%2520the%2520Dose%253A%2520Evidence%2520for%2520Mechanism-based%2520Inhibition%2520of%2520CYP2C8%2520In%2520Vivo%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2008%26volume%3D84%26spage%3D403%26epage%3D411%26doi%3D10.1038%2Fclpt.2008.34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Honkalammi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1977</span><span class="NLM_x">–</span> <span class="NLM_lpage">1986</span><span class="refDoi"> DOI: 10.1124/dmd.111.040931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.111.040931" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1977-1986&author=J.+Honkalammiauthor=M.+Niemiauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=Dose-Dependent+Interaction+between+Gemfibrozil+and+Repaglinide+in+Humans%3A+Strong+Inhibition+of+CYP2C8+with+Subtherapeutic+Gemfibrozil+Doses&doi=10.1124%2Fdmd.111.040931"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040931%26sid%3Dliteratum%253Aachs%26aulast%3DHonkalammi%26aufirst%3DJ.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DDose-Dependent%2520Interaction%2520between%2520Gemfibrozil%2520and%2520Repaglinide%2520in%2520Humans%253A%2520Strong%2520Inhibition%2520of%2520CYP2C8%2520with%2520Subtherapeutic%2520Gemfibrozil%2520Doses%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1977%26epage%3D1986%26doi%3D10.1124%2Fdmd.111.040931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Honkalammi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span><span class="refDoi"> DOI: 10.1038/clpt.2010.358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1038%2Fclpt.2010.358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=21368757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1Cls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=579-586&author=J.+Honkalammiauthor=M.+Niemiauthor=P.+J.+Neuvonenauthor=J.+T.+Backman&title=Mechanism-Based+Inactivation+of+CYP2C8+by+Gemfibrozil+Occurs+Rapidly+in+Humans&doi=10.1038%2Fclpt.2010.358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans</span></div><div class="casAuthors">Honkalammi, J.; Niemi, M.; Neuvonen, P. J.; Backman, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-586</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To study the time to onset of mechanism-based inactivation of cytochrome P 450 (CYP) 2C8 by gemfibrozil in vivo, we conducted a randomized five-phase crossover study in 10 healthy volunteers.  In one phase the volunteers ingested 0.25 mg of repaglinide alone (control), and in the other phases they received 600 mg of gemfibrozil 0-6 h prior to the repaglinide dose.  When gemfibrozil was taken 0, 1, 3, or 6 h before repaglinide, the geometric mean ratio relative to control (90% confidence interval (CI)) of repaglinide area under the plasma concn.-time curve (AUC0-∞) was 5.0-fold (4.3-5.7-fold), 6.3-fold (5.4-7.5-fold), 6.6-fold (5.6-7.7-fold), and 5.4-fold (4.8-6.1-fold), resp. (P < 0.001 vs. control).  The geometric mean ratio relative to control (90% CI) of the max. plasma concn. (Cmax) of the CYP2C8-mediated metabolite M4 was 1.0-fold (0.8-1.3-fold), 0.10-fold (0.06-0.17-fold, P < 0.001), 0.06-fold (0.04-0.10-fold, P < 0.001), and 0.09-fold (0.05-0.14-fold, P < 0.001), resp.  The strong inactivation of CYP2C8, evident as soon as 1 h after gemfibrozil dosing, has implications in clin. practice and in studies with gemfibrozil as a CYP2C8 model inhibitor.  Clin. Pharmacol. & Therapeutics (2011) 89 4, 579-586. doi:10.1038/clpt.2010.358.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0t7uqdCQkRLVg90H21EOLACvtfcHk0liiyTHL4w0kEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1Cls70%253D&md5=6aaf0c8576c45142bb428bad130cae77</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.358%26sid%3Dliteratum%253Aachs%26aulast%3DHonkalammi%26aufirst%3DJ.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DMechanism-Based%2520Inactivation%2520of%2520CYP2C8%2520by%2520Gemfibrozil%2520Occurs%2520Rapidly%2520in%2520Humans%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D579%26epage%3D586%26doi%3D10.1038%2Fclpt.2010.358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Shitara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span> </span><span class="NLM_article-title">Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span><span class="refDoi"> DOI: 10.1124/jpet.104.068536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fjpet.104.068536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=15194707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosVKrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2004&pages=228-236&author=Y.+Shitaraauthor=M.+Hiranoauthor=H.+Satoauthor=Y.+Sugiyama&title=Gemfibrozil+and+Its+Glucuronide+Inhibit+the+Organic+Anion+Transporting+Polypeptide+2+%28OATP2%2FOATP1B1%3ASLC21A6%29-Mediated+Hepatic+Uptake+and+CYP2C8-Mediated+Metabolism+of+Cerivastatin%3A+Analysis+of+the+Mechanism+of+the+Clinically+Relevant+Drug-Drug+Interaction+between+Cerivastatin+and+Gemfibrozil&doi=10.1124%2Fjpet.104.068536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil</span></div><div class="casAuthors">Shitara, Yoshihisa; Hirano, Masaru; Sato, Hitoshi; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-236</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A serious pharmacokinetic interaction between cerivastatin (CER) and gemfibrozil (GEM) has been reported.  In the present study, we examd. the inhibitory effects of GEM and its metabolites, M3 and gemfibrozil 1-O-β-glucuronide (GEM-1-O-glu), on the uptake of CER by human org. anion transporting polypeptide 2 (OATP2)-expressing cells and its metab. in cytochrome P 450 expression systems.  Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC50 values of 72 and 24 μM, resp.  They also inhibited the CYP2C8-mediated metab. of CER with IC50 values of 28 and 4 μM, resp., whereas M3 had no effects.  GEM and GEM-1-O-glu minimally inhibited the CYP3A4-mediated metab. of CER.  The IC50 values of GEM and GEM-1-O-glu for the uptake and the metab. of CER obtained in the present study were lower than their total, and not unbound, plasma concns.  However, considering the possibly concd. high unbound concns. of GEM-1-O-glu in the liver and its relatively larger plasma unbound fraction compared with GEM itself, the glucuronide inhibition of the CYP2C8-mediated metab. of CER appears to be the main mechanism for the clin. relevant drug-drug interaction.  Previously reported clin. drug interaction studies showing that coadministration of GEM with pravastatin or pitavastatin, both of which are known to be cleared from the plasma by the uptake transporters in the liver, only minimally (less than 2-fold) increased the area under the plasma concn.-time curve of these statins, also supported our present conclusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplgMf8fP3WyrVg90H21EOLACvtfcHk0liiyTHL4w0kEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosVKrt7g%253D&md5=47713127a0aa0747c2e9520811193a22</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.068536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.068536%26sid%3Dliteratum%253Aachs%26aulast%3DShitara%26aufirst%3DY.%26aulast%3DHirano%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DGemfibrozil%2520and%2520Its%2520Glucuronide%2520Inhibit%2520the%2520Organic%2520Anion%2520Transporting%2520Polypeptide%25202%2520%2528OATP2%252FOATP1B1%253ASLC21A6%2529-Mediated%2520Hepatic%2520Uptake%2520and%2520CYP2C8-Mediated%2520Metabolism%2520of%2520Cerivastatin%253A%2520Analysis%2520of%2520the%2520Mechanism%2520of%2520the%2520Clinically%2520Relevant%2520Drug-Drug%2520Interaction%2520between%2520Cerivastatin%2520and%2520Gemfibrozil%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D311%26spage%3D228%26epage%3D236%26doi%3D10.1124%2Fjpet.104.068536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Baer, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLisle, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Benzylic Oxidation of Gemfibrozil-1-O-β-Glucuronide by P450 2C8 Leads to Heme Alkylation and Irreversible Inhibition</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">–</span> <span class="NLM_lpage">1309</span><span class="refDoi"> DOI: 10.1021/tx900105n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx900105n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=1298-1309&author=B.+R.+Baerauthor=R.+K.+DeLisleauthor=A.+Allen&title=Benzylic+Oxidation+of+Gemfibrozil-1-O-%CE%B2-Glucuronide+by+P450+2C8+Leads+to+Heme+Alkylation+and+Irreversible+Inhibition&doi=10.1021%2Ftx900105n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Ftx900105n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900105n%26sid%3Dliteratum%253Aachs%26aulast%3DBaer%26aufirst%3DB.%2BR.%26aulast%3DDeLisle%26aufirst%3DR.%2BK.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DBenzylic%2520Oxidation%2520of%2520Gemfibrozil-1-O-%25CE%25B2-Glucuronide%2520by%2520P450%25202C8%2520Leads%2520to%2520Heme%2520Alkylation%2520and%2520Irreversible%2520Inhibition%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D1298%26epage%3D1309%26doi%3D10.1021%2Ftx900105n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Hollopeter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jantzen, H.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramakrishnan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julius, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conley, P. B.</span><span> </span><span class="NLM_article-title">Identification Of The Platelet ADP Receptor Targeted By Antithrombotic Drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">409</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span><span class="refDoi"> DOI: 10.1038/35051599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1038%2F35051599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=11196645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2001&pages=202-207&author=G.+Hollopeterauthor=H.-M.+Jantzenauthor=D.+Vincentauthor=G.+Liauthor=L.+Englandauthor=V.+Ramakrishnanauthor=R.-B.+Yangauthor=P.+Nurdenauthor=A.+Nurdenauthor=D.+Juliusauthor=P.+B.+Conley&title=Identification+Of+The+Platelet+ADP+Receptor+Targeted+By+Antithrombotic+Drugs&doi=10.1038%2F35051599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the platelet ADP receptor targeted by antithrombotic drugs</span></div><div class="casAuthors">Hollopeter, Gunther; Jantzen, Hans-Michiel; Vincent, Diana; Li, Georgia; England, Laura; Ramakrishnan, Vanitha; Yang, Ruey-Bing; Nurden, Paquita; Nurden, Alan; Julius, David; Conley, Pamela B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">6817</span>),
    <span class="NLM_cas:pages">202-207</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Platelets have a crucial role in the maintenance of normal hemostasis, and perturbations of this system can lead to pathol. thrombus formation and vascular occlusion, resulting in stroke; myocardial infarction and unstable angina.  ADP released from damaged vessels and red blood cells induces platelet aggregation through activation of the integrin GPIIb-IIIa and subsequent binding of fibrinogen.  ADP is also secreted from platelets on activation, providing pos. feedback that potentiates the actions of many platelet activators.  ADP mediates platelet aggregation through its action on two G-protein-coupled receptor subtypes.  The P2Y1 receptor couples to Gq and. mobilizes intracellular calcium ions to mediate platelet shape change and aggregation.  The second ADP receptor required for aggregation (variously called P2YADP, P2YAC, P2Ycyc or P2TAC) is coupled to the inhibition of adenylyl cyclase through Gi.  The mol. identity of the Gi-linked receptor is still elusive, even though it is the target of efficacious antithrombotic agents, such as ticlopidine and clopidogrel and AR-C66096. Here the authors describe the cloning of this receptor, designated P2Y12, and provide evidence that a patient with a bleeding disorder has a defect in this gene.  Cloning of the P2Y12 receptor should facilitate the development- of better antiplatelet agents to treat cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNuDi2tNS7bVg90H21EOLACvtfcHk0liX4f1eb_MDvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D&md5=fe30017f0d3bd9aacb4ad3bd6189c5d9</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2F35051599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35051599%26sid%3Dliteratum%253Aachs%26aulast%3DHollopeter%26aufirst%3DG.%26aulast%3DJantzen%26aufirst%3DH.-M.%26aulast%3DVincent%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DEngland%26aufirst%3DL.%26aulast%3DRamakrishnan%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DR.-B.%26aulast%3DNurden%26aufirst%3DP.%26aulast%3DNurden%26aufirst%3DA.%26aulast%3DJulius%26aufirst%3DD.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DIdentification%2520Of%2520The%2520Platelet%2520ADP%2520Receptor%2520Targeted%2520By%2520Antithrombotic%2520Drugs%26jtitle%3DNature%26date%3D2001%26volume%3D409%26spage%3D202%26epage%3D207%26doi%3D10.1038%2F35051599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Foster, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prosser, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agans, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monsma, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiekowski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbondanzo, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayne, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lira, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chintala, M. S.</span><span> </span><span class="NLM_article-title">Molecular Identification And Characterization Of The Platelet ADP Receptor Targeted By Thienopyridine Antithrombotic Drugs</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">–</span> <span class="NLM_lpage">1598</span><span class="refDoi"> DOI: 10.1172/JCI12242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1172%2FJCI12242" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2001&pages=1591-1598&author=C.+J.+Fosterauthor=D.+M.+Prosserauthor=J.+M.+Agansauthor=Y.+Zhaiauthor=M.+D.+Smithauthor=J.+E.+Lachowiczauthor=F.+L.+Zhangauthor=E.+Gustafsonauthor=F.+J.+Monsmaauthor=M.+T.+Wiekowskiauthor=S.+J.+Abbondanzoauthor=D.+N.+Cookauthor=M.+L.+Bayneauthor=S.+A.+Liraauthor=M.+S.+Chintala&title=Molecular+Identification+And+Characterization+Of+The+Platelet+ADP+Receptor+Targeted+By+Thienopyridine+Antithrombotic+Drugs&doi=10.1172%2FJCI12242"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1172%2FJCI12242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI12242%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DC.%2BJ.%26aulast%3DProsser%26aufirst%3DD.%2BM.%26aulast%3DAgans%26aufirst%3DJ.%2BM.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DF.%2BL.%26aulast%3DGustafson%26aufirst%3DE.%26aulast%3DMonsma%26aufirst%3DF.%2BJ.%26aulast%3DWiekowski%26aufirst%3DM.%2BT.%26aulast%3DAbbondanzo%26aufirst%3DS.%2BJ.%26aulast%3DCook%26aufirst%3DD.%2BN.%26aulast%3DBayne%26aufirst%3DM.%2BL.%26aulast%3DLira%26aufirst%3DS.%2BA.%26aulast%3DChintala%26aufirst%3DM.%2BS.%26atitle%3DMolecular%2520Identification%2520And%2520Characterization%2520Of%2520The%2520Platelet%2520ADP%2520Receptor%2520Targeted%2520By%2520Thienopyridine%2520Antithrombotic%2520Drugs%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2001%26volume%3D107%26spage%3D1591%26epage%3D1598%26doi%3D10.1172%2FJCI12242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Sangkuhl, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, R. B.</span><span> </span><span class="NLM_article-title">Clopidogrel Pathway</span> <span class="citation_source-journal">Pharmacogenet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1097/FPC.0b013e3283385420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1097%2FFPC.0b013e3283385420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=20440227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=463-465&author=K.+Sangkuhlauthor=T.+E.+Kleinauthor=R.+B.+Altman&title=Clopidogrel+Pathway&doi=10.1097%2FFPC.0b013e3283385420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Clopidogrel pathway</span></div><div class="casAuthors">Sangkuhl, Katrin; Klein, Teri E.; Altman, Russ B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">463-465</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQIszvQeq0HLVg90H21EOLACvtfcHk0liX4f1eb_MDvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFGqs70%253D&md5=36ee29ecbf5fdb9b606e275c3a36ef27</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e3283385420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e3283385420%26sid%3Dliteratum%253Aachs%26aulast%3DSangkuhl%26aufirst%3DK.%26aulast%3DKlein%26aufirst%3DT.%2BE.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26atitle%3DClopidogrel%2520Pathway%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2010%26volume%3D20%26spage%3D463%26epage%3D465%26doi%3D10.1097%2FFPC.0b013e3283385420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Kazui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishizuka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span> </span><span class="NLM_article-title">Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">92</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1124/dmd.109.029132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.109.029132" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=92-99&author=M.+Kazuiauthor=Y.+Nishiyaauthor=T.+Ishizukaauthor=K.+Hagiharaauthor=N.+A.+Faridauthor=O.+Okazakiauthor=T.+Ikedaauthor=A.+Kurihara&title=Identification+of+the+Human+Cytochrome+P450+Enzymes+Involved+in+the+Two+Oxidative+Steps+in+the+Bioactivation+of+Clopidogrel+to+Its+Pharmacologically+Active+Metabolite&doi=10.1124%2Fdmd.109.029132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.029132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.029132%26sid%3Dliteratum%253Aachs%26aulast%3DKazui%26aufirst%3DM.%26aulast%3DNishiya%26aufirst%3DY.%26aulast%3DIshizuka%26aufirst%3DT.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DOkazaki%26aufirst%3DO.%26aulast%3DIkeda%26aufirst%3DT.%26aulast%3DKurihara%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520the%2520Human%2520Cytochrome%2520P450%2520Enzymes%2520Involved%2520in%2520the%2520Two%2520Oxidative%2520Steps%2520in%2520the%2520Bioactivation%2520of%2520Clopidogrel%2520to%2520Its%2520Pharmacologically%2520Active%2520Metabolite%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D92%26epage%3D99%26doi%3D10.1124%2Fdmd.109.029132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Dansette, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libraire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertho, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Metabolic Oxidative Cleavage of Thioesters: Evidence for the Formation of Sulfenic Acid Intermediates in the Bioactivation of the Antithrombotic Prodrugs Ticlopidine and Clopidogrel</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span><span class="refDoi"> DOI: 10.1021/tx8004828</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx8004828" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=369-373&author=P.+M.+Dansetteauthor=J.+Libraireauthor=G.+Berthoauthor=D.+Mansuy&title=Metabolic+Oxidative+Cleavage+of+Thioesters%3A+Evidence+for+the+Formation+of+Sulfenic+Acid+Intermediates+in+the+Bioactivation+of+the+Antithrombotic+Prodrugs+Ticlopidine+and+Clopidogrel&doi=10.1021%2Ftx8004828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Oxidative Cleavage of Thioesters: Evidence for the Formation of Sulfenic Acid Intermediates in the Bioactivation of the Antithrombotic Prodrugs Ticlopidine and Clopidogrel</span></div><div class="casAuthors">Dansette, Patrick M.; Libraire, Julie; Bertho, Gildas; Mansuy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">369-373</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metabolic cleavage of the CO-S bond of some thioesters RCOSR' with the formation of RCOOH requires a monooxygenase-dependent oxidative activation of this bond.  The nature of the S-contg. product(s) resulting from this cleavage remains unclear in most cases.  This communication provides the first evidence for the formation of sulfenic acid intermediates 4a and 4b during the oxidative cleavage of the CO-S bond of thiolactone metabolites 2a and 2b of antithrombotic prodrugs, ticlopidine and clopidogrel, by rat and human liver microsomes.  These intermediates have been trapped by dimedone, and the corresponding adducts 5a and 5b have been characterized by mass spectrometry (MS) and 1H and 13C NMR spectroscopy.  Their formation is monooxygenase-dependent and almost completely inhibited by microsomal cytochrome P 450 inhibitors.  Moreover, they were also formed upon incubation with microsomes contg. recombinant human P 450 3A4, 3A5, 2C8, 2C9, 2C19, 2D6, or 1A2.  In the presence of thiols such as mercaptoethanol, N-acetylcysteine, or glutathione, microsomal incubations of 2a led to mixed disulfides that have been characterized by MS and should result from reaction of 4a with these thiols.  At high thiol concns., one obsd. in HPLC-MS the formation of a product exhibiting the MS expected for the previously described thiol metabolite 3a, a redn. product of 4a that has been reported as the pharmacol. active metabolite of ticlopidine.  These data provide the first evidence for the formation of sulfenic acid reactive metabolites upon P 450-catalyzed oxidative cleavage of thioesters.  They also provide a first detailed mechanism for the previously described formation of pharmacol. active thiols such as 3a upon oxidative metab. of ticlopidine and clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT08wJDRg6g7Vg90H21EOLACvtfcHk0lgmKFzoLr-B8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D&md5=5b7783f3cfabd4dff3de96558bf9a63a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Ftx8004828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx8004828%26sid%3Dliteratum%253Aachs%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DLibraire%26aufirst%3DJ.%26aulast%3DBertho%26aufirst%3DG.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DMetabolic%2520Oxidative%2520Cleavage%2520of%2520Thioesters%253A%2520Evidence%2520for%2520the%2520Formation%2520of%2520Sulfenic%2520Acid%2520Intermediates%2520in%2520the%2520Bioactivation%2520of%2520the%2520Antithrombotic%2520Prodrugs%2520Ticlopidine%2520and%2520Clopidogrel%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D369%26epage%3D373%26doi%3D10.1021%2Ftx8004828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Silvestro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheorghe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iordachescu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuca, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudoroniu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizea Savu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarcomnicu, I.</span><span> </span><span class="NLM_article-title">Development And Validation Of An HPLC–MS/MS Method To Quantify Clopidogrel Acyl Glucuronide, Clopidogrel Acid Metabolite, And Clopidogrel In Plasma Samples Avoiding Analyte Back-Conversion</span> <span class="citation_source-journal">Anal. Bioanal. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">1023</span><span class="NLM_x">–</span> <span class="NLM_lpage">1034</span><span class="refDoi"> DOI: 10.1007/s00216-011-5147-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1007%2Fs00216-011-5147-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=21656175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntF2ntrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=2011&pages=1023-1034&author=L.+Silvestroauthor=M.+Gheorgheauthor=A.+Iordachescuauthor=V.+Ciucaauthor=A.+Tudoroniuauthor=S.+Rizea+Savuauthor=I.+Tarcomnicu&title=Development+And+Validation+Of+An+HPLC%E2%80%93MS%2FMS+Method+To+Quantify+Clopidogrel+Acyl+Glucuronide%2C+Clopidogrel+Acid+Metabolite%2C+And+Clopidogrel+In+Plasma+Samples+Avoiding+Analyte+Back-Conversion&doi=10.1007%2Fs00216-011-5147-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of an HPLC-MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion</span></div><div class="casAuthors">Silvestro, Luigi; Gheorghe, Mihaela; Iordachescu, Adriana; Ciuca, Valentin; Tudoroniu, Ariana; Rizea Savu, Simona; Tarcomnicu, Isabela</div><div class="citationInfo"><span class="NLM_cas:title">Analytical and Bioanalytical Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1023-1034</span>CODEN:
                <span class="NLM_cas:coden">ABCNBP</span>;
        ISSN:<span class="NLM_cas:issn">1618-2642</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A new sensitive and fast quant. anal. method for the simultaneous detn. of clopidogrel, its main metabolite clopidogrel carboxylic acid, and the newly described acyl glucuronide metabolite, in human plasma samples, is presented.  The anal. procedures (plasma storage, handling, and ext. storage in the autosampler) were optimized to avoid back-conversion; a known drawback in measurements of clopidogrel.  Clopidogrel acyl glucuronide was confirmed as a major source of back-conversion to the parent drug in the presence of methanol, and thorough stability expts. were carried out to find the most appropriate conditions for an accurate anal. of clopidogrel and the two metabolites.  The method was validated by assessing selectivity, sensitivity, linearity, accuracy, and precision for all three analytes, in accordance to Food and Drug Administration guidelines.  Spiked quality controls in plasma as well as incurred samples were used to verify back-conversion in the selected conditions, with results meeting European Medicines Agency acceptance criteria (concns. within 80-120% of the first reading).  The method was then applied to a pharmacokinetic study, and for the first time, a pharmacokinetic curve of clopidogrel acyl glucuronide in human plasma is presented.  The concns. ranged up to 1048.684 ng/mL, with a mean of 470.268 ng/mL, while clopidogrel had a mean Cmax of 1.348 ng/mL; these orders of magnitude show how much the back-conversion of this metabolite may influence clopidogrel quantification if it is not properly controlled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi2UiVPQVdY7Vg90H21EOLACvtfcHk0lgmKFzoLr-B8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntF2ntrw%253D&md5=639623f564eefaa208c95f984335dad7</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs00216-011-5147-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00216-011-5147-4%26sid%3Dliteratum%253Aachs%26aulast%3DSilvestro%26aufirst%3DL.%26aulast%3DGheorghe%26aufirst%3DM.%26aulast%3DIordachescu%26aufirst%3DA.%26aulast%3DCiuca%26aufirst%3DV.%26aulast%3DTudoroniu%26aufirst%3DA.%26aulast%3DRizea%2BSavu%26aufirst%3DS.%26aulast%3DTarcomnicu%26aufirst%3DI.%26atitle%3DDevelopment%2520And%2520Validation%2520Of%2520An%2520HPLC%25E2%2580%2593MS%252FMS%2520Method%2520To%2520Quantify%2520Clopidogrel%2520Acyl%2520Glucuronide%252C%2520Clopidogrel%2520Acid%2520Metabolite%252C%2520And%2520Clopidogrel%2520In%2520Plasma%2520Samples%2520Avoiding%2520Analyte%2520Back-Conversion%26jtitle%3DAnal.%2520Bioanal.%2520Chem.%26date%3D2011%26volume%3D401%26spage%3D1023%26epage%3D1034%26doi%3D10.1007%2Fs00216-011-5147-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Tornio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filppula, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kailari, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyrönen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapaninen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuvonen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backman, J. T.</span><span> </span><span class="NLM_article-title">Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">–</span> <span class="NLM_lpage">507</span><span class="refDoi"> DOI: 10.1038/clpt.2014.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1038%2Fclpt.2014.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=24971633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWksr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2014&pages=498-507&author=A.+Tornioauthor=A.+M.+Filppulaauthor=O.+Kailariauthor=M.+Neuvonenauthor=T.+H.+Nyr%C3%B6nenauthor=T.+Tapaninenauthor=P.+J.+Neuvonenauthor=M.+Niemiauthor=J.+T.+Backman&title=Glucuronidation+Converts+Clopidogrel+to+a+Strong+Time-Dependent+Inhibitor+of+CYP2C8%3A+A+Phase+II+Metabolite+as+a+Perpetrator+of+Drug%E2%80%93Drug+Interactions&doi=10.1038%2Fclpt.2014.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions</span></div><div class="casAuthors">Tornio, A.; Filppula, A. M.; Kailari, O.; Neuvonen, M.; Nyronen, T. H.; Tapaninen, T.; Neuvonen, P. J.; Niemi, M.; Backman, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">498-507</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cerivastatin and repaglinide are substrates of cytochrome P 450 (CYP)2C8, CYP3A4, and org. anion-transporting polypeptide (OATP)1B1.  A recent study revealed an increased risk of rhabdomyolysis in patients using cerivastatin with clopidogrel, warranting further studies on clopidogrel interactions.  In healthy volunteers, repaglinide area under the concn.-time curve (AUC0-∞) was increased 5.1-fold by a 300-mg loading dose of clopidogrel and 3.9-fold by continued administration of 75 mg clopidogrel daily.  In vitro, we identified clopidogrel acyl-β-D-glucuronide as a potent time-dependent inhibitor of CYP2C8.  A physiol. based pharmacokinetic model indicated that inactivation of CYP2C8 by clopidogrel acyl-β-D-glucuronide leads to uninterrupted 60-85% inhibition of CYP2C8 during daily clopidogrel treatment.  Computational modeling resulted in docking of clopidogrel acyl-β-D-glucuronide at the CYP2C8 active site with its thiophene moiety close to heme.  The results indicate that clopidogrel is a strong CYP2C8 inhibitor via its acyl-β-D-glucuronide and imply that glucuronide metabolites should be considered potential inhibitors of CYP enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomkamVRNguLbVg90H21EOLACvtfcHk0lgmKFzoLr-B8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWksr3N&md5=9b034c0d2e4cfe17881ac79bbb87c613</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2014.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2014.141%26sid%3Dliteratum%253Aachs%26aulast%3DTornio%26aufirst%3DA.%26aulast%3DFilppula%26aufirst%3DA.%2BM.%26aulast%3DKailari%26aufirst%3DO.%26aulast%3DNeuvonen%26aufirst%3DM.%26aulast%3DNyr%25C3%25B6nen%26aufirst%3DT.%2BH.%26aulast%3DTapaninen%26aufirst%3DT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DBackman%26aufirst%3DJ.%2BT.%26atitle%3DGlucuronidation%2520Converts%2520Clopidogrel%2520to%2520a%2520Strong%2520Time-Dependent%2520Inhibitor%2520of%2520CYP2C8%253A%2520A%2520Phase%2520II%2520Metabolite%2520as%2520a%2520Perpetrator%2520of%2520Drug%25E2%2580%2593Drug%2520Interactions%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D96%26spage%3D498%26epage%3D507%26doi%3D10.1038%2Fclpt.2014.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Floyd, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciante, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckbert, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiggins, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamraz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwok, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totah, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Psaty, B. M.</span><span> </span><span class="NLM_article-title">A Screening Study of Drug–Drug Interactions in Cerivastatin Users: An Adverse Effect of Clopidogrel</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">–</span> <span class="NLM_lpage">904</span><span class="refDoi"> DOI: 10.1038/clpt.2011.295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1038%2Fclpt.2011.295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=22419147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=896-904&author=J.+S.+Floydauthor=R.+Kasperaauthor=K.+D.+Marcianteauthor=N.+S.+Weissauthor=S.+R.+Heckbertauthor=T.+Lumleyauthor=K.+L.+Wigginsauthor=B.+Tamrazauthor=P.+Y.+Kwokauthor=R.+A.+Totahauthor=B.+M.+Psaty&title=A+Screening+Study+of+Drug%E2%80%93Drug+Interactions+in+Cerivastatin+Users%3A+An+Adverse+Effect+of+Clopidogrel&doi=10.1038%2Fclpt.2011.295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">A Screening Study of Drug-Drug Interactions in Cerivastatin Users: An Adverse Effect of Clopidogrel</span></div><div class="casAuthors">Floyd, J. S.; Kaspera, R.; Marciante, K. D.; Weiss, N. S.; Heckbert, S. R.; Lumley, T.; Wiggins, K. L.; Tamraz, B.; Kwok, P.-Y.; Totah, R. A.; Psaty, B. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">896-904</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">An anal. of a case-control study of rhabdomyolysis was conducted to screen for previously unrecognized cytochrome P 450 enzyme (CYP) 2C8 inhibitors that may cause other clin. important drug-drug interactions.  Medication use in cases of rhabdomyolysis using cerivastatin (n = 72) was compared with that in controls using atorvastatin (n = 287) for the period 1998-2001.  The use of clopidogrel was strongly assocd. with rhabdomyolysis (odds ratio (OR) 29.6; 95% confidence interval (CI), 6.1-143).  In a replication effort that used the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS), it was found that clopidogrel was used more commonly in patients with rhabdomyolysis receiving cerivastatin (17%) than in those receiving atorvastatin (0%, OR infinity; 95% CI = 5.2-infinity).  Several medications were tested in vitro for their potential to cause drug-drug interactions.  Clopidogrel, rosiglitazone, and montelukast were the most potent inhibitors of cerivastatin metab.  Clopidogrel and its metabolites also inhibited cerivastatin metab. in human hepatocytes.  These epidemiol. and in vitro findings suggest that clopidogrel may cause clin. important, dose-dependent drug-drug interactions with other medications metabolized by CYP2C8.  Clin. Pharmacol. & Therapeutics (2012); 91 5, 896-904. doi:10.1038/clpt.2011.295.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-xKBvrbsLErVg90H21EOLACvtfcHk0lhRDcmFU6nvow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWmt7s%253D&md5=184c1a95c592fac6027061058c715e08</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2011.295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2011.295%26sid%3Dliteratum%253Aachs%26aulast%3DFloyd%26aufirst%3DJ.%2BS.%26aulast%3DKaspera%26aufirst%3DR.%26aulast%3DMarciante%26aufirst%3DK.%2BD.%26aulast%3DWeiss%26aufirst%3DN.%2BS.%26aulast%3DHeckbert%26aufirst%3DS.%2BR.%26aulast%3DLumley%26aufirst%3DT.%26aulast%3DWiggins%26aufirst%3DK.%2BL.%26aulast%3DTamraz%26aufirst%3DB.%26aulast%3DKwok%26aufirst%3DP.%2BY.%26aulast%3DTotah%26aufirst%3DR.%2BA.%26aulast%3DPsaty%26aufirst%3DB.%2BM.%26atitle%3DA%2520Screening%2520Study%2520of%2520Drug%25E2%2580%2593Drug%2520Interactions%2520in%2520Cerivastatin%2520Users%253A%2520An%2520Adverse%2520Effect%2520of%2520Clopidogrel%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D91%26spage%3D896%26epage%3D904%26doi%3D10.1038%2Fclpt.2011.295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amunugama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">Mechanism-Based Inactivation of Human Cytochrome P450 2B6 by Clopidogrel: Involvement of Both Covalent Modification of Cysteinyl Residue 475 and Loss of Heme</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">847</span><span class="refDoi"> DOI: 10.1124/mol.111.073783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fmol.111.073783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=839-847&author=H.+Zhangauthor=H.+Amunugamaauthor=S.+Neyauthor=N.+Cooperauthor=P.+F.+Hollenberg&title=Mechanism-Based+Inactivation+of+Human+Cytochrome+P450+2B6+by+Clopidogrel%3A+Involvement+of+Both+Covalent+Modification+of+Cysteinyl+Residue+475+and+Loss+of+Heme&doi=10.1124%2Fmol.111.073783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.073783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.073783%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DAmunugama%26aufirst%3DH.%26aulast%3DNey%26aufirst%3DS.%26aulast%3DCooper%26aufirst%3DN.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DMechanism-Based%2520Inactivation%2520of%2520Human%2520Cytochrome%2520P450%25202B6%2520by%2520Clopidogrel%253A%2520Involvement%2520of%2520Both%2520Covalent%2520Modification%2520of%2520Cysteinyl%2520Residue%2520475%2520and%2520Loss%2520of%2520Heme%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D839%26epage%3D847%26doi%3D10.1124%2Fmol.111.073783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Tamraz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukushima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totah, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciante, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckbert, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Psaty, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroetz, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwok, P.-Y.</span><span> </span><span class="NLM_article-title">OATP1B1-Related Drug–Drug And Drug–Gene Interactions As Potential Risk Factors For Cerivastatin-Induced Rhabdomyolysis</span> <span class="citation_source-journal">Pharmacogenet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span><span class="refDoi"> DOI: 10.1097/FPC.0b013e3283620c3b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1097%2FFPC.0b013e3283620c3b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=23652407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVeisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=355-364&author=B.+Tamrazauthor=H.+Fukushimaauthor=A.+R.+Wolfeauthor=R.+Kasperaauthor=R.+A.+Totahauthor=J.+S.+Floydauthor=B.+Maauthor=C.+Chuauthor=K.+D.+Marcianteauthor=S.+R.+Heckbertauthor=B.+M.+Psatyauthor=D.+L.+Kroetzauthor=P.-Y.+Kwok&title=OATP1B1-Related+Drug%E2%80%93Drug+And+Drug%E2%80%93Gene+Interactions+As+Potential+Risk+Factors+For+Cerivastatin-Induced+Rhabdomyolysis&doi=10.1097%2FFPC.0b013e3283620c3b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis</span></div><div class="casAuthors">Tamraz, Bani; Fukushima, Hisayo; Wolfe, Alan R.; Kaspera, Ruediger; Totah, Rheem A.; Floyd, James S.; Ma, Benjamin; Chu, Catherine; Marciante, Kristin D.; Heckbert, Susan R.; Psaty, Bruce M.; Kroetz, Deanna L.; Kwok, Pui-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">355-364</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: Genetic variation in drug metabolizing enzymes and membrane transporters as well as concomitant drug therapy can modulate the beneficial and the deleterious effects of drugs.  We investigated whether patients exhibiting rhabdomyolysis who were taking cerivastatin possess functional genetic variants in SLCO1B1 and whether they were on concomitant medications that inhibit OATP1B1, resulting in accumulation of cerivastatin.  Methods: This study had three components: (a) resequencing the SLCO1B1 gene in 122 patients who developed rhabdomyolysis while on cerivastatin; (b) functional evaluation of the identified SLCO1B1 nonsynonymous variants and haplotypes in in-vitro HEK293/FRT cells stably transfected with pcDNA5/FRT empty vector, SLCO1B1 ref., variants, and haplotypes; and (c) in-vitro screening of 15 drugs commonly used among the rhabdomyolysis cases for inhibition of OATP1B1-mediated uptake of cerivastatin in HEK293/FRT cells stably transfected with ref. SLCO1B1.  Results: The resequencing of the SLCO1B1 gene identified 54 variants.  In-vitro functional anal. of SLCO1B1 nonsynonymous variants and haplotypes showed that the V174A, R57Q, and P155T variants, a novel frameshift insertion, OATP1B1*14 and OATP1B1*15 haplotype were assocd. with a significant redn. (P<0.001) in cerivastatin uptake (32, 18, 72, 3.4, 2.1 and 5.7% of ref., resp.).  Furthermore, clopidogrel and seven other drugs were shown to inhibit OATP1B1-mediated uptake of cerivastatin.  Conclusion: Reduced function of OATP1B1 related to genetic variation and drug-drug interactions likely contributed to cerivastatin-induced rhabdomyolysis.  Although cerivastatin is no longer in clin. use, these findings may translate to related statins and other substrates of OATP1B1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow9hs2HfKb77Vg90H21EOLACvtfcHk0lhRDcmFU6nvow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVeisLk%253D&md5=5b9001693de71ddd48bcd8e1d6b5dcad</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e3283620c3b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e3283620c3b%26sid%3Dliteratum%253Aachs%26aulast%3DTamraz%26aufirst%3DB.%26aulast%3DFukushima%26aufirst%3DH.%26aulast%3DWolfe%26aufirst%3DA.%2BR.%26aulast%3DKaspera%26aufirst%3DR.%26aulast%3DTotah%26aufirst%3DR.%2BA.%26aulast%3DFloyd%26aufirst%3DJ.%2BS.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DC.%26aulast%3DMarciante%26aufirst%3DK.%2BD.%26aulast%3DHeckbert%26aufirst%3DS.%2BR.%26aulast%3DPsaty%26aufirst%3DB.%2BM.%26aulast%3DKroetz%26aufirst%3DD.%2BL.%26aulast%3DKwok%26aufirst%3DP.-Y.%26atitle%3DOATP1B1-Related%2520Drug%25E2%2580%2593Drug%2520And%2520Drug%25E2%2580%2593Gene%2520Interactions%2520As%2520Potential%2520Risk%2520Factors%2520For%2520Cerivastatin-Induced%2520Rhabdomyolysis%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2013%26volume%3D23%26spage%3D355%26epage%3D364%26doi%3D10.1097%2FFPC.0b013e3283620c3b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Sane, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsden, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowland, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ting, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitcher-Johnstone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D. J.</span><span> </span><span class="NLM_article-title">Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">475</span><span class="refDoi"> DOI: 10.1124/dmd.115.066985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1124%2Fdmd.115.066985" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=466-475&author=R.+S.+Saneauthor=D.+Ramsdenauthor=J.+P.+Saboauthor=C.+Cooperauthor=L.+Rowlandauthor=N.+Tingauthor=A.+Whitcher-Johnstoneauthor=D.+J.+Tweedie&title=Contribution+of+Major+Metabolites+toward+Complex+Drug-Drug+Interactions+of+Deleobuvir%3A+In+Vitro+Predictions+and+In+Vivo+Outcomes&doi=10.1124%2Fdmd.115.066985"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.066985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.066985%26sid%3Dliteratum%253Aachs%26aulast%3DSane%26aufirst%3DR.%2BS.%26aulast%3DRamsden%26aufirst%3DD.%26aulast%3DSabo%26aufirst%3DJ.%2BP.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DRowland%26aufirst%3DL.%26aulast%3DTing%26aufirst%3DN.%26aulast%3DWhitcher-Johnstone%26aufirst%3DA.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26atitle%3DContribution%2520of%2520Major%2520Metabolites%2520toward%2520Complex%2520Drug-Drug%2520Interactions%2520of%2520Deleobuvir%253A%2520In%2520Vitro%2520Predictions%2520and%2520In%2520Vivo%2520Outcomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D466%26epage%3D475%26doi%3D10.1124%2Fdmd.115.066985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Chen, L.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabo, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowland, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsden, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandarino, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sane, R. S.</span><span> </span><span class="NLM_article-title">Mass Balance, Metabolite Profile, and In Vitro-In Vivo Comparison of Clearance Pathways of Deleobuvir, a Hepatitis C Virus Polymerase Inhibitor</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1128/AAC.03861-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1128%2FAAC.03861-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=25-37&author=L.-Z.+Chenauthor=J.+P.+Saboauthor=E.+Philipauthor=L.+Rowlandauthor=Y.+Maoauthor=B.+Latliauthor=D.+Ramsdenauthor=D.+A.+Mandarinoauthor=R.+S.+Sane&title=Mass+Balance%2C+Metabolite+Profile%2C+and+In+Vitro-In+Vivo+Comparison+of+Clearance+Pathways+of+Deleobuvir%2C+a+Hepatitis+C+Virus+Polymerase+Inhibitor&doi=10.1128%2FAAC.03861-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1128%2FAAC.03861-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03861-14%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.-Z.%26aulast%3DSabo%26aufirst%3DJ.%2BP.%26aulast%3DPhilip%26aufirst%3DE.%26aulast%3DRowland%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DLatli%26aufirst%3DB.%26aulast%3DRamsden%26aufirst%3DD.%26aulast%3DMandarino%26aufirst%3DD.%2BA.%26aulast%3DSane%26aufirst%3DR.%2BS.%26atitle%3DMass%2520Balance%252C%2520Metabolite%2520Profile%252C%2520and%2520In%2520Vitro-In%2520Vivo%2520Comparison%2520of%2520Clearance%2520Pathways%2520of%2520Deleobuvir%252C%2520a%2520Hepatitis%2520C%2520Virus%2520Polymerase%2520Inhibitor%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D25%26epage%3D37%26doi%3D10.1128%2FAAC.03861-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Kazmi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hvenegaard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendahl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gipson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, A.</span><span> </span><span class="NLM_article-title">Identification Of A Novel Carbamoyl Glucuronide As A Metabolism-Dependent Inhibitor Of CYP2C8</span> <span class="citation_source-journal">Drug Metab. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=143&author=F.+Kazmiauthor=B.+Smithauthor=M.+Hvenegaardauthor=L.+Bendahlauthor=A.+Gipsonauthor=D.+Buckleyauthor=B.+Ogilvieauthor=A.+Parkinson&title=Identification+Of+A+Novel+Carbamoyl+Glucuronide+As+A+Metabolism-Dependent+Inhibitor+Of+CYP2C8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKazmi%26aufirst%3DF.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DHvenegaard%26aufirst%3DM.%26aulast%3DBendahl%26aufirst%3DL.%26aulast%3DGipson%26aufirst%3DA.%26aulast%3DBuckley%26aufirst%3DD.%26aulast%3DOgilvie%26aufirst%3DB.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DIdentification%2520Of%2520A%2520Novel%2520Carbamoyl%2520Glucuronide%2520As%2520A%2520Metabolism-Dependent%2520Inhibitor%2520Of%2520CYP2C8%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2010%26volume%3D42%26spage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Schaefer, W. H.</span><span> </span><span class="NLM_article-title">Reaction of Primary and Secondary Amines to Form Carbamic Acid Glucuronides</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">881</span><span class="refDoi"> DOI: 10.2174/138920006779010629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.2174%2F138920006779010629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=17168688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFymsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=873-881&author=W.+H.+Schaefer&title=Reaction+of+Primary+and+Secondary+Amines+to+Form+Carbamic+Acid+Glucuronides&doi=10.2174%2F138920006779010629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Reaction of primary and secondary amines to form carbamic acid glucuronides</span></div><div class="casAuthors">Schaefer, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">873-881</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Glucuronidation is an important mechanism used by mammalian systems to clear and eliminate both endogenous and foreign chems.  Many functional groups are susceptible to conjugation with glucuronic acid, including hydroxyls, phenols, carboxyls, activated carbons, thiols, amines, and selenium.  Primary and secondary amines can also react with carbon dioxide (CO2) via a reversible reaction to form a carbamic acid.  The carbamic acid is also a substrate for glucuronidation and results in a stable carbamate glucuronide metabolite.  The detection and characterization of these products has been facilitated greatly by the advent of soft ionization mass spectrometry techniques and high field NMR instrumentation.  The formation of carbamate glucuronide metabolites has been described for numerous pharmaceuticals and they have been identified in all of the species commonly used in drug metab. studies (rat, dog, mouse, rabbit, guinea pig, and human).  There has been no obvious species specificity for their formation and no preference for 1° or 2° amines.  Many biol. reactions have also been described in the literature that involve the reaction of CO2 with amino groups of biomols.  For example, CO2 generated from cellular respiration is expired in part through the reversible formation of a carbamate between CO2 and the α-amino groups of the α and β-chains of Hb.  Also, carbamic acid products of several amines, such as β-N-methylamino-L-alanine (BMAA), ethylenediamine, and L-cysteine have been implicated in toxicity.  Studies suggested that a significant portion of amino-compds. in biol. samples (that naturally contain CO2/bicarbonate) can be present as a carbamic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokytAdX5PD0LVg90H21EOLACvtfcHk0li-RadCT9mnqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFymsr7N&md5=bd81203dafb1337b5f8d83f2820ebaae</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2174%2F138920006779010629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920006779010629%26sid%3Dliteratum%253Aachs%26aulast%3DSchaefer%26aufirst%3DW.%2BH.%26atitle%3DReaction%2520of%2520Primary%2520and%2520Secondary%2520Amines%2520to%2520Form%2520Carbamic%2520Acid%2520Glucuronides%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2006%26volume%3D7%26spage%3D873%26epage%3D881%26doi%3D10.2174%2F138920006779010629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Williams, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRee, D. E.</span><span> </span><span class="NLM_article-title">Mammalian Microsomal Cytochrome P450 Monooxygenase: Structural Adaptations for Membrane Binding and Functional Diversity</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span><span class="refDoi"> DOI: 10.1016/S1097-2765(00)80408-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2FS1097-2765%2800%2980408-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10678174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD3cXpvFKnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2000&pages=121-131&author=P.+A.+Williamsauthor=J.+Cosmeauthor=V.+Sridharauthor=E.+F.+Johnsonauthor=D.+E.+McRee&title=Mammalian+Microsomal+Cytochrome+P450+Monooxygenase%3A+Structural+Adaptations+for+Membrane+Binding+and+Functional+Diversity&doi=10.1016%2FS1097-2765%2800%2980408-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity</span></div><div class="casAuthors">Williams, Pamela A.; Cosme, Jose; Sridhar, Vandana; Johnson, Eric F.; McRee, Duncan E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-131</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Microsomal cytochrome P 450s participate in xenobiotic detoxification, procarcinogen activation, and steroid hormone synthesis.  The first structure of a mammalian microsomal P 450 suggests that the assocn. of P 450s with the endoplasmic reticulum involves a hydrophobic surface of the protein formed by noncontiguous portions of the polypeptide chain.  This interaction places the entrance of the putative substrate access channel in or near the membrane and orients the face of the protein proximal to the heme cofactor perpendicular to the plane of the membrane for interaction with the cytochrome P 450 reductase.  This structure offers a template for modeling other mammalian P 450s and should aid drug discovery and the prediction of drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPvxT-fdyD1bVg90H21EOLACvtfcHk0li-RadCT9mnqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXpvFKnug%253D%253D&md5=6554880f1ae6291d7b03123bf68e533b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2980408-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252980408-6%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DP.%2BA.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DSridhar%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26atitle%3DMammalian%2520Microsomal%2520Cytochrome%2520P450%2520Monooxygenase%253A%2520Structural%2520Adaptations%2520for%2520Membrane%2520Binding%2520and%2520Functional%2520Diversity%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D5%26spage%3D121%26epage%3D131%26doi%3D10.1016%2FS1097-2765%2800%2980408-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Melet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marques-Soares, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoch, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macherey, A.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaouen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansette, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sari, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuy, D.</span><span> </span><span class="NLM_article-title">Analysis of Human Cytochrome P450 2C8 Substrate Specificity Using a Substrate Pharmacophore and Site-Directed Mutants</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">15379</span><span class="NLM_x">–</span> <span class="NLM_lpage">15392</span><span class="refDoi"> DOI: 10.1021/bi0489309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0489309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvVGgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=15379-15392&author=A.+Meletauthor=C.+Marques-Soaresauthor=G.+A.+Schochauthor=A.-C.+Machereyauthor=M.+Jaouenauthor=P.+M.+Dansetteauthor=M.-A.+Sariauthor=E.+F.+Johnsonauthor=D.+Mansuy&title=Analysis+of+Human+Cytochrome+P450+2C8+Substrate+Specificity+Using+a+Substrate+Pharmacophore+and+Site-Directed+Mutants&doi=10.1021%2Fbi0489309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Human Cytochrome P450 2C8 Substrate Specificity Using a Substrate Pharmacophore and Site-Directed Mutants</span></div><div class="casAuthors">Melet, Armelle; Marques-Soares, Cristina; Schoch, Guillaume A.; Macherey, Anne-Christine; Jaouen, Maryse; Dansette, Patrick M.; Sari, Marie-Agnes; Johnson, Eric F.; Mansuy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">15379-15392</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structural determinants of substrate specificity of human liver cytochrome P 450 2C8 (CYP2C8) were investigated using site-directed mutants chosen on the basis of a preliminary substrate pharmacophore and a three-dimensional (3D) model.  Anal. of the structural features common to CYP2C8 substrates exhibiting a micromolar Km led to a substrate pharmacophore in which the site of oxidn. by CYP2C8 is 12.9, 8.6, 4.4, and 3.9 Å from features that could establish ionic or hydrogen bonds, and hydrophobic interactions with protein amino acid residues.  Comparison of this pharmacophore with a 3D model of CYP2C8 constructed using the X-ray structure of CYP2C5 suggested potential CYP2C8 amino acid residues that could be involved in substrate recognition.  Twenty CYP2C8 site-directed mutants were constructed and expressed in yeast to compare their catalytic activities using five CYP2C8 substrates that exhibit different structures and sizes [paclitaxel, fluvastatin, retinoic acid, a sulfaphenazole deriv. (DMZ), and diclofenac].  Mutation of arginine 241 had marked effects on the hydroxylation of anionic substrates of CYP2C8 such as retinoic acid and fluvastatin.  Serine 100 appears to be involved in hydrogen bonding interactions with a polar site of the CYP2C8 substrate pharmacophore, as shown by the 3-4-fold increase in the Km of paclitaxel and DMZ hydroxylation after the S100A mutation.  Residues 114, 201, and 205 are predicted to be in close contact with substrates, and their mutations lead either to favorable hydrophobic interactions or to steric clashes with substrates.  For instance, the S114F mutant was unable to catalyze the 6α-hydroxylation of paclitaxel.  The S114F and F205A mutants were the best catalysts for retinoic acid and paclitaxel (or fluvastatin) hydroxylation, resp., with kcat/Km values 5 and 2.1 (or 2.4) times higher, resp., than those found for CYP2C8.  Preliminary expts. of docking of the substrate into the exptl. detd. X-ray structure of substrate-free CYP2C8, which became available quite recently [Schoch, G. A., et al. (2004) J. Biol. Chem. 279, 9497], were consistent with key roles for S100, S114, and F205 residues in substrate binding.  The results suggest that the effects of mutation of arginine 241 on anionic substrate hydroxylation could be indirect and result from alterations of the packing of helix G with helix B'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZZrn1vZeqlbVg90H21EOLACvtfcHk0lgLDojW2k8g-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvVGgsr4%253D&md5=7bf3aa2049f582ed0f5ddf912fa848df</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fbi0489309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0489309%26sid%3Dliteratum%253Aachs%26aulast%3DMelet%26aufirst%3DA.%26aulast%3DMarques-Soares%26aufirst%3DC.%26aulast%3DSchoch%26aufirst%3DG.%2BA.%26aulast%3DMacherey%26aufirst%3DA.-C.%26aulast%3DJaouen%26aufirst%3DM.%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DSari%26aufirst%3DM.-A.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DAnalysis%2520of%2520Human%2520Cytochrome%2520P450%25202C8%2520Substrate%2520Specificity%2520Using%2520a%2520Substrate%2520Pharmacophore%2520and%2520Site-Directed%2520Mutants%26jtitle%3DBiochemistry%26date%3D2004%26volume%3D43%26spage%3D15379%26epage%3D15392%26doi%3D10.1021%2Fbi0489309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Schoch, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wester, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span> </span><span class="NLM_article-title">Structure Of Human Microsomal Cytochrome P450 2c8: Evidence For A Peripheral Fatty Acid Binding Site</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">9497</span><span class="NLM_x">–</span> <span class="NLM_lpage">9503</span><span class="refDoi"> DOI: 10.1074/jbc.M312516200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1074%2Fjbc.M312516200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=14676196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Omt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=9497-9503&author=G.+A.+Schochauthor=J.+K.+Yanoauthor=M.+R.+Westerauthor=K.+J.+Griffinauthor=C.+D.+Stoutauthor=E.+F.+Johnson&title=Structure+Of+Human+Microsomal+Cytochrome+P450+2c8%3A+Evidence+For+A+Peripheral+Fatty+Acid+Binding+Site&doi=10.1074%2Fjbc.M312516200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Human Microsomal Cytochrome P450 2C8: evidence for a peripheral fatty acid binding site</span></div><div class="casAuthors">Schoch, Guillaume A.; Yano, Jason K.; Wester, Michael R.; Griffin, Keith J.; Stout, C. David; Johnson, Eric F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">9497-9503</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A 2.7-Å mol. structure of human microsomal cytochrome P 450 2C8 (CYP2C8) was detd. by x-ray crystallog.  The membrane protein was modified for crystn. by replacement of the hydrophobic N-terminal transmembrane domain with a short hydrophilic sequence before residue 28.  The structure of the native sequence is complete from residue 28 to the beginning of a C-terminal histidine tag used for purifn.  CYP2C8 is one of the principal hepatic drug-metabolizing enzymes that oxidizes therapeutic drugs such as taxol and cerivastatin and endobiotics such as retinoic acid and arachidonic acid.  Consistent with the relatively large size of its preferred substrates, the active site vol. is twice that obsd. for the structure of CYP2C5.  The extended active site cavity is bounded by the β1 sheet and helix F' that have not previously been implicated in substrate recognition by mammalian P450s.  CYP2C8 crystd. as a sym. dimer formed by the interaction of helixes F, F', G', and G.  Two mols. of palmitic acid are bound in the dimer interface.  The dimer is obsd. in soln., and mass spectrometry confirmed the assocn. of palmitic acid with the enzyme.  This novel finding identifies a peripheral binding site in P450s that may contribute to drug-drug interactions in P 450 metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM_mLgb6K1XrVg90H21EOLACvtfcHk0lgLDojW2k8g-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Omt78%253D&md5=433aca9f612b396ff3cc6f30291200a2</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M312516200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M312516200%26sid%3Dliteratum%253Aachs%26aulast%3DSchoch%26aufirst%3DG.%2BA.%26aulast%3DYano%26aufirst%3DJ.%2BK.%26aulast%3DWester%26aufirst%3DM.%2BR.%26aulast%3DGriffin%26aufirst%3DK.%2BJ.%26aulast%3DStout%26aufirst%3DC.%2BD.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26atitle%3DStructure%2520Of%2520Human%2520Microsomal%2520Cytochrome%2520P450%25202c8%253A%2520Evidence%2520For%2520A%2520Peripheral%2520Fatty%2520Acid%2520Binding%2520Site%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D9497%26epage%3D9503%26doi%3D10.1074%2Fjbc.M312516200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiguchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span> </span><span class="NLM_article-title">Characterization of the CYP2C8 Active Site by Homology Modeling</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">836</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span><span class="refDoi"> DOI: 10.1248/cpb.52.836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1248%2Fcpb.52.836" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=836-841&author=T.+Tanakaauthor=N.+Kamiguchiauthor=T.+Okudaauthor=Y.+Yamamoto&title=Characterization+of+the+CYP2C8+Active+Site+by+Homology+Modeling&doi=10.1248%2Fcpb.52.836"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1248%2Fcpb.52.836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.52.836%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKamiguchi%26aufirst%3DN.%26aulast%3DOkuda%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DCharacterization%2520of%2520the%2520CYP2C8%2520Active%2520Site%2520by%2520Homology%2520Modeling%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2004%26volume%3D52%26spage%3D836%26epage%3D841%26doi%3D10.1248%2Fcpb.52.836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Schoch, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansette, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span> </span><span class="NLM_article-title">Determinants Of Cytochrome P450 2c8 Substrate Binding: Structures Of Complexes With Montelukast, Troglitazone, Felodipine, And 9-Cis-Retinoic Acid</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">17227</span><span class="NLM_x">–</span> <span class="NLM_lpage">17237</span><span class="refDoi"> DOI: 10.1074/jbc.M802180200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1074%2Fjbc.M802180200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=18413310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFSntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=17227-17237&author=G.+A.+Schochauthor=J.+K.+Yanoauthor=S.+Sansenauthor=P.+M.+Dansetteauthor=C.+D.+Stoutauthor=E.+F.+Johnson&title=Determinants+Of+Cytochrome+P450+2c8+Substrate+Binding%3A+Structures+Of+Complexes+With+Montelukast%2C+Troglitazone%2C+Felodipine%2C+And+9-Cis-Retinoic+Acid&doi=10.1074%2Fjbc.M802180200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of Cytochrome P450 2C8 Substrate Binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid</span></div><div class="casAuthors">Schoch, Guillaume A.; Yano, Jason K.; Sansen, Stefaan; Dansette, Patrick M.; Stout, C. David; Johnson, Eric F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">17227-17237</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Although a crystal structure and a pharmacophore model are available for cytochrome P 450 2C8, the role of protein flexibility and specific ligand-protein interactions that govern substrate binding are poorly understood.  X-ray crystal structures of P 450 2C8 complexed with montelukast (2.8 Å), troglitazone (2.7 Å), felodipine (2.3 Å), and 9-cis-retinoic acid (2.6 Å) were detd. to examine ligand-protein interactions for these chem. diverse compds.  Montelukast is a relatively large anionic inhibitor that exhibits a tripartite structure and complements the size and shape of the active-site cavity.  The inhibitor troglitazone occupies the upper portion of the active-site cavity, leaving a substantial part of the cavity unoccupied.  The smaller neutral felodipine mol. is sequestered with its dichlorophenyl group positioned close to the heme iron, and water mols. fill the distal portion of the cavity.  The structure of the 9-cis-retinoic acid complex reveals that two substrate mols. bind simultaneously in the active site of P 450 2C8.  A second mol. of 9-cis-retinoic acid is located above the proximal mol. and can restrain the position of the latter for more efficient oxygenation.  Soln. binding studies do not discriminate between cooperative and noncooperative models for multiple substrate binding.  The complexes with structurally distinct ligands further demonstrate the conformational adaptability of active site-constituting residues, esp. Arg-241, that can reorient in the active-site cavity to stabilize a neg. charged functional group and define two spatially distinct binding sites for anionic moieties of substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKJYX0FJXu6rVg90H21EOLACvtfcHk0liNFl2PoSZo_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFSntLo%253D&md5=6c4d8f308239f45f3779e5e3015bcdc2</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M802180200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M802180200%26sid%3Dliteratum%253Aachs%26aulast%3DSchoch%26aufirst%3DG.%2BA.%26aulast%3DYano%26aufirst%3DJ.%2BK.%26aulast%3DSansen%26aufirst%3DS.%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DStout%26aufirst%3DC.%2BD.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26atitle%3DDeterminants%2520Of%2520Cytochrome%2520P450%25202c8%2520Substrate%2520Binding%253A%2520Structures%2520Of%2520Complexes%2520With%2520Montelukast%252C%2520Troglitazone%252C%2520Felodipine%252C%2520And%25209-Cis-Retinoic%2520Acid%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D17227%26epage%3D17237%26doi%3D10.1074%2Fjbc.M802180200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Mulder, G. J.</span><span> </span><span class="NLM_article-title">Glucuronidation and its Role in Regulation of Biological Activity of Drugs</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span><span class="refDoi"> DOI: 10.1146/annurev.pa.32.040192.000325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1146%2Fannurev.pa.32.040192.000325" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1992&pages=25-49&author=G.+J.+Mulder&title=Glucuronidation+and+its+Role+in+Regulation+of+Biological+Activity+of+Drugs&doi=10.1146%2Fannurev.pa.32.040192.000325"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pa.32.040192.000325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pa.32.040192.000325%26sid%3Dliteratum%253Aachs%26aulast%3DMulder%26aufirst%3DG.%2BJ.%26atitle%3DGlucuronidation%2520and%2520its%2520Role%2520in%2520Regulation%2520of%2520Biological%2520Activity%2520of%2520Drugs%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1992%26volume%3D32%26spage%3D25%26epage%3D49%26doi%3D10.1146%2Fannurev.pa.32.040192.000325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Mignat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wille, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegler, A.</span><span> </span><span class="NLM_article-title">Affinity Profiles Of Morphine, Codeine, Dihydrocodeine And Their Glucuronides At Opioid Receptor Subtypes</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">799</span><span class="refDoi"> DOI: 10.1016/0024-3205(95)00010-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;key=10.1016%2F0024-3205%2895%2900010-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1995&pages=793-799&author=C.+Mignatauthor=U.+Willeauthor=A.+Ziegler&title=Affinity+Profiles+Of+Morphine%2C+Codeine%2C+Dihydrocodeine+And+Their+Glucuronides+At+Opioid+Receptor+Subtypes&doi=10.1016%2F0024-3205%2895%2900010-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2895%2900010-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252895%252900010-4%26sid%3Dliteratum%253Aachs%26aulast%3DMignat%26aufirst%3DC.%26aulast%3DWille%26aufirst%3DU.%26aulast%3DZiegler%26aufirst%3DA.%26atitle%3DAffinity%2520Profiles%2520Of%2520Morphine%252C%2520Codeine%252C%2520Dihydrocodeine%2520And%2520Their%2520Glucuronides%2520At%2520Opioid%2520Receptor%2520Subtypes%26jtitle%3DLife%2520Sci.%26date%3D1995%26volume%3D56%26spage%3D793%26epage%3D799%26doi%3D10.1016%2F0024-3205%2895%2900010-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PQ2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PQ2','PDB','1PQ2'); return false;">PDB: 1PQ2</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00510&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-21%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00510%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00510" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679ac25ddfa03d42","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
